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A B S T R A C T
Background
Reduction and modification of dietary fats have differing effects on cardiovascular risk factors (such as serum cholesterol), but their
effects on important health outcomes are less clear.
Objectives
To assess the effect of reduction and/or modification of dietary fats on mortality, cardiovascular mortality, cardiovascular morbidity
and individual outcomes including myocardial infarction, stroke and cancer diagnoses in randomised clinical trials of at least 6 months
duration.
Search strategy
For this review update, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, were searched
through to June 2010. References of Included studies and reviews were also checked.
Selection criteria
Trials fulfilled the following criteria: 1) randomised with appropriate control group, 2) intention to reduce or modify fat or cholesterol
intake (excluding exclusively omega-3 fat interventions), 3) not multi factorial, 4) adult humans with or without cardiovascular disease,
5) intervention at least six months, 6) mortality or cardiovascular morbidity data available.
Data collection and analysis
Participant numbers experiencing health outcomes in each arm were extracted independently in duplicate and random effects meta-
analyses, meta-regression, sub-grouping, sensitivity analyses and funnel plots were performed.
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Main results
This updated review suggested that reducing saturated fat by reducing and/or modifying dietary fat reduced the risk of cardiovascular
events by 14% (RR 0.86, 95% CI 0.77 to 0.96, 24 comparisons, 65,508 participants of whom 7% had a cardiovascular event, I2 50%).
Subgrouping suggested that this reduction in cardiovascular events was seen in studies of fat modification (not reduction - which related
directly to the degree of effect on serum total and LDL cholesterol and triglycerides), of at least two years duration and in studies of
men (not of women). There were no clear effects of dietary fat changes on total mortality (RR 0.98, 95% CI 0.93 to 1.04, 71,790
participants) or cardiovascular mortality (RR 0.94, 95% CI 0.85 to 1.04, 65,978 participants). This did not alter with sub-grouping
or sensitivity analysis.
Few studies compared reduced with modified fat diets, so direct comparison was not possible.
Authors’ conclusions
The findings are suggestive of a small but potentially important reduction in cardiovascular risk on modification of dietary fat, but not
reduction of total fat, in longer trials. Lifestyle advice to all those at risk of cardiovascular disease and to lower risk population groups,
should continue to include permanent reduction of dietary saturated fat and partial replacement by unsaturates. The ideal type of
unsaturated fat is unclear.
P L A I N L A N G U A G E S U M M A R Y
Cutting down or changing the fat we eat may reduce our risk of heart disease
Modifying fat in our food (replacing some saturated (animal) fats with plant oils and unsaturated spreads) may reduce risk of heart
and vascular disease, but it is not clear whether monounsaturated or polyunsaturated fats are more beneficial. There are no clear health
benefits of replacing saturated fats with starchy foods (reducing the total amount of fat we eat). Heart and vascular disease includes
heart attacks, angina, strokes, sudden cardiovascular death and the need for heart surgery. Modifying the fat we eat seems to protect us
better if we adhere in doing so for at least two years. It is not clear whether people who are currently healthy benefit as much as those at
increased risk of cardiovascular disease (people with hypertension, raised serum lipids or diabetes for example) and people who already
have heart disease, but the suggestion is that they would all benefit to some extent.
B A C K G R O U N D
In 1949 Ryle and Russell in Oxford documented a dramatic in-
crease in coronary heart disease, and the Registrar General’s Sta-
tistical Tables of 1920 to 1955 showed that there had been a 70-
fold increase in coronary deaths during this 35 year period (Oliver
2000; Ryle 1949). This sudden surge in coronary heart disease
sparked research into its causes. A case control study published in
1953 of 200 post-myocardial infarction patients and age-matched
controls established that thosewith disease hadhigher LDLcholes-
terol levels (Oliver 1953).
Meanwhile in 1949 in the US Gofman had separated lipids into
lipoprotein classes through ultra centrifugation, describing the low
density lipoproteins (LDL) as ‘atherosclerogenic’ (Gofman 1949).
The following yearKeys proposed that the concentrationof plasma
cholesterol was proportional to dietary saturated fat intake (Keys
1950), and this relationship was confirmed in work by Hegsted
(Hegsted 1965; Hegsted 2000) who published an equation ex-
plaining the relationship in 1965 and subsequently in 2000, sug-
gesting that dietary saturated fat increases serum cholesterol and
so increases cardiovascular risk, while polyunsaturated fats reduce
both (this has since been further refined):
1 serum cholesterol (in mg/dl) = 2.16 * 1 dietary saturated fat
intake (as percentage of energy) - 1.65 *1 dietary polyunsaturated
intake (as percentage of energy) + 6.77 * 1 dietary cholesterol
intake (in units of 100mg/day) - 0.53
The Seven Countries Study compared CHD mortality in 12000
men aged 40-59 in seven countries and found positive correla-
tions between CHD mortality and total fat intake in 1970, then
in 1986 between CHD mortality and saturated fat intake (Keys
1986, Thorogood 1996). A migrant study of Japanese men con-
firmed in 1974 that men in California had the diet richest in sat-
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urated fat and cholesterol, and the highest CHD rates, those in
Hawaii had intermediate diet and CHD rates, and those in Japan
had a diet lowest in saturated fat and cholesterol, and the least
CHD (Kagan 1974, Robertson 1977). However, recent system-
atic reviews of the observational data have not confirmed these
early studies. Skeaff 2009 included 28 US and European cohorts
(including 6600 coronary heart disease deaths among 280,000
participants) investigating the effects of total, saturated, monoun-
saturated, trans and omega-3 fats on coronary heart disease deaths
and events. They found no clear relationship between total, sat-
urated or monounsaturated fat intake and coronary heart disease
events or deaths. There was evidence that trans fats increased both
coronary heart disease events and deaths, and that total polyun-
saturated fats and omega-3 fats decreased them. Siri-Tarino 2010
included 21 prospective epidemiologic studies assessing the rela-
tionship between saturated fats and coronary heart disease, stroke
and cardiovascular disease, finding that saturated fat intake was
not associated with risk of coronary heart disease, stroke or cardio-
vascular disease. Observational studies are potentially powerful at
providing associations between dietary factors and cardiovascular
risk, but the scale of measurement error is such that detecting such
effects may be difficult. Thus intervention studies are needed to
clarify cause and effect, to ensure that confounding is not either
hiding or generating true relationships. Trials also directly address
the issue of whether altering dietary fat in adults is helpful in re-
ducing the risk of cardiovascular diseases in the general population
and in those at high risk. It is essential that intervention trials form
the basis of evidence based practice in this area.
Most intervention studies have assessed the effect of dietary inter-
ventions on risk factors for heart disease, and separate work ties the
effect of altering these risk factors to changes in disease incidence
and mortality. Systematic review in this area follows the same pat-
tern, so that there are systematic reviews of the effect of dietary
fat advice on serum lipid levels (Brunner 1997; Brunner 2009;
Clarke 1997; Denke 1995; Kodama 2009; Mensink 1992; Shafiq
2010; Weggemans 2001; Yu-Poth 1999) suggesting that dietary
changes cause changes in serum lipids and reviews on the effect
of lipid level alterations on cardiovascular morbidity and mortal-
ity (Briel 2009; De Caterina 2010; Law 1994; Robinson 2009;
Rubins 1995; Walsh 1995), suggesting that changes in lipids do
affect cardiovascular risk. Other risk factors dealt with in a simi-
lar way are blood pressure (Bucher 1996; Law 1991; Shah 2007),
body weight or fatness (Astrup 2000;Hession 2009; SIGN 1996),
angiographic measurements (Marchioli 1994), antioxidant intake
(Ness 1997), metabolic profile (Kodama 2009) and alcohol intake
(Rimm 1996).
A problem with this two-level approach is that any single dietary
alteration may have effects over a wide range of risk factors for
cardiovascular disease. An example of this is the choice of sub-
stitution of saturated fats by carbohydrate, polyunsaturated fats
or monounsaturated fats in the diet. This choice may alter lipid
profile, and may also affect blood pressure, body weight, oxidative
state, rate of cholesterol efflux from fibroblasts, insulin resistance,
post-prandial triacylglycerol response, blood clotting factors, and
platelet aggregation.Theremay also be further risk factors ofwhich
we are not yet aware. Evidence of beneficial effect on one risk
factor does not rule out an opposite effect on another unstudied
risk factor, and therefore an overall null (or harmful) effect of in-
tervention. While understanding the effects of dietary advice on
intermediate risk factors helps to ensure diets are truly altered by
advice, and illuminates mechanisms, the best way of combining
the effects on all of these risk factors is to not study risk factors,
but to study the effects of dietary change on important outcomes,
on cardiovascular morbidity and mortality, and on total mortality.
Substantial randomised controlled trial data on the effects of di-
etary fat on mortality and morbidity does exist - the first ver-
sion of this systematic review included over 18,000 participants
in trials of at least six months duration, reporting on over 1400
deaths, over 800 cardiovascular deaths, and over 1200 cardiovas-
cular events (Hooper 2000, Hooper 2001). The review found no
clear relationship between fat modification (reduction of saturated
fats, including studies that replaced the missing calories with car-
bohydrates - low fat diets - and studies that replaced the missing
calories with other fats - modified fat diets) and total or cardiovas-
cular mortality, but did find that such modification reduced the
rate of cardiovascular events by around 16% (rate ratio 0.84, 95%
CI 0.72 to 0.99 compared with usual diet). Since 2000 several
important new studies have been published. These include some
very large studies that have modified dietary fat intake in women
over several years (including the Women’s Health Initiative that
included over 2000 women with, and over 48,000 women with-
out, cardiovascular disease at baseline for over eight years (WHI
with CVD 2006; WHI without CVD 2006) and the Women’s
Healthy Eating and Living Study including over 3000 women for
11 years (WHEL 2007)) allowing us to add a substantial body of
new research on low fat diets (many of the large studies included
in the first version of the review were of modified fat diets rather
than reduced fat diets), as well as information on the effects of
these changes in women (as previous large studies were mainly in
men). The results of WHI in particular have raised many ques-
tions about both the effects of fat on health and on how we best
conduct research to understand the relationship (Michels 2009;
Prentice 2007; Stein 2006; Yngve 2006).
Public health dietary advice on prevention of cardiovascular dis-
ease has changed a little over time, with a focus on fat modification
during the 1960s and fat reduction during the 1990s. Recent rec-
ommendations by the American Heart Association suggest that,
among other dietary measures, Americans should “limit intake of
saturated fat to 7% of energy, trans fat to 1% of energy, and choles-
terol to 300 mg/day by choosing lean meats and vegetable alterna-
tives, fat-free (skim) or low-fat (1% fat) dairy products and mini-
mize intake of partially hydrogenated fats” (Lichtenstein 2006).
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Howeffective are these alterations in dietary fat at reducing cardio-
vascular morbidity and mortality? Should we replace the energy
from saturated and trans fats with carbohydrates, polyunsaturated
or monounsaturated fats?
This systematic review aimed to assess the effects of reducing or
modifying dietary fat on mortality, cardiovascular mortality and
cardiovascular events, as well as on individual cardiovascular out-
comes and total cancers, and cardiovascular risk factors. Addition-
ally we used the whole database of studies to use meta-regression
to explore effects of changes in total, saturated, polyunsaturated,
monounsaturated, trans, weight and study duration on the pri-
mary outcomes. Finally we included studies that directly compare
reduced with modified dietary fats.
O B J E C T I V E S
The aim of this systematic review was to assess the effect of change
in dietary fats, which would be expected to result in lipid lower-
ing, on mortality and cardiovascular morbidity, using all available
randomised clinical trials. For this update interventions were clas-
sified as low fat, modified fat or combined low and modified fat
diets and effects of each type of dietary intervention were assessed.
Specific questions included:
1. Does reducing saturated fat intake, by reducing and/or
modifying dietary fat, in the longer term (at least six months)
reduce mortality, cardiovascular mortality or cardiovascular
morbidity (or individual health events such as myocardial
infarction, stroke, diabetes or cancer)?
2. Does a long term reduced fat diet, compared with usual
diet, reduce mortality, cardiovascular mortality or cardiovascular
morbidity (or individual health events such as myocardial
infarction, stroke, diabetes or cancer)?
3. Does a long term reduced fat diet alter classic cardiovascular
risk factors (weight, body mass index, systolic or diastolic blood
pressure, serum total, LDL or HDL cholesterol and triglyceride)?
4. Does a long term modified fat diet, compared with usual
diet, reduce mortality, cardiovascular mortality or cardiovascular
morbidity (or individual health events such as myocardial
infarction, stroke, diabetes or cancer)?
5. Does a long term modified fat diet alter classic
cardiovascular risk factors (weight, body mass index, systolic or
diastolic blood pressure, serum total, LDL or HDL cholesterol
and triglyceride)?
6. Does reducing and modifying dietary fat (as a combined
intervention) in the longer term reduce mortality, cardiovascular
mortality or cardiovascular morbidity (or individual health
events such as myocardial infarction, stroke, diabetes or cancer)?
7. Does a long term reduced and modified fat diet (as a
combined intervention) alter classic cardiovascular risk factors
(weight, body mass index, systolic or diastolic blood pressure,
serum total, LDL or HDL cholesterol and triglyceride)?
8. Are effects on mortality, cardiovascular mortality or
cardiovascular morbidity moderated by differences in baseline
cardiovascular risk, mode of intervention, control group total fat
intake, control group saturated fat intake, gender, setting or
decade of publication, or changes in total fat intake, saturated fat
intake, polyunsaturated fat intake, monounsaturated fat intake,
trans fat intake, dietary cholesterol, weight, serum LDL
cholesterol, or study duration?
9. Is a long term reduced fat diet or a modified fat diet more
effective in reducing mortality, cardiovascular mortality or
cardiovascular morbidity (or individual effects such as
myocardial infarction, stroke or cancer diagnoses)?
10. Is a long term reduced fat diet or a modified fat diet more
acceptable to people trying to adhere to these diets?
11. Is a long term reduced fat diet or a modified fat diet more
effective in altering classic cardiovascular risk factors (weight,
body mass index, systolic or diastolic blood pressure, serum total,
LDL or HDL cholesterol and triglyceride)?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials only. Randomization of individuals
was accepted, or of larger groups where there were at least six of
these groups randomized. Studies where allocation was not truly
randomised (e.g. divisions based on days of the week or first letter
of the family name were excluded) or where allocation was not
stated as randomised (and no further information was available
from the authors) were excluded.
Types of participants
Studies of adults (18 years or older, no upper age limit) at any risk
of cardiovascular disease (with or without existing cardiovascular
disease) were accepted. Participants could be of either gender, but
those who were acutely ill, pregnant or lactating were excluded.
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Types of interventions
All randomised controlled trials of interventions stating an inten-
tion to reduce or modify dietary fat or cholesterol, such as would
be expected to result in improvement of serum lipid profile, were
considered. These included an intention to reduce total fat intake,
modify fat intake (while maintaining total fat intake), and reduc-
tion and modification of fat intake, all compared to a usual diet
type control or modification of dietary fat compared to reduced
total fat. The intervention had to be dietary advice, supplementa-
tion (of fats, oils or modified or low fat foods) or a provided diet,
and the control group usual diet, placebo or a control diet.
A low fat diet was considered to be one that aimed to reduce fat
intake to < 30%E from fat, and at least partially replace the energy
lost with carbohydrates (simple or complex), protein or fruit and
vegetables. Amodified fat diet was considered to be one that aimed
to include 30%ormore energy from total fats, and included higher
levels of mono-unsaturated or poly-unsaturated fats than a ’usual’
diet.
Interventions excluded (unless they were present in addition to
those above) were addition of alpha-linolenic acid, omega-3 fats
or fish oils (as the effect of these is dealt with in a separate review),
high fibre diets and garlic (as pulses, fruits and vegetables may have
various effects other than lipid lowering) or exploration of varying
forms of carbohydrate (unless also specifically low in fat or fat
modified). Also excludedwere all multiple risk factor interventions
other than diet or supplementation (unless the effects of diet or
supplementation could be separated, as in a factorial design, so
the additional intervention was consistent or randomised between
the intervention and control groups), and studies that aimed for
weight loss in one arm but not the other. Atkins-type diet aiming
to increase protein and fat intake were excluded, as were studies
where fat was reduced by means of a fat-substitute (like Olestra).
Enteral and parenteral feeds were excluded, as were formulaweight
reducing diets.
Examples: studies that reduced or modified fats and encouraged
physical activity in one arm and compared with encouraging phys-
ical activity in the control were included; studies that reduced or
modified fats and encouraged physical activity in one arm and
compared with no intervention in the control were excluded; stud-
ies that reduced or modified fats and encouraged fruit and vegeta-
bles in one arm and compared with no intervention in the control
were included.
Types of outcome measures
Primary outcomes:
The main outcomes were total and cardiovascular mortality and
combined cardiovascular events. Combined cardiovascular events
included any of the following data available from a trial: car-
diovascular deaths, cardiovascular morbidity (non-fatal myocar-
dial infarction, angina, stroke, heart failure, peripheral vascular
events, atrial fibrillation) and unplanned cardiovascular interven-
tions (coronary artery bypass surgery or angioplasty).
Secondary outcomes:
Secondary outcomes included individual types of cardiovascular
events, including total myocardial infarction, non-fatal myocardial
infarction, stroke (fatal and non-fatal), diabetes diagnosis, cancer
deaths and cancer diagnoses, and quality of life measures (includ-
ing informal outcomes such as feelings of health, time off work).
Tertiary outcomes:
Tertiary outcomes were process outcomes, and included changes
in saturated and total fat intakes, and classic cardiovascular risk
factors (weight, body mass index, systolic or diastolic blood pres-
sure, serum total, LDL or HDL cholesterol and triglyceride).
Trials were only included where primary outcome data (mortality
or cardiovascular morbidity) could be collected (by communica-
tion with authors if necessary). Studies where it was known that
no events occurred were included, and their data used to assess
tertiary outcomes.
Search methods for identification of studies
Electronic searches
The initial searches were run in March to June 1998 and in-
cluded The Cochrane Library, MEDLINE, EMBASE, CAB Ab-
stracts, CVRCT Registry, SIGLE, bibliographies and experts. A
comprehensive search strategy was developed to search for nutri-
tion based randomised controlled trials with morbidity or mortal-
ity outcomes.
MEDLINE on SilverPlatter was searched for randomised con-
trolled trials on diet and cardiovascular disease or mortality from
1966 to May 1998. An additional MEDLINE (SilverPlatter 1966
to June 1998) search strategy was run to collect papers where only
lipid outcomes were mentioned (see Appendix 1 for details of
both searches). These search strategies were adapted for use onThe
Cochrane Library (Issue 2, 1998), EMBASE (Ovid online to May
1998), the CVRCT Registry (May 1998), CAB Abstracts (Ovid
online, 1973 toMarch 1998) and SIGLE (to January 1999). Pub-
lished systematic reviews addressing diet and heart health were
sought as a source of RCTs using similar strategies on MEDLINE
(Silver Platter, 1966-March 1998) and The Cochrane Library (Is-
sue 1, 1998).
Cochrane Review Groups in areas related to this review include
the Diabetes Group (now the Endocrine and Metabolic Disorders
Group), Stroke Group, Renal Group, Hypertension Group and
Peripheral Vascular Disease Group. The groups were contacted
and asked to search their trial registers for relevant trials.
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The review authors updated the searches in June 2010, and modi-
fied searches were run on Cochrane Central Register of Controlled
Trials (CENTRAL on The Cochrane Library), Ovid MEDLINE
and EMBASE. Modification was due to altered database accessi-
bility as well as altered recommended RCT filters. The searches for
the earlier review were run as a wider search for studies for several
reviews (including a variety of dietary factors), the recent searches
were focused on dietary fat interventions only. As databases other
than these three had not provided any included studies during the
first version of the review, and the numbers of titles and abstracts
were not feasible to handle for the update, these were the only
databases used for this update. The search strategies used for the
update search are shown in Appendix 2.
No language restrictions were applied to the searches.
Searching other resources
Bibliographies of all identified systematic reviews, major non-sys-
tematic reviews and included trials were searched for further tri-
als for the first review and the update. Experts in the field were
contacted for references to studies not yet identified by the search
process. Attempts were made to obtain translations of relevant
non-English articles, or contact with the author was established to
enable assessment of eligibility.
Data collection and analysis
Selection of studies
Articles were only rejected on initial screen if the reviewer could
determine from the title and abstract that the article was not a
report of a randomized controlled trial; the trial did not address a
low or modified fat diet; the trial was exclusively in children less
than 18 years old, pregnant women or the critically ill; the trial
was of less than 6 months duration; or the intervention was multi-
factorial.When a title/abstract could not be rejectedwith certainty,
the full text of the article was obtained for further evaluation.
The inclusion of studies was assessed independently by two as-
sessors (LH and one of RLT, DS, FR, HM, Indra Tumur and
Dorotheé Fagard) and differences between reviewers’ results re-
solved by discussion and, when necessary, in consultation with
a third reviewer (Rudolph Reimersma, see acknowledgements).
Trials were categorised as “possible” (where all inclusion criteria
appeared to be met or where the ascertainment, or otherwise, of
outcome events was uncertain, to be resolved by writing to the au-
thor) or “excluded”. Attempts were made to contact all authors of
“possible” trials in order to confirm or ascertain whether inclusion
criteria were met.
Data extraction and management
A data extraction formwas designed for this review. Data concern-
ing participants, interventions and outcomes, trial quality charac-
teristics (Chalmers 1990), data on potential effect modifiers in-
cludingparticipants baseline risk of cardiovascular disease, trial du-
ration, intensity of intervention (dietary advice, diet provided, di-
etary advice plus supplementation, supplementation alone), med-
ications used (particularly lipid lowering medication) and smok-
ing status, numbers of events and total patient years in trial were
extracted. Where provided, data on risk factors for cardiovascular
disease including blood pressure, lipids and weight were collected.
Baseline risk of cardiovascular disease was defined as follows: high
risk are participants with existing vascular disease including a his-
tory of myocardial infarction, stroke, peripheral vascular disease,
angina, heart failure or previous coronary artery bypass grafting
or angioplasty; moderate risk are participants with a familial risk,
dyslipidaemia, diabetes mellitus, hypertension, chronic renal fail-
ure; low risk are other participants or mixed population groups.
Original reports of trial results were independently extracted by
two reviewers (LH and one of CDS, RLT, DS, FR, HM, Indra
Tumur, Dorotheé Fagard, Rudolph Reimersma), differences were
resolved by discussion.
Assessment of risk of bias in included studies
Trial quality characteristics were assessed using the Cochane Col-
laboration’s tool for assessment of risk of bias; studies already in-
cluded were re-assessed using this tool (Higgins 2011). All valid-
ity data were extracted by two reviewers independently (LH and
one of CDS, RLT, DS, FR, HM, Indra Tumur, Dorotheé Fagard,
Rudolph Reimersma), and differences resolved by discussion.
Measures of treatment effect
Primary measures of interest were the effect of intervention on:
1. total and cardiovascular mortality
2. combined cardiovascular events (including cardiovascular
deaths, non-fatal myocardial infarction, stroke, angina, heart fail-
ure, peripheral vascular disease, angioplasty and coronary artery
bypass grafting)
3. quality of life measures.
Unit of analysis issues
We did not include any cluster randomised trials in this review,
and cross-over studies (such as the Finnish Mental Hospital study,
Finnish Mental Hosp 1972) were excluded as this design would
be inappropriate for assessing effects on cardiovascular events or
mortality.
Where there wasmore than one relevant intervention armbut only
one control arm the relevant intervention arms were either pooled
to create a single pair-wise comparison (where the intervention
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arms were equivalently appropriate for this review) as described
in the Cochrane Handbook (Higgins 2011). Intervention arms
that were not appropriate for this review, or less appropriate than
another arm, were excluded. When two arms were appropriate for
different subgroups then the control group was used once with
each intervention arm, but the subgroups were not pooled overall.
When assessing event data we aimed to avoid counting more than
one outcome event for any one individual within any one compar-
ison. Where we were unclear (for example, where a paper reported
numbers of heart attacks, but did not report the number of people
who experienced a heart attack, in each arm) we asked authors for
further information.
Dealing with missing data
As the outcomes of our review were often not the planned out-
comes of relevant trials (many studies with relevant methods, par-
ticipants, intervention, control and duration had other primary
and secondary outcomes, so mortality and morbidity were re-
ported inmany studies only as reasons for dropout, or not reported
at all), we tried to contact the authors of all identified studies that
were appropriate for inclusion on the basis of participants, inter-
vention, comparison andmethodology, to ask about mortality and
morbidity, the review’s primary and secondary outcomes. This al-
lowed inclusion of many studies that would otherwise have had
to be omitted. Studies which were otherwise relevant but where
presence or absence of primary outcomes could not be established
were retained in the section of studies awaiting classification.
It was often unclear where data on primary or secondary outcome
events may still have been missing, and so data were not imputed
for this review.
Assessment of heterogeneity
Heterogeneity was examined using the I2 test, and considered
important where > 50% (Higgins 2003; Higgins 2011).
Assessment of reporting biases
Funnel plots were drawn to examine the possibility of small study
bias, including publication bias (Egger 1997), for the primary
outcomes total mortality and combined cardiovascular events.
Data synthesis
The data within the original review were in the form of rates.
Treatment effect was measured as a rate ratio and meta-analysis
performed as a weighted average of (ln) rate ratios (as described
by Hasselblad 1995). For trials with a zero in one arm of the
data a small number (0.5) was added to the number of events
in both groups.Meta-analysis was performed using random ef-
fects methodology (DerSimonian 1986) within S-PLUS (Higgins
1999). For the update of the review we checked that using event
data gave similar results to rate data as described above - using
the same studies the outcomes of the meta-analysis using Man-
tel-Haenszel random effects methods were almost identical (pres-
ence or absence of statistical significance was never different, and
scale of effect size was always similar). For this reason, within the
update, numbers of events in each study arm, and total number
of participants randomised, were extracted, and Mantel-Haenszel
random effects meta-analysis carried out in Review Manager soft-
ware. Event and continuous outcome data were extracted for the
latest time point available within the trial (and always at least six
months from inception).
Trials where it was known that there were no events in either in-
tervention group were included in the review for completeness,
but were not included in the meta-analysis (where it was stated
that no events of particular type occurred this was detailed in
Characteristics of included studies). These studies inclusion or
otherwise would not influence the results of the review. Where
trials ran one control group and more than one included interven-
tion group, data from the intervention group providing the com-
parison that best assessed the effect of altering dietary fat was used.
Where the intervention groups appeared equal in this respect the
intervention groups were merged (simply added for dichotomous
data, and using the techniques described in the Higgins 2011 for
continuous data). It was planned that if trials randomized by clus-
ter were identified the patient numbers would be reduced to an “ef-
fective sample size” (as described by Hauck 1991), however none
were identified that were both included and had cardiovascular
events or deaths.
Subgroup analysis and investigation of heterogeneity
For this update dietary interventions were classified as low fat,
modified fat or combined low andmodified fat diets. Pre-specified
analyses included:
Effects of low, modified, and combined low and modified fat diets
compared with usual or standard diet on the following outcomes:
• total mortality
• cardiovascular mortality
• combined cardiovascular events
Pre-specified subgroups for primary outcomes included:
• mean follow-up time of up to and including, or over, 2 years
• initial level of cardiovascular risk (low, medium, high)
• mode of intervention (advice, supplementation or provision
of diet).
Further subgroups, added into the updating of the systematic re-
view, included:
• control group total fat intake,
• control group saturated fat intake,
• year of first publication of results
• gender, and
• setting (workplace, community, outpatient), at the request
of the Cochrane Occupational Health Field.
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We explored the effects of different levels of dietary fats achieved in
trials (all difference between the intervention and control groups,
as a percentage of energy) using meta-regression on total mortality,
cardiovascular mortality and total cardiovascular events by:
• total fat intake
• saturated fat intake
• monounsaturated fat intake
• polyunsaturated fat intake
• trans fat intake
• body weight
• LDL cholesterol
The effects of low fat, modified fat and low and modified fat diets
(all compared with control or usual diet), and low fat vs modified
fat diets on secondary and tertiary outcomes were assessed.
Random effectsmeta-regression (Berkley 1995)was performed us-
ing the STATA command metareg (Sharp 1998, Sterne, Bradburn
and Egger 2001, Sterne 2009).
Sensitivity analysis
Sensitivity analyses were carried out for primary outcomes, sub-
grouping by type of dietary fat intervention (reduced fat, modified
fat or both) assessing the effect of
• running Mantel-Haenszel fixed effects relative risk meta-
analyses (rather than random effects), as events could be
considered to be rare (percentages of participants experiencing
events was 6% for mortality, 2% for cardiovascular mortality and
7% for cardiovascular events) (Higgins 2011),
• running Peto fixed effects odds ratio meta-analysis, which
may be more useful than Mantel-Haenszel when events are rare
but works better when studies have similar numbers of
participants in each arm (not the case with several included
studies such as WHI)
• excluding the largest study (WHI with CVD 2006, WHI
without CVD 2006),
• excluding studies which were not free of systematic
difference in care (or unclear)
• excluding studies that were not free of dietary differences
other than fat (or unclear).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
The initial search strategy resulted in 16,821 potential titles and
abstracts, which were scanned for relevant studies. The 2010 up-
date search found an additional 5,191 titles and abstracts to assess
for inclusion, making 22,012 titles and abstracts screened in total.
Two hundred and seventy six papers were collected as full text in
the first review, and a further 254 were collected in the review
update, and all 530 were assessed for inclusion in duplicate. The
papers were then amalgamated into studies. Of these a total of 48
randomised controlled trials were included in the review. For all
included studies we searched for additional publications to ensure
that we did not miss any relevant methodology or outcome data
from that dataset. This full set of published papers (along with any
additional information provided by authors) was data extracted
(along with assessment of validity) in duplicate for each included
trial. A further 15 studies (17 papers) were allocated to Studies
awaiting classification as it could not be established whether they
had collected data on mortality or morbidity, the outcomes of this
review (Characteristics of studies awaiting classification).
Included studies
Forty eight studies were included in the review (Included stud-
ies) and were described in Characteristics of included studies.
Some included studies included several comparison arms (e.g.
the Kuopio study includes four comparisons: Sarkkinen Fat Mod
1995; Sarkkinen Red & Mod 1995; Sarkkinen Red Fat 1995;
Sarkkinen Red vs Mod1995 and the Monounsaturated fat Obe-
sity study includes three comparisons: Due Low fat 2008; Due
Mod fat 2008; Due Low vs Mod 2008); and some studies were re-
ported in several sections for ease of analysing subgroup data (e.g.
the Minnesota Coronary Study was reported separately for men
(Minnesota Coron men 1989) and women (Minnesota Coron
women1989); the National Diet-Heart Study was reported in its
various sub-studies (NDHS Faribault 1968; NDHS Open 1st
L&M 1968; NDHS Open 1st mod 1968, NDHS Open 2nd
L&M 1968, NDHS Open 2nd Mod 1968); and the Women’s
Health Initiative was reported by cardiovascular risk (WHI with
CVD 2006, WHI without CVD 2006). In total there were 60
comparisons included in the review.
The main study papers ranged in publication date from 1965 to
2009, and the comparisons were conducted in North America
(30), Europe (26), Australia/ New Zealand (3) and the Middle
East (1). Ten of the comparisons included only people at high risk
of cardiovascular disease, 17 at moderate risk, and 33 at low risk.
Sixteen comparisons included only men, 14 only women, and 30
both men and women.
Dietary interventions varied from trials which provided dietary
advice (in varying degrees of intensity and duration, 35 studies),
provided advice plus some dietary supplementation (such as oils
or margarines, nine studies), to studies that provided most food
eaten by participants (via institutional provision, meals provided
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for those living independently or study shops, 16 studies). The set-
ting for most studies was the community (in that participants were
living in the community - the actual setting for provision of advice,
group work etc was usually unclear, although interventional advice
was occasionally clearly in a home or community setting, and oc-
casionally in a primary or secondary healthcare setting), but three
studies took place in institutions (Minnesota Coron men 1989;
Minnesota Coron women1989; NDHS Faribault 1968; Veterans
Admin 1969), and no studies appeared to have been carried out
in occupational settings.
Twenty five comparisons, including 61,958 participants and first
published between 1965 and 2007, compared a reduced fat diet
with usual or control diet (Ley 2004; BDIT Pilot Studies 1996;
BRIDGES 2001; CARMEN 2000; CARMEN MS sub-study
2002; DO IT 2006; Seppelt 1996; Lean 1997; Anderson 1990;
Sarkkinen Red Fat 1995; Ball 1965; Boyd 1988; Moy 2001;
MSFAT 1997; Due Low fat 2008; Nutrition & Breast Health;
Ole Study 2002; Polyp Prevention 1996; Simon 1997;McKeown-
Eyssen 1994; Black 1994; WHEL 2007; WHI with CVD 2006;
WHI without CVD 2006; WINS 2006).
Fifteen comparisons, including 13,004 participants and published
between 1965 and 2007, compared a modified fat diet with con-
trol or usual diet (Frenkiel 1986, Houtsmuller 1979, Sarkkinen
Fat Mod 1995, Dullaart 1992, Rose 1965, Minnesota Coron men
1989, Minnesota Coron women1989, MRC 1968, Due Mod
fat 2008, NDHS Faribault 1968, NDHS Open 1st mod 1968,
NDHS Open 2nd Mod 1968, Oslo Diet-Heart 1966, Sydney
Diet-Heart 1978, Veterans Admin 1969). Ten interventions, in-
cluding 4,931 participants and published between 1968 and 2006,
compared a reduced andmodified fat dietwith usual or control diet
(beFIT 1997; DART 1989; Sarkkinen Red &Mod 1995;MeDiet
2002; NDHS Open 1st L&M 1968; NDHS Open 2nd L&M
1968; Oxford Retinopathy 1978; PREMIER 2003; Sondergaard
2003; STARS 1992). Nine interventions, including 1,290 partic-
ipants and published between 1994 and 2009, compared a low fat
diet with a modified fat diet (Sarkkinen Red vs Mod1995; Due
Low vs Mod 2008; McAuley 2005; Rivellese 1994; Azadbakht
2007; THIS DIET 2008; Sacks high protein 2009; Sacks low
protein 2009; Strychar 2009).One intervention (144participants)
was not classifiable (Curzio 1989).
Of these comparisons 12 stated that an intended outcome was to
assess mortality or cardiovascular morbidity of some sort (DART
1989; DO IT 2006; Rose 1965; Ball 1965; Minnesota Coron
men 1989; Minnesota Coron women1989; MRC 1968; Oslo
Diet-Heart 1966; Sydney Diet-Heart 1978; THIS DIET 2008;
Veterans Admin 1969; WHEL 2007). A further 36 intended to
monitor lipids, blood pressure, weight or other cardiovascular risk
factor outcomes, seven aimed to assess effects on cancers or can-
cer related outcomes such as polyps, two the feasibility of dietary
intake, and the remaining three studies aimed to assess bile acid
kinetics or diabetic retinopathy. Of the 48 included studies, nine
recruited participants with cardiovascular disease (were secondary
prevention studies), 12 recruited those at increased risk of CVD
(including those recruited on the basis of raised lipids, blood pres-
sure or weight), and 25 recruited people from the general popu-
lation or without specific CVD risk (primary prevention). A fur-
ther two studies recruited a mix of participants (at high and lower
CVD risk).
Of the 51 comparisons of a modified and/or low fat diet with
a control or usual diet, four measured the total fat intake in the
control arm as less than 30%of energy (30%E), 18 30% - 34.9%E,
19 35% - 39.9%E, six had a control arm with at least 40%E, and it
was unclear what the total fat intake in the control arm was in the
remaining four comparisons. Three of the included comparisons
had a saturated fat intake in the control group of less than 10%
of energy (10%E), 19 10% - 14.9%E, 14 15% - 19.9%E and
one comparison 20+%E, while saturated fat intake in the control
group was unclear in a further 14 comparisons.
Of the 60 intervention arms only 21 provided data on mortality
(including 71,790 participants and 4292 deaths), 16 on cardio-
vascular mortality (65,978 participants and 1407 cardiovascular
deaths), and 23 on combined cardiovascular events (65,508 par-
ticipants and 4887 events). In 25 of the included arms none of the
participants experienced any deaths or cardiovascular events, and
in three further studies it was clear that events had occurred, but
it was not clear in which arm(s) the events had occurred (BDIT
Pilot Studies 1996; Oxford Retinopathy 1978; Simon 1997), so
that data could not be included in the meta-analyses.
Excluded studies
Two hundred and eighty eight trials have been excluded (Excluded
studies, the full texts assessed in duplicate for inclusion), and the
reasons for these exclusions were described in Characteristics of
excluded studies.
One more trial was ongoing (Ongoing studies) and described in
Characteristics of ongoing studies.
Risk of bias in included studies
To understand the risk of bias in the individual included studies
in a visual way, see Figure 1, and the summary of studies included
in the review, see Figure 2.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
All trials included were randomised controlled trials, those with
detected pseudo random allocation (for example where partici-
pants are randomised according to birth date or alphabetically
from their name) were excluded. Allocation concealment was
judged well done in 26 comparisons (Ley 2004; BRIDGES 2001;
CARMEN 2000; CARMENMS sub-study 2002; Dullaart 1992;
MSFAT 1997; NDHS Faribault 1968; NDHS Open 1st L&M
1968; NDHS Open 1st mod 1968; NDHS Open 2nd L&M
1968; NDHS Open 2nd Mod 1968; Nutrition & Breast Health;
Ole Study 2002; Oslo Diet-Heart 1966; Oxford Retinopathy
1978; Polyp Prevention 1996; PREMIER 2003; Sacks low protein
2009; Sacks high protein 2009; STARS 1992; THIS DIET
2008; McKeown-Eyssen 1994; WHEL 2007; WHI with CVD
2006; WHI without CVD 2006; WINS 2006), not done in one
(Sondergaard 2003) and unclear in the remainder.
Blinding
Blinding of participants is not easy in dietary studies, as the par-
ticipants usually have to follow instructions to attain the specific
dietary goals. However, it is feasible in some circumstances, in-
cluding when food is provided via an institutional setting, or meals
provided at a central setting and remaining meals packed to take
away, through use of a trial shop, where very specific food-based
dietary advice is provided for all participants, or where the same
dietary advice is provided to both groups but a different supple-
ment (e.g. dietary advice to reduce fats, then provision of differ-
ent oils or fats) is provided. Where participants are not blinded
it is difficult to ensure that study staff, health care providers and
outcome assessors are blinded. The 11 comparisons that appear to
have had adequate participant and study personnel blinding were
Minnesota Coron men 1989, Minnesota Coron women1989,
NDHS Faribault 1968, NDHS Open 1st L&M 1968, NDHS
Open 1st mod 1968, half the participants in NDHS Open 2nd
L&M1968, half the participants inNDHSOpen 2ndMod 1968,
Sacks low protein 2009, Sacks high protein 2009, the Ole Study
2002 and Veterans Admin 1969), and blinding was inadequate or
unclear in the remaining studies.
Incomplete outcome data
Assessing whether incomplete outcome data have been addressed
was difficult as the primary outcomes for this review were often
seen as dropouts and exclusions from the original studies. When
mortality and/or cardiovascular events were noted in any one study
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it is still feasible that some participants left that study feeling un-
well or because the diet was inconvenient (so were simply lost
to follow up from the perspective of the study) and later died or
experienced a cardiovascular event. However, in some cases stud-
ies checked medical records or death registers to ensure that such
events were all collected (these 10 studies included DART 1989,
NDHS Faribault 1968, Oslo Diet-Heart 1966, PREMIER 2003,
Sydney Diet-Heart 1978, THIS DIET 2008, Veterans Admin
1969, Black 1994, WHEL 2007, WINS 2006). In the other stud-
ies it is not possible to know whether additional deaths or car-
diovascular events occurred, that were not counted or ascertained
within this review.
Selective reporting
Assessment of selective reporting is difficult when the outcome of
interest is simply a cause of dropouts in most included studies. We
tried to contact all of the trialists to ask about deaths and outcome
events, but it is possible that some trialists did not reply as they felt
that their data did not reflect the expected or hoped for pattern
of events. All of the included studies have either reported that
the participants did not experience any of our primary outcomes,
published their outcome data or have provided the data they did
possess. For this reason all the included studies have been graded
as ’Free of selective reporting’.
Other potential sources of bias
The studies were assessed for risk of bias in relation to ’system-
atic difference in care’ and ’dietary differences other than fat’. The
29 comparisons free of systematic differences in care between the
study arms included CARMEN 2000, CARMEN MS sub-study
2002, Frenkiel 1986, Seppelt 1996, Lean 1997, Sarkkinen Fat
Mod 1995, Sarkkinen Red Fat 1995, Sarkkinen Red & Mod
1995, Sarkkinen Red vs Mod1995 Rose 1965, Minnesota Coron
men 1989, Minnesota Coron women1989, MSFAT 1997, Due
Low fat 2008, NDHS Faribault 1968, NDHS Open 1st L&M
1968, NDHS Open 1st mod 1968, NDHS Open 2nd L&M
1968, NDHS Open 2nd Mod 1968, Ole Study 2002, Oxford
Retinopathy 1978, PREMIER 2003, Rivellese 1994, Sacks low
protein 2009, Sacks high protein 2009, Strychar 2009, Azadbakht
2007, THIS DIET 2008, Veterans Admin 1969), while 27 com-
parisons clearly did have differences in care (such as differential
time provided for those on the intervention to learn a new diet,
and/or differential medical follow-up), and four were unclear.
Some comparisons were partially confounded by dietary changes
other than those directly related to dietary fat intakes (for exam-
ple, some studies encouraged intervention participants to make
changes to their fat intake as well as changes to fruit and veg-
etable or fibre or salt intakes). The 39 comparisons that appeared
free of such differences included Ley 2004, BDIT Pilot Studies
1996, beFIT 1997, CARMEN 2000, CARMEN MS sub-study
2002, DART 1989, Houtsmuller 1979, Seppelt 1996, Lean 1997,
Anderson 1990, Sarkkinen Fat Mod 1995, Sarkkinen Red Fat
1995, Sarkkinen Red & Mod 1995, Sarkkinen Red vs Mod1995,
Dullaart 1992, Rose 1965, Ball 1965, Boyd 1988, Minnesota
Coron men 1989, Minnesota Coron women1989, MRC 1968,
MSFAT 1997, NDHS Faribault 1968, NDHS Open 1st L&M
1968, NDHS Open 1st mod 1968, NDHS Open 2nd L&M
1968, NDHS Open 2nd Mod 1968, Nutrition & Breast Health,
Oxford Retinopathy 1978, Sacks low protein 2009, Sacks high
protein 2009, Simon 1997, Strychar 2009, Sydney Diet-Heart
1978, Azadbakht 2007, THISDIET 2008, Veterans Admin 1969,
Black 1994, WINS 2006. A further three comparisons were un-
clear, and the remainder, 18 comparisons, were confounded as to
the effects of changes in fat.
Effects of interventions
Reduced, modified or reduced and modified dietary
fat vs. usual or control diet
Primary outcomes
Total mortality
There was no clear effect of any dietary fat intervention compared
to usual or control diet on mortality (RR 0.98, 95% CI 0.93
to 1.04, I2 0%, 71,790 participants, 4292 deaths, peff ect 0.53,
Analysis 1.1). Similarly there was no effect of modified fat vs usual
diet (RR 1.02, 95% CI 0.88 to 1.18, I2 34%, 11,441 participants,
1120deaths, peff ect 0.81), reduced fat vs usual diet (RR0.97, 95%
CI 0.90 to 1.04, I2 0%, 58,130 participants, 2936 deaths, peff ect
0.42), or reduced and modified fat vs usual diet (RR 0.97, 95%
CI 0.76 to 1.23, I2 0%, 2219 participants, 236 deaths, peff ect
0.78).
Sensitivity analyses (using Mantel-Haenszel fixed effects relative
risk meta-analysis, Peto odds ratio (fixed effects), removing the
largest single study (WHI), removing studies with a systematic
difference in care between the intervention and control arms, and
removing studies with dietary differences between arms other than
in dietary fat intake) did not alter the lack of statistically signif-
icant effect overall or for modified fat intake, reduced fat intake
or reduced and modified fat intake compared with usual or con-
trol diet (Table 1). The funnel plot does not suggest severe small
study bias, although there may be some smaller studies missing
suggesting increased total mortality in the intervention group (so
addition of any such studies would further lessen the likelihood
of a protective effect of dietary fat modification or reduction on
mortality). The funnel plot is shown in Figure 3.
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Figure 3. Funnel plot of comparison: fat modification or reduction vs usual diet - total mortality.
Table 1. Sensitivity analyses of primary outcomes
Outcome Sensitivity Analy-
sis








Overall analysis 0.98 (0.93 to 1.04) 21/ 71795 / 4292 0%
Total mortality Mantel-Haenszel,
Fixed effects
Modified fat intake 1.03 (0.92 to 1.14) 8/ 11441/ 1120 34%
Total mortality Mantel-Haenszel,
Fixed effects





0.96 (0.76 to 1.22) 2/ 2224/ 236 0%
Total mortality Peto Odds Ratio
(fixed effects)
Overall analysis OR 0.98 (0.92 to
1.05)
21/ 71795 / 4292 0%
Total mortality Peto Odds Ratio
(fixed effects)
Modified fat intake OR 1.03 (0.91 to
1.18)
8/ 11441/ 1120 39%
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Table 1. Sensitivity analyses of primary outcomes (Continued)
Total mortality Peto Odds Ratio
(fixed effects)
Reduced fat intake OR 0.97 (0.90 to
1.04)
10/ 58130/ 2936 0%




OR 0.96 (0.73 to
1.25)
2/ 2224/ 236 0%
Total mortality Excluding WHI Overall analysis 0.98 (0.91 to 1.07) 20/ 22960/ 1888 0%
Total mortality Excluding WHI Reduced fat intake 0.94 (0.80 to 1.10) 9/ 9295/ 532 0%
Total mortality Excluding studies
with systematic dif-
ference in care
Overall analysis 1.03 (0.92 to 1.16) 6/ 10715/ 882 0%
Total mortality Excluding studies
with systematic dif-
ference in care
Modified fat intake 1.03 (0.92 to 1.16) 5/ 10178/ 881 0%
Total mortality Excluding studies
with systematic dif-
ference in care
Reduced fat intake 0.33 (0.01 to 8.12) 1/ 537/ 1 NR





NR 0/ 0/ 0 NR




Overall analysis 1.03 (0.93 to 1.13) 12/ 16060/ 1320 0%




Modified fat intake 1.05 (0.93 to 1.18) 7/ 11029/ 1005 7%




Reduced fat intake 0.90 (0.60 to 1.34) 4/ 2998/ 89 0%











Overall analysis 0.95 (0.85 to 1.05) 16/ 65983/ 1407 0%
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Overall analysis OR 0.94 (0.84 to
1.05)





Modified fat intake OR 0.91 (0.77 to
1.08)





Reduced fat intake OR 0.96 (0.81 to
1.13)







OR 0.97 (0.73 to
1.29)
3/ 2224/ 212 0%
Cardiovascular
mortality
Excluding WHI 5Overall analysis 0.91 (0.79 to 1.04) 14/ 17148/ 874 7%
Cardiovascular
mortality

































Overall analysis 0.95 (0.80 to 1.13) 9/ 12970/ 748 22%
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Overall analysis OR 0.92 (0.86 to
0.97)





Modified fat intake OR 0.78 (0.67 to
0.91)





Reduced fat intake OR 0.96 (0.90 to
1.03)







OR 0.79 (0.63 to
1.00)
6/ 3193/ 400 60%
Combined cardio-
vascular events
Excluding WHI Overall analysis 0.81 (0.70 to 0.93) 21/ 16673/ 1442 39%
Combined cardio-
vascular events






Overall analysis 0.93 (0.77 to 1.12) 9/ 12158/ 533 12%
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0.91 (0.73 to 1.13) 3/ 2901/ 287 0%
No important effects of reduced and/or modified fat diets com-
pared to usual or control diets onmortality were seen when studies
were subgrouped by duration (mean duration up to two years or
over two years), cardiovascular risk (low, moderate or high cardio-
vascular risk), mode of intervention (dietary advice, advice plus
supplementation or diet provided), total fat in the control group
(less than 30% of energy from fat, 30% - 34.9%E, 35% - 39.9%E
or 40%E and over from fat), saturated fat in the control group (less
than 10% of energy from saturated fat, 10% - 14.9%E or 15% -
19.9%E from saturated fat), by gender (studies of men, of women
and of men and women combined), by setting (community or
residential institution, no studies of workplaces were identified)
or by year of first publication of results (Table 2).
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21, 71790, 4292 0.98 (0.93 to
1.04), 0
16, 65978, 1407 0.94 (0.85 to
1.04), 0





9, 12272, 767 1.05 (0.91 to
1.20), 0
6, 11434, 523 1.04 (0.88 to
1.23), 0





12, 59518, 3525 0.97 (0.91 to
1.03), 0
10, 54544, 884 0.89 (0.78 to
1.01), 0




10, 66776, 3717 0.99 (0.93 to
1.05), 0
6, 59682, 879 0.93 (0.77 to
1.13), 35





3, 1200, 47 0.69 (0.39 to
1.21), 0
2, 663, 23 0.66 (0.28 to
1.53), 0




8, 3814, 528 0.95 (0.78 to
1.17), 24
8, 5633, 505 0.95 (0.80 to
1.12), 0




13, 60320, 3201 0.98 (0.92 to
1.05), 0
9, 54703, 796 0.97 (0.85 to
1.12), 0






4, 1372, 219 0.80 (0.63 to
1.02), 0
4, 1372, 169 0.87 (0.62 to
1.21), 15




4, 10098, 872 1.03 (0.92 to
1.15), 0
3, 9903, 442 0.93 (0.69 to
1.26), 63
7, 11541, 494 0.91 (0.73 to
1.14), 19
Sub-
group ’total fat in
control <30%E’
4, 3592, 81 0.93 (0.61 to
1.43), 0
2, 618, 25 0.76 (0.35 to
1.64), 0
3, 1155, 152 0.82 (0.65 to
1.03), 1
Sub-group ’total
fat in control 30-
34.9%E’
4, 3450, 333 0.91 (0.46 to
1.81), 23
3, 3344, 21 0.72 (0.15 to
3.53), 51
5, 1429, 74 0.93 (0.62 to
1.39), 0
Sub-group ’total
fat in control 35-
39.9%E’
8, 62820, 3311 1.00 (0.94 to
1.07), 0
6, 60088, 1054 1.00 (0.88 to
1.12), 0
10, 60919, 4034 0.96 (0.84 to
1.10), 44
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Table 2. Subgrouping data for primary outcomes (Continued)
Sub-
group ’total fat in
control 40+%E’
3, 1491, 454 0.96 (0.83 to
1.11), 0
3, 1491, 227 0.80 (0.63 to
1.02), 0
3, 1491, 435 0.83 (0.71 to
0.97), 0
Sub-group ’satu-
rated fat in con-
trol <10%E’
2, 3625, 316 0.97 (0.79 to
1.20), 0
1, 3088, 7 0.40 (0.08 to
2.08), -
1, 537, 2 0.20 (0.01 to
4.13), -
Sub-group ’satu-
rated fat in con-
trol 10-14.9%E’
5, 50089, 2520 1.01 (0.77 to
1.32), 32
5, 49631, 558 0.98 (0.83 to
1.16), 0
11, 51610, 3565 0.97 (0.87 to
1.07), 10
Sub-group ’satu-
rated fat in con-
trol 15-19.9%E’
6, 14598, 1134 1.02 (0.92 to
1.13), 0
4, 11966, 657 0.90 (0.74 to
1.11), 37
5, 11991, 793 0.86 (0.68 to
1.09), 64
Sub-group ’satu-
rated fat in con-
trol 20+%E’
0, 0, 0 - 0, 0, 0 - 0, 0, 0 -
Sub-group ’stud-
ies of men’
11, 9604, 1224 0.97 (0.87 to
1.08), 7
9, 8951, 735 0.89 (0.77 to
1.02), 0




5, 59130, 2960 0.99 (0.92 to
1.07), 0
4, 56587, 658 1.03 (0.88 to
1.20), 0
4, 53605, 3566 1.04 (0.89 to
1.21), 53
Sub-group ’stud-
ies of men and
women’
5, 3056, 108 0.84 (0.58 to
1.22), 0
3, 440, 14 0.45 (0.15 to
1.37), 0




17, 61692, 3420 0.97 (0.91 to
1.03), 0
13, 56077, 965 0.95 (0.84 to
1.07), 0




4, 10098, 872 1.03 (0.92 to
1.15), 0
3, 9903, 442 0.93 (0.69 to
1.26), 63




6, 2178, 580 0.92 (0.80 to
1.06), 2
5, 1983, 326 0.80, 0.64 to
1.00), 11




3, 9515, 584 1.13 (0.95 to
1.33), 9
2, 9057, 304 1.06 (0.85 to
1.33), 0




1, 2033, 224 0.98 (0.76 to
1.25), -
1, 2033, 201 1.01 (0.77 to
1.31), -




5, 4880, 137 0.90 (0.65 to
1.26), 0
3, 364, 11 0.27 (0.07 to
1.08), 0
3, 364, 57 0.51 (0.32 to
0.81), 0
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6, 53184, 2767 0.98 (0.91 to
1.05), 0
5, 52541, 565 0.98 (0.83 to
1.15), 0
7, 50331, 3608 0.96 (0.85 to
1.08), 29
We explored the effects of dietary fats on total mortality, by us-
ing meta-regression of the difference between the control and in-
tervention of duration, total fat intake, saturated fat intake, mo-
nounsaturated fat intake, polyunsaturated fat intake, trans fat in-
take (all by percentage of energy), weight (in kg) and serum LDL
cholesterol (in mmol/L) achieved in trials. The results of all meta-
regressions are shown in Table 3. As only two trials reported trans
fat intakes achieved by study arm meta-regression on trans fats
could not be carried out, and with only six of the studies reporting
serum LDL cholesterol levels achieved the power of this analysis
to suggest a result was limited. Because so few studies reported
LDL cholesterol, we also ran a post-hoc meta-regression by total
serum cholesterol (as a surrogate for LDL cholesterol) achieved
in each arm. We did not observe any clear relationships between
treatment-control group differences in dietary or serum character-
istics and mortality, but power for this analysis was limited.
Table 3. Meta-regression, exploring effects of dietary changes on the primary outcomes
Outcome / Variable Total mortality, coeffi-
cient (95% CI), number
of studies, I2
Cardiovascular mortal-
ity, coefficient (95% CI)
, number of studies, I2
Cardiovascular
events, coefficient (95%
CI), number of studies, I
2
CVD events (co-regres-
sion with duration) coef-
ficient (95% CI), num-
ber of studies, I2,
Difference in total fat in-
take, %E




-0.012 (-0.037 to 0.012)
, 21, 25%
-0.016 (-0.045 to 0.013)
, 21, 23%
Difference in SFA in-
take, %E
0.005 (-0.016 to 0.026),
18, 0%
-0.006 (-0.050 to 0.037)
, 14, 3%
-.013 (-0.043 to 0.017),
21, 19%
-0.008 (-0.048 to 0.032)
, 21, 22%
Difference in MUFA in-
take, %E
-0.036 (-0.112 to 0.040)
, 15, 0%
-0.073 (-0.203 to 0.056)
, 13, 3%
-0.023 (-0.067 to 0.021)
, 14, 41%
-0.024 (-0.071 to 0.022)
, 14, 36%
Difference in PUFA in-
take, %E
-0.004 (-0.016 to 0.008)
, 17, 0%
-0.000 (-0.027 to 0.026)
, 14, 4%
-0.002 (-0.022 to 0.019)
, 19, 24%
-0.006 (-0.032 to 0.021)
, 19, 27%
Difference in trans fat in-
take, %E
Insufficient data, 2 stud-
ies
Insufficient data, 2 stud-
ies
Insufficient data, 2 stud-
ies
Insufficient data, 2 stud-
ies
Difference in weight, kg -0.035 (-0.138 to 0.068)
, 14, 0%
-0.067 (-0.240 to 0.106)
, 9, 17%
-0.038 (-0.154 to 0.078)
, 14, 47%








-1.600 (-3.815 to 0.616)
, 7, 28%
-1.465 (-4.094 to 1.164)
, 7, 25%
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Table 3. Meta-regression, exploring effects of dietary changes on the primary outcomes (Continued)
Difference in serum total
cholesterol, mmol/L
0.024 (-0.168 to 0.217),
18, 0%
-0.187 (-0.505 to 0.131)
, 15, 0%
-0.155 (-0.554 to 0.244)
, 17, 49%
-0.155 (-0.635 to 0.325)
, 17, 53%
Study duration, years -0.004 (-0.024 to 0.016)
, 22, 0%





There was no clear effect of any dietary fat intervention compared
to usual diet on cardiovascular mortality (RR 0.94, 95% CI 0.85
to 1.04, I2 0%, 65,978 participants, 1407 cardiovascular deaths,
peff ect 0.23), Analysis 1.2. Again, there was no effect within any
dietary fat subgroup: modified fat diet vs usual diet RR 0.92 (95%
CI 0.73 to 1.15, I2 45%, 10,788 participants, 593 cardiovascu-
lar deaths, peff ect 0.46); reduced fat vs usual diet RR 0.96 (95%
CI 0.82 to 1.13, I2 0%, 52,971 participants, 602 cardiovascular
deaths, peff ect 0.65); or reduced and modified fat vs usual diet RR
0.98 (95% CI 0.76 to 1.27, I2 0%, 2219 participants, 212 cardio-
vascular deaths, peff ect 0.88), Analysis 1.2. Sensitivity analyses did
not alter the lack of clear effects of modified fat intake, reduced fat
intake, reduced and modified fat intake or all combined compared
to usual or control diets on cardiovascular mortality (Table 1).
Subgrouping (as above) did not suggest important effects of re-
duced and/or modified fat diets on cardiovascular mortality (Table
2).
We explored the effects of dietary fats on cardiovascular mortal-
ity in meta-regression (Table 3). There were insufficient studies
to explore the effects of trans fats. As only six of the studies re-
ported serum LDL cholesterol levels achieved, we also ran a post-
hoc meta-regression by total serum cholesterol (as a surrogate for
LDL cholesterol) achieved in each arm. We did not observe any
clear relationships between duration, weight, any dietary or serum
characteristics and mortality, but power for this analysis was lim-
ited.
Cardiovascular events
There was a reduction in cardiovascular events for any dietary fat
intervention compared with usual diet (RR 0.86, 95% CI 0.77 to
0.96, I2 50%, 65,508 participants, 4887 people with cardiovas-
cular events, peff ect 0.007) Analysis 1.3. Sensitivity analyses, us-
ing Mantel-Haenszel fixed effects meta-analysis, Peto fixed effects
odds ratio, and removing the largest study comparisons (WHI
with CVD 2006,WHI without CVD 2006) maintained this clear
effect of the intervention, while removing studies with a system-
atic difference in care between the intervention and control arms,
or removing studies with dietary differences other than dietary fat
differences both removed the statistical significance of the effect
(Table 1). A funnel plot did not suggest severe small study (or
publication) bias, but it is likely that a few small studies with more
cardiovascular events in the intervention groups may be missing
from the review (Figure 4).
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Figure 4. Funnel plot of comparison: fat modification or reduction vs usual diet - combined cardiovascular
events.
None of the subgroups of types of dietary fat change showed a clear
effect of dietary fat change compared with usual diet in its own
right, but the effects in both groups that included modification of
fat were of marginal significance: modified fat vs usual fat RR 0.82
(95% CI 0.66 to 1.02, I2 61%, 11,660 participants, 855 people
with CVD events, peff ect 0.07); reduced and modified fat vs usual
diet RR 0.77 (95% CI 0.57 to 1.03, I2 40%, 3193 participants,
400 people with events, peff ect 0.08). There was no suggestion of
an effect on cardiovascular events in studies that compared reduced
fat vs usual intake (RR 0.97, 95%CI 0.87 to 1.08, I2 17%, 50,655
participants, 3632 people with CVD events, peff ect 0.55).
Sensitivity analyses of the modified fat studies, using Mantel-
Haenszel fixed effects relative risk meta-analysis suggested a strong
and statistically significant effect of modified fat on cardiovascular
events (RR 0.83, 95% CI 0.73 to 0.93, I2 61%, 11,660 partici-
pants, 855 events, peff ect 0.002), as did the Peto odds ratio, and
using fixed effects meta-analysis on the reduced and modified fat
subgroup suggested risk reduction of 16% and of marginal statis-
tical significance (RR 0.84, 95% CI 0.71 to 1.00, I2 40%, 3193
participants, 400 events, peff ect 0.05, also reiterated by the Peto
odds ratio analysis). Removing studies with systematic differences
in care between intervention and control groups, or other dietary
differences, both removed statistical significance. No sensitivity
analyses of the reduced fat intake compared with control or usual
diet suggested important or statistically significant effects (Table
1).
As multiple analyses were run for sub-grouping, only those sub-
groups statistically significant to P < 0.01 are reported here (and
in Table 2) as being statistically significant. Subgrouping by dura-
tion suggested no important effect in studies with duration of two
years or less, but a clear and statistically significant effect in studies
of more than two years duration. There was little suggestion of
different effects of fat modification and/or reduction in those at
low, moderate or high cardiovascular risk. Subgrouping suggested
a strong effect of dietary advice plus supplementation, only mar-
ginal effect in those given dietary advice (without supplementa-
tion, but often with high levels of support and encouragement),
and no effect in those provided with their food (via shops or group
eating). There was no clear effect of baseline total fat intake on
cardiovascular events. Many studies did not report saturated fat
intakes, and sub-grouping by saturated fat intake in the control
group did not result in important effects. Dietary fat intervention
reduced cardiovascular events in men, but not in women or in
combined studies of men and women, and studies in community
settings reduced events, but those in residential institutions did
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not. Studies published in the 1960s, and in the 1990s, reduced
cardiovascular events significantly, but not studies published in
other decades (Table 2).
We explored the effects of dietary fats on cardiovascular events, by
using meta-regression of the difference between the control and
intervention of total fat intake, saturated fat intake, monounsatu-
rated fat intake, polyunsaturated fat intake, trans fat intake (all by
percentage of energy), weight (in kg) and serum LDL cholesterol
(in mmol/L) achieved in trials (Table 3). Meta-regression of trans
fats was not feasible due to lack of trials. As only seven studies
reported LDL cholesterol, we also ran a post-hoc meta-regression
by total serum cholesterol (as a surrogate for LDL cholesterol)
achieved in each arm. As studies of shorter duration appeared to
have less effect on events than longer interventions, we also per-
formed a second post-hoc analysis, in which we carried out the
meta-regression on duration alongside each dietary or serum fac-
tor. We did not observe any clear relationships between any di-
etary or serum characteristic and cardiovascular events (with or




There was no clear effect of altering dietary fat intakes (compared
to usual diet) on myocardial infarction (RR 0.93, 95% CI 0.84 to
1.02, I2 6%, 64,891 participants, 2068 people with fatal or non-
fatal myocardial infarcts, peff ect 0.13) (Analysis 2.1). Neither was
there any effect of any of the distinct dietary fat changes: modified
fat intake RR 0.91 (95% CI 0.72 to 1.16, I2 45%, 11,831 par-
ticipants, 579 people with at least one myocardial infarct, peff ect
0.46); reduced fat vs usual fat intake RR 0.97 (95% CI 0.86 to
1.08, I2 0%, 50,522 participants, 1203 people having a myocar-
dial infarct, peff ect 0.54); and reduced and modified fat vs usual
intake RR 0.90 (95% CI 0.72 to 1.11, I2 0%, 2538 participants,
286 people with myocardial infarcts, peff ect 0.32).
Stroke
There was no evidence of an effect of general dietary fat advice
(RR 0.99, 95% CI 0.89 to 1.11, I2 0%, 59,853 participants, 1140
people with at least one fatal or non-fatal stroke, peff ect 0.87), or
modified, reduced or both vs usual diet on stroke (Analysis 2.2).
As 95% of the weight of this analysis was due to inclusion of the
WHI trial (WHI with CVD 2006, WHI without CVD 2006),
we also checked the effect of dietary fat advice on stroke excluding
both parts of this study, and there was the suggestion of an effect
of dietary change on stroke (RR 0.61, 95% CI 0.37 to 1.02, I2
0%, 11,018 participants, 64 people with a stroke, peff ect 0.06).
Cancer deaths
There was no effect of altering dietary fat intakes on cancer deaths
(RR 0.98, 95% CI 0.91 to 1.06, I2 0%, 65724 participants, 2818
cancer deaths, peff ect 0.66), or of any specific type of fat changes,
although there was a marginally significant effect of modified fat
intake increasing cancer deaths, although this included only 91
cancer deaths (Analysis 2.3).
Cancer diagnoses
There was no evidence of an effect of altered dietary fat intake
on cancer diagnoses (RR 0.96, 95% CI 0.91 to 1.01, I2 1%,
59,082 participants, 6115 people with at least one cancer diagno-
sis, peff ect 0.11) (Analysis 2.4). Almost all the evidence on cancer
diagnoses come from studies that reduced dietary fat, and only
138 diagnoses were made in studies where modified fat or reduced
and modified fat interventions had been undertaken.
Diabetes diagnoses
Most data on diabetes diagnoses came from the WHI study, and
neither the study itself, or the combined data set suggested that
the intervention reduced the risk of diabetes being diagnosed (RR
0.96, 95% CI 0.90 to 1.02, I2 0%, 49,859 participants, 3367
diabetic diagnoses, peff ect 0.20) (Analysis 2.5).
Non-fatal myocardial infarction
There was no evidence of an effect of reduced and/or modified
dietary fat vs usual fat diet on people diagnosed with at least one
non-fatal MI, overall or within any subgroup of fat change (overall
RR 0.95, 95%CI 0.81 to 1.12, I2 21%, 54,883 participants, 1403
people with at least one infarct, peff ect 0.55 (Analysis 2.6).
Quality of life
Few studies considered quality of life. TheWomen’s Health Initia-
tive assessed quality of life at baseline using the SF-36 tool, but we
were unable to find whether quality of life was compared between
dietary intervention and control groups during the study. The Ole
Study 2002 did not use a formal quality of life tool, but asked
participants about their feelings about the diet they were on. They
provided a scale of 1 (dislike extremely) to 7 (like extremely). Of
the 13 control participants (eating meals 5 days per week in the
study centre, with other meals in takeout containers) 6 partici-
pants were neutral about the diet (neither like nor dislike, 4 on
the scale), and the remaining control participants were a little mor
positive, choosing number 5 or 6. Results were very similar in the
low fat group, with 5 being neutral, 8 choosing 5 or 6 on the scale,
and one choosing 3 (a little on the negative side of neutral).
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Tertiary outcomes
Note that the effects of dietary fat changes on tertiary outcomes
discussed below represent a subset of all trials - we have only in-
cluded assessment of effect of dietary interventions on these out-
comes presented in studies that reported on occurrence of deaths
and/or cardiovascular events (the review’s primary or secondary
outcomes). These outcomes are reported here as providing infor-
mation on the potential mechanisms of any effects of dietary fat
changes and also on whether participants adhered appropriately
to their allocated interventions.
Weight and Body Mass Index (BMI)
Only two studies, including 99 participants, assessed the effects of
modified fat intake compared to usual diet on weight, and did not
find any clear effect (Analysis 3.1). One of these studies, and an
additional study (116 participants in total) assessed the effect of a
modified fat diet on BMI, again finding no clear effect (Analysis
3.2).
Sixteen studies (11,058 participants) compared reduced fat diets
with usual diets and assessed effects onweight, finding a significant
reduction in weight in those on low fat diets compared to usual
diets (MD-0.83kg, 95%CI -1.37 to -0.30, I2 54%, peff ect 0.002).
Similarly, the ten comparisons of reduced fat with usual intake
found a reduction in BMI in those on the reduced fat diets (MD
-0.47kg/m2 , 95% CI -0.72 to -0.23, I2 51%, peff ect 0.0002).
No studies assessed the impact of reduced andmodified fat intakes
compared to usual diets on weight, and only two studies (111
participants) assessed impact on BMI, finding no clear effect (MD
-0.20kg/m2 , 95% CI -1.30 to 0.91, I2 0%, peff ect 0.73).
In understanding the causative pathway between dietary advice
or provision and mortality or morbidity it is useful to understand
whether intermediate outcomes are being modified. Within this
review this is complicated by the problem that some studies expe-
rienced outcomes, but did not report intermediate markers, and
other studies experienced no events, but reported intermediate
outcomes. For this reason we carried out a post-hoc analysis of the
intermediate markers (tertiary outcomes) only for the studies that
reported the primary outcomes. These are reported briefly below
for weight and BMI, confirming clear and statistically significant
reductions in both weight and BMI for those on reduced fat diets
compared with control, but with no studies reporting these out-
comes for modified or reduced and modified fat diets:
• Total mortality, modified fat intake: no studies reported
weight or BMI
• Total mortality, reduced fat intake: 7 studies reported
weight (MD -0.92kg, 95%CI -1.41 to -0.43, no heterogeneity),
3 studies reported BMI (MD -0.48kg/m2 , 95%CI -0.65 to -
0.31, no heterogeneity)
• Total mortality, reduced and modified fat intake: no studies
reported weight or BMI
• Cardiovascular mortality, modified fat intake: no studies
reported weight or BMI
• Cardiovascular mortality, reduced fat intake: 3 studies
reported weight (MD -0.55kg, 95%CI -1.70 to 0.61, no
heterogeneity), 2 studies reported BMI (MD -0.44kg/m2,
95%CI -0.60 to -0.29, no heterogeneity)
• Cardiovascular mortality, reduced and modified fat intake:
no studies reported weight or BMI
• Cardiovascular events, modified fat intake: no studies
reported weight or BMI
• Cardiovascular events, reduced fat intake: 3 studies reported
weight (MD -1.00kg, 95%CI -1.60 to -0.40, no heterogeneity),
3 studies reported BMI (MD -0.43kg/m2 , 95%CI -0.57 to -
0.28, no heterogeneity)
• Cardiovascular events, reduced and modified fat intake: no
studies reported weight or BMI
Low density lipoprotein (LDL) cholesterol
Two studies (116 participants) assessed the effect of a modified
fat intake compared to usual or control diet on LDL cholesterol,
finding no significant effect (MD -0.20mmol/L, 95% CI -0.47
to 0.07, I2 0%, peff ect 0.14). The 14 comparisons (6971 partici-
pants) that assessed the effect of a low fat diet compared to usual
diet on LDL cholesterol found a significant reduction in LDL on
a low fat diet (MD -0.10mmol/L, 95% CI -0.14 to -0.05, I2 0%,
peff ect <0.0001). A reduced and modified fat intake also appeared
to reduce LDL cholesterol in comparison to a usual diet (MD -
0.21mmol/L, 95% CI -0.35 to -0.08, 4 comparisons, 627 partic-
ipants, I2 0%, peff ect 0.002), see Analysis 3.3.
Post-hoc analysis of LDL cholesterol only for the studies that re-
ported the primary outcomes confirmed clear reductions in LDL
in the reduced fat subgroup, non-statistically significant reduc-
tions in the reduced and modified fat subgroup, and no relevant
studies for the modified fat subgroup:
• Total mortality, modified fat intake: no studies reported
LDL
• Total mortality, reduced fat intake: four studies reported
LDL (MD -0.09mmol/L, 95%CI -0.14 to -0.03, no
heterogeneity)
• Total mortality, reduced and modified fat intake: two
studies reported LDL (MD -0.25mmol/L, 95%CI -0.63 to 0.12,
I2 56%)
• Cardiovascular mortality, modified fat intake: no studies
reported LDL
• Cardiovascular mortality, reduced fat intake: four studies
reported LDL (MD -0.09mmol/L, 95%CI -0.14 to -0.03, no
heterogeneity)
• Cardiovascular mortality, reduced and modified fat intake:
two studies reported LDL (MD -0.25mmol/L, 95%CI -0.63 to
0.12, I2 56%)
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• Cardiovascular events, modified fat intake: no studies
reported LDL
• Cardiovascular events, reduced fat intake: four studies
reported LDL (MD -0.10mmol/L, 95%CI -0.15 to -0.04, no
heterogeneity)
• Cardiovascular events, reduced and modified fat intake: two
studies reported LDL (MD -0.25mmol/L, 95%CI -0.63 to 0.12,
I2 56%)
High density lipoprotein (HDL) cholesterol
None of the interventions appeared to alter HDL cholesterol:
modified fat intake MD -0.04mmol/L (95% CI -0.18 to 0.09, 3
comparisons, 152 participants, I2 0%, peff ect 0.54); reduced fat
intakeMD -0.01mmol/L (95%CI -0.02 to 0.01, 15 comparisons,
7082 participants, I2 0%, peff ect 0.30); and reduced and mod-
ified fat intake MD -0.01mmol/L (95% CI -0.04 to 0.01, four
comparisons, 2073 participants, I2 0%, peff ect 0.36), see Analysis
3.4.
Post-hoc analysis of HDL cholesterol only for the studies that
reported the primary outcomes confirmed a lack of effects onHDL
cholesterol in any group (with no studies reporting HDL in the
modified fat subgroup):
• Total mortality, modified fat intake: no studies reported
HDL
• Total mortality, reduced fat intake: four studies reported
HDL (MD 0.00mmol/L, 95%CI -0.03 to 0.04, no
heterogeneity)
• Total mortality, reduced and modified fat intake: three
studies reported HDL (MD -0.01mmol/L, 95%CI -0.04 to
0.02, no heterogeneity)
• Cardiovascular mortality, modified fat intake: no studies
reported HDL
• Cardiovascular mortality, reduced fat intake: four studies
reported HDL (MD 0.00mmol/L, 95%CI -0.03 to 0.04, no
heterogeneity)
• Cardiovascular mortality, reduced and modified fat intake:
three studies reported HDL (MD -0.01mmol/L, 95%CI -0.04
to 0.02, no heterogeneity)
• Cardiovascular events, modified fat intake: no studies
reported HDL
• Cardiovascular events, reduced fat intake: four studies
reported LDL (MD 0.10mmol/L, 95%CI -0.03 to 0.04, no
heterogeneity)
• Cardiovascular events, reduced and modified fat intake:
three studies reported HDL (MD -0.01mmol/L, 95%CI -0.04
to 0.02, no heterogeneity)
Total cholesterol
More studies reported total than LDL or HDL cholesterol, and
all three dietary fat interventions found significant reductions in
total cholesterol: modified fat intake MD -0.44mmol/L (95%
CI -0.60 to -0.28, 8 comparisons, 2280 participants, I2 59%,
peff ect <0.00001); reduced fat intake MD -0.10mmol/L (95%CI
-0.14 to -0.05, 15 comparisons, 7602 participants, I2 0%, peff ect
<0.0001); reduced and modified fat intake MD -0.26mmol/L
(95% CI -0.47 to -0.04, 5 comparisons, 2131 participants, I2
51%, peff ect 0.02).
Post-hoc analysis of total cholesterol only for the studies that re-
ported the primary outcomes confirmed clear total cholesterol re-
ductions for most comparisons:
• Total mortality, modified fat intake: four studies reported
total cholesterol (MD -0.47mmol/L, 95%CI -0.85 to -0.10, no
heterogeneity)
• Total mortality, reduced fat intake: five studies reported
total cholesterol (MD -0.08mmol/L, 95%CI -0.13 to -0.03, no
heterogeneity)
• Total mortality, reduced and modified fat intake: three
studies reported total cholesterol (MD -0.33mmol/L, 95%CI -
0.61 to -0.06, I2 65%)
• Cardiovascular mortality, modified fat intake: two studies
reported total cholesterol (MD -0.32mmol/L, 95%CI -0.67 to
0.04, no heterogeneity)
• Cardiovascular mortality, reduced fat intake: four studies
reported total cholesterol (MD -0.08mmol/L, 95%CI -0.14 to -
0.02, no heterogeneity)
• Cardiovascular mortality, reduced and modified fat intake:
three studies reported total cholesterol (MD -0.33mmol/L,
95%CI -0.61 to -0.06, I2 65%)
• Cardiovascular events, modified fat intake: four studies
reported total cholesterol (MD -0.44mmol/L, 95%CI -0.54 to -
0.35, no heterogeneity)
• Cardiovascular events, reduced fat intake: three studies
reported total cholesterol (MD -0.08mmol/L, 95%CI -0.14 to -
0.02, no heterogeneity)
• Cardiovascular events, reduced and modified fat intake:
three studies reported total cholesterol (MD -0.33mmol/L,
95%CI -0.61 to -0.06, I2 65%)
Triglycerides
Modified fat intake and reduced and modified fat intake stud-
ies both reduced fasting triglycerides (modified fat intake MD -
0.11mmol/L, 95% CI -0.22 to -0.00, 5 comparisons, 706 partic-
ipants, I2 0%, peff ect 0.04; reduced and modified fat intake MD
-0.27mmol/L, 95% CI -0.53 to -0.00, 3 comparisons, 218 par-
ticipants, I2 0%, peff ect 0.05), see Analysis 3.6. However, studies
that reduced total fat intake compared to usual diet did not have
any effect on fasting triglycerides (MD -0.00mmol/L, 95% CI -
0.00 to 0.00, 13 comparisons, 6875 participants, I2 0%, peff ect
1.00).
Post-hoc analysis of the triglycerides for the studies that reported
the primary outcomes only confirmed that diets both reducing
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and modifying dietary fats appeared to reduce triglycerides, while
there were insufficient studies to tell for modified fat and reduced
fat diets:
• Total mortality, modified fat intake: one study reported
triglycerides (MD -0.10mol/L, 95%CI -0.26 to 0.06)
• Total mortality, reduced fat intake: four studies reported
triglycerides (MD -0.02mmol/L, 95%CI -0.13 to 0.08, no
heterogeneity)
• Total mortality, reduced and modified fat intake: two
studies reported triglycerides (MD -0.31mmol/L, 95%CI -0.62
to -0.01, no heterogeneity)
• Cardiovascular mortality, modified fat intake: no studies
reported triglycerides
• Cardiovascular mortality, reduced fat intake: four studies
reported triglycerides (MD -0.02mmol/L, 95%CI -0.13 to 0.08,
no heterogeneity)
• Cardiovascular mortality, reduced and modified fat intake:
two studies reported triglycerides (MD -0.31mmol/L, 95%CI -
0.62 to -0.01, no heterogeneity)
• Cardiovascular events, modified fat intake: one study
reported triglycerides (MD -0.26mol/L, 95%CI -0.50 to -0.02)
• Cardiovascular events, reduced fat intake: four studies
reported triglycerides (MD -0.50mmol/L, 95%CI -1.05 to 0.05,
I2 52%)
• Cardiovascular events, reduced and modified fat intake: two
studies reported triglycerides (MD -0.31mmol/L, 95%CI -0.62
to -0.01, no heterogeneity)
Systolic and diastolic blood pressure (BP)
No studies reported the effects of modified fat intake on systolic
or diastolic BP, and only one reported (non-significant) effects of
reduced and modified fat on systolic and diastolic BP. Six included
comparisons reported effects of reduced fat diets onbloodpressure,
but again pooled results did not suggest clear effects (systolic BP
MD -0.56mmHg, 95% CI -11.22 to 1.06, 6 comparisons, 3981
participants, I2 0%, peff ect 0.25; diastolic BP MD -0.35mmHg,
95% CI -0.96 to 0.26, 6 comparisons, 3543 participants, I2 0%,
peff ect 0.26). See Analysis 3.7 and Analysis 3.8 for blood pressure
analyses.
Post-hoc analysis of the systolic and diastolic blood pressure only
for the studies that reported the primary outcomes confirmed that
few studies reported blood pressure and there was no clear effect
on blood pressure in those studies that did:
• Total mortality, reduced fat intake: four studies reported
sBP (MD -0.55mmHg, 95%CI -1.54 to 0.43, no heterogeneity)
• Total mortality, reduced fat intake: three studies reported
dBP (MD -0.32mmHg, 95%CI -0.94 to 0.30, no heterogeneity)
• Total mortality, reduced and modified fat intake: no studies
reported systolic or diastolic BP
• Cardiovascular mortality, reduced fat intake: three studies
reported sBP (MD -0.67mmHg, 95%CI -2.23 to 0.89, no
heterogeneity)
• Cardiovascular mortality, reduced fat intake: two studies
reported dBP (MD -0.43mmHg, 95%CI -6.20 to 1.58, no
heterogeneity)
• Cardiovascular mortality, reduced and modified fat intake:
no studies reported systolic or diastolic BP
• Cardiovascular events, reduced fat intake: four studies
reported sBP (MD -0.55mmHg, 95%CI -11.22 to 1.06, no
heterogeneity)
• Cardiovascular events, reduced fat intake: three studies
reported dBP (MD -0.32mmHg, 95%CI -0.94 to 0.30, no
heterogeneity)
• Cardiovascular events, reduced and modified fat intake: no
studies reported systolic or diastolic BP
Reduced fat vs. modified fat diet
Primary outcomes
There were no included studies comparing reduced with modi-
fied fat diets that reported total or cardiovascular mortality. Three
studies (with 912 participants) reported 28 cardiovascular events,
and not suggesting any difference in the effects of a reduced or
modified fat diet (RR 1.13, 95% CI 0.41 to 3.06, Analysis 4.3).
Secondary outcomes
No studies compared reduced with modified fat diets and pro-
vided data on diabetes diagnoses. One small study provided data
on myocardial infarction, stroke and non-fatal MI, and there were
no clear effects for any outcome. A further study with two compar-
isons found no cancer deaths and there was no difference between
low and modified fat in terms of cancer diagnoses (with only 4
diagnoses). See Analysis 5.1, Analysis 5.2, Analysis 5.3, Analysis
5.4, Analysis 5.5 and Analysis 5.6 for further details.
Tertiary outcomes
Several small studies comparing reducedwithmodified fat diets re-
ported tertiary outcomes. There were no clear differences between
reduced and modified fat diets for weight, BMI, total, LDL or
HDL cholesterol, triglycerides, systolic or diastolic blood pressure.
See Analysis 6.1, Analysis 6.2, Analysis 6.3, Analysis 6.4, Analysis
6.5, Analysis 6.6, Analysis 6.7 and Analysis 6.8 for further details.
There were insufficient studies in this section of the review to
carry out sensitivity analyses or sub-grouping. One study directly
addressed the acceptability of modified compared to reduced fat
diets finding little difference between low andmodified fat diets in
terms of craving, fullness, hunger, desire to eat, wellness, distaste,
cost, personal inconvenience, family inconvenience or feelings of
deprivation. This study also assessed quality of life for all four arms
using the SF-36, but data have not yet been reported (Sacks low
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protein 2009, Sacks high protein 2009). A further study reported
that themodified fat diet advised was ’monotonous’ in comparison
to the low fat diet, although it was not clear why this was (Rivellese
1994).
In the nine studies that directly compared reduced with modified
fat diets there was little difference in numbers of dropouts in those
on modified fat diets (RR of dropping out 0.84, 95%CI 0.58 to
1.22 in reduced compared to modified fat diets, P=0.36, 1353
participants, 237 dropouts, I2 44%), Analysis 6.9.
D I S C U S S I O N
Addressing the specific questions
Does reducing saturated fat intake, by reducing
and/or modifying dietary fat, in the longer term (at
least 6 months) reduce mortality, cardiovascular
mortality or cardiovascular morbidity (or individual
health events such as myocardial infarction, stroke,
diabetes or cancer)?
• This review suggested that dietary saturated fat reduction
(through reduction and/or modification of dietary fat) may be
protective of cardiovascular events overall, reducing them by
14% (RR 0.86, 95% CI 0.77 to 0.96, 24 comparisons, 65,614
participants, with marginal I2 of 50%, Analysis 1.3). This was
moderate GRADE evidence (See summary of findings, Figure 5).
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Figure 5. Summary of findings, for reduced or modified fat diets vs usual diet (primary outcomes).
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• Despite the reduction in total cardiovascular events, there
was no clear evidence of reductions in any individual outcome
(total or non-fatal myocardial infarction, stroke, cancer deaths or
diagnoses, diabetes diagnoses).
• Despite a large number of participants involved in
randomised controlled trials of at least six months duration there
were no clear effects of dietary fat changes on total mortality (RR
0.98, 95% CI 0.93 to 1.04, 21 comparisons, 71,795
participants, without important heterogeneity, Analysis 1.1) or
cardiovascular mortality (RR 0.94, 95% CI 0.85 to 1.04, 16
comparisons, 65,983 participants, without important
heterogeneity, Analysis 1.2).
Does a long term reduced fat diet, compared with
usual diet, reduce mortality, cardiovascular mortality
or cardiovascular morbidity (or individual health
events such as myocardial infarction, stroke, diabetes
or cancer)?
• There were no clear effects of reduced fat diets on any of
these outcomes despite the inclusion of almost 62000
participants in studies of over 6 months. This was despite clear
and statistically significant reductions in weight, BMI and total
and LDL cholesterol in reduced fat vs. usual diet studies.
Does a long term reduced fat diet alter classic
cardiovascular risk factors (weight, body mass index,
systolic or diastolic blood pressure, serum total, LDL
or HDL cholesterol and triglyceride)?
• The studies included in this review represent a subset of all
relevant studies assessing the effect of reduced fat diets on classic
cardiovascular risk factors, so should be treated with caution.
However, they do represent a good set of data from which to
assess the longer term effects of such interventions in people
living in the community.
• There was evidence that reduced fat diets resulted in
modestly lower weight (MD -0.83kg, 95%CI -1.37 to -0.30,
11,058 participants, I2 54%) and body mass index (MD -
0.47kgm−2 , 95%CI -0.72 to -0.23, 5972 participants, I2 51%).
Similary modest improvements were seen in LDL cholesterol
(MD -0.10mmol/L, 95%CI -0.14 to -0.05, 5971 participants, I2
0%) and total cholesterol (MD -0.10mmol/L, 95%CI -0.14 to -
0.05, 7602 participants, I2 0%), compared with those on usual
or control diets.
• Other risk factors (HDL cholesterol, triglycerides, systolic
and diastolic blood pressure) did not appear to alter with reduced
fat diets.
Does a long term modified fat diet, compared with
usual diet, reduce mortality, cardiovascular mortality
or cardiovascular morbidity (or individual health
events such as myocardial infarction, stroke, diabetes
or cancer)?
• There were no clear effects of modified fat diets on total or
cardiovascular mortality, despite the inclusion of over 13000
participants in studies of over six months.
• There was a suggestion (but without statistical significance)
that modified fat diets reduced cardiovascular events by 18%
(RR 0.82, 95%CI 0.66 to 1.02, peff ect 0.07, 11,660
participants, I2 61%).
• There were no suggestions of effects on individual health
outcomes (with no data found on diabetes diagnosis), except for
a suggestion that modified fat diets increased the risk of cancer
deaths (RR 1.46, 95%CI 0.96 to 2.21, peff ect 0.08, 9903
participants, I2 0%).
Does a long term modified fat diet alter classic
cardiovascular risk factors (weight, body mass index,
systolic or diastolic blood pressure, serum total, LDL
or HDL cholesterol and triglyceride)?
• The studies included in this review represent a subset of all
relevant studies assessing the effect of modified fat diets on classic
cardiovascular risk factors, so should be treated with caution.
However, they do represent a good set of data from which to
assess the longer term effects of such interventions in people
living in the community.
• A modified fat diet appeared to reduce serum total
cholesterol by around 7% (MD -0.44mmol/L, 95%CI -0.60 to -
0.28, 2280 participants, I2 59%) and modestly reduce fasting
serum triglycerides (MD -0.11mmol/L, 95%CI -0.22 to -0.00,
701 participants, I2 0%).
• There were no clear effects on serum LDL or HDL
cholesterol, weight or BMI, although the numbers of
participants in these comparisons were low (99 to 150 only). We
found no data assessing the effect of modified fat diets on systolic
or diastolic blood pressure.
• Few of the studies that compared a modified fat diet with a
usual diet and experienced deaths or cardiovascular events
reported intermediate outcomes.
Does reducing and modifying dietary fat (as a
combined intervention) in the longer term reduce
mortality, cardiovascular mortality or cardiovascular
morbidity (or individual health events such as
myocardial infarction, stroke, diabetes or cancer)?
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• There were no clear effects of reduced and modified fat
diets on total or cardiovascular mortality, despite the inclusion of
almost 5000 participants in studies of over 6 months.
• There was a suggestion (with marginal statistical
significance), that reduced and modified fat diets reduced
cardiovascular events by 23% (RR 0.77, 95%CI 0.57 to 1.03,
peff ect 0.08, 3193 participants, I
2 40%).
• There were no suggestions of effects on individual health
outcomes (with no data found on diabetes diagnosis and few
events for most outcomes).
Does a long term reduced and modified fat diet (as a
combined intervention) alter classic cardiovascular
risk factors (weight, body mass index, systolic or
diastolic blood pressure, serum total, LDL or HDL
cholesterol and triglyceride)?
• The studies included in this review represent a subset of all
relevant studies assessing the effect of reduced and modified fat
diets on classic cardiovascular risk factors, so should be treated
with caution. However, they do represent a good set of data from
which to assess the longer term effects of such interventions in
people living in the community.
• A reduced and modified fat diet appeared to modestly
reduce serum total cholesterol (MD -0.26mmol/L, 95%CI -0.47
to -0.04, 2131 participants, I2 51%), serum LDL cholesterol
(MD -0.21mmol/L, 95%CI -0.35 to -0.08, 627 participants, I2
0%) and fasting serum triglycerides (MD -0.27mmol/L, 95%CI
-0.53 to -0.00, 218 participants, I2 0%).
• There were no clear effects on serum HDL cholesterol or
BMI.
• Few of the studies that compared a reduced and modified
fat diet with a usual diet and experienced deaths or
cardiovascular events reported intermediate outcomes.
• We located only one study that assessed effects on systolic
and diastolic blood pressure, and no studies reported weight.
Are effects on mortality, cardiovascular mortality or
cardiovascular morbidity moderated by differences in
baseline cardiovascular risk, mode of intervention,
control group total fat intake, control group saturated
fat intake, gender, setting or decade of publication, or
changes in total fat intake, saturated fat intake,
polyunsaturated fat intake, monounsaturated fat
intake, trans fat intake, dietary cholesterol, weight,
serum LDL cholesterol, or study duration?
• Lack of effects of reduced and/or modified dietary fat on
total and cardiovascular mortality did not alter with any sub-
grouping, and no meta-regression suggested relationships with
these outcomes and any continuous factor tested.
• Subgrouping suggested that effects on cardiovascular events
of reduced and/or modified fat diets were due to studies with
duration greater than two years (not those of two years or less),
those given dietary advice plus a supplement (not diet alone or
diet provided), studies of men (not of women), those in a
community rather than residential setting (no studies in
workplace locations were identified). There was no suggestion
that baseline CVD risk or baseline total fat intakes altered the
effects of dietary fat changes on cardiovascular events. There was
a suggestion of an effect in studies published in the 1960s and
1990s. Overall, the data suggest that modified or modified and
reduced fat diets (but not reduced fat diets), help to reduce
cardiovascular events in longer studies of men.
• Meta-regression suggested no clear effects of the amount of
difference between intervention and control arms in total fat
intake, saturated fat intake, polyunsaturated fat intake,
monounsaturated fat intake or total cholesterol on cardiovascular
events. Nor were there clear effects of duration.
• There were insufficient data to assess the associations of
trans fats or LDL cholesterol with cardiovascular mortality or
events.
Is a long term reduced fat diet or a modified fat diet
more effective in reducing mortality, cardiovascular
mortality or cardiovascular morbidity (or individual
effects such as myocardial infarction, stroke or cancer
diagnoses)?
• There were no studies that provided data to assess the
differences between reduced and modified fat diets on total or
cardiovascular mortality. Only three studies assessed the
comparative effects of reduced compared to modified fat diets on
cardiovascular events (28 events in total).
• One study provided some data on myocardial infarction
and stroke, and two comparisons provided information on
cancer diagnoses.
Is a long term reduced fat diet or a modified fat diet
more acceptable to people trying to adhere to these
diets?
• One study (two comparisons) directly addressed the
acceptability of modified compared to reduced fat diets - no clear
differences were identified and the quality of life data have not
yet been reported (Sacks high protein 2009; Sacks low protein
2009). One further study reported that the modified fat diet
advised was ’monotonous’ in comparison to the low fat diet
(Rivellese 1994).
• In the eight studies that directly compared reduced with
modified fat diets there was no difference in numbers of
dropouts in either arm.
Is a long term reduced fat diet or a modified fat diet
more effective in altering classic cardiovascular risk
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factors (weight, body mass index, systolic or diastolic
blood pressure, serum total, LDL or HDL cholesterol
and triglyceride)?
• Several small studies provided outcome data comparing the
effects of reduced and modified fat diets on these risk factors.
There were no clear differences.
• When (indirectly) comparing effects on risk factors in
studies that compared reduced fat with usual diets with those in
studies that compared modified fat with usual diets, effects in
reducing risk factors in the modified fat studies were greater than
those in the reduced fat trials for total and LDL cholesterol, and
triglycerides (with similarly little effect on HDL cholesterol).
Data for weight, BMI and blood pressure were scarce for
modified fat trials, so data were not comparable.
• The stronger effect of modified fat diets over reduced fat
diets in reducing serum lipids may relate to the apparently
stronger effect of modified fat diets than reduced fat diets on
cardiovascular events. It is not clear from the included studies
whether this is due to the greater intrinsic effect of modified fat
diets on cardiovascular events, or that modified fat diets are easier
to comply with than reduced fat diets.
Summary of main results
This review suggested that dietary fat manipulation (reduction
and/or modification) may be protective of cardiovascular events,
reducing them by 14% (RR 0.86, 95% CI 0.77 to 0.96, 24
comparisons, 65,614 participants, with marginal heterogeneity,
Analysis 1.3). This was moderate GRADE evidence (See summary
of findings, Figure 5). Subgrouping suggested that this reduction
in cardiovascular events was due to studies of fat modification, or
fat modification and reduction (not studies of fat reduction alone),
seen in studies of at least two years duration, in studies of men
(and not those of women), and in those with moderate or high
cardiovascular risk at baseline (not general population groups).
Despite a large number of participants involved in randomised
controlled trials of at least six months duration there were no clear
effects of dietary fat changes on total mortality (RR 0.98, 95%
CI 0.93 to 1.04, 21 comparisons, 71,795 participants, without
important heterogeneity, Analysis 1.1) or cardiovascular mortality
(RR 0.94, 95% CI 0.85 to 1.04, 16 comparisons, 65,983 partic-
ipants, without important heterogeneity, Analysis 1.2). This did
not alter with sub-grouping or sensitivity analysis, and was mod-
erate GRADE evidence (Figure 5).
Few studies directly compared reduced fat diets with modified
fat diets, and only three trials reported on cardiovascular events,
so direct comparison of these two diets in randomised controlled
trials was not possible (Figure 6).
Figure 6. Summary of findings, reduced fat vs modified fat diets, cardiovascular events.
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The stronger effect of modified fat diets over reduced fat diets
in reducing serum lipids may relate to the apparently stronger
effect of modified fat diets than reduced fat diets on cardiovascular
events. It is not clear from the included studies whether this is due
to the greater intrinsic effect of modified fat diets on cardiovascular
events, or that modified fat diets are easier to comply with than
reduced fat diets.
Meta-regression did not suggest any clear effects of changes in
any dietary fat component (total fat, saturated fat, polyunsatu-
rated fats, monounsaturated fats) or serum lipids (LDL or total
cholesterol) on mortality, cardiovascular mortality or cardiovascu-
lar events (data on trans fats were not available, and those on LDL
cholesterol were very limited, Table 3).
No effects of dietary fat manipulation overall, or modifying or
reducing dietary fat intake, were seen on risk of myocardial in-
farction, stroke or cancer diagnosis (GRADE moderate evidence,
see Figure 7), nor non-fatal myocardial infarction, diabetes diag-
nosis or cancer deaths, and little information on the effect of diet
on quality of life was found. However, reduced fat diets caused
significant reductions in weight, body mass index, LDL and total
cholesterol, with no change in HDL cholesterol, triglycerides, or
blood pressure. Fat modified diets appeared to reduce total choles-
terol and triglycerides, but there was no evidence of effects on
weight, body mass index, LDL or HDL cholesterol or blood pres-
sure (although few fat modification studies measured or reported
these outcomes in ways that allowed meta-analysis). Modification
of fat appeared did not alter classic CVD risk factors when di-
rectly compared to low fat diets. Studies that aimed to reduce and
modify fat intake appeared to reduce total and LDL cholesterol,
and triglycerides, but there was no suggestion of improvements
in body mass index or HDL cholesterol and little data on blood
pressure.
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Figure 7. Summary of findings, reduced or modified dietary fat vs usual diet, important secondary
outcomes (myocardial infarction, stroke, cancer diagnosis)
Overall completeness and applicability of
evidence
The review included adult participants at varying levels of risk of
cardiovascular disease, men and women, in free-living and institu-
tional settings, and across the past 50 years. Almost all the studies
were conducted in industrialised countries, and almost no data
were available from developing or transition countries. The effec-
tiveness of reduced fat diets and modified fat diets have been well
assessed (trials of at least 6 months included 62,000 and 13,000
participants respectively), but studies of the combined diet (re-
duced and modified fat) included fewer than 5000 participants.
Over 4000 participants in the included trials died, 1400 died of
a cardiovascular cause, and almost 5000 experienced at least one
cardiovascular event.
Overall the external validity of the review in industrialised coun-
tries, men and women, people with low, moderate and high risk
of cardiovascular disease was high, but it is not clear how this evi-
dence relates to diets in developing and transition countries.
Quality of the evidence
All 48 trials and 60 comparisons included were randomised con-
trolled trials, allocation concealment was judged well done in 26
comparisons, and 11 had adequate participant and study person-
nel blinding (difficult and expensive in dietary trials), see Figure 1.
Ten comparisons ensured compete outcome data through check-
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ing of medical records or death registers, and we attempted to
contact all trialists to ascertain deaths and cardiovascular events
(that were often not important outcomes for the original studies).
Just under half of the included comparisons (29) were free of sys-
tematic differences in care between study arms, and 39 were free
of dietary changes other than those relating to dietary fat.
The lack of blinding in most dietary trials is unlikely to alter out-
come assessment when outcomes include death and cardiovascular
events, but lack of blinding in the participants may have lead those
in the control groups to alter their lifestyle and dietary practices
(for example, feeling that they have not been helped to reduce
their cardiovascular risk, they may act to reduce their own risk
by altering other lifestyle behaviours such as smoking or exercise,
leading to a potential lessening of the apparent effect of the dietary
intervention). Systematic differences in care between arms may
have lead to intervention groups receiving additional support in
areas like self-efficacy and gaining support from new social circles,
potentially beneficial to health regardless of dietary fat intake, or
gaining additional health care professional time, possibly leading
to earlier diagnosis and treatment of other risk factors such as raised
blood pressure. Additional dietary messages (such as those around
fruit and vegetable intake, fibre, alcohol and sugars), present in
many studies, may have been protective, or may have diluted the
effect and/or attainability of the fat goals.
This suggests that the evidence base for the dietary effects of
changes in dietary fats on cardiovascular risk is not ideally valid,
although it is large. In light of the uncertainty over allocation con-
cealment, lack of blinding and presence of systematic differences
in care and additional dietary differences between arms, the quality
of evidence cannot be described as high (Figure 2). On the other
hand, the scale and consistency of the evidence across studies and
across decades, with very different designs and design flaws may
make up for these deficits to some extent. For this reason, it is
likely that the review provides robust conclusions on the effects of
dietary fat modification in industrialised countries.
Complex interventions
With complex interventions, such as dietary ones, there are ad-
ditional questions that need to be asked about included studies.
Important issues to consider include defining the intervention,
searching for and identifying all relevant studies, selecting studies
for inclusion and data synthesis (Lenz 2007; Sheppherd 2009).
For this review we have worked to define the interventions clearly
(see Characteristics of studies table), providing information on the
type of intervention, stating the study aims and methods for each
arm and the assessed total and saturated fat intakes attained within
the study. However, while we have characterised the interventions
(for example, sub-grouping studies into those that aimed to re-
duce, modify or reduce and modify dietary fat) no two studies
that reduced dietary fat had exactly the same dietary goals for the
intervention groups. Methods of attaining the dietary goals varied
from providing a whole diet over several years (in studies based
in institutions); to providing shops that sold either full or low fat
versions of foods depending on the intervention or control status
of the participant; to providing advice on diet alongside supple-
mentary foods such as margarines or oils; to providing dietary ad-
vice with or without supplementary support in the way of group
sessions, cooking classes, shopping tours, feedback, self-efficacy
sessions and/or individual counselling. We aimed to use this va-
riety in helping us to understand which dietary fat interventions
are more useful, by using sub grouping (by reduced or modified
fat aim, and by food provided or dietary advice for example) and
meta-regression (on study duration and the difference between in-
tervention and control arms in saturated or monounsaturated fat
intake for example).
We addressed identifying all the relevant studies through use of
a wide search strategy, that was time consuming. However, we
believe that we have includedmost relevant trials.We also carefully
defined acceptable interventions for each arm, so that decisions on
inclusion were simpler, and the two independent assessors more
often agreed. Data synthesis was augmented by sub-grouping and
meta-regression to help us understand the effects of individual
elements of dietary fat changes.
A study that sets out to assess the effect of a 30% reduction in
saturated fat intake may attain this level of reduction in some par-
ticipants, exceed it in some and not achieve it at all in others. The
actual mean change attained in the intervention group may be less
dramatic than that aimed for, and the participants in the control
groupmay also reduce their saturated fat intake by a small amount,
reducing the difference in saturated fat between the groups fur-
ther and so reducing the scale of any outcome. This can be dealt
with in the systematic review if we meta-regress the difference in
saturated fat intake between the intervention and control group
with the scale of the outcome (assuming a linear dose response),
still allowing us to understand the effect of altering saturated fat
intake. However, there is also a problem of measuring actual satu-
rated fat intake achieved - some trials did not report this (whether
because they did not assess it, or did assess it and were embarrassed
by the results or simply didn’t have space to report this relatively
uninteresting outcome), and others did report the results of asking
people what they are eating (using a food frequency questionnaire
or several 24 hour food recalls). However, there is good evidence to
believe that asking people how they are eating may produce some-
what biased information (Kristal 2005; Schatzkin 2003), and this
may be a greater problem where the participant has been recently
urged to eat in a particular way, as in a dietary trial.
A better solution to measuring the saturated fat intake achieved
individually and as a mean in each study arm may be use of a
biomarker of saturated fat intake. Our understanding of the re-
lationship between dietary saturated fat intake and serum choles-
terol has been quite clear since Hegsted’s work in 1965 (Hegsted
1965). Meta-analysis by Mensink and Katan provided even more
specific relationships between serum HDL and LDL cholesterol
and triglycerides and changes in saturated, polyunsaturated and
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monounsaturated fats and carbohydrate from highly controlled
short term studies (Mensink 1992). Unless long term dietary fat
changes differ from these short term effects, understanding the
changes in serum lipids in the trials included in this systematic re-
view should allow us to understand the dietary fat changes. How-
ever, unfortunately few studies that experienced substantial num-
bers of deaths or cardiovascular events also report HDL, LDL or
triglycerides (most older studies do not even report the composite
serum total cholesterol). This has made it very difficult to under-
stand whether lack of effect of dietary fat changes on total and
cardiovascular mortality was due to minimal differences in fat in-
take between the control and intervention arms, or because such
changes make no difference to mortality.
Potential biases in the review process
In compiling the included studies we worked hard to locate ran-
domised studies that altered dietary fat for at least 6 months, even
when cardiovascular events were not reported in study publica-
tions, or where such events were reported incidentally as reasons
for participant drop outs. We attempted to contact all authors
of potential studies to verify the presence, or not, of our out-
comes. In many included studies no outcomes relevant to this re-
view occurred within the participants, and the numbers of events
occurring within single studies varied from none to over 2000
deaths, over 500 cardiovascular deaths, and over 3000 cardiovas-
cular events (all within theWHI trial, the largest single study with
almost 50,000 participants for many years). The addition of the
WHI trial (WHI with CVD 2006, WHI without CVD 2006),
despite its size, did not alter the results substantially from the pre-
vious review, and did not introduce heterogeneity to the review.
The number of cardiovascular deaths was relatively small, so while
we canbe quite confident in reporting a reduction in cardiovascular
events with dietary fat intervention (especially fat modification),
and a lack of effect on total mortality, the effect on cardiovascular
mortality is less clear. The relative risk of 0.94 (95% CI 0.85 to
1.04) may translate into a small protective effect, however this is
unclear. The lack of effect on individual cardiovascular events is
harder to explain - there were over 2000 myocardial infarctions,
over 1000 strokes and non-fatal MI, almost 3000 cancer deaths,
over 3000 diabetes diagnoses and 6000 cancer diagnoses. Lack of
clear effects on any of these outcomes is surprising given the effects
on total cardiovascular events.
The funnel plots are difficult to interpret (Figure 3, Figure 4) but
there is some suggestion that there may be some trials of reduced
fat interventions with higher relative risks missing, and some of
modified fat interventions with lower relative risks missing (there
are too few studies of reduced and modified interventions to tell).
If additional studies of reduced fat diets with higher relative risks
were found thiswouldnot alter the lack of effect of reduced fat diets
on total mortality or cardiovascular events. If further modified fat
studies were found these would be unlikely to alter the lack of effect
of modified fat on mortality, but may strengthen its preventive
effect on cardiovascular events.
Agreements and disagreements with other
studies or reviews
All of the studies included in this review, whether they reduced or
modified dietary fat, aimed to reduce saturated fat intake. Over-
all reduction and/or modification of dietary fat had no effect on
total mortality or cardiovascular mortality but did appear to re-
duce cardiovascular events by 14% (although effects on myocar-
dial infarction and stroke individually were not clear). This result
was rather different from those of Siri-Tarino 2010 who systemat-
ically reviewed cohort studies that assessed relationships between
saturated fat and cardiovascular events. They included 21 studies
and did not find statistically significant associations between satu-
rated fat intake and cardiovascular disease (RR 1.0, 95% CI 0.89
to 1.11). As with our review they found no relationship between
saturated fat intake and coronary heart disease (RR 1.07, 95%CI
0.96 to 1.19) or stroke (RR 0.81, 95%CI 0.62 to 1.05).
In our review there was no effect of reducing total fat on total or
cardiovascularmortality or cardiovascular events. This was also ob-
served in a systematic review of observational studies. Skeaff 2009
included 28 US and European cohorts (including 6600 coronary
heart disease deaths among 280000 participants) finding that total
fat intake was not significantly associated with coronary heart dis-
ease mortality (RR 0.94, 95%CI 0.74 to 1.18) or coronary heart
events (RR 1.02, 95%CI 0.98 to 1.05). Skeaff 2009 also partly
updated the previous version of this review, adding in the Finnish
Mental Hosp 1972 studies (excluded from both versions of this
review as this was a cluster randomised study with only 2 clus-
ters, and also because it carried out a crossover study, inappropri-
ate in a progressive condition such as cardiovascular disease) and
the Women’s Health Initiative (WHI without CVD 2006; WHI
with CVD 2006), the largest of the studies published between
the versions of our review. They also found that studies reducing
total fat had no effect on cardiovascular mortality or events. They
also observed a marginally significant relationship between P/S
(polyunsaturated / saturated fat) ratio and cardiovascular events,
but no relationship with cardiovascular mortality (similar to our
suggestion thatmodifying dietary fat reduces cardiovascular events
by 18%, without an important effect on total or cardiovascular
mortality).
While we found in this review that replacing saturated with un-
saturated fats appeared to be beneficial in terms of cardiovascular
events, it was not clear whether replacing saturated fats by polyun-
saturated or monounsaturated fats, either or both, was beneficial.
Meta-regression did not suggest any significant relationship be-
tween either polyunsaturated ormonounsaturated fats and cardio-
vascular events in this review.A recent reviewbyMozaffarian 2010,
which again included very similar studies to the last version of
this review, with the Finnish Mental Hospital study and Women’s
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Health Initiative data added, stated that their findings provided
evidence that consuming polyunsaturated fat in place of saturated
fat would reduce coronary heart disease. However, their evidence
for this was limited and circumstantial, as they found that modify-
ing fat reduced the risk of myocardial infarction or coronary heart
disease death (combined) by 19% (similar to our result). As the
mean increase in polyunsaturated fat in these studies was 9.9%
of energy they infer an effect of increasing polyunsaturated fat by
5% of energy of 10% reduction in risk of myocardial infarction
or coronary heart disease death. They provided no suggestion or
evidence of a relationship between degree of polyunsaturated fat
increase and level of risk reduction.
Within the meta-regression we hoped to combine studies that ef-
fectively altered saturated fat by different degrees (so that studies
that reduced saturated fat very little and studies that reduced it
a great deal would all offer data points for the meta-regression
against mortality and morbidity endpoints, and similarly for total
fat, polyunsaturated, monounsaturated and trans fats). Unfortu-
nately many of the included studies did not report data on as-
sessed dietary intake during the trial, reducing the quantity of data
available to understand the relationships. Another limitation in
understanding effects of individual classes of fatty acids on mor-
tality and morbidity (in both trials and observational studies) was
our ability to correctly assess participant’s intake. We could over-
come this by using biomarkers such as serum LDL cholesterol
(differences between the LDL concentration in the intervention
and control arms could be seen as a reasonable and independent
approximation of saturated fat intake), however as many studies
were carried out in the 1960s to 1990s fewmeasured and reported
LDL cholesterol. We tried using meta-regression with serum total
cholesterol (although this is a composite marker and so less related
to saturated fat intake), but although this was available for more
studies that LDL it was still not available for all studies. It should
be noted that the meta-regression with the smallest P value (less
than 0.1) was the effect of difference in serum LDL cholesterol
between intervention and control arms and cardiovascular events.
Pooled results of dietary fat trials indicate that reduction or modi-
fication of dietary fat intake does significantly reduce the incidence
of combined cardiovascular events. The effect is consistent with a
benefit as large as a 23% reduction, or as small as a 4% reduction,
with a best estimate of 14% reduction in events (the first version
of this review suggested an effect of 16% with slightly wider confi-
dence intervals). This effect is seen almost exclusively in those who
continue to modify their diet over at least two years. Duration of
intervention does appear to be crucial. In the 4S trial (4S 1994)
4,444 participants were followed for roughly 19,339 person-years
of observation, amean of 4.35 years each. TheKaplan-Meier curve
for all-cause mortality for the 4S trial only showed a clear separa-
tion between the two randomisation groups at roughly two years.
For this reason trials within the systematic review were grouped in
the first version of this review into those with a mean follow-up of
two years or less, and those with mean follow-up of more than two
years. In our meta-analysis, studies of at least two years duration
reduced the risk of cardiovascular events (by 22%) while studies
shorter than 2 years did not (best estimate of effect was a reduc-
tion in risk of 5%), Analysis 7.17. The trials with follow-up times
from 6 months to 2 years may be diluting the effect of the trials
with more than two years follow-up in the overall meta-analysis.
Despite this meta-regression of study duration vs. cardiovascular
events does not suggest a statically significant relationship. This
may be due to confounding effect of the diet being less rigorously
adhered to over longer durations, but we have no evidence of this.
Total mortality was examined as it is an important outcome, and
there is little likelihood of ascertainment or diagnostic bias which
may occur with cause-specific event outcomes. The data follow a
similar trend, with no effect in the shorter trials and a suggestion
of benefit in the trials of more than two years, but here the trend
is not significant (the rate ratio for total mortality was 0.98 overall
in the 2000 version of this review, and the relative risk is 0.98
in this version), with a relative risk of 1.05 in trials with mean
follow-up of two years or less, 0.97 in trials with a mean follow-up
of more than two years). This pattern suggests that the effects of
dietary fat modification will take time to manifest themselves, and
there is little evidence of immediate effects of fat reduction and/or
modification on factors such as thrombosis. The main effects of
dietary fat reduction and modification are likely to be on the scale
and type of atherosclerotic plaque, but other mechanisms may be
operating.
Participants level of risk
As the rate of events is higher in high risk groups (by definition),
it should require smaller sample sizes and shorter follow up to
observe an effect of an intervention in a high risk group of par-
ticipants (Davey Smith 1993). There have been suggestions that
randomised controlled trials are unsuitable for assessing the effec-
tiveness of interventions with very modest levels of effect in low
risk populations, because of the huge numbers of person-years
of observation needed to gain sufficient statistical power to avoid
Type II errors (Ebrahim 1997). However, with the publication of
the Women’s Health Intervention trial (WHI with CVD 2006;
WHI without CVD 2006) we now have data on more cardiovas-
cular events in people at low risk of cardiovascular disease (3408
events) than in people with moderate (143 events) or high risk
(1336 events). The same is true for cardiovascular deaths (879,
23 and 505 respectively) and total mortality (3717, 47, and 528
deaths respectively). Given reasonable sized data sets for those at
both high and low risk of cardiovascular disease, a similar level
of risk reduction of combined cardiovascular events was seen in
high and low risk groups (a 7% reduction in risk, or RR 0.93),
but this effect only reaches statistical significance in the high risk
participants. The reason for this is unclear.
When endpoints such as total mortality are used the situation be-
comes more difficult as in low risk groups the proportion of deaths
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which are unrelated to cardiovascular disease (and perhaps unlikely
to be influenced by dietary fat changes) rises, again diluting any
differences in the numbers of deaths between intervention and
control groups. It is more likely that significant changes in car-
diovascular deaths will be seen than in total mortality. The trend
is certainly in this direction (pooled relative risk for total mortal-
ity 0.98, 95%CI 0.93 to 1.04, for cardiovascular mortality 0.94,
95%CI 0.85 to 1.04). Our best estimate is that dietary fat reduc-
tion and modification result in a reduction of 6% in deaths due to
cardiovascular disease, and a reduction of 2% in total deaths, but
the confidence intervals are wide.
The high risk participants in the dietary fat trials all show evi-
dence of cardiovascular disease at baseline. Under current guide-
lines most high risk participants with raised lipid levels should
be on lipid lowering medication (ACC/AHA 2008; Fraker 2007;
NICE 2006). This raises the question of whether there is any
additional advantage of adherence to a low or modified fat diet
in addition to statin therapy. Little evidence exists at present to
answer this question. However, in all parts of the world where
drug budgets are restricted and use of lipid lowering medication
remains rationed even for those at high risk the use of modified
fat diets would appear to be a cost-effective option leading to con-
siderable reductions in cardiovascular events for populations (and
so in health budgets) in only a few years.
Low risk participants are unlikely to be on lipid lowering medi-
cation under current guidelines. The suggestion of protection of
this group from cardiovascular events, with a reduction of roughly
7% of events, by dietary fat modification (even though this does
not reach statistical significance, but taking into account our best
estimate) would appear to merit continued public health action.
Low fat or modified fat diets
An individuals dietary intake is a complex mixture of foods, each
of which is a complex mixture of nutrients. Altering one dietary
component leads to unintentional alterations inmany others, each
of whichmay have positive or negative effects on several risk factors
and, eventually, health.
The fat interventions included in this review were low fat diets
(where total fat is reduced, and energy is usually replaced by in-
creasing carbohydrate intake), modified fat diets (where a propor-
tion of saturated fat is replaced by unsaturated fats, and total fat
intakes do not alter) and combinations of the two (with some fat
reduction and some replacement with unsaturates). Modified fat
diets appear to have rather better effects on major cardiovascular
risk factors than reduced fat diets in indirect comparison, but not
in direct comparisons (where the numbers of studies and partici-
pants are small). The indirect comparison data fits with data from
Mensink 1992, suggesting that low fat, high carbohydrate diets
are likely to result in higher triglyceride and lower HDL choles-
terol levels than diets where saturated fats are wholly replaced by
unsaturated fats, but direct comparisons will be important in con-
firming this.
It is important that individuals and populations are receiving clear,
evidence-based advice about the types of dietary fat changes which
are most effective in reducing cardiovascular risk, as well as ways
to achieve those changes. Further research comparing low fat and
modified fat changes on cardiovascular disease risk factors would
be feasible and helpful.
This review suggests that modified fat intake, or modified and
reduced fat intake combined (but not reduced fat intake alone)
are protective against combined cardiovascular events. No clear
effects of these interventions on total or cardiovascular mortality
were seen.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Dietary change to reduce saturated fat and partly replace it with
unsaturated fats appears to reduce the incidence of cardiovascular
events, but replacing the saturated fat with carbohydrate (creating
a low fat diet) was not clearly protective of cardiovascular events
(despite small improvements in weight, body mass index, total and
LDL cholesterol). The protective effect was seen almost exclusively
in those who continue to modify their diet over at least two years,
and in studies of men (not those of women). Dietary advice to
those at high risk of cardiovascular disease (particularly where lipid
lowering medication may not be available), and probably also to
lower risk population groups, should continue to include dietary
fat modification, possibly as part of a Mediterranean dietary pat-
tern, and it should be stressed that this is a permanent pattern of
eating.
Effects on total and cardiovascular mortality are much less clear.
No evidence was found on the long term health effects of altering
trans fat intake.
Implications for research
Long term research to help us understand what types of unsat-
urated fats are most useful in the diet when replacing saturated
fats (monounsaturated fats, polyunsaturated fats and the relevant
specific fatty acids) are urgently needed.
The financial implications (costs and savings) of appropriate ad-
vice and legislation to modify fat intake in those at various levels
of cardiovascular risk should be assessed and reflected in health
policy. Whilst interventions to alter dietary fat intake in individ-
uals at high cardiovascular risk have been fairly successful, such
health promotion initiatives in the general population have been
less successful. Further work is needed to help high and low risk
individuals to make effective changes to dietary fat and to main-
tain these changes over their lifetimes. Research into the effects of
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legislation to alter fat contents of foods, improved labelling, pric-
ing initiatives and improved availability of healthier foods, linking
food production and processing into the health agenda may yield
huge advances in this area.
It is not clear whether there is additional benefit of modifying di-
etary fat in those at high risk of cardiovascular disease who are on
lipid lowering medication. Further research to examine the need
for maintenance of dietary fat modification whilst on lipid lower-
ing medication would be useful, but not as useful as understand-
ing specific dietary fat replacements for saturated fat.
No trials assessing the long term health implications of reducing
trans fat intake were found, and most trials did not report trans fat
intake in intervention and control arms, so the evidence on long
term impact of trans fat alteration rests on intermediate outcomes
only. Long term trials of reductions in trans fats would be helpful
to clarify effects on cardiovascular health and mortality.
A C K N OW L E D G E M E N T S
The help of the following investigators in providing informa-
tion about their own and others trials is gratefully acknowledged:
H Arnesen (Ullevål University Hospital), AV Astrup (University
of Copenhagen), K Aziz (NICVD, Karachi), F Azizi (Research
Institute for Endocrine Sciences, Tehran), SAA Beresford (Uni-
versity of Washington), HS Black (Baylor College of Medicine),
BPM Bloemberg (National Institute of Public Health and Envi-
ronmental Protection, Netherlands), DJ Bowen (Fred Hutchin-
son Cancer Research Center, Seattle), NF Boyd (University of
Toronto), GA Bray (Pennington Biomedical Research Center, Ba-
ton Rouge), ML Burr (University of Wales), G Carruba (Univer-
sity of Palermo), L Castagnetta (University of Palermo), JL Curzio
(University of Glasgow), RFDeBusk (Stanford University), CDe-
foort (Méditerranée University), Z Djuric (Wayne State Univer-
sity), A Due (University of Copenhagen), S Druker (University
of Massachusetts), RPF Dullaart (University Hospital, Gronin-
gen), GE Eyssen (University of Toronto), TM Hayes (University
Hospital of Wales, Cardiff ), JA Heady (retired, formerly of MRC
Social Medicine Research Unit), J Hebert (University of South
Carolina), RJ Heine (Free University Hospital, Amsterdam), M-
L Hellenius (Karolinska Institute), RF Heller (University of New-
castle), TDR Hockaday (retired, formerly Radcliffe Infirmary),
L-E Holm (Swedish Radiation Protection Institute), DJ Hyman
(Baylor College of Medicine, Houston), AFM Kardinaal (Univer-
sity of Wageningen), F Khan (Ninewells Hospital and Medical
School, Dundee), RH Knopp (University of Washington), D La-
iron (Méditerranée University), MEJ Lean (University of Glas-
gow), B Leelarthaepin (University of Sydney), P Leren (University
of Oslo), A Lindman (University of Oslo), S Mackey (Stanford
University), R MacLennan (retired, formerly of Queensland In-
stitute of Medical Research), F Macrae (Royal Melbourne Hospi-
tal), JI Mann (University of Otago), J Marniemi (Social Insurance
Institute), K McManus (Harvard Medical School), RP Mensink
(Maastricht University), PA Metcalf (University of Aukland), A
Michalsen (University Duisburg-Essen), TFMoy (Johns Hopkins
University), AR Ness (University of Bristol), I Okene (Univer-
sity of Massachusetts), GS Oostenbrug (Maastricht University), J
Pierce (University of California, San Diego), SD Poppitt (Univer-
sity of Aukland), RJ Reber (University of Illinois), JE Reseland
(University of Oslo), BM Retzlaff (University of Washington),
AARivellese (Federico II University, Naples), P Roderick (Univer-
sity of Southampton), DP Rose (American Health Foundation),
FM Sacks (Harvard School of Public Health), WHM Saris (Uni-
versity of Maastricht), ES Sarkkinen (University of Kuopio), A
Schatzkin (National Cancer Institute), B Seppelt (German Insti-
tute of Human Nutrition), MS Simon (Wayne State University),
B Smith (University of Kentucky), E Søndergaard (Svendborg
Hospital, Svendborg), AS St. Leger (University of Manchester),
VJ Stevens (Kaiser Permanente Centre for Health Research), A
Stoddard (University of Massachusetts), LP Svetkey (Duke Uni-
versity Medical Center), LC Tapsell (University of Wollongong),
BC Tilley (Medical University of South Carolina), H van den
Berg (TNO Nutrition and Food Research Institute), W van Her-
pen (Unilever), K van het Hof (Unilever, Rotterdam), MW Ver-
heijden (Wageningen University), GF Watts (University Hospi-
tal of Perth), AS Wierzbichi (St. Thomas’s Hospital, London),
PTWilliams (Stanford University), RRWing (University of Pitts-
burgh), PD Wood (Stanford University), I Zazpe (University of
Navarra), PL Zock (Wageningen Centre for Food Studies).
The expertise and help of the following is also gratefully acknowl-
edged: S Adams (Royal Free Hospital, London), B Anagnostelis
(Royal Free Hospital, London), M Brand (Cochrane Hyperten-
sion Group), R Clarke (Universtiy of Oxford), D Darrah-Morgan
(Russian translation), A Donner (University of Western Ontario),
D Fagard (University of East Anglia for duplication of inclusion
and data extraction), ShwetaGidwani (University ofManchester),
G Gubitz (Cochrane Stroke Group), M Haugh (Cochrane Renal
Group), IUHaq (NorthernGeneralHospital, Sheffield), JHooper
(Danish, Swedish and Norwegian translation), BKHurley (Italian
translation), L Jones (Systematic Reviews Training Unit, London),
SPH Keen (Cochrane Diabetes Group), S Logan (Systematic Re-
views Training Unit, London), LI Mennen (INSERM), T Moore
(CochraneHeartGroup), JMuscroft (German and French transla-
tion), HLNewmark (Rutgers), E Royle (Cochrane Peripheral Vas-
cular Diseases Group), I Tumur (Pfizer Ltd), AS Truswell (Univer-
sity of Sydney), M Turner (Chinese translation), JMWalsh (Uni-
versity of California), A Wierzbicki (St. Thomas’ Hospital, Lon-
don), WCWillett (Harvard School of Public Health), AFWinder
(University of London).
Many thanks to those people who were co-authors of the first
version of this review: Julian PTHiggins, Shah Ebrahim, Rudolph
Riemersma, Nigel E Capps and Gillian Clements, and to those
38Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
reviewers who worked on study inclusion, data extraction and/
or assessment of validity for the update but who are not authors
(Indra Tumur and Dorotheé Fagard).
R E F E R E N C E S
References to studies included in this review
Anderson 1990 {published and unpublished data}
∗ Anderson JW, Garrity TF, Smith BM, Whitis SE. Follow-
up on a clinical trial comparing the effects of two lipid
lowering diets. Arteriosclerosis 1990;10(5):882a.
Anderson JW, Garrity TF, Wood CL, Whitis SE, Smith
BM, Oeltgen PR. Prospective, randomized, controlled
comparison of the effects of low-fat and low-fat plus high-
fiber diets on serum lipid concentrations. American Journal
of Clinical Nutrition 1992;56(5):887–94.
Azadbakht 2007 {published and unpublished data}
Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi F. Better
dietary adherence and weight maintenance achieved by a
long-term moderate fat diet. British Journal of Nutrition
2007;97:399–404.
Ball 1965 {published data only}
Ball KP, Hanington E, McAllen PM, Pilkington TRE,
Richards JM, Sharland DE, et al.Low-fat diet in myocardial
infarction: A controlled trial. Lancet 1965;2(411):501–4.
BDIT Pilot Studies 1996 {published and unpublished data}
Boyd NF, Cousins M, Beaton M, Fishell E, Wright B, Fish
E, et al.Clinical trial of low-fat, high-carbohydrate diet in
subjects with mammographic dysplasia: report of early
outcomes. Journal of the National Cancer Institute 1988;80:
1244–8.
Boyd NF, Cousins M, Beaton M, Han L, McGuire V.
Methodological issues in clinical trials of dietary fat
reduction in patients with breast dysplasia. Progress in
Clininical and Biological Research 1986;222:117–24.
Boyd NF, Cousins M, Beaton M, Kriukov V, Lockwood G,
Tritchler D. Quantitative changes in dietary fat intake and
serum cholesterol in women: results from a randomized,
controlled trial. American Journal of Clinical Nutrition
1990;52(3):470–6.
Boyd NF, Cousins M, Kriukov V. A randomised controlled
trial of dietary fat reduction: the retention of subjects and
characteristics of drop outs. Journal of Clinical Epidemiology
1992;45(1):31–8.
Boyd NF, Cousins M, Lockwood G, Tritchler D. Dietary
fat and breast cancer risk: the feasibility of a clinical trial of
breast cancer prevention. Lipids 1992;27(10):821–6.
Boyd NF, Cousins M, Lockwood G, Tritchler D. The
feasibility of testing experimentally the dietary fat-breast
cancer hypothesis. Progress in Clinical and Biological Research
1990;346:231–41.
∗ Boyd NF, Martin LJ, Beaton M, Cousins M, Kriukov V.
Long-term effects of participation in a randomized trial
of a low-fat, high-carbohydrate diet. Cancer Epidemiology,
Biomarkers & Prevention 1996;5(3):217–22.
Lee-Han H, Cousins M, Beaton M, McGuire V, Kriukov V,
Chipman M, et al.Compliance in a randomized clinical trial
of dietary fat reduction in patients with breast dysplasia.
American Journal of Clinical Nutrition 1988;48(3):575–86.
beFIT 1997 {published and unpublished data}
Retzlaff BM, Walden CE, McNeney WB, Buck BL,
McCann BS, Knopp RH. Nutritional intake of women and
men on the NCEP Step I and Step II diets. Journal of the
American College of Nutrition 1997;16(1):52–61.
∗ Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp
RH. Lipoprotein lipid response to the National Cholesterol
Education Program Step II diet by hypercholesterolemic and
combined hyperlipidemic women and men. Arteriosclerosis,
Thrombosis and Vascular Biology 1997;17:375–82.
Walden CE, Retzlaff BM, Buck BL, Wallick S, McCann
BS, Knopp RH. Differential effect of National Cholesterol
Education Program (NCEP) Step II Diet on HDL
cholesterol, its subfractions, and apoprotein A-1 levels
in hypercholesterolemic women and men after 1 year:
the beFIT study. Arteriosclerosis, Thrombosis and Vascular
Biology 2000;20(6):1580–7.
Black 1994 {published and unpublished data}
∗ Black HS, Herd JA, Goldberg LH, Wolf-JE J, Thornby JI,
Rosen T, et al.Effect of a low-fat diet on the incidence of
actinic keratosis. New England Journal of Medicine 1994;
330(18):1272–5.
Black HS, Thornby JI, Wolf-JE J, Goldberg LH, Herd
JA, Rosen T, et al.Evidence that a low-fat diet reduces the
occurrence of non-melanoma skin cancer. International
Journal of Cancer 1995;62(2):165–9.
Jaax S, Scott LW, Wolf-JE J, Thornby JI, Black HS. General
guidelines for a low-fat diet effective in the management
and prevention of nonmelanoma skin cancer. Nutrition and
Cancer 1997;27(2):150–6.
Boyd 1988 {published and unpublished data}
Boyd NF, McGuire V, Shannon P, Cousins M, Kriukov V,
Mahoney L, et al.Effect of a low-fat high-carbohydrate diet
on symptoms of cyclical mastopathy. Lancet 1988;2(8603):
128–32.
BRIDGES 2001 {published and unpublished data}
Hebert JR, Ebbeling CB, Olendzki BC, Hurley TG, Ma
Y, Saal N, et al.Change in women’s diet and body mass
following intensive intervention for early-stage breast cancer.
Journal of the American Dietetic Association 2001;101(4):
421–31.
39Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CARMEN 2000 {published and unpublished data}
Poppitt SD, Keogh GF, Prentice AM, Williams DEM,
Sonnemans HMW, Valk EEJ, et al.Long-term effects of ad
libitum low-fat, high-carbohydrate diets on body weight
and serum lipids in overweight subjects with metabolic
syndrome. American Journal of Clinical Nutrition 2002;75:
11–20.
Raben A, Astrup A, Vasilaras TH, Prentice AM,
Zunft H-JF, Formiguera X, et al.The CARMEN study
[CARMEN–studiet]. Ugeskrift fur Laeger 2002;164(5):
627–31.
Saris WHM, Astrup A, Prentice AM, Zunft FJF, Formiguera
X. CARMEN Project: European multicentre study on the
impact of dietary fat/CHO ratio and simple/complex CHO
changes on long term weight control in overweight subjects.
International Journal of Obesity 1997;21(Suppl 2):S71.
∗ Saris WHM, Astrup A, Prentice AM, Zunft HJF,
Formiguera X, Verboeket-van de Venne WPHG, et
al.Randomized controlled trial of changes in dietary
carbohydrate/fat ratio and simple vs complex carbohydrates
on body weight and blood lipids: the CARMEN study.
International Journal of Obesity 2000;24:1310–8.
Vasilaras TH, Astrup A, Raben A. Micronutrient intake in
overweight subjects is not deficient on and ad libitum fat-
reduced, high-simple carbohydrate diet. European Journal of
Clinical Nutrition 2004;58:326–36.
CARMENMS sub-study 2002 {published and unpublished data}
Poppitt SD, Keogh GF, Prentice AM, Williams DEM,
Sonnemans HMW, Valk EEJ, et al.Long-term effects of ad
libitum low-fat, high-carbohydrate diets on body weight
and serum lipids in overweight subjects with metabolic
syndrome. American Journal of Clinical Nutrition 2002;75:
11–20.
Curzio 1989 {published and unpublished data}
Curzio JL, Kennedy SS, Elliott HL, Farish E, Barnes
JF, Howie CA, et al.Hypercholesterolaemia in treated
hypertensives: a controlled trial of intensive dietary advice.
Journal of Hypertension. Supplement 1989;7(6):S254–5.
DART 1989 {published and unpublished data}
Burr ML, Fehily AM. Fish and the heart. Lancet 1989;ii:
1450–2.
∗ Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM,
Sweetnam PM, et al.Effects of changes in fat, fish, and fibre
intakes on death and myocardial reinfarction: diet and
reinfarction trial (DART). Lancet 1989;2(8666):757–61.
Burr ML, Fehily AM, Rogers S, Welsby E, King S, Sandham
S. Diet and reinfarction trial (DART): design, recruitment,
and compliance. European Heart Journal 1989;10(6):
558–67.
Burr ML, Holliday RM, Fehily AM, Whitehead PJ.
Haematological prognostic indices after myocardial
infarction: evidence from the diet and reinfarction trial
(DART). European Heart Journal 1992;13(2):166–70.
Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction
[letter]. European Heart Journal 1994;15(8):1152–3.
Fehily AM, Vaughan-Williams E, Shiels K, Williams AH,
Horner M, Bingham G, et al.The effect of dietary advice
on nutrient intakes: evidence from the diet and reinfarction
trial (DART). Journal of Human Nutrition & Dietetics 1989;
2(4):225–5.
DO IT 2006 {published and unpublished data}
Berstad P, Seljeflot I, Veierod MB, Hjerkinn EM, Arnesen
H, Pedersen JI, et al.Supplementation with fish oil affects
the association between very long-chain n-3 polyunsaturated
fatty acids in serum non-esterified fatty acids and soluble
vascular cell adhesion molecule-1. Clinical Science 2003;
105(1):13–20.
Ellingsen I, Hjerkinn EM, Seljeflot I, Arnesen H, Tonstad
S, Ellingsen I, et al.Consumption of fruit and berries is
inversely associated with carotid atherosclerosis in elderly
men.[Erratum appears in British Journal of Nutrition 2008;
99(3):697]. British Journal of Nutrition 2008;99(3):674–81.
Ellingsen I, Seljeflot I, Arnesen H, Tonstad S, Ellingsen
Ingrid, Seljeflot Ingebjorg, et al.Vitamin C consumption is
associated with less progression in carotid intima media
thickness in elderly men: A 3-year intervention study.
Nutrition Metabolism & Cardiovascular Diseases 2009;19(1):
8–14.
Furenes EB, Seljeflot I, Solheim S, Hjerkinn EM, Arnesen
H, Furenes EB, et al.Long-term influence of diet and/or
omega-3 fatty acids on matrix metalloproteinase-9 and
pregnancy-associated plasma protein-A in men at high risk
of coronary heart disease. Scandinavian Journal of Clinical
& Laboratory Investigation 2008;68(3):177–84.
∗ Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L,
Ellingsen I, Seljeflot I, et al.Effect of diet or very long
chain omega-3 fatty acids on progression of atherosclerosis,
evaluated by carotid plaques, intima-media thickness
and by pulse wave propagation in elderly men with
hypercholesterolaemia. European Journal of Cardiovascular
Prevention & Rehabilitation 2006;13(3):325–33.
Hjerkinn EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann
I, Sandvik L, et al.Influence of long-term intervention with
dietary counselling, long-chain n-3 fatty acid supplements,
or both on circulating markers of endothelial activation in
men with long-standing hyperlipidemia. American Journal
of Clinical Nutrition 2005;81(3):583–9.
Lindman AS, Pedersen JI, Hjerkinn EM, Arnesen H,
Veierod MB, Ellingsen I, et al.The effects of long-term diet
and omega-3 fatty acid supplementation on coagulation
factor VII and serum phospholipids with special emphasis
on the R353Q polymorphism of the FVII gene. Thrombosis
& Haemostasis 2004;91(6):1097–104.
Troseid M, Arnesen H, Hjerkinn EM, Seljeflot I. Serum
levels of interleukin-18 are reduced by diet and n-3 fatty
acid intervention in elderly high-risk men. Metabolism:
Clinical & Experimental 2009;58(11):1543–9.
Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H.
Interleukin-18 is a strong predictor of cardiovascular events
in elderly men with the metabolic syndrome: synergistic
effect of inflammation and hyperglycemia. Diabetes Care
2009;32(3):486–92.
Due Low fat 2008 {published and unpublished data}
Due A, Larsen TM, Hermansen K, Stender S, Holst
40Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
JJ, Toubro S, et al.Comparison of the effects on
insulin resistance and glucose tolerance of 6-mo high-
monounsaturated-fat, low-fat, and control diets. American
Journal of Clinical Nutrition 2008;87(4):855–62.
∗ Due A, Larsen TM, Mu H, Hermansen K, Stender S,
Astrup A. Comparison of 3 ad libitum diets for weight-loss
maintenance, risk of cardiovascular disease, and diabetes:
a 6-mo randomized, controlled trial. American Journal of
Clinical Nutrition 2008;88(5):1232–41.
Rasmussen LG, Larsen TM, Mortensen PK, Due A, Astrup
A. Effect on 24-h energy expenditure of a moderate-fat diet
high in monounsaturated fatty acids compared with that of
a low-fat, carbohydrate-rich diet: a 6-mo controlled dietary
intervention trial. American Journal of Clinical Nutrition
2007;85(4):1014–22.
Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup
A, et al.The effect of a high-MUFA, low-glycaemic index
diet and a low-fat diet on appetite and glucose metabolism
during a 6-month weight maintenance period. British
Journal of Nutrition 2009;101(12):1846–58.
Due Low vs Mod 2008 {published and unpublished data}
Due A, Larsen TM, Hermansen K, Stender S, Holst
JJ, Toubro S, et al.Comparison of the effects on
insulin resistance and glucose tolerance of 6-mo high-
monounsaturated-fat, low-fat, and control diets. American
Journal of Clinical Nutrition 2008;87(4):855–62.
∗ Due A, Larsen TM, Mu H, Hermansen K, Stender
S, Astrup A, et al.Comparison of 3 ad libitum diets for
weight-loss maintenance, risk of cardiovascular disease, and
diabetes: a 6-mo randomized, controlled trial. American
Journal of Clinical Nutrition 2008;88(5):1232–41.
Rasmussen LG, Larsen TM, Mortensen PK, Due A, Astrup
A. Effect on 24-h energy expenditure of a moderate-fat diet
high in monounsaturated fatty acids compared with that of
a low-fat, carbohydrate-rich diet: a 6-mo controlled dietary
intervention trial. American Journal of Clinical Nutrition
2007;85(4):1014–22.
Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup
A, et al.The effect of a high-MUFA, low-glycaemic index
diet and a low-fat diet on appetite and glucose metabolism
during a 6-month weight maintenance period. British
Journal of Nutrition 2009;101(12):1846–58.
Due Mod fat 2008 {published and unpublished data}
Due A, Larsen TM, Hermansen K, Stender S, Holst
JJ, Toubro S, et al.Comparison of the effects on
insulin resistance and glucose tolerance of 6-mo high-
monounsaturated-fat, low-fat, and control diets. American
Journal of Clinical Nutrition 2008;87(4):855–62.
∗ Due A, Larsen TM, Mu H, Hermansen K, Stender
S, Astrup A, et al.Comparison of 3 ad libitum diets for
weight-loss maintenance, risk of cardiovascular disease, and
diabetes: a 6-mo randomized, controlled trial. American
Journal of Clinical Nutrition 2008;88(5):1232–41.
Rasmussen LG, Larsen TM, Mortensen PK, Due A, Astrup
A. Effect on 24-h energy expenditure of a moderate-fat diet
high in monounsaturated fatty acids compared with that of
a low-fat, carbohydrate-rich diet: a 6-mo controlled dietary
intervention trial. American Journal of Clinical Nutrition
2007;85(4):1014–22.
Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup
A, et al.The effect of a high-MUFA, low-glycaemic index
diet and a low-fat diet on appetite and glucose metabolism
during a 6-month weight maintenance period. British
Journal of Nutrition 2009;101(12):1846–58.
Dullaart 1992 {published and unpublished data}
Dullaart RP, Beusekamp BJ, Meijer S, Hoogenberg K, van
DJ, Sluiter WJ. Long-term effects of linoleic-acid-enriched
diet on albuminuria and lipid levels in type 1 (insulin-
dependent) diabetic patients with elevated urinary albumin
excretion. Diabetologia 1992;35(2):165–72.
Frenkiel 1986 {published data only}
Frenkiel PG, Lee DW, Cohen H, Gilmore CJ, Resser K,
Bonorris GG, et al.The effect of diet on bile acid kinetics
and biliary lipid secretion in gallstone patients treated with
ursodeoxycholic acid. American Journal of Clinical Nutrition
1986;43(2):239–50.
Houtsmuller 1979 {published data only}
Houtsmuller AJ, van Hal-Ferwerda J, Zahn KJ, Henkes HE.
Favourable influences of linoleic acid on the progression
of diabetic micro- and macroangiopathy. Nutrition and
Metabolism 1980;24(Suppl 1):105–18.
Houtsmuller AJ, van Hal-Ferwerda J, Zahn KJ, Henkes HE.
Influence of different diets on the progression of diabetic
retinopathy. Progress in Food Nutritition and Science 1980;4
(5):41–6.
∗ Houtsmuller AJ, Zahn KJ, Henkes HE. Unsaturated
fats and progression of diabetic retinopathy. Documenta
Ophthalmologia 1979;48(2):363–71.
Lean 1997 {published and unpublished data}
Han TS, Richmond P, Avenell A, Lean ME. Waist
circumference reduction and cardiovascular benefits during
weight loss in women. International Journal of Obesity and
Related Metabolic Disorders 1997;21(2):127–34.
∗ Lean MEJ, Han TS, Prvan T, Richmond PR, Avenell A.
Weight loss with high and low carbohydrate 1200 kcal diets
in free living women. European Journal of Clinical Nutrition
1997;51(4):243–8.
Ley 2004 {published and unpublished data}
∗ Ley SJ,Metcalf PA, Scragg RKR, Swinburn BA. Long-term
effects of a reduced fat diet intervention on cardiovascular
disease risk factors in individuals with glucose intolerance.
Diabetes Research and Clinical Practice 2004;63:103–12.
Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year)
effects of a reduced-fat diet intervention in individuals with
glucose intolerance. Diabetes Care 2001;24(4):619–24.
Swinburn BA, Woollard GA, Chang EC, Wilson MR.
Effects of reduced-fat diets consumed ad libitum on intake
of nutrients particularly antioxidant vitamins. Journal of the
American Dietetic Association 1999;99(11):1400–5.
McAuley 2005 {published and unpublished data}
∗ McAuley KA, Hopkins CM, Smith KJ, McLay RT,
Williams SM, Taylor RW, et al.Comparison of a high-fat
41Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and high-protein diets with a high-carbohydrate diet in
insulin-resistant obese women. Diabetologia 2005;48:8–16.
McAuley KA, Smith KJ, Taylor RW, McLay RT, Williams
SM, Mann JI. Long-term effects of popular dietary
approaches on weight loss and features of insulin resistance.
International Journal of Obesity 2006;30:342–9.
McKeown-Eyssen 1994 {published and unpublished data}
McKeown-Eyssen GE, Bright SE, Bruce WR, Jazmaji V. A
randomized trial of a low fat high fibre diet in the recurrence
of colorectal polyps. Journal of Clinical Epidemiology 1994;
47(5):525–36.
MeDiet 2002 {published and unpublished data}
Carruba G, Granata OM, Pala V, Campisi I, Agostara
B, Cusimano R, et al.A traditional Mediterranean diet
decreases endogenous estrogens in healthy postmenopausal
women. Nutrition and Cancer 2006;56(2):253–9.
∗ Castagnetta L, Granata OM, Cusimano R, Ravazzolo B,
Liquori M, Polito L, et al.The Mediet Project. Annals of the
New York Academy of Science 2002;963:282–9.
Granata OM, Traina A, Ramirez S, Campisi I, Zarcone M,
Amodio R, et al.Dietary enterolactone affects androgen and
estrogen levels in healthy postmenopausal women. Annals
of the New York Academy of Science 2009;1155:232–6.
Minnesota Coron men 1989 {published data only}
Brewer ER, Ashman PL, Kuba K. The Minnesota Coronary
Survey: composition of diets, adherence and serum lipid
response [Abstract]. Circulation 1975;51 and 52(Suppl II):
269.
Dawson EA, Gatewood LC. The Minnesota Coronary
Survey: methodology and characteristics of the population
[Abstract]. Circulation 1975;51 and 52(Suppl II):271.
Frantz ID, Dawson EA, Kuba K, et al.The Minnesota
Coronary Survey: effect of diet on cardiovascular events and
deaths [abstract]. Circulation 1975;51 and 52(Suppl II):4.
∗ Frantz ID Jr, Dawson EA, Ashman PL, Gatewood LC,
Bartsch GE, Kuba K, et al.Test of effect of lipid lowering
by diet on cardiovascular risk. The Minnesota Coronary
Survey. Arteriosclerosis 1989;9(1):129–35.
Minnesota Coron women1989 {published data only}
Brewer ER, Ashman PL, Kuba K. The Minnesota Coronary
Survey: composition of diets, adherence and serum lipid
response [Abstract]. Circulation 1975;51 and 52(Suppl II):
269.
Dawson EA, Gatewood LC. The Minnesota Coronary
Survey: methodology and characteristics of the population
[Abstract]. Circulation 1975;51 and 52(Suppl II):271.
Frantz ID, Dawson EA, Kuba K, et al.The Minnesota
Coronary Survey: effect of diet on cardiovascular events and
deaths [abstract]. Circulation 1975;51 and 52(Suppl II):4.
∗ Frantz ID Jr, Dawson EA, Ashman PL, Gatewood LC,
Bartsch GE, Kuba K, et al.Test of effect of lipid lowering
by diet on cardiovascular risk. The Minnesota Coronary
Survey. Arteriosclerosis 1989;9(1):129–35.
Moy 2001 {published and unpublished data}
Moy TF, Yanek LR, Raqueno JV, Bezirdjian PJ, Blumenthal
RS, Wilder LB, et al.Dietary counseling for high blood
cholesterol in families at risk of coronary disease. Preventive
Cardiology 2001;4(4):158–64.
MRC 1968 {published and unpublished data}
Ederer F, Leren P, Turpeinen O, Frantz ID Jr. Cancer
among men on cholesterol lowering diets: experience of five
clinical trials. Lancet 1971;2:203–6.
Heady JA. Are PUFA harmful?. British Medical Journal
1974;1(898):115–6.
∗ MRC. Controlled trial of soya-bean oil in myocardial
infarction. Lancet 1968;2(570):693–9.
MSFAT 1997 {published and unpublished data}
∗ van het Hoff K, Weststrate JA, van-den BH, Velthuis-
te WE, de Graaf C, Zimmermanns NJ, et al.A long-term
study on the effect of spontaneous consumption of reduced
fat products as part of a normal diet on indicators of health.
International Journal of Food Sciences and Nutrition 1997;48
(1):19–29.
Velthuis-te WE, van-den BH, Weststrate JA, van het Hoff
K, de Graaf C. Consumption of reduced-fat products:
effects on parameters of anti-oxidative capacity. European
Journal of Clinical Nutrition 1996;50(4):214–9.
Velthuis-te WE, van Leeuwen REW, Hendriks HF,
Verhagen H, Loft S, Poulsen HE, et al.Short-term moderate
energy restriction does not affect indicators of oxidative
stress and genotoxicity in humans. Journal of Nutrition
1995;125:2631–9.
Weststrate JA, van het Hof KH, van den Berg H, Velthuis-te
WE, de Graaf C, Zimmermanns NJ, et al.A comparison of
the effect of free access to reduced fat products or their full
fat equivalents on food intake, body weight, blood lipids
and fat-soluble antioxidants levels and haemostasis variables.
European Journal of Clinical Nutrition 1998;52:389–95.
NDHS Faribault 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;26
(5):133–6.
∗ The national diet-heart study final report. Circulation
1968;37(II):1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al.The National Diet-Heart Study: An initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
Dietetic Association 1968;52:279–87.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
NDHS Open 1st L&M 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;26
(5):133–6.
∗ The national diet-heart study final report. Circulation
1968;37(II):1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al.The National Diet-Heart Study: An initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
42Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dietetic Association 1968;52:279–87.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
NDHS Open 1st mod 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;26
(5):133–6.
∗ The national diet-heart study final report. Circulation
1968;37(II):1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al.The National Diet-Heart Study: An initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
Dietetic Association 1968;52:279–87.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
NDHS Open 2nd L&M 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;26
(5):133–6.
∗ The national diet-heart study final report. Circulation
1968;37(II):1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al.The National Diet-Heart Study: An initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
Dietetic Association 1968;52:279–87.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
NDHS Open 2nd Mod 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;26
(5):133–6.
∗ The national diet-heart study final report. Circulation
1968;37(II):1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al.The National Diet-Heart Study: An initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
Dietetic Association 1968;52:279–87.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
Nutrition & Breast Health {published and unpublished data}
Djuric Z, Poore KM, Depper JB, Uhley VE, Lababidi S,
Covington C, et al.Methods to increase fruit and vegetable
intake with and without a decrease in fat intake: compliance
and effects on body weight in the Nutrition and Breast
Health Study. Nutrition and Cancer 2002;43(2):141–51.
Ole Study 2002 {published and unpublished data}
∗ Bray GA, Lovejoy JC, Most-Windhauser M, Smith SR,
Volaufova J, Denkins Y, et al.A 9-mo randomized clinical
trial comparing fat-substituted and fat-reduced diets in
healthy obese men: the Ole Study. American Journal of
Clinical Nutrition 2002;76:928–34.
Lovejoy JC, Bray GA, Lefevre M, Smith SR, Most MM,
Denkins YM, et al.Consumption of a controlled low-fat diet
containing olestra for 9 months improves health risk factors
in conjunction with weight loss in obese men: the Ole
Study. International Journal of Obesity 2003;27:1242–9.
Oslo Diet-Heart 1966 {published and unpublished data}
Leren P. Prevention of coronary heart disease, some results
from the Oslo secondary and primary intervention studies.
Journal of the American College of Nutrition 1989;8:407–10.
∗ Leren P. The effect of plasma cholesterol lowering diet
in male survivors of myocardial infarction. A controlled
clinical trial. Acta Medica Scandinavia. Supplementum
1966;466:1–92.
Leren P. The effect of plasma-cholesterol-lowering diet
in male survivors of myocardial infarction. A controlled
clinical trial. Bulletin of the New York Academy of Medicine
1968;44:1012–20.
Leren P. The Oslo diet-heart study. Eleven year report.
Circulation 1970;42:935–42.
Leren P. The effect of a cholesterol lowering diet in male
survivors of myocardial infarction. (A controlled clinical
trial) [Virkningen av cholesterolsenkende diett hos menn
som har gjennomgatt hjerteinfarkt. Et kontrollert klinisk
fors/ok]. Nordisk Medicin 1967;77(21):658–61.
Oxford Retinopathy 1978 {published and unpublished data}
Coppack SW, Doll HA, Pim B, Hockaday TDR.
Intravenous glucose tollerance and mortality in non-insulin-
dependant diabetes mellitus. Quarterly Journal of Medicine
1990;75:451–60.
Hillson RM, Hockaday TDR, Mann JI, Newton DJ.
Hyperinsulinaemia is associated with development of ECG
abnormalities in diabetics. Diabetes Research 1984;1:143–9.
∗ Hockaday TD, Hockaday JM, Mann JI, Turner RC.
Prospective comparison of modified fat-high-carbohydrate
with standard low-carbohydrate dietary advice in the
treatment of diabetes: one year follow-up study. British
Journal of Nutrition 1978;39(2):357–62.
Howard-Williams J, Patel P, Jelfs R, Carter RD, Awdry
P, Bron A, et al.Polyunsaturated fatty acids and diabetic
retinopathy. British Journal of Ophthalmology 1985;69(1):
15–8.
Lopez-Espinoza I, Howard WJ, Mann JI, Carter RD,
Hockaday TD. Fatty acid composition of platelet
phospholipids in non-insulin-dependent diabetics
randomized for dietary advice. British Journal of Nutrition
1984;52(1):41–7.
Polyp Prevention 1996 {published and unpublished data}
Lanza E, Schatzkin A, Ballard BR, Clifford DC, Paskett
E, Hayes D, et al.The polyp prevention trial II: dietary
intervention program and participant baseline dietary
characteristics. Cancer Epidemiology, Biomarkers and
Prevention 1996;5(5):385–92.
∗ Schatzkin A, Lanza E, Freedman LS, Tangrea J, Cooper
MR, Marshall JR, et al.The polyp prevention trial I:
rationale, design, recruitment, and baseline participant
characteristics. Cancer Epidemiology, Biomarkers and
Prevention 1996;5(5):375–83.
43Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PREMIER 2003 {published and unpublished data}
∗ Appel LJ, Champagne CM, Harsha DW, Cooper LS,
Obarzanek E, Elmer PJ, et al.Effects of comprehensive
lifestyle modification on blood pressure control: main
results of the PREMIER clinical trial. JAMA 2003;289(16):
2083–93.
Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton
D, Stevens VJ, Young DR, et al.Effects of comprehensive
lifestyle modification on diet, weight, physical fitness, and
blood pressure control: 18-month results of a randomized
trial. Annals of Internal Medicine 2006;144(7):485–95.
Ledikwe JH, Rolls BJ, Smiciklas-Wright H, Mitchell DC,
Ard JD, Champagne C, et al.Reductions in dietary energy
density are associated with weight loss in overweight and
obese participants in the PREMIER trial. American Journal
of Clinical Nutrition 2007;85(5):1212–21.
Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein
AC, et al.Effects of PREMIER lifestyle modifications on
participants with and without the metabolic syndrome.
Hypertension 2007;50(4):609–16.
Lin PH, Appel LJ, Funk K, Craddick S, Chen C, Elmer
P, et al.The PREMIER intervention helps participants
follow the Dietary Approaches to Stop Hypertension
dietary pattern and the current Dietary Reference Intakes
recommendations. Journal of the American Dietetic
Association 2007;107(9):1541–51.
Maruthur NM, Wang NY, Appel LJ, Maruthur Nisa M,
Wang Nae Yuh, Appel Lawrence J. Lifestyle interventions
reduce coronary heart disease risk: results from the
PREMIER Trial. Circulation 2009;119(15):2026–31.
McGuire HL, Svetkey LP, Harsha DW, Elmer PJ, Appel LJ,
Ard JD. Comprehensive lifestyle modification and blood
pressure control: a review of the PREMIER trial. Journal of
clinical hypertension (Greenwich., Conn.) 2004;6(7):383–90.
Obarzanek E, Vollmer WM, Lin PH, Cooper LS, Young
DR, Ard JD, et al.Effects of individual components of
multiple behavior changes: the PREMIER trial. American
Journal of Health Behavior 2007;31(5):545–60.
Svetkey LP, Erlinger TP, Vollmer WM, Feldstein A, Cooper
LS, Appel LJ, et al.Effect of lifestyle modifications on blood
pressure by race, sex, hypertension status, and age. Journal
of Human Hypertension 2005;19(1):21–31.
Svetkey LP, Harsha DW, Vollmer WM, Stevens VJ,
Obarzanek E, Elmer PJ, et al.Premier: a clinical trial of
comprehensive lifestyle modification for blood pressure
control: rationale, design and baseline characteristics.
Annals of Epidemiology 2003;13(6):462–71.
Rivellese 1994 {published and unpublished data}
Rivellese AA, Auletta P, Marotta G, Saldalamacchia G,
Giacoo A, Mastrilli V, et al.Long term metabolic effects
of two dietary methods of treating hyperlipidaemia. BMJ
1994;308:227–31.
Rose 1965 {published data only}
Rose GA, Thomson WB, Williams RT. Corn oil in
treatment of ischaemic heart disease. British Medical Journal
1965;1:1531–3.
Sacks high protein 2009 {published and unpublished data}
Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton
SD, et al.Comparison of weight-loss diets with different
compositions of fat, protein, and carbohydrates. New
England Journal of Medicine 2009;360(9):859–73.
Sacks low protein 2009 {published and unpublished data}
Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton
SD, et al.Comparison of weight-loss diets with different
compositions of fat, protein, and carbohydrates. New
England Journal of Medicine 2009;360(9):859–73.
Sarkkinen Fat Mod 1995 {published and unpublished data}
Makinen E, Uusitupa MI, Pietinen P, Aro A, Penttila I.
Long term effects of three fat modified diets on serum lipids
in free living hypercholesterolaemic subjects (abstract).
European Heart Journal 1991;12:162.
∗ Sarkkinen, E. Long-term feasibility and effects of three
different fat-modified diets in free-living hypercholesterolemic
subjects. Kuopio, Finland: Univ. of Kuopio, 1995.
Sarkkinen ES, Agren JJ, Ahola I, Ovaskainen ML, Uusitupa
MI. Fatty acid composition of serum cholesterol esters, and
erythrocyte and platelet membranes as indicators of long-
term adherence to fat-modified diets. American Journal of
Clinical Nutrition 1994;59(2):364–70.
Sarkkinen ES, Uusitupa MI, Nyyssonen K, Parviainen
M, Penttila I, Salonen JT. Effects of two low-fat diets,
high and low in polyunsaturated fatty acids, on plasma
lipid peroxides and serum vitamin E levels in free-living
hypercholesterolaemic men. European Journal of Clinical
Nutrition 1993;47(9):623–30.
Sarkkinen ES, Uusitupa MI, Pietinen P, Aro A, Ahola I,
Penttila I, et al.Long-term effects of three fat-modified diets
in hypercholesterolemic subjects. Atherosclerosis 1994;105
(1):9–23.
Uusitupa MI, Sarkkinen ES, Torpstrom J, Pietinen P, Aro
A. Long-term effects of four fat-modified diets on blood
pressure. Journal of Human Hypertension 1994;8(3):209–18.
Sarkkinen Red & Mod 1995 {published and unpublished data}
Makinen E, Uusitupa MI, Pietinen P, Aro A, Penttila I.
Long term effects of three fat modified diets on serum lipids
in free living hypercholesterolaemic subjects (abstract).
European Heart Journal 1991;12:162.
∗ Sarkkinen, E. Long-term feasibility and effects of three
different fat-modified diets in free-living hypercholesterolemic
subjects. Kuopio, Finland: Univ. of Kuopio, 1995.
Sarkkinen ES, Agren JJ, Ahola I, Ovaskainen ML, Uusitupa
MI. Fatty acid composition of serum cholesterol esters, and
erythrocyte and platelet membranes as indicators of long-
term adherence to fat-modified diets. American Journal of
Clinical Nutrition 1994;59(2):364–70.
Sarkkinen ES, Uusitupa MI, Nyyssonen K, Parviainen
M, Penttila I, Salonen JT. Effects of two low-fat diets,
high and low in polyunsaturated fatty acids, on plasma
lipid peroxides and serum vitamin E levels in free-living
hypercholesterolaemic men. European Journal of Clinical
Nutrition 1993;47(9):623–30.
Sarkkinen ES, Uusitupa MI, Pietinen P, Aro A, Ahola I,
Penttila I, et al.Long-term effects of three fat-modified diets
44Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in hypercholesterolemic subjects. Atherosclerosis 1994;105
(1):9–23.
Uusitupa MI, Sarkkinen ES, Torpstrom J, Pietinen P, Aro
A. Long-term effects of four fat-modified diets on blood
pressure. Journal of Human Hypertension 1994;8(3):209–18.
Sarkkinen Red Fat 1995 {published and unpublished data}
Makinen E, Uusitupa MI, Pietinen P, Aro A, Penttila I.
Long term effects of three fat modified diets on serum lipids
in free living hypercholesterolaemic subjects (abstract).
European Heart Journal 1991;12:162.
∗ Sarkkinen, E. Long-term feasibility and effects of three
different fat-modified diets in free-living hypercholesterolemic
subjects. Kuopio, Finland: Univ. of Kuopio, 1995.
Sarkkinen ES, Agren JJ, Ahola I, Ovaskainen ML, Uusitupa
MI. Fatty acid composition of serum cholesterol esters, and
erythrocyte and platelet membranes as indicators of long-
term adherence to fat-modified diets. American Journal of
Clinical Nutrition 1994;59(2):364–70.
Sarkkinen ES, Uusitupa MI, Nyyssonen K, Parviainen
M, Penttila I, Salonen JT. Effects of two low-fat diets,
high and low in polyunsaturated fatty acids, on plasma
lipid peroxides and serum vitamin E levels in free-living
hypercholesterolaemic men. European Journal of Clinical
Nutrition 1993;47(9):623–30.
Sarkkinen ES, Uusitupa MI, Pietinen P, Aro A, Ahola I,
Penttila I, et al.Long-term effects of three fat-modified diets
in hypercholesterolemic subjects. Atherosclerosis 1994;105
(1):9–23.
Uusitupa MI, Sarkkinen ES, Torpstrom J, Pietinen P, Aro
A. Long-term effects of four fat-modified diets on blood
pressure. Journal of Human Hypertension 1994;8(3):209–18.
Sarkkinen Red vs Mod1995 {published and unpublished data}
Makinen E, Uusitupa MI, Pietinen P, Aro A, Penttila I.
Long term effects of three fat modified diets on serum lipids
in free living hypercholesterolaemic subjects (abstract).
European Heart Journal 1991;12:162.
∗ Sarkkinen, E. Long-term feasibility and effects of three
different fat-modified diets in free-living hypercholesterolemic
subjects. Kuopio, Finland: Univ. of Kuopio, 1995.
Sarkkinen ES, Agren JJ, Ahola I, Ovaskainen ML, Uusitupa
MI. Fatty acid composition of serum cholesterol esters, and
erythrocyte and platelet membranes as indicators of long-
term adherence to fat-modified diets. American Journal of
Clinical Nutrition 1994;59(2):364–70.
Sarkkinen ES, Uusitupa MI, Nyyssonen K, Parviainen
M, Penttila I, Salonen JT. Effects of two low-fat diets,
high and low in polyunsaturated fatty acids, on plasma
lipid peroxides and serum vitamin E levels in free-living
hypercholesterolaemic men. European Journal of Clinical
Nutrition 1993;47(9):623–30.
Sarkkinen ES, Uusitupa MI, Pietinen P, Aro A, Ahola I,
Penttila I, et al.Long-term effects of three fat-modified diets
in hypercholesterolemic subjects. Atherosclerosis 1994;105
(1):9–23.
Uusitupa MI, Sarkkinen ES, Torpstrom J, Pietinen P, Aro
A. Long-term effects of four fat-modified diets on blood
pressure. Journal of Human Hypertension 1994;8(3):209–18.
Seppelt 1996 {published and unpublished data}
Seppelt B, Weststrate JA, Reinert A, Johnson D, Luder
W, Zunft HJ. Long-term effects of nutrition with fat-
reduced foods on energy consumption and body weight
[Langzeiteffekte einer Ernährung mit fettreduzierten
Lebensmitteln auf die Energieaufnahme und das
Körpergewicht]. Zeitschrift für Ernährungswissenschaft 1996;
35(4):369–77.
Simon 1997 {published and unpublished data}
Djuric Z, Heilbrun LK, Reading BA, Boomer A, Valeriote
FA, Martino S. Effects of a low fat diet on levels of oxidative
damage to DNA in human peripheral nucleated blood cells.
Journal of the National Cancer Institute 1991;83(11):766–9.
Djuric Z, Martino S, Heilbrun LK, Hart RW. Dietary
modulation of oxidative DNA damage. Advances In
Experimental Medicine and Biology 1994;354:71–83.
Kasim SE, Martino S, Kim P-N, Khilnani S, Boomer A,
Depper J, et al.Dietary and anthropometric determinants
of plasma lipoproteins during a long-term low-fat diet in
healthy women. American Journal of Clinical Nutrition
1993;57:146–53.
∗ Simon MS, Heilbrun LK, Boomer A, Kresge C, Depper
J, Kim PN, et al.A randomised trial of a low-fat dietary
intervention in women at high risk for breast cancer.
Nutrition and Cancer 1997;27(2):136–42.
Sondergaard 2003 {published and unpublished data}
Sondergaard E, Moller JE, Egstrup K. Effect of dietary
intervention and lipid-lowering treatment on brachial
vasoreactivity in patients with ischemic heart disease and
hypercholesterolemia. American Heart Journal 2003;145
(5):E19.
STARS 1992 {published and unpublished data}
Blann AD, Jackson P, Bath PM, Watts GF. von Willebrand
factor, a possible indicator of endothelial cell damage,
decreases during long-term compliance with a lipid-lowering
diet. Journal of Internal Medicine 1995;237:557–61.
Watts GF. Nutritional, metabolic, and genetic determinants
of the progression of coronary heart disease. STARS Group.
Journal of Cardiovascular Pharmacology 1995;25(Suppl 4):
S11–9.
Watts GF, Brunt JNH, Coltart DJ, Lewis B. The St.
Thomas Atherosclerosis Regression Study (STARS).
Atherosclerosis 1992;97:231.
Watts GF, Jackson P, Burke V, Lewis B. Dietary fatty acids
and progression of coronary artery disease in men. American
Journal of Clinical Nutrition 1996;64:202–9.
Watts GF, Jackson P, Mandalia S, Brunt JN, Lewis ES,
Coltart DJ, et al.Nutrient intake and progression of
coronary artery disease. American Journal of Cardiology
1994;73(5):328–32.
∗ Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ,
Smith LD, et al.Effects on coronary artery disease of lipid-
lowering diet, or diet plus cholestyramine, in the St Thomas’
Atherosclerosis Regression Study (STARS). Lancet 1992;
45Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
339(8793):563–9.
Watts GF, Lewis B, Brunt JNH, Swan AV. Coronary
Atheroma Regression Trials. Lancet 1992;339(i):1241–3.
Watts GF, Lewis B, Jackson P, Burke V, Lewis ES, Brunt JN,
et al.Relationships between nutrient intake and progression/
regression of coronary atherosclerosis as assessed by serial
quantitative angiography. Canadian Journal of Cardiology
1995;11(Suppl G):110G–4G.
Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart
DJ, Lewis B. Independent associations between plasma
lipoprotein subfraction levels and the course of coronary
artery disease in the St. Thomas’ Atherosclerosis Regression
Study (STARS). Metabolism: Clinical and Experimental
1993;42:1461–7.
Watts GF, Mandalia S, Slavin BM, Brunt JN, Coltart DJ,
Lewis B. Metabolic determinants of the course of coronary
artery disease in men. Clinical Chemistry 1994;40(12):
2240–6.
Strychar 2009 {published and unpublished data}
Strychar I, Cohn JS, Renier G, Rivard M, ris-Jilwan
N, Beauregard H, et al.Effects of a diet higher in
carbohydrate/lower in fat versus lower in carbohydrate/
higher in monounsaturated fat on postmeal triglyceride
concentrations and other cardiovascular risk factors in type
1 diabetes. Diabetes Care 2009;32(9):1597–9.
Sydney Diet-Heart 1978 {published and unpublished data}
Blacket RB, Leelarthaepin B, McGilchrist C, Palmer AJ,
Woodhill JM. The synergistic effect of weight loss and
changes in dietary lipids on the serum cholesterol of
obese men with hypercholesterolaemia: implications for
prevention of coronary heart disease. Australian and New
Zealand Journal of Medicine 1979;9:521–9.
∗ Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist
C, Blacket RB. Low fat, low cholesterol diet in secondary
prevention of coronary heart disease. Advances in
Experimental Medicine and Biology 1978;109:317–30.
THIS DIET 2008 {published data only}
Tuttle KR, Shuler LA, Packard DP, Milton JE, Daratha
KB, Bibus DM, et al.Comparison of low-fat versus
Mediterranean-style dietary intervention after first
myocardial infarction (from The Heart Institute of Spokane
Diet Intervention and Evaluation Trial). American Journal
of Cardiology 2008;101(11):1523–30.
Veterans Admin 1969 {published data only}
Dayton S, Hashimoto S, DixonW, PearceML. Composition
of lipids in human serum and adipose tissue during
prolonged feeding of a diet high in unsaturated fat. Journal
of Lipid Research 1966;7:103–11.
Dayton S, Hashimoto S, Pearce ML. Adipose tissue linoleic
acid as a criterion of adherence to a modified diet. Journal
of Lipid Research 1967;8:508–10.
Dayton S, Hashimoto S, Pearce ML. Influence of a diet
high in unsaturated fat upon composition of arterial tissue
and atheromata in man. Circulation 1965;32:911–24.
Dayton S, Hashimoto S, Rosenblum D, Pearce M. Vitamin
E status of humans during prolonged feeding of unsaturated
fats. Journal of Laboratory and Clinical Medicine 1965;65
(5):739–47.
Dayton S, Pearce ML. Diet and atherosclerosis. Lancet
1970;1(644):473–4.
Dayton S, Pearce ML. Diet and cardiovascular diseases.
Lancet 1969;1(584):51–2.
Dayton S, Pearce ML. Diet high in unsaturated fat: a
controlled clinical trial. Minnesota Medicine 1969;1969:
1237–42.
Dayton S, Pearce ML. Prevention of coronary heart disease
and other complications of atherosclerosis by modified diet.
American Journal of Medicine 1969;46:751–62.
Dayton S, Pearce ML. Trial of unsaturated-fat diet. Lancet
1968;2(581):1296–7.
Dayton S, Pearce ML, Goldman H, Harnish A, Plotkin
D, Shickman M, et al.Controlled trial of a diet high
in unsaturated fat for prevention of atherosclerotic
complications. Lancet 1968;2(577):1060–2.
∗ Dayton S, PearceML, Hashimoto S, DixonWJ, Tomayasu
U. A controlled clinical trial of a diet high in unsaturated fat
in preventing complications of atherosclerosis. Circulation
1969;15(1, Suppl 2):II–1-63.
Dayton S, Pearce ML, Hashimoto S, Fakler LJ, Hiscock
E, Dixon WJ. A controlled clinical trial of a diet high in
unsaturated fat. New England Journal of Medicine 1962;
266:1017–23.
Hiscock E, Dayton S, Pearce ML, Hashimoto S. A palatable
diet high in unsaturated fat. Journal of the American Dietetic
Association 1962;40:427–31.
Pearce ML, Dayton S. Incidence of cancer in men on a diet
high in polyunsaturated fat. Lancet 1971;1(697):464–7.
Sturdevant RA, Pearce ML, Dayton S. Increased prevalence
of cholelithiasis in men ingesting a serum-cholesterol-
lowering diet. New England Journal of Medicine 1973;288
(1):24–7.
Tompkins MJ, Dayton S, Pearce ML. Effect of long-term
feeding of various fats on whole blood clotting times in
men. Journal of Laboratory and Clinical Medicine 1964;64
(5):763–72.
WHEL 2007 {published data only}
Bardwell WA, Profant J, Casden DR, Dimsdale JE, ncoli-
Israel S, Natarajan L, et al.The relative importance of
specific risk factors for insomnia in women treated for early-
stage breast cancer. Psycho-Oncology 2008;17(1):9–18.
Caan BJ, Flatt SW, Rock CL, Ritenbaugh C, Newman
V, Pierce JP, et al.Low-energy reporting in women at risk
for breast cancer recurrence. Women’s Healthy Eating
and Living Group. Cancer Epidemiology, Biomarkers &
Prevention 2000;9(10):1091–7.
Gold EB, Flatt SW, Pierce JP, Bardwell WA, Hajek RA,
Newman VA, et al.Dietary factors and vasomotor symptoms
in breast cancer survivors: the WHEL Study. Menopause
2006;13(3):423–33.
Gold EB, Pierce JP, Natarajan L, Stefanick ML, Laughlin
GA, Caan BJ, et al.Dietary pattern influences breast cancer
prognosis in women without hot flashes: the women’s
healthy eating and living trial. Journal of Clinical Oncology
46Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2009;27(3):352–9.
Hernandez-Valero MA, Thomson CA, Hernandez M, Tran
T, Detry MA, Theriault RL, et al.Comparison of baseline
dietary intake of Hispanic and matched non-Hispanic white
breast cancer survivors enrolled in the Women’s Healthy
Eating and Living study. Journal of the American Dietetic
Association 2008;108(8):1323–9.
Hong S, Bardwell WA, Natarajan L, Flatt SW, Rock CL,
Newman VA, et al.Correlates of physical activity level
in breast cancer survivors participating in the Women’s
Healthy Eating and Living (WHEL) Study. Breast Cancer
Research & Treatment 2007;101(2):225–32.
Hyder JA, Thomson CA, Natarajan L, Madlensky L, Pu
M, Emond J, et al.Adopting a plant-based diet minimally
increased food costs in WHEL Study. American Journal of
Health Behavior 2009;33(5):530–9.
Madlensky L, Natarajan L, Flatt SW, Faerber S, Newman
VA, Pierce JP, et al.Timing of dietary change in response to
a telephone counseling intervention: evidence from the
WHEL study. Health Psychology 2008;27(5):539–47.
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L,
Natarajan L, et al.Tamoxifen, hot flashes and recurrence in
breast cancer. Breast Cancer Research & Treatment 2008;108
(3):421–6.
Newman VA, Thomson CA, Rock CL, Flatt SW, Kealey S,
Bardwell WA, et al.Achieving substantial changes in eating
behavior among women previously treated for breast cancer:
an overview of the intervention. Journal of the American
Dietetic Association 2005;105(3):382–91.
Pierce JP. Diet and breast cancer prognosis: making sense
of the Women’s Healthy Eating and Living and Women’s
Intervention Nutrition Study trials. Current Opinion in
Obstetrics & Gynecology 2009;21(1):86–91.
Pierce JP, Faerber S, Wright FA, Rock CL, Newman V,
Flatt SW, et al.A randomized trial of the effect of a plant-
based dietary pattern on additional breast cancer events and
survival: the Women’s Healthy Eating and Living (WHEL)
Study. Controlled Clinical Trials 2002;23(6):728–56.
Pierce JP, Natarajan L, Caan BJ, Flatt SW, Kealey S, Gold
EB, et al.Dietary change and reduced breast cancer events
among women without hot flashes after treatment of early-
stage breast cancer: subgroup analysis of the Women’s
Healthy Eating and Living Study. American Journal of
Clinical Nutrition 2009;89(5):1565S–71S.
∗ Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER,
Flatt SW, et al.Influence of a diet very high in vegetables,
fruit, and fiber and low in fat on prognosis following
treatment for breast cancer: the Women’s Healthy Eating
and Living (WHEL) randomized trial. JAMA 2007;298(3):
289–98.
Pierce JP, Natarajan L, Sun S, Al-Delaimy W, Flatt SW,
Kealey S, et al.Increases in plasma carotenoid concentrations
in response to a major dietary change in the women’s healthy
eating and living study. Cancer Epidemiology, Biomarkers &
Prevention 2006;15(10):1886–92.
Pierce JP, Newman VA, Flatt SW, Faerber S, Rock CL,
Natarajan L, et al.Telephone counseling intervention
increases intakes of micronutrient- and phytochemical-rich
vegetables, fruit and fiber in breast cancer survivors. Journal
of Nutrition 2004;134(2):452–8.
Pierce JPF. A randomized trial of the effect of a plant-
based dietary pattern on additional breast cancer events and
survival: The Women’s Healthy Eating and Living (WHEL)
Study. Controlled Clinical Trials 2002;23(6):728–56.
Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson
CA, Natarajan L, et al.Reproductive steroid hormones and
recurrence-free survival in women with a history of breast
cancer. Cancer Epidemiology, Biomarkers & Prevention 2008;
17(3):614–20.
Rock CL, Flatt SW, Newman V, Caan BJ, Haan MN,
Stefanick ML, et al.Factors associated with weight gain in
women after diagnosis of breast cancer. Women’s Healthy
Eating and Living Study Group. Journal of the American
Dietetic Association 1999;99(10):1212–21.
Rock CL, Flatt SW, Thomson CA, Stefanick ML, Newman
VA, Jones L, et al.Plasma triacylglycerol and HDL
cholesterol concentrations confirm self-reported changes in
carbohydrate and fat intakes in women in a diet intervention
trial. Journal of Nutrition 2004;134(2):342–7.
Rock CL, Natarajan L, PuM, Thomson CA, Flatt SW, Caan
BJ, et al.Longitudinal biological exposure to carotenoids is
associated with breast cancer-free survival in the Women’s
Healthy Eating and Living Study. Cancer Epidemiology,
Biomarkers & Prevention 2009;18(2):486–94.
Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell
WA, Caan B, et al.Weight gain and recovery of pre-cancer
weight after breast cancer treatments: evidence from the
women’s healthy eating and living (WHEL) study. Breast
Cancer Research & Treatment 2007;105(2):177–86.
Saxe GA, Madlensky L, Kealey S, Wu DP, Freeman KL,
Pierce JP, et al.Disclosure to physicians of CAM use by
breast cancer patients: findings from the Women’s Healthy
Eating and Living Study. Integrative Cancer Therapies 2008;
7(3):122–9.
WHI with CVD 2006 {published data only}
Anderson G, Cummings S, Freedman LS, Furberg C,
Henderson M, Johnson SR, et al.Design of the Women’s
Health Initiative clinical trial and observational study.
Controlled Clinical Trials 1998;19(1):61–109.
∗ Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick
ML, Wassertheil-Smoller S, et al.Low-fat dietary pattern
and risk of cardiovascular disease: the Women’s Health
Initiative Randomized Controlled Dietary Modification
Trial. JAMA 2006;295(6):655–66.
Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford
C, McGowan JA. The evolution of the Women’s Health
Initiative: perspectives from the NIH. Journal of the
American Medical Women’s Association 1995;50(2):50–5.
WHI without CVD 2006 {published data only}
Anderson G, Cummings S, Freedman LS, Furberg C,
Henderson M, Johnson SR, et al.Design of the Women’s
Health Initiative clinical trial and observational study.
Controlled Clinical Trials 1998;19(1):61–109.
Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis
47Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S, et al.Implementation of the Women’s Health Initiative
study design. Annals of Epidemiology 2003;13(9 Suppl):
S5–17.
Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL,
Snetselaar LG, Black HR, et al.Low-fat dietary pattern and
risk of colorectal cancer: the Women’s Health Initiative
Randomized Controlled Dietary Modification Trial. JAMA
2006;295(6):643–54.
Bowen D, Ehret C, Pedersen M, Snetselaar L, Johnson M,
Tinker L, et al.Results of an adjunct dietary intervention
program in the Women’s Health Initiative. Journal of the
American Dietetic Association 2002;102(11):1631–7.
Curb JD, McTiernan A, Heckbert SR, Kooperberg C,
Stanford J, Nevitt M, et al.Outcomes ascertainment and
adjudication methods in the Women’s Health Initiative.
Annals of Epidemiology 2003;13(9 Suppl):S122–8.
Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M,
Allen C, et al.The Women’s Health Initiative recruitment
methods and results. Annals of Epidemiology 2003;13(9
Suppl):S18–77.
Hebert JR, Patterson RE, Gorfine M, Ebbeling CB, St Jeor
ST, Chlebowski RT, et al.Differences between estimated
caloric requirements and self-reported caloric intake in the
women’s health initiative. Annals of Epidemiology 2003;13
(9):629–37.
Howard BV. Dietary fat and cardiovascular disease: putting
the Women’s Health Initiative in perspective. Nutrition
Metabolism & Cardiovascular Diseases 2007;17(3):171–4.
Howard BV, Manson JE, Stefanick ML, Beresford SA,
Frank G, Jones B, et al.Low-fat dietary pattern and weight
change over 7 years: the Women’s Health Initiative Dietary
Modification Trial. JAMA 2006;295(1):39–49.
∗ Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick
ML, Wassertheil-Smoller S, et al.Low-fat dietary pattern
and risk of cardiovascular disease: the Women’s Health
Initiative Randomized Controlled Dietary Modification
Trial. JAMA 2006;295(6):655–66.
Neuhouser ML, Tinker L, Shaw PA, Schoeller D, Bingham
SA, Horn LV, et al.Use of recovery biomarkers to calibrate
nutrient consumption self-reports in the Women’s Health
Initiative. American Journal of Epidemiology 2008;167(10):
1247–59.
Patterson RE, Kristal A, Rodabough R, Caan B, Lillington
L, Mossavar-Rahmani Y, et al.Changes in food sources
of dietary fat in response to an intensive low-fat dietary
intervention: early results from the Women’s Health
Initiative. Journal of the American Dietetic Association 2003;
103(4):454–60.
Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton
MP, gurs-Collins T, et al.Measurement characteristics of the
Women’s Health Initiative food frequency questionnaire.
Annals of Epidemiology 1999;9(3):178–87.
Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller
LH, Ockene JK, et al.Low-fat dietary pattern and risk
of invasive breast cancer: the Women’s Health Initiative
Randomized Controlled Dietary Modification Trial. JAMA
2006;295(6):629–42.
Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson
GL, Beresford SA, et al.Low-fat dietary pattern and
cancer incidence in the Women’s Health Initiative Dietary
Modification Randomized Controlled Trial. Journal of the
National Cancer Institute 2007;99(20):1534–43.
Ritenbaugh C, Patterson RE, Chlebowski RT, Caan B,
Fels-Tinker L, Howard B, et al.The Women’s Health
Initiative Dietary Modification trial: overview and baseline
characteristics of participants. Annals of Epidemiology 2003;
13(9 Suppl):S87–97.
Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford
C, McGowan JA. The evolution of the Women’s Health
Initiative: perspectives from the NIH. Journal of the
American Medical Women’s Association 1995;50(2):50–5.
The Women’s Health Initiative Study Group. Design of the
Women’s Health Initiative clinical trial and observational
study. Controlled Clinical Trials 1998;19(1):61–109.
Tinker LF, Bonds DE, Margolis KL, Manson JE, Howard
BV, Larson J, et al.Low-fat dietary pattern and risk of
treated diabetes mellitus in postmenopausal women: the
Women’s Health Initiative randomized controlled dietary
modification trial. Archives of Internal Medicine 2008;168
(14):1500–11.
Tinker LF, Perri MG, Patterson RE, Bowen DJ, McIntosh
M, Parker LM, et al.The effects of physical and emotional
status on adherence to a low-fat dietary pattern in the
Women’s Health Initiative. Journal of the American Dietetic
Association 2002;102(6):789–800.
Tinker LF, Rosal MC, Young AF, Perri MG, Patterson
RE, Van Horn L, et al.Predictors of dietary change and
maintenance in the Women’s Health Initiative Dietary
Modification Trial. Journal of the American Dietetic
Association 2007;107(7):1155–66.
Women’s Health Initiative Study Group. Dietary adherence
in the Women’s Health Initiative Dietary Modification
Trial. Journal of the American Dietetic Association 2004;104
(4):654–8.
WINS 2006 {published and unpublished data}
Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP,
Martino S, Khandekar JD, et al.Adherence to a dietary
fat intake reduction program in postmenopausal women
receiving therapy for early breast cancer. The Women’s
Intervention Nutrition Study. Journal of Clinical Oncology
1993;11(11):2072–80.
∗ Chlebowski RT, Blackburn GL, Thomson CA, Nixon
DW, Shapiro A, Hoy MK, et al.Dietary fat reduction and
breast cancer outcome: interim efficacy results from the
women’s intervention nutrition study. JNCI Journal of the
National Cancer Institute 2006;98(24):1767–76.
Chlebowski RT, Rose DP, Buzzard IM, Blackburn GL, York
M, Insull W, et al.Dietary fat reduction in adjuvant breast
cancer therapy: current rationale and feasibility issues.
Adjuvant. The Cancer Journal 1990;6:357–63.
Hoy MK, Winters BL, Chlebowski RT, Papoutsakis C,
Shapiro A, Lubin MP, et al.Implementing a low-fat eating
plan in the Women’s Intervention Nutrition Study. Journal
48Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of the American Dietetic Association 2009;109(4):688–96.
Rose DP, Chlebowski RT, Connolly JM, Jones LA, Wynder
EL. Effects of tamoxifen adjuvant therapy and a low-fat
diet on serum binding proteins and estradiol bioavailability
in postmenopausal breast cancer patients. Cancer Research
1992;52:5386–90.
Rose DP, Connolly JM, Chlebowski RT, Buzzard IM,
Wynder EL. The effects of a low-fat dietary intervention
and tamoxifen adjuvant therapy on the serum estrogen
and sex hormone-binding globulin concentrations of
postmenopausal breast cancer patients. Breast Cancer
Research & Treatment 1993;27(3):253–62.
Wynder EL, Cohen LA, Winters BL. The challenges of
assessing fat intake in cancer research investigations. Journal
of the American Dietetic Association 1997;97(7 Suppl):S5–8.
References to studies excluded from this review
Agewall 2001 {published data only}
Agewall S. Multiple risk intervention trial in high risk
hypertensive men: comparison of ultrasound intima-media
thickness and clinical outcome during 6 years of follow-up.
Journal of Internal Medicine 2001;249(4):305–14.
Ammerman 2003 {published data only}
Ammerman AS, Keyserling TC, Atwood JR, Hosking JD,
Zayed H, Krasny C. A randomized controlled trial of a
public health nurse directed treatment program for rural
patients with high blood cholesterol. Preventive Medicine
2003;36(3):340–51.
Anti-Coronary C 1966 {published data only}
Christakis G, Rinzler SH, Archer M, et al.Effect of the
Anti-Coronary Club Program on coronary heart disease risk
factor status. JAMA 1969;198:129–36.
∗ Christakis G, Rinzler SH, Archer M, Maslansky E.
Summary of the research activities of the Anti-Coronary
Club. Public Health Report (Washington) 1966;81:64–70.
Jolliffe N, Baumgarter L, Rinzler SH, ArcherM, Stephenson
JH, Christakis GJ. The Anti-Coronary Club: The first four
years. New York State Journal of Medicine 1963;63:69–79.
Singman HS, Berman SN, Cowell C, Maslansky E, Archer
M. The Anti-Coronary Club: 1957-1972. American Journal
of Clinical Nutrition 1980;33(6):1183–91.
Aquilani 2000 {published data only}
Aquilani R, Tramarin R, Pedretti RFE, Bertolotti G,
Sommaruga M, Mariani P, et al.Can a very-low-fat diet
achieve cholesterol goals in CAD?. Cardiology Review 2000;
17(10):36–40.
Arntzenius 1985 {published data only}
Arntzenius AC, Kromhout D, Bartn JE, Reiber JHC,
Bruschke AVG, Buis Van Gent CM. Diet, lipoprotiens
and progression of coronary atherosclerosis: The leiden
intervention trial. New England Journal of Medicine 1985;
312:805–8.
Aro 1990 {published data only}
Aro A, Ahola I, Jauhiainen M, et al.Effects of plasma
phospholipid fatty acids of rapeseed oil and sunflower oil
diets [Abstract]. Arteriosclerosis 1990;10:877a.
ASSIST 2001 {published data only}
Moher M, Yudkin P,Wright L, Turner R, Fuller A, Schofield
T, et al.Cluster randomised controlled trial to compare three
methods of promoting secondary prevention of coronary
heart disease in primary care. BMJ 2001;322(7298):1338.
Australian Polyp Prev 95 {published and unpublished data}
MacLennan R. Effect of fat, fibre and beta-carotene on
colorectal adenomas after 24 months. Gastroenterology
1991;100:A382.
∗ MacLennan R, Macrae F, Bain C, Battistutta D, Chapuis
P, Gratten H, et al.Randomized trial of intake of fat, fiber,
and beta carotene to prevent colorectal adenomas. The
Australian Polyp Prevention Project. Journal of the National
Cancer Institute 1995;87(23):1760–6.
Macrae FA, Hughes NR, Bhathal PS, Tay D, Selbie L,
MacLennan R. Dietary suppression of rectal epthelial cell
proliferation. Gastroenterology 1991;100:A383.
Baer 1993 {published data only}
Baer JT. Improved plasma cholesterol levels in men after a
nutrition education program at the worksite. Journal of the
American Dietetic Association 1993;93(6):658–63.
Bakx 1997 {published data only}
Bakx JC, Stafleu A, van SW, van-den HH, van WC. Long-
term effect of nutritional counseling: a study in family
medicine. American Journal of Clinical Nutrition 1997;65(6
Suppl):1946S–50S.
Barnard 2009 {published data only}
Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy
G, Gloede L, Green A, et al.A low-fat vegan diet and
a conventional diabetes diet in the treatment of type
2 diabetes: a randomized, controlled, 74-wk clinical
trial. American Journal of Clinical Nutrition 2009;89(5):
1588S–96S.
Barndt 1977 {published data only}
Barndt R, Blankenhorn CH, Crawford DW, et al.Regression
and progression of early femoral atherosclerosis in treated
hyperlipidaemic patients. Annals of Internal Medicine 1977;
86:139–46.
Baron 1990 {published data only}
Baron JA, Gleason R, Crowe B, Mann JI. Preliminary trial
of the effect of general practice based nutritional advice.
British Journal of General Practice 1990;40(333):137–41.
Barr 1990 {published data only}
Barr SL, Ramakrishnan R, Holleran S. A 30% fat
diet high in polyunsaturates and a 30% fat diet high
in monounsaturates both lower total and low density
lipoprotein cholesterol levels in normal males [Abstract].
Arteriosclerosis 1990;10:872a.
Baumann 1982 {published data only}
Baumann J, Martschick R. Therapy of hyperlipidemia with
xanthinol nicotinate as opposed to low fat diet [Therapie der
Hyperlipidämie mit Xantinolnicotinat gegenüber fettarmer
Diät]. Die Medizinische Welt 1982;33(4):139–41.
Beckmann 1988 {published data only}
Beckmann SL, Os I, Kjeldsen SE, Mogensen B, Norum
KR, Hjermann I. Non-pharmacological treatment of mild
49Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
to moderate hypertension. A randomized, controlled
study--results 1 1/2 years later. Tidsskrift For Den Norske
Laegeforening 1988;108:1593–7.
Beckmann 1995 {published data only}
Beckmann SL, Os I, Kjeldsen SE, Eide IK, Westheim AS,
Hjermann I. Effect of dietary counselling on blood pressure
and arterial plasma catecholamines in primary hypertension.
American Journal of Hypertension 1995;8(7):704–11.
Beresford 1992 {published data only}
Beresford SAA, Farmer EMZ, Feingold L, Graves KL,
Sumner SK, Baker RM. Evaluation of a self-help dietary
intervention in a primary care setting. American Journal of
Public Health 1992;82:79–84.
Bergstrom 1967 {published data only}
Bergstrom G, Svanborg A. Dietary treatment of acute
myocardial infarction. Acta Medica Scandinavica 1967;181
(6):717–21.
Bierenbaum 1963 {published data only}
Bierenbaum ML, Fleischman AI, Raichelson RI, Hayton
T, Watson P. Ten year experience of modified fat diets on
younger men with coronary heart disease. Lancet 1973;i:
1404–7.
Bierenbaum ML, Green DP, Florin A, Fleischman AI,
Caldwell AB. Modified-fat dietary management of the
young male with coronary disease. A five-year report.
JAMA 1967;202(13):1119–23.
∗ Bierenbaum ML, Green DP, Gherman C, Florin A,
Caldwell AB. The effects of two low fat dietary patterns on
the blood cholesterol levels of young male coronary patients.
Journal of Chronic Diseases 1963;16:1073–83.
Bloemberg 1991 {published and unpublished data}
Bloemberg BPM, Kromhout D, Goddijn HE, Jansen A,
Obermann de Boer GL. The impact for the guidelines
for a healthy diet of the Netherlands Nutrition Council
on total and high density lipoprotein cholesterol in
hypercholesterolemic free living men. American Journal of
Epidemiology 1991;134:39–48.
Bloomgarden 1987 {published data only}
Bloomgarden ZT, Karmally W, Metzger MJ, Brothers M,
Nechemias C, Bookman J, et al.Randomized, controlled
trial of diabetic patient education: improved knowledge
without improved metabolic status. Diabetes Care 1987;10:
263–72.
Bonnema 1995 {published data only}
Bonnema SJ, Jespersen LT, Marving J, Gregersen G.
Supplementation with olive oil rather than fish oil increases
small arterial compliance in diabetic patients. Diabetes,
Nutrition and Metabolism Clinical and Experimental 1995;8:
81–7.
Bosaeus 1992 {published data only}
Bosaeus I, Belfrage L, Lindgren C, Andersson H. Olive oil
instead of butter increases net cholesterol excretion from the
small bowel. European Journal of Clinical Nutrition 1992;46
(2):111–5.
Boyar 1988 {published data only}
Boyar AP, Rose DP, Loughridge JR, Engle A, Palge A,
Laakso K, et al.Response to a diet low in total fat in women
with postmenopausal breast cancer: a pilot study. Nutrition
and Cancer 1988;11:93–9.
Brensike 1982 {published data only}
Brensike JF, Kelsey SF, Passamani ER, Fisher MR,
Richardson JM, Loh IK, et al.National Heart, Lung, and
Blood Institute type II Coronary Intervention Study:
design, methods, and baseline characteristics. Controlled
Clinical Trials 1982;3(2):91–111.
Broekmans 2003 {published and unpublished data}
Broekmans WMR, Klopping-Ketelaars IAA, Weststrate JA,
Tijburg LBM, van Poppel G, Vink AA, et al.Decreased
carotenoid concentrations due to dietary sucrose polyesters
do not affect possible markers of disease risk in humans.
Journal of Nutrition 2003;133:720–6.
Brown 1984 {published data only}
Brown GD, Whyte L, Gee MI, Crockford PM, Grace M,
Oberle K, et al.Effects of two “lipid-lowering” diets on
plasma lipid levels of patients with peripheral vascular
disease. Journal of the American Dietetic Association 1984;84
(5):546–50.
Bruce 1994 {published data only}
Bruce SL, Grove SK. The effect of a coronary artery risk
evaluation program on serum lipid values and cardiovascular
risk levels. Applied Nursing Research 1994;7(2):67–74.
Bruno 1983 {published data only}
Bruno R, Arnold C, Jacobson L, Winick M, Wynder
E. Randomized controlled trial of a nonpharmacologic
cholesterol reduction program at the worksite. Preventive
Medicine 1983;12(4):523–32.
Butcher 1990 {published data only}
Butcher LA, O’Dea K, Sinclair AJ, Parkin JD, Smith IL,
Blombery P. The effects of very low fat diets enriched with
fish or kangaroo meat on cold-induced vasoconstriction and
platelet function. Prostaglandins Leukot Essent. Fatty Acids
1990;39(3):221–6.
Butowski 1998 {published data only}
Butowski PF, Winder AF. Usual care dietary practice,
achievement and implications for medication in the
management of hypercholesterolaemia. European Heart
Journal 1998;19:1328–33.
Byers 1995 {published data only}
Byers T, Mullis R, Anderson J, Dusenbury L, Gorsky R,
Kimber C, et al.The costs and effects of a nutritional
education program following work-site cholesterol
screening. American Journal of Public Health 1995;85(5):
650–5.
Caggiula 1996 {published data only}
Caggiula AW,Watson JE, Kuller LH, Olson MB, Milas NC,
Berry M, et al.Cholesterol-lowering intervention program.
Effect of the step I diet in community office practices.
Archives of Internal Medicine 1996;156(11):1205–13.
50Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cerin 1993 {published data only}
Cerin A, Collins A, Landgren BM, Eneroth P. Hormonal
and biochemical profiles of premenstrual syndrome.
Treatment with essential fatty acids. Acta Obstetricia et
Gynecologica Scandinavica 1993;72(5):337–43.
Chan 1993 {published data only}
Chan JK, McDonald BE, Gerrard JM, Bruce VM, Weaver
BJ, Holub BJ. Effect of dietary alpha-linolenic acid and its
ratio to linolenic acid on platelet and plasma fatty acids and
thrombogenesis. Lipids 1993;28:811–7.
Chapman 1950 {published data only}
Chapman CB, Gibbons T, Henschel A. The effect of the
rice-fruit diet on the composition of the body. New England
Journal of Medicine 1950;243:899–905.
Charbonnier 1975 {published data only}
Charbonnier A, Nepveux P, Fluteau G, Fluteau D.
Immediate effects of ingestion of olive oil on the principal
lipid constituents of the plasma. Comparison with other
edible fats. Medecine & Chirurgie Digestives 1975;4:73–9.
Cheng 2004 {published data only}
Cheng C, Graziani C, Diamond JJ. Cholesterol-lowering
effect of the Food for Heart Nutrition Education Program.
Journal of the American Dietetic Association 2004;104(12):
1868–72.
Chicago CPEP 1977 {published data only}
Farinaro E, Stamler J, Upton M, et al.Plasma glucose levels:
long term effect of diet in the Chicago Coronary Prevention
Evaluation Program. Annals of Internal Medicine 1977;86:
147–54.
Chiostri 1988 {published data only}
Chiostri JE, Kwiterovich PO. Effect of American Heart
Association Phase 2 diet versus eater’s choice based diet on
hypercholesterolaemia. Circulation 1988;78(4):II–385.
Choudhury 1984 {published data only}
Choudhury S, Jackson P, Katan MB, Marenah CB, Cortese
C, Miller NE, et al.A multifactorial diet in the management
of hyperlipidaemia. Atherosclerosis 1984;50:93–103.
Clark 1997 {published data only}
Clark M, Ghandour G, Miller NH, Taylor CB, Bandura A,
DeBusk RF. Development and evaluation of a computer-
based system for dietary management of hyperlipidemia.
Journal of the American Dietetic Association 1997;97(2):
146–50.
Clifton 1992 {published data only}
Clifton PM, Wight MB, Nestel PJ. Is fat restriction
needed with HMGCoA reductase inhibitor treatment?.
Atherosclerosis 1992;93(1-2):59–70.
Cobb 1991 {published data only}
Cobb MM, Teitelbaum HS, Breslow JL. Lovastatin efficacy
in reducing low-density lipoprotein cholesterol levels on
high- vs low-fat diets. JAMA 1991;265(8):997–1001.
Cohen 1991 {published data only}
Cohen MD, D’Amico FJ, Merenstein JH. Weight reduction
in obese hypertensive patients. Family Medicine 1991;23
(1):25–8.
Cole 1988 {published data only}
Cole TG, Schmeisser D, Prewitt TE. AHA phase 3 diet
reduces cholesterol in moderately hypercholesterolemic
premenopausal women [Abstract]. Circulation 1988;78(4):
II–73.
Colquhoun 1990 {published data only}
Colquhoun DM, Moores D, Somerset SM. Comparison
of the effects of an avocado enriched and american heart
association diets on lipid levels [Abstract]. Arteriosclerosis
1990;10:875a.
Consolazio 1946 {published data only}
Consolazio FC, Forbes WH. The effects of high fat diet in
a temperate environment. Journal of Nutrition 1946;32:
195–204.
Cox 1996 {published data only}
Cox RH, Gonzales-Vigilar MCRV, Novascone MA, Silva-
Barbeau I. Impact of a cancer intervention on diet-related
cardiovascular disease risks of white and african-american
EFNEP clients. Journal of Nutrition Education 1996;28:
209–18.
Croft 1986 {published data only}
Croft PR, Brigg D, Smith S, Harrison CB, Branthwaite
A, Collins MF. How useful is weight reduction in the
management of hypertension?. Journal of the Royal College
of General Practitioners 1986;36(291):445–8.
Crouch 1986 {published data only}
Crouch M, Sallis JF, Farquar JW, et al.Personal and
mediated health counselling for sustained dietary reduction
of hypercholesterolaemia. Preventive Medicine 1986;15:
282–91.
Da Qing IGT 1997 {published data only}
Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et
al.Effects of diet and exercise in preventing NIDDM in
people with impaired glucose tolerance. The Da Qing IGT
and Diabetes Study. Diabetes Care 1997;20(4):537–44.
Dalgard 2001 {published data only}
Dalgard C, Thuroe A, Haastrup B, Haghfelt T, Stender S.
Saturated fat intake is reduced in patients with ischemic
heart disease 1 year after comprehensive counseling but
not after brief counseling. Journal of the American Dietetic
Association 2001;101(12):1420–9.
DAS 2000 {published data only}
Bovbjerg VE, McCann BS, Brief DJ, Follette WC, Retzlaff
BM, Dowdy AA, et al.Spouse support and long-term
adherence to lipid-lowering diets. American Journal of
Epidemiology 1995;141(5):451–60.
∗ Knopp RH, Retzlaff B, Walden C, Fish B, Buck B,
McCann B. One-year effects of increasingly fat-restricted,
carbohydrate-enriched diets on lipoprotein levels in free-
living subjects. Proceedings of the Society for Experimental
Biology & Medicine 2000;225(3):191–9.
Knopp RH, Walden CE, McCann BS, Retzlaff B, Dowdy
A, Gey G, Cooper MN. Serial changes in lipoprotein
51Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
cholesterol in hypercholesterolemic men treated with
alternative diets [abstract]. Arteriosclerosis 1989;9:745A.
Knopp RH, Walden CE, Retzlaff BM, McCann BS,
Dowdy AA, Albers JJ, et al.Long-term cholesterol-lowering
effects of 4 fat-restricted diets in hypercholesterolaemic and
combined hyperlipidaemic men: the Dietary Alternatives
Study. JAMA 1997;278:1509–15.
Walden CE, McCann BS, Retzlaff B, Dowdy A, Hanson
M, Fish B, et al.Alternative fat-restricted diets for
hypercholesterolemia and combined hyperlipidemia:
feasibility, design, subject recruitment, and baseline
characteristics of the dietary alternatives study. Journal of
the American College of Nutrition 1991;10(5):429–42.
DASH 1997 {published data only}
∗ Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey
LP, Sacks FM, et al.A clinical trial of the effects of dietary
patterns on blood pressure. DASH Collaborative Research
Group. New England Journal of Medicine 1997;336(16):
1117–24.
Blackburn GL. Functional foods in the prevention and
treatment of disease: significance of the Dietary Approaches
to Stop Hypertension Study. American Journal of Clinical
Nutrition 1997;66(5):1067–71.
Davey Smith 2005 {published data only}
Davey Smith G, Bracha Y, Svendsen KH, Neaton JD,
Haffner SM, Kuller LH, et al.Incidence of type 2 diabetes
in the randomized multiple risk factor intervention trial.
Annals of Internal Medicine 2005;142(5):313–22.
de Boer 1983 {published data only}
de Boer AC, Turek JV, Pannebakker MA, den OG. The
effect of diets high in polyunsaturated and high in saturated
fatty acids on blood lipids and platelet tests in patients with
coronary artery disease (CAD) [abstract]. Thrombosis and
Haemostasis 1983;50:96.
de Bont 1981 {published and unpublished data}
de Bont AJ, Baker IA, St, Sweetnam PM, Wragg KG,
Stephens SM, Hayes TM. A randomised controlled trial
of the effect of low fat diet advice on dietary response in
insulin independent diabetic women. Diabetologia 1981;21
(6):529–33.
DeBusk 1994 {published data only}
DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas
RJ, Lew HT, et al.A case-management system for coronary
risk factor modification after acute myocardial infarction
[see comments]. Annals of Internal Medicine 1994;120(9):
721–9.
Delahanty 2001 {published data only}
Delahanty LM, Hayden D, Ammerman A, Nathan
DM. Medical nutrition therapy for hypercholesterolemia
positively affects patient satisfaction and quality of life
outcomes. Annals of Behavioral Medicine 2002;24(4):
269–78.
∗ Delahanty LM, Sonnenberg LM, Hayden D, Nathan
DM. Clinical and cost outcomes of medical nutrition
therapy for hypercholesterolemia: a controlled trial. Journal
of the American Dietetic Association 2001;101(9):1012–23.
Delius 1969 {published data only}
Delius L. Treatment of hypotensive circulatory disorder [Die
Behandlung der hypotonen Kreislaufregulationsstörung].
Deutsche Medizinische Wochenschrift 1969;94(42):2172–3.
Demark 1990 {published data only}
Demark WW, Bowering J, Cohen PS. Reduced serum
cholesterol with dietary change using fat-modified and oat
bran supplemented diets. Journal of the American Dietetic
Association 1990;90(2):223–9.
Dengel 1995 {published data only}
Dengel JL, Katzel LI, Goldberg AP. Effect of an American
Heart Association diet, with or without weight loss, on
lipids in obese middle-aged and older men. American
Journal of Clinical Nutrition 1995;62(4):715–21.
Denke 1994 {published data only}
Denke MA, Grundy SM. Individual responses to a
cholesterol lowering diet in 50 men with moderate
hypercholesterolaemia. Archives of Internal Medicine 1994;
154:17–25.
Diabetes CCT 1995 {published data only}
Effect of intensive diabetes management on macrovascular
events and risk factors in the Diabetes Control and
Complications Trial. American Journal of Cardiology 1995;
75:894–903.
DIET 1998 {published data only}
Dornelas EA, Wylie-Rosett J, Swencionis C. The DIET
study: long term outcomes of a cognitive-behavioural
weight control intervention in independent-living elders.
Journal of the American Dietetic Association 1998;98(11):
1276–81.
Ding 1992 {published data only}
Ding Q. Clinical study of qianxining in the treatment of
60 cases of yang hyperactivity due to yin deficiency type of
hypertension. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih
1992;12:409-11, 388.
Dobs 1991 {published data only}
Dobs AS, Sarma PS, Wilder L. Lipid-lowering diets in
patients taking pravastatin, a new HMG-CoA reductase
inhibitor: compliance and adequacy. American Journal of
Clinical Nutrition 1991;54(4):696–700.
Duffield 1982 {published data only}
Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt
JN, Colchester AC. Treatment of hyperlipidaemia retards
progression of symptomatic femoral atherosclerosis. A
randomised controlled trial. Lancet 1983;2(8351):639–42.
∗ Duffield RG, Miller NE, Jamieson CW, Lewis B. A
controlled trial of plasma lipid reduction in peripheral
atherosclerosis--an interim report. British Journal of Surgery
1982;69(Suppl):S3–S5.
Dullaart 1997 {published and unpublished data}
Dullaart RP, Hoogenberg K, Riemens SC, Groener JE, van
TA, Sluiter WJ, et al.Cholesteryl ester transfer protein gene
polymorphism is a determinant of HDL cholesterol and of
the lipoprotein response to a lipid-lowering diet in type 1
diabetes. Diabetes 1997;46(12):2082–7.
52Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eating Patterns 1997 {published and unpublished data}
Beresford SA, Curry SJ, Kristal AR, Lazovich D, Feng Z,
Wagner EH. A dietary intervention in primary care practice:
the Eating Patterns Study. American Journal of Public Health
1997;87(4):610–6.
Ehnholm 1982 {published data only}
Ehnholm C, Huttunen JK, Pietinen P, Leino U, Mutanen
M, Kostiainen E, et al.Effect of diet on serum lipoproteins
in a population with a high risk of coronary heart disease.
New England Journal of Medicine 1982;307:850–5.
Ehnholm 1984 {published data only}
Ehnholm C, Huttunen JK, Pietinen P, Leino U, Mutanen
M, Kostiainen E, et al.Effect of a diet low in saturated fatty
acids on plasma lipids, lipoproteins, and HDL subfractions.
Arteriosclerosis 1984;4(3):265–9.
Eisenberg 1990 {published data only}
Eisenberg S. The effect of dietary substitution of
monounsaturated fatty acids with carbohydrates on
lipoprotein levels, structure, and function in a free-living
population [abstract]. Arteriosclerosis 1990;10:872A.
Elder 2000 {published data only}
Elder JP, Candelaria JI, Woodruff SI, Criqui MH, Talavera
GA, Rupp JW. Results of language for health: cardiovascular
disease nutrition education for Latino English-as-a-second-
language students. Health Education & Behavior 2000;27
(1):50–63.
Ellegard 1991 {published data only}
Ellegard L, Bosaeus I. Sterol and nutrient excretion in
ileostomists on prudent diets. European Journal of Clinical
Nutrition 1991;45(9):451–7.
Esposito 2003 {published data only}
Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M,
Marfella R, et al.Effect of weight loss and lifestyle changes
on vascular inflammatory markers in obese women: a
randomized trial. JAMA 2003;289(14):1799–804.
EUROACTION 2008 {published data only}
Wood DA, Kotseva K, Connolly S, Jennings C, Mead
A, Jones J, et al.Nurse-coordinated multidisciplinary,
family-based cardiovascular disease prevention programme
(EUROACTION) for patients with coronary heart disease
and asymptomatic individuals at high risk of cardiovascular
disease: a paired, cluster-randomised controlled trial. Lancet
2008;371(9629):1999–2012.
FARIS 1997 {published data only}
Goble A, Jackson B, Phillips P, Race E, Oliver RG,Worcester
MC. The Family Atherosclerosis Risk Intervention Study
(FARIS): risk factor profiles of patients and their relatives
following an acute cardiac event. Australian and New
Zealand Journal of Medicine 1997;27:568–77.
Fasting HGS 1997 {published data only}
Dyson PA, Hammersley MS, Morris RJ, Holman RR,
Turner RC. The Fasting Hyperglycaemia Study: II.
Randomized controlled trial of reinforced healthy-living
advice in subjects with increased but not diabetic fasting
plasma glucose. Metabolism 1997;46(12 Suppl 1):50–5.
Ferrara 2000 {published data only}
Ferrara LA, Raimondi AS, d’Episcopo L, Guida L, Dello
Russo A, Marotta T. Olive oil and reduced need for
antihypertensive medications. Archives of Internal Medicine
2000;160:837–42.
Fielding 1995 {published data only}
Fielding CJ, Havel RJ, Todd KM, Yeo KE, Schloetter MC,
Weinberg V, et al.Effects of dietary cholesterol and fat
saturation on plasma lipoproteins in an ethnically diverse
population of healthy young men. Journal of Clinical
Investigation 1995;95(2):611–8.
Finckenor 2000 {published data only}
Finckenor M. Nutrition intervention group program
based on preaction-stage-oriented change processes of the
Transtheoretical Model promotes long-term reduction
in dietary fat intake. Journal of the American Dietetic
Association 2000;100(3):335–42.
Finnish Diabet Prev 2000 {published data only}
Uusitupa M, Louheranta A, Lindstrom J, Valle T, Sundvall
J, Eriksson J, et al.The Finnish Diabetes Prevention Study.
British Journal of Nutrition 2000;83(Suppl 1):S137–42.
Finnish Mental Hosp 1972 {published data only}
∗ Miettinen M, Turpeinen O, Karvonen MJ, Elosuo
R, Paavilainen E. Effect of cholesterol-lowering diet on
mortality from coronary heart-disease and other causes: a
twelve-year clinical trial in men and women. Lancet 1972;2
(782):835–8.
Miettinen M, Turpeinen O, Karvonen MJ, Pekkarinen M,
Paavilainen E, Elosuo R. Dietary prevention of coronary
heart disease in women: the Finnish mental hospital study.
International Journal of Epidemiology 1983;12(1):17–25.
Turpeinen O, Miettinen M, Karvonen M, Roine P,
Pekkarinen M, Lehtosuo EJ, et al.Dietary prevention
of coronary heart disease: long-term experiment. I.
Observations on male. American Journal of Clinical
Nutrition 1968;21(4):255–76.
Fisher 1981 {published data only}
Fisher EA, Breslow JL, Zannis VI, Shen G, Blum CB.
Dietary saturated fat, not cholesterol, affects plasma lipids
and Apo E. Arteriosclerosis 1981;1(5):364a.
Fleming 2002 {published data only}
Fleming RM. The effect of high-, moderate-, and low-fat
diets on weight loss and cardiovascular disease risk factors.
Preventive Cardiology 2002;5:110–5.
Fortmann 1988 {published data only}
Fortmann SP, Haskell WL, Wood PD. Effects of weight loss
on clinic and ambulatory blood pressure in normotensive
men. American Journal of Cardiology 1988;62(1):89–93.
Foster 2003 {published data only}
Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill
C, Mohammed BS, et al.A randomized trial of a low-
carbohydrate diet for obesity. New England Journal of
Medicine 2003;348(21):2082–90.
FRESH START 2007 {published data only}
Denmark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D,
Snyder DC, Sloane R, et al.Main outcomes of the FRESH
53Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
START trial: a sequentially tailored, diet and exercise
mailed print intervention among breast and prostate
cancer survivors. Journal of Clinical Oncology 2007;25(19):
2709–18.
Gambera 1995 {published data only}
Gambera PJ, Schneeman BO, Davis PA. Use of the Food
Guide Pyramid and US Dietary Guidelines to improve
dietary intake and reduce cardiovascular risk in active-
duty Air Force members. Journal of the American Dietetic
Association 1995;95(11):1268–73.
Gaullier 2007 {published data only}
Gaullier J-M, Halse J, Hoivik HO, Hoye K, Syvertsen
C, Nurminiemi M, et al.Six months supplementation
with conjugated linoleic acid induces regional-specific fat
mass decreases in overweight and obese. British Journal of
Nutrition 2007;97:550–60.
Ginsberg 1988 {published data only}
Ginsberg H. Both a high monounsaturated fat diet and the
step 1 AHA diet significantly reduce plasma cholesterol
levels in healthy males [abstract]. Circulation 1988;78:II73.
Gjone 1972 {published data only}
Gjone E, Nordoy A, Blomhoff JP, Wiencke I. The effects of
unsaturated and saturated dietary fats on plasma cholesterol,
phospholipids and lecithin: cholesterol acyltransferase
activity. Acta Medica Scandinavica 1972;191(6):481–4.
Glatzel 1966 {published data only}
Glatzel H. The relationship between postprandial
triglyceridemia and the fat content of the basic diet
[Die Abhängigkeit der postcenalen Triglyceridamie vom
Fettgehalt der Grundkost]. Klinische Wochenschrift 1966;44
(5):283–4.
Goodpaster 1999 {published data only}
Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete
FL. Effects of weight loss on regional fat distribution and
insulin sensitivity in obesity. Diabetes 1999;48:839–47.
Grundy 1986 {published data only}
Grundy SM, Nix D, Whelan MF, Franklin L. Comparison
of three cholesterol-lowering diets in normolipidaemic men.
JAMA 1986;256:2351–5.
Hardcastle 2008 {published data only}
Hardcastle S, Taylor A, Bailey M, Castle R, Hardcastle
Sarah, Taylor Adrian, et al.A randomised controlled trial on
the effectiveness of a primary health care based counselling
intervention on physical activity, diet and CHD risk factors.
Patient Education & Counseling 2008;70(1):31–9.
Harris 1990 {published data only}
Harris WS, Feldman EB. Intensive dietary intervention in
hypercholesterolemic patients. Observed versus predicted
changes in cholesterol levels [abstract]. Arteriosclerosis 1990;
10:853A.
Hartman 1993 {published data only}
Hartman T, McCarthy P, Himes J. Use of eating pattern
messages to evaluate changes in eating behaviors in a
worksite cholesterol education program. Journal of the
American Dietetic Association 1993;93:1119–23.
Hartwell 1986 {published data only}
Hartwell SL, Kaplan RM, Wallace JP. Comparison of
behavioral interventions for control of type II diabetes
mellitus. Behavior Therapy 1986;17:447–61.
Hashim 1960 {published data only}
Hashim SA, Arteaga A, van Itallie TB. Effect of saturated
medium-chain triglyceride on serum-lipids in man. Lancet
1960;1:1105–7.
Haynes 1984 {published data only}
Haynes RB, Harper AC, Costley SR, Johnston M, Logan
AG, Flanagan PT, et al.Failure of weight reduction to reduce
mildly elevated blood pressure: a randomized trial. Journal
of Hypertension 1984;2(5):535–9.
Heber 1991 {published data only}
Heber D, Ashley JM, Leaf DA, Barnard JA. Reduction
of serum estradiol in postmenopausal women given free
access to low-fat high carbohydrate diet. Nutrition 1991;7:
137–41.
Heine 1989 {published and unpublished data}
Heine RJ, Mulder C, Popp-Snijders C, van der Meer J, van
der Veen EA. Linoleic-acid-enriched diet: long-term effects
on serum lipoprotein and apolipoprotein concentration
and insulin sensitivity in noninsulin-dependent diabetic
patients. American Journal of Clinical Nutrition 1989;49:
448–56.
Hellenius Diet & Ex 95 {published and unpublished data}
∗ Hellenius, ML. Prevention of cardiovascular disease:
studies on the role of diet and exercise in the prevention of
cardiovascular disease among middle-aged men. Huddinge,
Sweden: Karolinska Intitute, 1995.
Hellenius ML, Brismar KE, Berglund BH, de Faire U.
Effects on glucose tolerance, insulin secretion, insulin-like
growth factor 1 and its binding protein, IGFBP-1, in a
randomized controlled diet and exercise study in healthy,
middle-aged men. Journal of Internal Medicine 1995;238
(2):121–30.
Hellenius ML, Dahlof C, Aberg H, Krakau I, de Faire U.
Quality of life is not negatively affected by diet and exercise
intervention in healthy men with cardiovascular risk factors.
Quality of Life Research 1995;4(1):13–20.
Hellenius ML, de Faire U, Berglund B, Hamsten A,
Krakau I. Diet and exercise are equally effective in reducing
risk for cardiovascular disease. Results of a randomized
controlled study in men with slightly to moderately raised
cardiovascular risk factors. Atherosclerosis 1993;103(1):
81–91.
Hellenius ML, Krakau I, De Faire U. Favourable long-term
effects from advice on diet and exercise given to healthy
men with raised cardiovascular risks. Nutrition, Metabolism
and Cardiovascular Diseases 1997;7:293–300.
Naslund GK, Fredrikson M, Hellenius ML, de Faire U.
Effect of diet and physical exercise intervention programmes
on coronary heart disease risk in smoking and non-smoking
men in Sweden. Journal of Epidemiology and Community
Health 1996;50(2):131–6.
54Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hellenius Diet 1995 {published and unpublished data}
∗ Hellenius, ML. Prevention of cardiovascular disease:
studies on the role of diet and exercise in the prevention of
cardiovascular disease among middle-aged men. Huddinge,
Sweden: Karolinska Intitute, 1995.
Hellenius ML, Brismar KE, Berglund BH, de Faire U.
Effects on glucose tolerance, insulin secretion, insulin-like
growth factor 1 and its binding protein, IGFBP-1, in a
randomized controlled diet and exercise study in healthy,
middle-aged men. Journal of Internal Medicine 1995;238
(2):121–30.
Hellenius ML, Dahlof C, Aberg H, Krakau I, de Faire U.
Quality of life is not negatively affected by diet and exercise
intervention in healthy men with cardiovascular risk factors.
Quality of Life Research 1995;4(1):13–20.
Hellenius ML, de Faire U, Berglund B, Hamsten A,
Krakau I. Diet and exercise are equally effective in reducing
risk for cardiovascular disease. Results of a randomized
controlled study in men with slightly to moderately raised
cardiovascular risk factors. Atherosclerosis 1993;103(1):
81–91.
Hellenius ML, Krakau I, De Faire U. Favourable long-term
effects from advice on diet and exercise given to healthy
men with raised cardiovascular risks. Nutrition, Metabolism
and Cardiovascular Diseases 1997;7:293–300.
Naslund GK, Fredrikson M, Hellenius ML, de FU. Effect
of diet and physical exercise intervention programmes on
coronary heart disease risk in smoking and non-smoking
men in Sweden. J.Epidemiol.Community Health 1996;50
(2):131–6.
Heller 1993 {published and unpublished data}
∗ Heller RF, Knapp JC, Valenti LA, Dobson AJ. Secondary
prevention after acute myocardial infarction. American
Journal of Cardiology 1993;72(11):759–62.
Heller RF, Walker RJ, Boyle CA, O’Connell DL,
Rusakaniko S, Dobson AJ. A randomised controlled trial of
a dietary advice program for relatives of heart attack victims.
Medical Journal of Australia 1994;161(9):529–31.
Hildreth 1951 {published data only}
Hildreth EA, Mellinkoff SM, Blair GW, Hildreth DM. The
effect of vegetable fat ingestion on human serum cholesterol
concentration. Circulation 1951;3:641–6.
Holm 1990 {published data only (unpublished sought but not used)}
∗ Holm LE, Nordevang E, Ikkala E, Hallstrom L, Callmer
E. Dietary intervention as adjuvant therapy in breast cancer
patients--a feasibility study. Breast Cancer Research and
Treatment 1990;16(2):103–9.
Nordevang E, Callmer E, Marmur A, Holm LE. Dietary
intervention in breast cancer patients: effects on food
choice. European Journal of Clinical Nutrition 1992;46(6):
387–96.
Nordevang E, Ikkala E, Callmer E, Hallstrom L, Holm
LE. Dietary intervention in breast cancer patients: effects
on dietary habits and nutrient intake. European Journal of
Clinical Nutrition 1990;44(9):681–7.
Hood 1965 {published data only}
Hood B, Sanne H, Orndahl G, Ahlstrom M, Welin G.
Long term prognosis in essential hypercholesterolaemia: the
effect of a strict diet. Acta Medica Scandinavica 1965;178:
161–73.
Horlick 1957 {published data only}
∗ Horlick L, Craig BM. Effect of long-chain polyunsaturated
and saturated fatty acids on the serum-lipids of man. Lancet
1957;2:566–9.
Horlick 1960 {published data only}
Horlick L, O’Neil JB. Effect of modified egg-yolk fats on
blood-cholesterol levels [letter]. Lancet 1960;1:438.
Howard 1977 {published data only}
Howard AN, Marks J. Hypocholesterolaemic effect of milk
[letter]. Lancet 1977;2(8031):255–6.
Hunninghake 1990 {published data only}
Hunninghake DB, Laskarzewski PM. Gender difference in
the response to lovastatin administration with and without
a cholesterol lowering diet [abstract]. Arteriosclerosis 1990;
10:786A.
Hutchison 1983 {published data only}
Hutchison K, Oberle K, Crockford P, Grace M, Whyte L,
Gee M, et al.Effects of dietary manipulation on vascular
status of patients with peripheral vascular disease. JAMA
1983;249(24):3326–30.
Hyman 1998 {published and unpublished data}
Hyman DJ, Ho KSI, Dunn K, Simons-Morton D. Dietary
intervention for cholesterol reduction in public clinic
patients. American Journal of Preventive Medicine 1998;15:
139–45.
Iacono 1981 {published data only}
Iacono JM, Judd JT, Marshall MW, Canary JJ, Dougherty
RM, Mackin JF, et al.The role of dietary essential fatty acids
and prostaglandins in reducing blood pressure. Progress in
Lipid Research 1981;20:349–64.
IMPACT 1995 {published data only}
Fielding JE, Mason T, Kinght K, Klesges R, Pelletier KR.
A randomized trial of the IMPACT worksite cholesterol
reduction program. American Journal of Preventive Medicine
1995;11:120–3.
Ishikawa 1995 {published data only}
Ishikawa H, Akedo I, Suzuki T, Otani T, Sobue T.
Interventional trial for colorectal cancer prevention in
Osaka: an introduction to the protocol. Japanese Journal of
Cancer Research 1995;86(8):707–10.
Iso 1991 {published data only}
Iso H, Konishi M, Terao A, Kiyama M, Tanigaki M,
Baba M, et al.A community-based education program for
serum cholesterol reduction in urban hypercholesterolemic
persons: comparison of intensive and usual education
groups. Nippon.Koshu.Eisei.Zasshi [Japanese Journal of
Public Health] 1991;38(9):751–61.
Ives 1993 {published data only}
Ives DG, Kuller LH, Traven ND. Use and outcomes of a
cholesterol-lowering intervention for rural elderly subjects.
American Journal of Preventive Medicine 1993;9(5):274–81.
55Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jalkanen 1991 {published data only}
Jalkanen L. The effect of a weight reduction program on
cardiovascular risk factors among overweight hypertensives
in primary health care. Scandinavian Journal of Social
Medicine 1991;19(1):66–71.
Jepson 1969 {published data only}
Jepson EM, Fahmy MF, Torrens PE, Billimoria JD,
Maclagan NF. Treatment of essential hyperlipidaemia.
Lancet 1969;2(7634):1315–9.
Jerusalem Nut 1992 {published data only}
Berry EM, Eisenberg S, Friedlander Y, Harats D,
Kaufmann NA, Norman Y, et al.Effects of diets rich in
monounsaturated fatty acids on plasma lipoproteins: the
Jerusalem Nutrition Study. II. Monounsaturated fatty acids
vs carbohydrates. American Journal of Clinical Nutrition
1992;56(2):394–403.
Jula 1990 {published data only}
Jula A, Ronnemaa T, Rastas M, Karvetti RL, Maki J. Long-
term nopharmacological treatment for mild to moderate
hypertension. Journal of Internal Medicine 1990;227(6):
413–21.
Junker 2001 {published data only}
Junker R, Pieke B, Schulte H, Nofer R, Neufeld M,
Assmann G, et al.Changes in hemostasis during treatment
of hypertriglyceridemia with a diet rich in monounsaturated
and n-3 polyunsaturated fatty acids in comparison with a
low-fat diet. Thrombosis Research 2001;101(5):355–66.
Karmally 1990 {published data only}
Karmally W, Carpentiri C, Viscardi T, Cheverez V, Holleran
S, Ramakrishnan R, et al.Replacing monounsaturated by
polyunsaturated fatty acids within an AHA step I diet does
not affect the plasma levels or metabolism of low density
and high density lipoproteins in normal men [abstract].
Arteriosclerosis 1990;10:877A.
Karvetti 1992 {published data only}
Karvetti RL, Hakala P. A seven-year follow-up of a weight
reduction programme in Finnish primary health care.
European Journal of Clinical Nutrition 1992;46:743–52.
Kastarinen 2002 {published data only}
Kastarinen MJ, Puska PM, Korhonen MH, Mustonen
JN, Salomaa VV, Sundvall JE, et al.Non-pharmacological
treatment of hypertension in primary health care: A 2-year
open randomized controlled trial of lifestyle intervention
against hypertension in eastern Finland. Journal of
Hypertension 2002;20(12):01.
Kather 1985 {published data only}
Kather H, Wildenberg U, Wieland E. Influence of different
dietary conditions in ideal-weight subjects on serum levels
of free fatty acids and of glycerol in vivo and on lipid
mobilization in vitro [abstract]. European Journal of Clinical
Investigation 1985;15:A.
Katzel 1995a {published data only}
Katzel LI, Coon PJ, Dengel J, Goldberg AP. Effect of an
American Heart Association Step I diet and weight loss on
lipoprotein lipid levels in obese men with silent myocardial
ischaemia and reduced high density lipoprotein cholesterol.
Metabolism 1995;44:307–14.
Katzel 1995b {published data only}
Katzel LI, Bleecker ER, Colman EG, Rogus EM, Sorkin
JD, Goldberg AP. Effects of weight loss vs aerobic exercise
training on risk factors for coronary disease in healthy, obese,
middle-aged and older men. A randomized controlled trial
[see comments]. JAMA 1995;274(24):1915–21.
Kawamura 1993 {published data only}
Kawamura M, Akasaka T, Kasatsuki T, Nakajima J,
Onodera S, Fujiwara T, et al.Blood pressure is reduced by
short-time calorie restriction in overweight hypertensive
women with a constant intake of sodium and potassium.
Journal of Hypertension. Supplement 1993;11(Suppl 5):
S320–1.
Keidar 1988 {published data only}
Keidar S, Krul ES, Goldberg AC, Bateman J, Schonfield
G. Fat-free diet modulates epitope expression of LDL-apo
[abstract]. Arteriosclerosis 1988;8:565A.
Kempner 1948 {published data only}
Kempner W. Treatment of hypertensive vascular disease
with rice diet. American Journal of Medicine 1948;4:545–77.
Keys 1952 {published data only}
Keys A. Human atherosclerosis and the diet. Circulation
1952;5:115–8.
Keys 1957a {published data only}
Keys A, Anderson JT, Grande F. Serum-cholesterol response
to dietary fat [letter]. Lancet 1957;1:787.
Keys 1957b {published data only}
Keys A, Anderson JT, Grande F. Essential fatty acids, degree
of unsaturation, and effect of corn (maize) oil on the serum-
cholesterol level in man. Lancet 1957;1:66–8.
Keys 1957c {published data only}
Keys A. Prediction of serum-cholesterol responses of man to
changes in fats in the diet. Lancet 1957;2:959–66.
Khan 2003 {published and unpublished data}
Khan F, Elherik K, Bolton-Smith C, Barr R, Hill A, Murrie
I, et al.The effects of dietary fatty acid supplementation on
endothelial function and vascular tone in healthy subjects.
Cardiovascular Research 2003;59:955–62.
King 2000 {published data only}
King S, David S, Newton H, Hevey D, Rafferty F, Horgan
JH. The effect of dietary modification on the training
outcome and body composition in patients undergoing
undergoing a cardiac rehabilitation programme. Coronary
Health Care 2000;4(2):76–81.
Kingsbury 1961 {published data only}
Kingsbury KJ, Morgan DM, Aylott C, Emmerson R.
Effects of ethyl arachidonate, cod-liver oil, and corn oil
on the plasma-cholesterol level: a comparison in normal
volunteers. Lancet 1961;1:739–41.
Kohler 1986 {published data only}
Kohler VH, Voigt H, Reuter W, Peters H-J, Kuklinski
B, Scheel H, et al.Results of a long-term study of
arteriosclerotic circulatory disorders with polyene fatty
56Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
acid therapy [German]. Zeitschrift für die Gesamte Innere
Medizin und ihre Grenzgebiete 1986;41:91–3.
Koopman 1990 {published data only}
Koopman H, Spreeuwenberg C, Westerman RF, Donker
AJ. Dietary treatment of patients with mild to moderate
hypertension in a general practice: a pilot intervention study
(2). Beyond three months. Journal of Human Hypertension
1990;4(4):372–4.
Korhonen 2003 {published data only}
Korhonen M, Kastarinen M, Uusitupa M, Puska P, Nissinen
A. The effect of intensified diet counselling on the diet of
hypertensive subjects in primary health care: a 2-year open
randomized controlled trial of lifestyle intervention against
hypertension in eastern Finland. Preventive Medicine 2003;
36(1):8–16.
Kriketos 2001 {published data only}
Kriketos AD, Robertson RM, Sharp TA, Drougas H,
Reed GW, Storlien LH, et al.Role of weight loss and
polyunsaturated fatty acids in improving metabolic fitness
in moderately obese, moderately hypertensive subjects.
Journal of Hypertension 2001;19(10):1745–54.
Kris 1994 {published data only}
Kris EP, Mustad VA. Chocolate feeding studies: a novel
approach for evaluating the plasma lipid effects of stearic
acid. American Journal of Clinical Nutrition 1994;60(6
Suppl):1029S–36S.
Kristal 1997 {published data only}
Kristal AR, Shattuck AL, Bowen DJ, Sponzo RW, Nixon
DW. Feasibility of using volunteer research staff to deliver
and evaluate a low-fat dietary intervention: the American
Cancer Society Breast Cancer Dietary Intervention Project.
Cancer Epidemiology, Biomarkers and Prevention 1997;6(6):
459–67.
Kromhout 1987 {published data only}
Kromhout D, Arntzenius AC, Kempen-Voogd N, Kempen
HJ, Barth JD, van der Voort HA, et al.Long-term effects
of linoleic-acid enriched diet, changes in body weight and
alcohol consumption on serum total and HDL cholesterol.
Atherosclerosis 1987;66:99–105.
Kummel 2008 {published data only}
Kummel M V. Effects of an intervention on health behaviors
of older coronary artery bypass (CAB) patients. Archives of
Gerontology and Geriatrics 2008;2(2):227–44.
Laitinen 1993 {published data only}
Laitinen JH, Ahola IE, Sarkkinen ES, Winberg RL,
Harmaakorpi IP, Uusitupa MI. Impact of intensified
dietary therapy on energy and nutrient intakes and fatty
acid composition of serum lipids in patients with recently
diagnosed non-insulin-dependent diabetes mellitus. Journal
of the American Dietetic Association 1993;93(3):276–83.
Laitinen 1994 {published data only}
Laitinen J, Uusitupa M, Ahola I, Siitonen O. Metabolic and
dietary determinants of serum lipids in obese patients with
recently diagnosed non-insulin-dependent diabetes. Annals
of Medicine 1994;26(2):119–24.
Leduc 1994 {published data only}
Leduc CP, Cherniak D, Faucher J. Effectiveness of a
group dietary intervention on hypercholesterolaemia:
a randomised controlled clinical trial [poster abstract].
Atherosclerosis 1994;19:149.
Lewis 1958 {published data only}
Lewis B. Effect of certain dietary oils on bile-acid secretion
and serum-cholesterol. Lancet 1958;1:1090–2.
Lewis 1981 {published data only}
Lewis B, Hammett F, Katan M, Kay RM, Merkx I, Nobels
A, et al.Towards an improved lipid-lowering diet: additive
effects of changes in nutrient intake. Lancet 1981;2(8259):
1310–3.
Lewis 1985 {published data only}
Lewis B. Randomised controlled trial of the treatment of
hyperlipidaemia on progression of atherosclerosis. Acta
Medica Scandinavica. Supplement 1985;701:53–7.
Lichtenstein 2002 {published data only}
Lichtenstein AH, Ausman LM, Jalbert SM, Vilella-Bach
M, Jauhiainen M, McGladdery S, et al.Efficacy of a
therapeutic lifestyle change/step 2 diet in moderately
hypercholesterolemic middle-aged and elderly female and
male subjects. Journal of Lipid Research 2002;43(2):264–73.
Linko 1957 {published data only}
Linko E. Vegetable oils and serum cholesterol: short-term
experiments with rapeseed and sunflower oils. Acta Medica
Scandinavica 1957;159:475–88.
Lipid Res Clinic 1984 {published data only}
∗ The Lipid Research Clinics Coronary Primary Prevention
Trial results. I. Reduction in incidence of coronary heart
disease. JAMA 1984;251(3):351–64.
The Lipid Research Clinics Coronary Primary Prevention
Trial results. II. The relationship of reduction in incidence
of coronary heart disease to cholesterol lowering. JAMA
1984;251(3):365–74.
Gordon DJ, Salz KM, Roggenkamp KJ. Dietary
determinants of plasma cholesterol change in the
recruitment phase of the Lipid Research Clinics Coronary
Primary Prevention Trial. Arteriosclerosis 1982;2(6):537–48.
Little 1990 {published data only}
Little P, Girling G, Hasler A, Craven A, Trafford A. The
effect of a combination low sodium, low fat, high fibre diet
on serum lipids in treated hypertensive patients. European
Journal of Clinical Nutrition 1990;44(4):293–300.
Little 1991 {published data only}
Little P, Girling G, Hasler A, Trafford A. A controlled trial of
a low sodium, low fat, high fibre diet in treated hypertensive
patients: effect on antihypertensive drug requirement in
clinical practice. Journal of Human Hypertension 1991;5(3):
175–81.
Little 2004 {published data only}
Little P, Kelly J, Barnett J, Dorward M, Margetts B, Warm
D, et al.Randomised controlled factorial trial of dietary
advice for patients with a single high blood pressure reading
in primary care. BMJ 2004;328(7447):1054.
57Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lottenberg 1996 {published data only}
Lottenberg AM, Nunes VS, Lottenberg SA, Shimabukuro
AF, Carrilho AJ, Malagutti S, et al.Plasma cholesteryl ester
synthesis, cholesteryl ester transfer protein concentration
and activity in hypercholesterolemic women: effects of the
degree of saturation of dietary fatty acids in the fasting and
postprandial states. Atherosclerosis 1996;126(2):265–75.
Luszczynska 2007 {published data only}
Luszczynska A, Scholz U, Sutton S. Planning to change
diet: a controlled trial of an implementation intentions
training intervention to reduce saturated fat intake among
patients after myocardial infarction. Journal of Psychosomatic
Research 2007;63(5):491–7.
Lyon Diet Heart 1994 {published data only}
∗ De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin
JL, Monjaud I, et al.Mediterranean alpha-linolenic acid-
rich diet in secondary prevention of coronary heart disease.
Lancet 1994;343(8911):1454–9.
De Lorgeril M, Salen P. Mediterranean diet in secondary
prevention of coronary heart disease. Australian Journal of
Nutrition and Dietetics 1998;55(Suppl):s16–s20.
De Lorgeril M, Salen P, Caillat-Vallet E, Hanauer M-T,
Barthelemy JC, Mamelle N. Control of bias in dietary trial
to prevent coronary recurrences: the Lyon Diet Heart study.
European Journal of Clinical Nutrition 1997;51(2):116–22.
De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I,
Touboul P, et al.Effect of a Mediterranean type of diet on
the rate of cardiovascular complications in patients with
coronary artery disease. insights into the cardioprotective
effect of certain nutriments. Journal of the American College
of Cardiology 1996;28:1103–8.
De Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P,
Mamelle N. Mediterranean dietary pattern in a randomised
trial. Archives of Internal Medicine 1998;158:1181–7.
De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J,
Mamelle N. Mediterranean diet, traditional risk factors, and
the rate of cardiovascular complications after myocardial
infarction: final report of the Lyon Diet Heart study.
Circulation 1999;99:779–85.
Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F,
Mamelle N, et al.Cretan Mediterranean diet for prevention
of coronary heart disease. American Journal of Clinical
Nutrition 1995;61(6, Suppl):1360S–7S.
Lysikova 2003 {published data only}
Lysikova SL, Pogozheva AV, Akol’zina SE, Vasil’ev AV,
Vorob’eva LS. The study of the clinical potency of
antiatherogenic diet containing flavonoids in cardiovascular
patients [Russian]. Voprosy Pitaniia 2003;72(3):8–11.
Macdonald 1972 {published data only}
Macdonald I. Relationship between dietary carbohydrates
and fats in their influence on serum lipid concentrations.
Clinical Science 1972;43(2):265–74.
Mansel 1990 {published data only}
Mansel RE, Harrison BJ, Melhuish J, Sheridan W, Pye JK,
Pritchard G, et al.A randomized trial of dietary intervention
with essential fatty acids in patients with categorized cysts.
Annals of the New York Academy of Sciences 1990;586:
288–94.
Marckmann 1993 {published data only}
Marckmann P, Sandstrom B, Jespersen J. Favorable long-
term effect of a low-fat/high fiber diet on human blood
coagulation and fibrinolysis. Arteriosclerosis and Thrombosis
1993;13:505–11.
MARGARIN 2002 {published data only}
Bemelmans WJE, Broer J, Feskens EJM, Smit AJ, Muskiet
FAJ, Lefrandt JD, et al.Effect of an increased intake of
alpha-linolenic acid and group nutritional education on
cardiovascular risk factors: the Mediterranean Alpha-
linolenic Enriched Groningen Dietary Intervention
(MARGARIN) study. American Journal of Clinical Nutrition
2002;75:221–7.
Marniemi 1990 {published and unpublished data}
Hakala P, Karvetti RL. Weight reduction on lactovegetarian
and mixed diets. European Journal of Clinical Nutrition
1989;43:421–30.
∗ Marniemi J, Seppanen A, Hakala P. Long-term effects on
lipid metabolism of weight reduction on lactovegetarian
and mixed diet. International Journal of Obesity 1990;14:
113–25.
Mattson 1985 {published data only}
Mattson FH, Grundy SM. Comparison of effects of dietary
saturated, monounsaturated and polyunsaturated fatty acids
on plasma lipids and lipoproteins in man. Journal of Lipid
Research 1985;26:194–202.
McCarron 1997 {published data only}
McCarron DA, Oparil S, Chait A, Haynes RB, Kris EP,
Stern JS, et al.Nutritional management of cardiovascular
risk factors. A randomized clinical trial. Archives of Internal
Medicine 1997;157(2):169–77.
McCarron 2001 {published data only}
McCarron DA, Reusser ME. Reducing cardiovascular
disease risk with diet. Obesity Research 2001;9(Suppl 4):
335S–40S.
McManus 2001 {published and unpublished data}
McManus K, Antinoro L, Sacks F. Randomized controlled
trial of a moderate-fat low-energy diet compared with a low
fat, low-energy diet for weight loss in overweight adults.
International Journal of Obesity 2001;25:1503–11.
McNamara 1981 {published data only}
McNamara DJ, Kolb R, Parker T, Batwin H, Brown C,
Samuel P, et al.Diet and cholesterol homeostasis in men
[abstract]. Arteriosclerosis 1981;1:369A.
Medi-RIVAGE 2004 {published and unpublished data}
Borel P, Moussa M, Reboul E, Lyan B, Defoort C, Vincent-
Baudry S, et al.Human fasting plasma concentrations of
vitamin E and carotenoids, and their association with
genetic variants in apo C-III, cholesteryl ester transfer
protein, hepatic lipase, intestinal fatty acid binding protein
and microsomal triacylglycerol transfer protein. British
Journal of Nutrition 2009;101(5):680–7.
Borel P, Moussa M, Reboul E, Lyan B, Defoort C, Vincent-
Baudry S, et al.Human plasma levels of vitamin E and
58Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
carotenoids are associated with genetic polymorphisms in
genes involved in lipid metabolism. Journal of Nutrition
2007;137(12):2653–9.
Gastaldi M, Diziere S, Defoort C, Portugal H, Lairon
D, Darmon M, et al.Sex-specific association of fatty acid
binding protein 2 and microsomal triacylglycerol transfer
protein variants with response to dietary lipid changes in the
3-mo Medi-RIVAGE primary intervention study. American
Journal of Clinical Nutrition 2007;86(6):1633–41.
Vincent-Baudry S, Defoort C, Gerber M, Bernard
MC, Verger P, Helal O, et al.The Medi-RIVAGE study:
reduction of cardiovascular disease risk factors after a 3-
mo intervention with a Mediterranean-type diet or a low-
fat diet. American Journal of Clinical Nutrition 2005;82(5):
964–71.
∗ Vincent S, Gerber M, Bernard MC, Defoort C,
Loundou A, Portugal H, et al.The Medi-RIVAGE study
(Mediterranean Diet, Cardiovascular Risks and Gene
Polymorphisms): rationale, recruitment, design, dietary
intervention and baseline characteristics of participants.
Public Health Nutrition 2004;7(4):531–42.
Mensink 1987 {published data only}
Mensink RP, Katan MB. Effect of monounsaturated
fatty acids versus complex carbohydrates on high-density
lipoproteins in healthy men and women. Lancet 1987;1
(8525):122–5.
Mensink 1989 {published data only}
Mensink RP, Katan MB. Effect of a diet enriched with
monounsaturated or polyunsaturated fatty acids on levels
of low density and high density lipoprotein cholesterol in
healthy women and men. New England Journal of Medicine
1989;321:436–41.
Mensink 1990a {published data only}
Mensink RP, Katan MB. Effect of dietary trans fatty acids
on high density and low density lipoprotein cholesterol
levels in healthy subjects. New England Journal of Medicine
1990;323:439–45.
Mensink 1990b {published and unpublished data}
Mensink RP. Effect of monounsaturated fatty acids on high-
density and low-density lipoprotein cholesterol levels and
blood pressure in healthy men and women. Wageningen,
Netherlands: Wageningen University and Research Centre,
1990.
Michalsen 2006 {published and unpublished data}
Michalsen A, Lehmann N, Pithan C, Knoblauch NT,
Moebus S, Kannenberg F, et al.Mediterranean diet has no
effect on markers of inflammation and metabolic risk factors
in patients with coronary artery disease. European Journal of
Clinical Nutrition 2006;60(4):478–85.
Miettinen 1994 {published data only}
Miettinen TA, Vanhanen H. Dietary sitostanol related to
absorption, synthesis and serum level of cholesterol in
different apolipoprotein E phenotypes. Atherosclerosis 1994;
105(2):217–26.
Millar 1973 {published data only}
Millar JH, Zilkha KJ, Langman MJS, Payling-Wright H,
Smith AD, Belin J, et al.Double-blind trial of linoleate
supplementation of the diet in multiple sclerosis. BMJ
1973;1(5856):765–8.
Miller 1998 {published data only}
Miller ER, Appel LJ, Risby TH. Effect of dietary patterns on
measures of lipid peroxidation: results from a randomised
clinical trial. Circulation 1998;98:2390–5.
Miller 2001 {published and unpublished data}
Miller SL, Reber RJ, Chapman-Novakofski K. Prevalence
of CVD risk factors and impact of a two-year education
program for premenopausal women. Women’s Health Issues
2001;11(6):486–93.
Milne 1994 {published data only}
Milne RM, Mann JI, Chisholm AW, Williams SM. Long-
term comparison of three dietary prescriptions in the
treatment of NIDDM. Diabetes Care 1994;17(1):74–80.
Minnesota HHP 1990 {published data only}
Murray DM, Kurth C, Mullis R, Jeffery RW. Cholesterol
reduction through low-intensity interventions: results from
the Minnesota Heart Health Program. Preventive Medicine
1990;19(2):181–9.
Mokuno 1988 {published data only}
Mokuno H, Yamada N, Sugimoto T. Cholesterol free
diet in heterozygous familial hypercholesterolaemia:
significant lowering effect on plasma cholesterol (abstract).
Arteriosclerosis 1988;8(5):590a.
Moreno 1994 {published data only}
Moreno VJ, Garcia AJ, Campillo AJ. Influence of diet
and physical exercise on plasma lipid concentrations in an
homogeneous sample of young Spanish Air Force pilots.
European Journal of Applied Physiology and Occupational
Physiology 1994;69(1):75–80.
Morrison 1950 {published data only}
Morrison LM, Awierlein M, Wolfson E. The effects of low
fat low cholesterol diets on the serum lipids. Circulation
1950;2:475–6.
Morrison 1951 {published data only}
Morrison LM. Reduction of mortality rate in coronary
atherosclerosis by a low cholesterol low fat diet. American
Heart Journal 1951;42:538–45.
Morrison 1960 {published data only}
Morrison LM. Diet in coronary atherosclerosis. JAMA
1960;173:884–8.
Mortensen 1983 {published data only}
Mortensen JZ, Schmidt EB, Nielsen AH, Dyerberg J.
The effect of N-6 and N-3 polyunsaturated fatty acids on
hemostasis, blood lipids and blood pressure. Thrombosis
and Haemostasis 1983;50(2):543–6.
MRFIT substudy 1986 {published data only}
Daniel GJ, Dolecek TA, Caggiula AW, Van HL, Epley
L, Randall BL. Increasing the use of meatless meals: a
nutrition intervention substudy in the Multiple Risk Factor
59Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Intervention Trial (MRFIT). Journal of the AmericanDietetic
Association 1986;86(6):778–81.
MSDELTA 1995 {published data only}
Ginsberg HN. New directions in dietary studies and heart
disease: the National Heart, Lung and Blood Institute
sponsored Multicenter Study of Diet Effects on Lipoproteins
and Thrombogenic Activity. Advances In Experimental
Medicine and Biology 1995;369:241–7.
Mujeres Felices 2003 {published data only}
∗ Fitzgibbon ML, Gapstur SM, Knight SJ. Mujeres felices
por ser saludables: a breast cancer risk reduction program
for Latino women. Preventive Medicine 2003;36(5):536–46.
Fitzgibbon ML, Gapstur SM, Knight SJ. Results of
Mujeres Felices por ser Saludables: a dietary/breast health
randomized clinical trial for Latino women. Annals of
Behavioral Medicine 2004;28(2):95–104.
Mutanen 1997 {published data only}
MutanenM.Comparison between dietary monounsaturated
and polyunsaturated fatty acids as regards diet-related
diseases. Biomedicine and Pharmacotherapy 1997;51(8):
314–7.
Muzio 2007 {published data only}
Muzio F, Mondazzi L, Harris WS, Sommariva D, Branchi
A. Effects of moderate variations in the macronutrient
content of the diet on cardiovascular disease risk factors
in obese patients with the metabolic syndrome. American
Journal of Clinical Nutrition 2007;86(4):946–51.
NAS 1987 {published data only}
Chlebowski RT, Nixon DW, Blackburn GL, Jochimsen
P, Scanlon EF, Insull W, et al.A breast cancer Nutrition
Adjuvant Study (NAS): protocol design and initial patient
adherence. Breast Cancer Research and Treatment 1987;10
(1):21–9.
NCEP weight 1991 {published and unpublished data}
Wood PD, Stefanick ML, Williams PT, Haskell WL. The
effects on plasma lipoproteins of a prudent weight-reducing
diet, with or without exercise, in overweight men and
women. New England Journal of Medicine 1991;325(7):
461–6.
Neil 1995 {published data only}
Neil HA, Roe L, Godlee RJ, Moore JW, Clark GM, Brown
J, et al.Randomised trial of lipid lowering dietary advice in
general practice: the effects on serum lipids, lipoproteins,
and antioxidants [see comments]. BMJ 1995;310(6979):
569–73.
Neverov 1997 {published data only}
Neverov NI, Kaysen GA, Tareyeva IE. Effect of lipid-
lowering therapy on the progression of renal disease in
nondiabetic nephrotic patients. Contributions to Nephrology
1997;120:68–78.
Next Step 1995 {published and unpublished data}
Tilley BC, Vernon SW, Glanz K, Myers R, Sanders K, LuM,
et al.Worksite cancer screening and nutrition intervention
for high-risk auto workers: design and baseline findings
of the Next Step Trial. Preventive Medicine 1997;26(2):
227–35.
∗ Tilley BC, Vernon SW, Myers R, Glanz K, Lu M, Sanders
K, et al.Planning the next step. A screening promotion and
nutrition intervention trial in the work site. Annals of the
New York Academy of Sciences 1995;768:296–9.
Nordoy 1971 {published data only}
Nordoy A, Rodset JM. The influence of dietary fats on
platelets in man. Acta Medica Scandinavica 1971;190(1-2):
27–34.
Norway Veg Oil 1968 {published data only}
Natvig H, Borchgrevink CF, Dedichen J, Owren PA, Schiotz
EH, Westlund K. A controlled trial of the effect of linolenic
acid on incidence of coronary heart disease: the Norwegian
Vegetable Oil Experiment of 1965-66. Scandinavian Journal
of Clinical and Laboratory Investigation. Supplement 1968;
105:1–20.
O’Brien 1976 {published data only}
O’Brien JR, Etherington MD, Jamieson S. Effect of a diet
of polyunsaturated fats on some platelet-function tests.
Lancet 1976;2(7993):995–6.
ODES 2006 {published data only}
Anderssen S, Holme I, Urdal P, Hjermann I. Diet and
exercise intervention have favourable effects on blood
pressure in mild hypertensives: the Oslo Diet and Exercise
Study (ODES). Blood Pressure 1995;4(6):343–9.
Anderssen SA, Hjermann I, Urdal P, Torjesen PA, Holme
I. Improved carbohydrate metabolism after physical
training and dietary intervention in individuals with the
“atherothrombogenic syndrome’. Oslo Diet and Exercise
Study (ODES). A randomized trial. Journal of Internal
Medicine 1996;240(4):203–9.
∗ Holme I, Haaheim LL, Tonstad S, Hjermann I, Holme I,
Haaheim LL, et al.Effect of dietary and antismoking advice
on the incidence of myocardial infarction: a 16-year follow-
up of the Oslo Diet and Antismoking Study after its close.
Nutrition Metabolism & Cardiovascular Diseases 2006;16(5):
330–8.
Rokling-Andersen MH, Reseland JE, Veierod MB,
Anderssen SA, Jacobs DR Jr, Urdal P, et al.Effects of long-
term exercise and diet intervention on plasma adipokine
concentrations. American Journal of Clinical Nutrition
2007;86(5):1293–301.
The ODES Investigators. The Oslo Diet and Exercise
Study (ODES): design and objectives. Controlled Clinical
Trials 1993;14(3):229–43.
Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I,
Holme I, Urdal P. Lifestyle changes may reverse development
of the insulin resistance syndrome. The Oslo Diet and
Exercise Study: a randomized trial. Diabetes Care 1997;20
(1):26–31.
Oldroyd 2001 {published data only}
Oldroyd JC, Unwin NC, White M, Mathers JC, Alberti
KG. Randomised controlled trial evaluating lifestyle
60Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
interventions in people with impaired glucose tolerance.
Diabetes Research & Clinical Practice 2006;72(2):117–27.
∗ Oldroyd JCU. Randomised controlled trial evaluating
the effectiveness of behavioural interventions to modify
cardiovascular risk factors in men and women with impaired
glucose tolerance: Outcomes at 6 months. Diabetes Research
and Clinical Practice 2001;52(1):29–43.
ORIGIN 2008 {published data only}
Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J.
Rationale, design, and baseline characteristics for a large
international trial of cardiovascular disease prevention in
people with dysglycemia: the ORIGIN Trial (Outcome
Reduction with an Initial Glargine Intervention). American
Heart Journal 2008;155(1):26–32.
Oslo Study 2004 {published data only}
∗ Hjerkinn EM, Sandvik L, Hjermann I, Arnesen H. Effect
of diet intervention on long-term mortality in healthy
middle-aged men with combined hyperlipidaemia. Journal
of Internal Medicine 2004;255(1):68–73.
Hjermann I. Intervention of smoking and eating habits in
healthy men carrying high risk for coronary heart disease.
The Oslo Study. Acta Medica Scandinavica. Supplementum
1981;651:281–4.
Hjermann I. Smoking and diet intervention in healthy
coronary high risk men. Methods and 5-year follow-up of
risk factors in a randomized trial. The Oslo study. Journal
of the Oslo City Hospitals 1980;30(1):3–17.
Hjermann I, Leren P, Norman N, Helgeland A, Holme I.
Serum insulin response to oral glucose load during a dietary
intervention trial in healthy coronary high risk men: the
Oslo study. Scandinavian Journal of Clinical and Laboratory
Investigation 1980;40(1):89–94.
Hjermann I, Velve BK, Holme I, Leren P. Effect of diet and
smoking intervention on the incidence of coronary heart
disease. Report from the Oslo Study Group of a randomised
trial in healthy men. Lancet 1981;2(8259):1303–10.
Pascale 1995 {published data only}
Pascale RW, Wing RR, Butler BA, Mullen M, Bononi
P. Effects of a behavioral weight loss program stressing
calorie restriction versus calorie plus fat restriction in obese
individuals with NIDDM or a family history of diabetes.
Diabetes Care 1995;18(9):1241–8.
PEP 2001 {published data only}
Ohrig E, Geib HC, Haas G-M, Schwandt P. The prevention
education program (PEP) Nuremberg: design and baseline
data of a family oriented intervention study. International
Journal of Obesity 2001;25(Suppl 1):S89–92.
PHYLLIS 1993 {published data only}
∗ Bond GM, Crepaldi G, Zanchetti A, Avogaro P, Marubini
E, Maseri A, et al.Plaque hypertension lipid-lowering Italian
study (PHYLLIS): A protocol for non-invasive evaluation
of carotid atherosclerosis in hypercholesterolaemic
hypertensive subjects. Journal of Hypertension 1993;11
(Suppl 5):S314–5.
Pilkington 1960 {published and unpublished data}
Pilkington TRE, Stafford JL, Hankin VS, Simmonds FM,
Koerselman HB. Practical diets for lowering serum lipids.
British Medical Journal 1960;1(5165):23–5.
Pritchard 2002 {published data only}
Pritchard JE, Nowson CA, Billington T, Wark JD.
Benefits of a year-long workplace weight loss program on
cardiovascular risk factors. Nutrition and Dietetics 2002;59
(2):87–96.
Puget Sound EP 2000 {published and unpublished data}
Kristal AR, Curry SJ, Shattuck AL, Feng Z, Li S. A
randomized trial of a tailored, self-help dietary intervention:
the Puget Sound Eating Patterns Study. Preventive Medicine
2000;31:380–9.
Rabast 1979 {published data only}
Rabast U, Schonborn J, Kasper H. Dietetic treatment of
obesity with low and high-carbohydrate diets: comparative
studies and clinical results. International Journal of Obesity
1979;3(3):201–11.
Rabkin 1981 {published data only}
Rabkin SW, Boyko E, Streja DA. Relationship of weight loss
and cigarette smoking to changes in high-density lipoprotein
cholesterol. American Journal of Clinical Nutrition 1981;34:
1764–8.
Radack 1990 {published data only}
Radack K, Deck C, Huster G. The comparative effects of n-
3 and n-6 polyunsaturated fatty acids on plasma fibrinogen
levels: a controlled clinical trial in hypertriglyceridemic
subjects. Journal of the American College of Nutrition 1990;9
(4):352–7.
Rasmussen 1995 {published data only}
Rasmussen OW, Thomsen CH, Hansen KW, Vesterlund
M, Winther E, Hermansen K. Favourable effect of olive
oil in patients with non-insulin-dependent diabetes. The
effect on blood pressure, blood glucose and lipid levels of a
high-fat diet rich in monounsaturated fat compared with a
carbohydrate-rich diet [Gunstig virkning af olivenolie hos
ikkeinsulinkraevende diabetikere. Virkningen pa blodtryk,
blodglukose og lipidniveauer af en dioet med et hojt indhold
af monoumoettet fedt sammenlignet med en kulhydratrig
dioet]. Ugeskrift for Laeger 1995;157(8):1028–32.
Reaven 2001 {published data only}
Reaven GM, Abbasi F, Bernhart S, Coulston A, Darnell
B, Dashti N, et al.Insulin resistance, dietary cholesterol,
and cholesterol concentration in postmenopausal women.
Metabolism: Clinical & Experimental 2001;50(5):594–7.
Reid 2002 {published data only}
Reid R, Fodor G, Lydon-Hassen K, D’Angelo MS, McCrea
J, Bowlby M, et al.Dietary counselling for dyslipidemia
in primary care: results of a randomized trial. Canadian
Journal of Dietetic Practice & Research 2002;63(4):169–75.
Renaud 1986 {published data only}
Renaud S, Godsey F, Dumont E, Thevenon C, Ortchanian
E, Martin JL. Influence of long-term diet modification
on platelet function and composition in Moselle farmers.
American Journal of Clinical Nutrition 1986;43:136–50.
61Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rivellese 2003 {published data only}
Rivellese AA, Maffettone A, Vessby B, Uusitupa M,
Hermansen K, Berglund L, et al.Effects of dietary saturated,
monounsaturated and n-3 fatty acids on fasting lipoproteins,
LDL size and post-prandial lipid metabolism in healthy
subjects. Atherosclerosis 2003;167(1):149–58.
Roderick 1997 {published and unpublished data}
Roderick P, Ruddock V, Hunt P, Miller G. A randomized
trial to evaluate the effectiveness of dietary advice by practice
nurses in lowering diet-related coronary heart disease risk.
British Journal of General Practice 1997;47(414):7–12.
Roman CHD prev 1986 {published data only}
The Roman Coronary Disease Prevention Project:
effectiveness of intervention and reduction of mortality over
a 10-year period [II Progetto Romano di Prevenzione della
Cardiopatia Coronarica: efficacia dell’intervento e riduzione
della mortalita in 10 anni]. Giornale Italiano di Cardiologia
1986;16(3):196–202.
∗ Research Group of the Rome Project of Coronary Heart
Disease Prevention. Eight-year follow-up results from
the Rome Project of Coronary Heart Disease Prevention.
Research Group of the Rome Project of Coronary Heart
Disease Prevention. Preventive Medicine 1986;15(2):
176–91.
Rose 1987 {published data only}
Rose DP, Boyar AP, Cohen C, Strong LE. Effect of a low fat
diet on hormone levels in women with cystic breast disease I
Serum steroids and gonadotropins. Journal of the National
Cancer Institute 1987;78:623–6.
Sandstrom 1992 {published data only}
Sandstrom B, Marckmann P, Bindslev N. An eight-month
controlled study of a low-fat high-fibre diet: effects on
blood lipids and blood pressure in healthy young subjects.
European Journal of Clinical Nutrition 1992;46(2):95–109.
Sasaki 2000 {published data only}
Sasaki S. Change and 1-year maintenance of nutrient
and food group intakes at a 12-week worksite dietary
intervention trial for men at high risk of coronary heart
disease. Journal of Nutritional Science & Vitaminology 2000;
46(1):15–22.
Schaefer 1995a {published data only}
Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al.Body
weight and low density lipoprotein cholesterol changes after
consumption of a low fat ad libitum diet. JAMA 1995;274:
1450–5.
Schaefer 1995b {published data only}
Schaefer EJ, Lichtenstein AH, Lamon-Fava S, Contois JH,
Li Z, Rasmussen H, et al.Efficacy of a National Cholesterol
Education Program Step 2 diet in normolipidaemic and
hypercholesterolaemic middle-aged and elderly men and
women. Arteriosclerosis, Thrombosis, and Vascular Biology
1995;15:1079–85.
Schectman 1996 {published data only}
Schectman G, Wolff N, Byrd JC, Hiatt JG, Hartz A.
Physician extenders for cost-effective management of
hypercholesterolemia. Journal of General Internal Medicine
1996;11(5):277–86.
Schlierf 1995 {published data only}
Schlierf G, Schuler G, Hambrecht R, Niebauer J, Hauer K,
Vogel G, et al.Treatment of coronary heart disease by diet
and exercise. Journal of Cardiovascular Pharmacology 1995;
25(Suppl 4):S32–4.
Seppanen-Laakso 1992 {published data only}
Seppanen-Laakso T, Vanhanen H, Laakso I, Kohtamaki H,
Viikari J. Replacement of butter on bread by rapeseed oil
and rapeseed oil-containing margarine: effects on plasma
fatty acid composition and serum cholesterol. British
Journal of Nutrition 1992;68:639–54.
Singh 1990 {published data only}
Singh RB, Sircar AR, Rastogi SS, Singh R. Dietary
modulators of blood pressure in hypertension. European
Journal of Clinical Nutrition 1990;44(4):319–27.
Singh 1991 {published data only}
Singh RB, Rastogi SS, Sircar AR. Dietary strategies for
risk-factor modification to prevent cardiovascular diseases.
Nutrition 1991;7(3):210–4.
Singh 1992 {published data only}
Singh RB, Niaz MA, Agarwal P, Begom R, Rastogi SS. Effect
of antioxidant-rich foods on plasma ascorbic acid, cardiac
enzyme, and lipid peroxide levels in patients hospitalized
with acute myocardial infarction. Journal of the American
Dietetic Association 1995;95(7):775–80.
Singh RB, Niaz MA, Ghosh S. Effect on central obesity and
associated disturbances of low-energy, fruit- and vegetable-
enriched prudent diet in north Indians. Postgraduate
Medical Journal 1994;70(830):895–900.
∗ Singh RB, Rastogi SS, Verma R, Bolaki L, Singh R. An
Indian experiment with nutritional modulation in acute
myocardial infarction. American Journal of Cardiology 1992;
69(9):879–85.
Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R, Ghosh
S, et al.Randomised controlled trial of cardioprotective diet
in patients with recent acute myocardial infarction: results
of one year follow up. BMJ 1992;304(6833):1015–9.
Sirtori 1992 {published data only}
Sirtori CR, Gatti E, Tremoli E, Galli C, Gianfranceschi
G, Franceschini G, et al.Olive oil, corn oil, and n-3 fatty
acids differently affect lipids, lipoproteins, platelets, and
superoxide formation in type II hypercholesterolemia.
American Journal of Clinical Nutrition 1992;56(1):113–22.
SLIM 2008 {published data only}
Roumen C, Corpeleijn E, Feskens EJ, Mensink M, Saris
WH, Blaak EE, et al.Impact of 3-year lifestyle intervention
on postprandial glucose metabolism: the SLIM study.
Diabetic Medicine 2008;25(5):597–605.
Sopotsinskaia 1992 {published data only}
Sopotsinskaia EB, Balitskii KP, Tarutinov VI, Zhukova
VM, Semenchuk DD, Kozlovskaia SG, et al.Experience
with the use of a low-calorie diet in breast cancer patients to
prevent metastasis [Opyt primeneniia nizkokaloriinoi diety
62Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
u bol’nykh rakom molochnoi zhelezy s tsel’iu profilaktiki
metastazi]. Voprosy Onkologii 1992;38(5):592–9.
Staff HHP 1994 {published data only}
Barratt A, Reznik R, Irwig L, Cuff A, Simpson JM,
Oldenburg B, et al.Work-site cholesterol screening and
dietary intervention: the Staff Healthy Heart Project.
Steering Committee. American Journal of Public Health
1994;84(5):779–82.
Stanford NAP 1997 {published data only}
Howard PB, Winkleby MA, Albright CL, Bruce B,
Fortmann SP. The Stanford Nutrition Action Program: a
dietary fat intervention for low-literacy adults. American
Journal of Public Health 1997;87(12):1971–6.
Stanford Weight 1994 {published and unpublished data}
Williams PT, Krauss RM, Stefanick ML, Vranizan KM,
Wood PD. Effects of low-fat diet, calorie restriction, and
running on lipoprotein subfraction concentrations in
moderately overweight men. Metabolism 1994;43(5):
655–63.
Starmans 1995 {published data only}
Starmans KM, Lustermans FT, Kragten HA, Struijker
BH, Rilla H. Lowering cholesterol in patients with
mild hypercholesterolaemia does not improve functional
properties of large arteries [Abstract]. Netherlands Journal
Of Medicine 1995;46:A70.
Steinbach 1996 {published data only}
Steinbach M. A Romanian contribution to the epidemiology
and prevention of cardiovascular diseases. Romanian Journal
of Internal Medicine 1996;34(1-2):137–48.
Steptoe 2001 {published data only}
Steptoe A, Kerry S, Rink E, Hilton S. The impact of
behavioral counselling on stage of change in fat intake,
physical activity, and cigarette smoking in adults at increased
risk of coronary heart disease. American Journal of Public
Health 2001;91(2):265–9.
Stevens 2002 {published and unpublished data}
Stevens VJ, Glasgow RE, Toobert DJ, Karanja N, Smith
KS. One-year results from a brief, computer-assisted
intervention to decrease consumption of fat and increase
consumption of fruits and vegetables. Preventive Medicine
2003;36:594–600.
∗ Stevens VJ, Glasgow RE, Toobert DJ, Karanja N, Smith
KS. Randomized trial of a brief dietary intervention to
decrease consumption of fat and increase consumption of
fruits and vegetables. American Journal of Health Promotion
2002;16(3):129–34.
Stevenson 1988 {published data only}
Stevenson DW, Darga LL, Spafford TR, Ahmad N, Lucas
CP. Variable effects of weight loss on serum lipids and
lipoproteins in obese patients. International Journal of
Obesity 1988;12:495–502.
Sweeney 2004 {published data only}
Sweeney M, Sweeney Michael. Effects of very low-fat diets
on anginal symptoms. Medical Hypotheses 2004;63(3):553.
TAIM 1992 {published data only}
Davis BR, Blaufox MD, Hawkins CM, Langford HG,
Oberman A, Swencionis C, et al.Trial of antihypertensive
interventions and management. Design, methods, and
selected baseline results. Controlled Clinical Trials 1989;10
(1):11–30.
Davis BR, Blaufox MD, Oberman A, Wassertheil SS,
Zimbaldi N, Cutler JA, et al.Reduction in long-term
antihypertensive medication requirements. Effects of weight
reduction by dietary intervention in overweight persons
with mild hypertension. Archives of Internal Medicine 1993;
153(15):1773–82.
Davis BR, Oberman A, Blaufox MD, Wassertheil SS,
Hawkins CM, Cutler JA, et al.Effect of antihypertensive
therapy on weight loss. The Trial of Antihypertensive
Interventions and Management Research Group.
Hypertension 1992;19(4):393–9.
Langford HG, Davis BR, Blaufox D, Oberman A,
Wassertheil Smoller S, et al.Effect of drug and diet treatment
of mild hypertension on diastolic blood pressure. The
TAIM Research. Hypertension 1991;17(2):210–7.
Oberman A, Wassertheil Smoller S, Langford HG, Blaufox
MD, Davis BR, Blaszkowski T, et al.Pharmacologic and
nutritional treatment of mild hypertension: changes in
cardiovascular risk status. Annals of Internal Medicine 1990;
112(2):89–95.
Wassertheil Smoller S, Davis BR, Breuer B, Chee JC,
Oberman A, Blaufox MD. Differences in precision of
dietary estimates among different population subgroups.
Annals of Epidemiology 1993;3:619–28.
∗ Wassertheil Smoller S, Oberman A, Blaufox MD, Davis
B, Langford H. The Trial of Antihypertensive Interventions
and Management (TAIM) Study. Final results with regard
to blood pressure, cardiovascular risk, and quality of life.
American Journal of Hypertension 1992;5(1):37–44.
Wylie Rosett J, Wassertheil Smoller S, Blaufox MD,
Davis BR, Langford HG, Oberman A, et al.Trial of
antihypertensive intervention and management: greater
efficacy with weight reduction than with a sodium-
potassium intervention. Journal of the American Dietetic
Association 1993;93(4):408–15.
Take Heart II 1997 {published data only}
Glasgow RE, Terborg JR, Strycker LK, Boles SM, Hollis JF.
Take Heart II: Replication of a worksite health promotion
trial. Journal of Behavioral Medicine 1997;20:143–61.
Taylor 1991 {published data only}
Taylor CB, Fortmann SP, Flora J, Kayman S, Barrett DC,
Jatulis D, et al.Effect of long-term community health
education on body mass index. The Stanford Five-City
Project. American Journal of Epidemiology 1991;134:
235–49.
TOHP I 1992 {published data only}
∗ The effects of nonpharmacologic interventions on blood
pressure of persons with high normal levels. Results of the
Trials of Hypertension Prevention, Phase I. JAMA 1992;
267(9):1213–20.
Kumanyika SK, Hebert PR, Cutler JA, Lasser VI, Sugars
63Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CP, Steffen Batey L, et al.Feasibility and efficacy of sodium
reduction in the Trials of Hypertension Prevention, phase I.
Hypertension 1993;22(4):502–12.
Satterfield S, Cutler JA, Langford HG, Applegate WB,
Borhani NO, Brittain E, et al.Trials of hypertension
prevention. Annals of Epidemiology 1991;1(5):455–71.
Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook
NR, Hebert P, et al.Weight loss intervention in phase
I of the trials of hypertension prevention. The TOHP
Collaborative Research Group. Archives of Internal Medicine
1993;153(7):849–58.
Whelton PK, Hebert PR, Cutler J, Applegate WB, Eberlein
KA, Klag MJ, et al.Baseline characteristics of participants in
phase I of the Trials of Hypertension Prevention. Annals of
Epidemiology 1992;2(3):295–310.
Whelton PK, Kumanyika SK, Cook NR, Cutler JA, Borhani
NO, Hennekens CH, et al.Efficacy of nonpharmacologic
interventions in adults with high-normal blood pressure:
results from phase 1 of the Trials of Hypertension
Prevention. American Journal of Clinical Nutrition 1997;65
(2 Suppl):652S–60S.
TONE 1997 {published data only}
Whelton PK, Appel LJ, Espeland MA, Applegate WB,
Ettinger-WH J, Kostis JB, et al.Sodium reduction and
weight loss in the treatment of hypertension in older
persons: a randomized controlled trial of nonpharmacologic
interventions in the elderly (TONE). JAMA 1998;279(11):
839–46.
∗ Whelton PK, Babnson J, Appel LJ, Charleston J,
Cosgrove N, Espeland MA, et al.Recruitment in the Trial of
Nonpharmacologic Intervention in the Elderly (TONE).
Journal of the American Geriatrics Society 1997;45(2):
185–93.
Toobert 2003 {published data only}
Toobert DJ, Glasgow RE, Strycker LA, Barrera M Jr,
Radcliffe JL, Wander RC, et al.Biologic and quality-of-
life outcomes from the Mediterranean Lifestyle Program:
a randomized clinical trial. Diabetes Care 2003;26(8):
2288–93.
Towle 1994 {published data only}
Towle LA, Bergman EA, Joseph E. Low-fat bison-hybrid
ground meat has no effects on serum lipid levels in a study
of 12 men. Journal of the American Dietetic Association
1994;94(5):546–8.
TRANSFACT 2006 {published data only}
∗ Chardigny JM, Malpuech-Brugere C, Dionisi F, Bauman
DE, German B, Mensink RP, et al.Rationale and design
of the TRANSFACT project phase I: a study to assess the
effect of the two different dietary sources of trans fatty acids
on cardiovascular risk factors in humans. Contemporary
Clinical Trials 2006;27(4):364–73.
Chardigny JMD. Do trans fatty acids from industrially
produced sources and from natural sources have the same
effect on cardiovascular disease risk factors in healthy
subjects? Results of the trans Fatty Acids Collaboration
(TRANSFACT) study. American Journal of Clinical
Nutrition 2008;108(3):558–66.
Treatwell 1992 {published and unpublished data}
Sorensen G, Morris DM, Hunt MK, Hebert JR, Harris
DR, Stoddard A, et al.Work-site nutrition intervention and
employees’ dietary habits: the Treatwell program. American
Journal of Public Health 1992;82(6):877–80.
Tromso Heart 1989 {published data only}
Knutsen SF, Knutsen R. The Tromso Heart Study: family
approach to intervention on CHD. Feasibility of risk
factor reduction in high-risk persons--project description.
Scandinavian Journal of Social Medicine 1989;17:109–19.
Turpeinen 1960 {published data only}
Turpeinen O, Roine P, Pekkarinen M, Karvonen MJ,
Rautanen Y, Runeberg J, et al.Effect on serum-cholesterol
level of replacement of dietary milk fat by soybean oil.
Lancet 1960;1:196–8.
UK PDS 1996 {published data only}
∗ Turner R, Cull C, Holman R. United Kingdom
Prospective Diabetes Study 17: a 9-year update of a
randomized, controlled trial on the effect of improved
metabolic control on complications in non-insulin-
dependent diabetes mellitus. Annals of Internal Medicine
1996;124(1 Pt 2):136–45.
Turner RC, Holman RR. Lessons from UK prospective
diabetes study. Diabetes Research and Clinical Practice 1995;
28(Suppl):S151–7.
Urbach 1952 {published data only}
Urbach R, Hildreth EA, Wackerman MT. The therapeutic
uses of low fat, low cholesterol diets: I. Treatment of
essential familial xanthomatosis. Journal of Clinical
Nutrition 1952;1:52–6.
Uusitupa 1993 {published data only}
Uusitupa M, Laitinen J, Siitonen O, Vanninen E, Pyorala
K. The maintenance of improved metabolic control after
intensified diet therapy in recent type 2 diabetes. Diabetes
Research and Clinical Practice 1993;19(3):227–38.
Vavrikova 1958 {published data only}
Vavrikova J. Essential fatty acids, lipid metabolism, and
atherosclerosis [letter]. Lancet 1958;1:1337.
Wass 1981 {published data only}
Wass VJ, Jarrett RJ, Meilton V, Start MK, Mattock M, Ogg
CS, et al.Effect of a long-term fat-modified diet on serum
lipoprotein levels of cholesterol and triglyceride in patie.
Clinical Science 1981;60(1):81–6.
Wassertheil 1985 {published data only}
Wassertheil SS, Blaufox MD, Langford HG, Oberman
A, Cutter G, Pressel S. Prediction of response to sodium
intervention for blood pressure control. Journal of
Hypertension.Supplement 1986;4(5):S343–6.
∗ Wassertheil SS, Langford HG, Blaufox MD, Oberman A,
Hawkins M, Levine B, et al.Effective dietary intervention
in hypertensives: sodium restriction and weight reduction.
Journal of the American Dietetic Association 1985;85(4):
423–30.
WATCH 1999 {published and unpublished data}
Ockene IS, Hebert JR, Ockene JK, Saperia GM, Stanek E,
Nicolosi R, et al.Effect of a physician-delivered nutrition
64Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
counselling training and an office-support program on
saturated fat intake, weight, and serum lipid measurements
in a hyperlipidemic population: Worcester Area Trial for
Counseling in Hyperlipidemia. Archives of Internal Medicine
1999;159:725–31.
Watts 1988 {published data only}
Watts GF, Ahmed W, Quiney J, Houlston R, Jackson P, Iles
C, et al.Effective lipid lowering diets including lean meat.
British Medical Journal (Clinical Research Ed.) 1988;296
(6617):235–7.
Weintraub 1992 {published data only}
Weintraub M, Sundaresan PR, Schuster B. Long-term
weight control study. VII (weeks 0 to 210). Serum lipid
changes. Clinical Pharmacology and Therapeutics 1992;51
(5):634–41.
Westman 2006 {published data only}
Westman EC, Yancy WS Jr, Olsen MK, Dudley T, Guyton
JR. Effect of a low-carbohydrate, ketogenic diet program
compared to a low-fat diet on fasting lipoprotein subclasses.
International Journal of Cardiology 2006;110(2):212–6.
Weststrate 1998 {published data only}
Weststrate JA, Meijer GW. Plant sterol enriched margarines
and reduction of plasma total-and LDL-cholesterol
concentrations in normocholesterolaemic and mildly
hypercholesterolaemic subjects. European Journal of Clinical
Nutrition 1998;52:334–43.
WHO primary prev 1979 {published data only}
Primary prevention of ischaemic heart disease: WHO
coordinated cooperative trial. A summary report. Bulletin
Of The World Health Organization 1979;57:801–5.
WHT 1990 {published and unpublished data}
Bowen D. The role of participation in the women’s health
trial: feasibility study in minority populations. Preventive
Medicine 2000;31(5):474–80.
Bowen D, Clifford CK, Coates R, Evans M, Feng Z, Fouad
M, et al.The Women’s Health Trial feasibility study in
minority populations: design and baseline descriptions.
Annals of Epidemiology 1996;6(6):507–19.
Bowen DJ, Kestin M, McTiernan A, Carrell D, Green
P. Effects of dietary fat intervention on mental health in
women. Cancer Epidemiology, Biomarkers and Prevention
1995;4(5):555–9.
Gorbach SL, Morrill LA, Woods MN, Dwyer JT, Selles
WD, Henderson M, et al.Changes in food patterns during
a low-fat dietary intervention in women. Journal of the
American Dietetic Association 1990;90(6):802–9.
Henderson MM, Kushi LH, Thompson DJ, Gorbach SL,
Clifford CK, Insull W, et al.Feasibility of a randomized trial
of a low-fat diet for the prevention of breast cancer: dietary
compliance in the Women’s Health Trial Vanguard Study.
Preventive Medicine 1990;19(2):115–33.
∗ Insull W, Henderson MM, Prentice RL, Thompson DJ,
Clifford C, Goldman S, et al.Results of a randomized
feasibility study of a low-fat diet. Archives of Internal
Medicine 1990;150(2):421–7.
Kristal AR, White E, Shattuck AL, Curry S, Anderson
GL, Fowler A, et al.Long-term maintenance of a low-fat
diet: durability of fat-related dietary habits in the Women’s
Health Trial. Journal of the American Dietetic Association
1992;92(5):553–9.
Prentice RL, Kakar F, Hursting S, Sheppard L, Klein R,
Kushi LH. Aspects of the rationale for the Women’s Health
Trial. Journal of the National Cancer Institute 1988;80(11):
802–14.
Self S, Prentice R, Iverson D, Henderson M, Thompson D,
Byar D, et al.Statistical design of the Women’s Health Trial.
Controlled Clininical Trials 1988;9(2):119–36.
Sheppard L, Kristal AR, Kushi LH. Weight loss in women
participating in a randomised trial of low-fat diets. American
Journal of Clinical Nutrition 1991;54:821–8.
Urban N, Baker M. The Women’s Health Trial as an
investment. Medical Decision Making 1989;9(1):59–64.
White E, Shattuck AL, Kristal AR, Urban N, Prentice RL,
Henderson MM, et al.Maintenance of a low-fat diet: follow-
up of the Women’s Health Trial. Cancer Epidemiology,
Biomarkers and Prevention 1992;1(4):315–23.
WHT Feasibility 2003 {published and unpublished data}
Bowen D, Clifford CK, Coates R, Evans M, Feng Z, Fouad
M, et al.The Women’s Health Trial Feasibility Study in
Minority Populations: design and baseline descriptions.
Annals of Epidemiology 1996;6(6):507–19.
∗ Hall WD, Feng Z, George VA, Lewis CE, Oberman A,
Huber M, et al.Low-fat diet: effect on anthropometrics,
blood pressure, glucose, and insulin in older women.
Ethnicity and Disease 2003;13:337–43.
Wilke 1974 {published data only}
Wilke H, Frahm H. Influence of low-caloric-diet and d-
triiodothyronine on serum lipids and body weight (author’s
trans) [Verhalten der Serumlipide und des Körpergewichts
unter Reduktionsdiät und medikamentöser Behandlung
mit D–Trijodthyronin]. Medizinische Klinik 1974;69(48):
1986–9.
Williams 1990 {published data only}
Williams PT, Krauss RM, Vranizan KM, Wood PS.
Changes in lipoprotein subfractions during diet-induced
and exercise-induced weight loss in moderately overweight
men. Circulation 1990;81:1293–304.
Williams 1992 {published data only}
Williams PT, Krauss RM, Vranizan KM, Albers JJ,
Wood PD. Effects of weight-loss by exercise and by
diet on apolipoproteins A-I and A-II and the particle-
size distribution of high-density lipoproteins in men.
Metabolism: Clinical and Experimental 1992;41:441–9.
Williams 1994 {published data only}
Williams PT, Stefanick ML, Vranizan KM, Wood PD.
The effects of weight loss by exercise or by dieting on
plasma high-density lipoprotein (HDL) levels in men with
low, intermediate, and normal-to-high HDL at baseline.
Metabolism 1994;43(7):917–24.
65Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wilmot 1952 {published data only}
Wilmot VA, Swank RL. The influence of low fat diet
on blood lipid levels in health and in multiple sclerosis.
American Journal of the Medical Sciences 1952;223:25–34.
Wing 1998 {published data only}
Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W.
Lifestyle intervention in overweight individuals with a
family history of diabetes. Diabetes Care 1998;21(3):350–9.
WOMAN 2007 {published data only}
Kuller LH, Kriska AM, Kinzel LS, Simkin-Silverman LR,
Sutton-Tyrrell K, Johnson BD, et al.The clinical trial of
Women On the Move through Activity and Nutrition
(WOMAN) study. Contemporary Clinical Trials 2007;28
(4):370–81.
Wood 1988 {published data only}
Wood PD, Stefanick ML, Dreon DM, Frey HB, Garay SC,
Williams PT, et al.Changes in plasma lipids and lipoproteins
in overweight men during weight loss through dieting as
compared with exercise. New England Journal of Medicine
1988;319(18):1173–9.
Woollard 2003 {published data only}
Woollard J, Burke V, Beilin LJ, Verheijden M, Bulsara MK.
Effects of a general practice-based intervention on diet, body
mass index and blood lipids in patients at cardiovascular
risk. Journal of Cardiovascular Risk 2003;10(1):31–40.
Working Well 1996 {published data only}
Sorensen G, Thompson B, Glanz K, Feng Z, Kinne S,
DiClemente C, et al.Work site-based cancer prevention:
primary results from the Working Well Trial. American
Journal of Public Health 1996;86(7):939–47.
Zock 1995 {published and unpublished data}
∗ Zock PL. Dietary fatty acids and risk factors for coronary
heart disease : controlled studies in healthy volunteers.
Wageningen, Netherlands: Landbouwuniversiteit te
Wageningen, 1995.
Zock PL, Mensink RP, Harryvan J, de VJ, Katan MB.
Fatty acids in serum cholesteryl esters as quantitative
biomarkers of dietary intake in humans. American Journal
of Epidemiology 1997;145(12):1114–22.
References to studies awaiting assessment
Barsotti 1991 {published data only}
Barsotti A. Modern trends in the therapy of arteriosclerosis
in the light of new physiopathological findings [Moderne
tendenze della terapia dell’arteriosclerosi alla luce delle
nuove acquisizioni fisiopatologiche]. Cardiologia 1991;36
(12, Suppl 1):33–48.
Bonk 1975 {published data only}
Bonk S, Hubotter E, Nickel C, Stocksmeier U, Vahey
P, Volk I, et al.Myocardial infarct patients with and
without intensive nutrition consultation over several
years-- comparison of physiological and social variables
[Herzinfarktpatienten mit und ohne mehrjährige intensive
Ernährungsberatung – Vergleich von physiologischen
und sozialen Variablen]. Infusionstherapie und Klinische
Ernährung 1975;2(4):290–6.
Brehm 2009 {published data only (unpublished sought but not used)}
Brehm BJ, Lattin BL, Summer SS, Boback JA, Gilchrist
GM, Jandacek RJ, et al.One-year comparison of a high-
monounsaturated fat diet with a high-carbohydrate diet in
type 2 diabetes. Diabetes Care 2009;32(2):215–20.
Canadian DBCP 1997 {published data only (unpublished sought but
not used)}
Boyd NF, Greenberg C, Lockwood G, Little L, Martin
L, Byng J, et al.Effects at two years of a low-fat, high-
carbohydrate diet on radiologic features of the breast: results
from a randomized trial. Journal of the Nationl Cancer
Institute 1997;89(7):488–96.
DEER 1998 {published data only (unpublished sought but not used)}
Stefanick ML, Mackey S, Sheehan RD, Ellsworth N,
Haskell WL, Wood PD. Effects of diet and exercise in
men and postmenopausal women with low levels of HDL
cholesterol and high levels of LDL cholesterol. New England
Journal of Medicine 1998;339(1):12–20.
Diet & Hormone Study 2003 {published data only (unpublished
sought but not used)}
Gann PH, Chatterton RT, Gapstur SM, Liu K, Garside D,
Giovanazzi S, et al.The effects of a low-fat/high-fiber diet on
sex hormone levels and menstrual cycling in premenopausal
women: a 12-month randomized trial (the Diet and
Hormone Study). Cancer 2003;98:1870–9.
DIRECT 2009 {published data only (unpublished sought but not
used)}
∗ Ben-Avraham S, Harman-Boehm I, Schwarzfuchs D, Shai
I. Dietary strategies for patients with type 2 diabetes in the
era of multi-approaches; review and results from the Dietary
Intervention Randomized Controlled Trial (DIRECT).
Diabetes Research and Clinical Practice 2009;86(Suppl 1):
S41–8.
Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow
S, Greenberg I, et al.Weight loss with a low-carbohydrate,
Mediterranean, or low-fat diet. New England Journal of
Medicine 2008;359:229–41.
Esposito 2004 {published data only}
Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano
F, Giugliano G, et al.Effect of a Mediterranean-style
diet on endothelial dysfunction and markers of vascular
inflammation in the metabolic syndrome: a randomized
trial. JAMA 2004;292(12):1440–6.
Koranyi 1963 {published data only}
Koranyi A. Prophylaxis and treatment of the coronary
syndrome. Therapia Hungarica 1963;11:17–20.
Metroville Health 2003 {published data only (unpublished sought but
not used)}
Aziz KU, Dennis B, Davis CE, Sun K, Burke G, Manolio T,
et al.Efficacy of CVD risk factor modification in a lower-
middle class community in Pakistan: the Metroville Health
Study. Asia Pacific Journal of Public Health 2003;15(1):
30–6.
66Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mojonnier 1980 {published data only}
Mojonnier ML, Hall Y, Berkson DM, Robinson E, Wethers
B, Pannbacker B, et al.Experience in changing food habits of
hyperlipidaemic men and women. Journal of the American
Dietetic Association 1980;77:140–8.
Naglak 2000 {published data only (unpublished sought but not used)}
Naglak MC, Mitchell DC, Shannon BM, Pearson TA,
Harkness WL, Kris-Etherton PM. Nutrient adequacy of
diets of adults with hypercholesterolemia after a cholesterol-
lowering intervention: long term assessment. Journal of the
American Dietetic Association 2000;100(11):1385–91.
OLIVE 1997 {published data only (unpublished sought but not used)}
∗ Colquhoun DM. Rationale and design of the ”OLIVE“
study (Comparison of an Olive oil enriched to a low fat diet
intervention study using vascular endpoints) [Abstract].
11th International Symposium on Atherosclerosis, Paris.
October 1997:326.
Colquhoun DM, Somerset S, Glasziou PP, Richards D,
Weyers J. Comparison of an olive oil enriched diet to a
low fat diet intervention study using vascular endpoints:
assessed by repeat quantitative angiography (OLIVE study).
Australian Journal of Nutrition and Dietetics 1998;55(Suppl
4):S24–9.
Tapsell 2004 {published data only (unpublished sought but not used)}
Tapsell LC, Hokman A, Sebastiao A, Denmeade S, Martin
G, Calvert GD, et al.The impact of usual dietary patterns,
selection of significant foods and cuisine choices on
changing dietary fat under ’free living’ conditions. Asia
Pacific Journal of Clinical Nutrition 2004;13(1):86–91.
Verheiden 2003 {published data only (unpublished sought but not
used)}
Verheiden MW, van der Veen JE, van Zadelhoff
WM, Bakx C, Koelen MA, van den Hoogen HJM, et
al.Nutrition guidance in Dutch family practice: behavioural
determinants of reduction in fat consumption. American
Journal of Clinical Nutrition 2003;77(Suppl):1058S–64S.
References to ongoing studies
PREDIMED 2008 {published data only (unpublished sought but not
used)}
Buil-Cosiales P, Irimia P, Ros E, Riverol M, Gilabert R,
Martinez-Vila E, et al.Dietary fibre intake is inversely
associated with carotid intima-media thickness: a cross-
sectional assessment in the PREDIMED study. European
Journal of Clinical Nutrition 2009;63(10):1213–9.
Estruch R, Martinez-Gonzalez MA, Corella D, Salas-
Salvado J, Ruiz-Gutierrez V, Covas MI, et al.Effects of a
Mediterranean-style diet on cardiovascular risk factors: a
randomized trial. Annals of Internal Medicine 2006;145(1):
1–11.
Razquin C, Martinez JA, Martinez-Gonzalez MA, Mitjavila
MT, Estruch R, Marti A, et al.A 3 years follow-up of a
Mediterranean diet rich in virgin olive oil is associated with
high plasma antioxidant capacity and reduced body weight
gain. European Journal of Clinical Nutrition 2009;63(12):
1387–93.
Salas-Salvado J, Fernandez-Ballart J, Ros E, Martinez-
Gonzalez MA, Fito M, Estruch R, et al.Effect of a
Mediterranean diet supplemented with nuts on metabolic
syndrome status: one-year results of the PREDIMED
randomized trial. Archives of Internal Medicine 2008;168
(22):2449–58.
Salas-Salvado J, Garcia-Arellano A, Estruch R, Marquez-
Sandoval F, Corella D, Fiol M, et al.Components of the
Mediterranean-type food pattern and serum inflammatory
markers among patients at high risk for cardiovascular
disease. European Journal of Clinical Nutrition 2008;62(5):
651–9.
Sanchez-Tainta A, Estruch R, Bullo M, Corella D, Gomez-
Gracia E, Fiol M, et al.Adherence to a Mediterranean-type
diet and reduced prevalence of clustered cardiovascular risk
factors in a cohort of 3,204 high-risk patients. European
Journal of Cardiovascular Prevention & Rehabilitation 2008;
15(5):589–93.
Schroder H, de la Torre R, Estruch R, Corella D,
Martinez-Gonzalez MA, Salas-Salvado J, et al.Alcohol
consumption is associated with high concentrations of
urinary hydroxytyrosol. American Journal of Clinical
Nutrition 2009;90(5):1329–35.
Toledo E, Delgado-Rodriguez M, Estruch R, Salas-Salvado
J, Corella D, Gomez-Gracia E, et al.Low-fat dairy products
and blood pressure: follow-up of 2290 older persons at high
cardiovascular risk participating in the PREDIMED study.
British Journal of Nutrition 2009;101(1):59–67.
Waterhouse AL. Resveratrol metabolites in urine as
biomarker of wine intake in free-living subjects: The
PREDIMED Study. Free Radical Biology & Medicine 2009;
46(12):1561.
Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos
RM, Estruch R, Martinez-Gonzalez MA, Bullo M, et
al.Resveratrol metabolites in urine as a biomarker of wine
intake in free-living subjects: The PREDIMED Study. Free
Radical Biology & Medicine 2009;46(12):1562–6.
Zazpe I, Estruch R, Toledo E, Sanchez-Tainta A, Corella D,
Bullo M, et al.Predictors of adherence to a Mediterranean-
type diet in the PREDIMED trial. European Journal of
Nutrition 2010;49(2):91–9.
∗ Zazpe I, Sanchez-Tainta A, Estruch R, Lamuela-Raventos
RM, Schroder H, Salas-Salvado J, et al.A large randomized
individual and group intervention conducted by registered
dietitians increased adherence to Mediterranean-type diets:




Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients
with coronary heart disease: the Scandinavian Simvastatin
Survival Study (4S). Lancet 1994;344(8934):1383–9.
67Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ACC/AHA 2008
ACC/AHA Writing group. ACC/AHA 2008 performance
measures for adults with ST-elevation and non-ST-elevation
myocardial infarction. Circulation 2008;118:2596–2648.
Astrup 2000
Astrup A, Ryan L, Grunwald GK, Storgaard M, Saris W,
Melanson E, et al.The role of dietary fat in body fatness:
evidence from a preliminary meta-analysis of ad libitum
low-fat dietary intervention studies. British Journal of
Nutrition 2000;83(Suppl 1):S25–32.
Berkley 1995
Berkley CS, Hoaglin DC, Mosteller F, Colditz GA. A
random-effects regression model for meta-analysis. Statistics
in Medicine 1995;14:395–411.
Briel 2009
Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl
EA, Wu P, et al.Association between change in high density
lipoprotein cholesterol and cardiovascular disease morbidity
and mortality: systematic review and meta-regression
analysis. BMJ 2009;338:b92. [DOI: 10.1136/bmj.b92]
Brunner 1997
Brunner E, White I, Thorogood M, Bristow A, Curle D,
Marmot M. Can dietary interventions change diet and
cardiovascular risk factors? A meta-analysis of randomized
controlled trials. American Journal of Public Health 1997;87
(9):1415–22.
Brunner 2009
Brunner E, Rees K, Ward K, Burke M, Thorogood M.
Dietary advice for reducing cardiovascular risk. Cochrane
Database of Systematic Reviews 2007, Issue 4. [DOI:
10.1002/14651858.CD002128.pub3]
Bucher 1996
Bucher HC, et al.Effects of dietary calcium supplementation
on blood pressure: a meta-analysis of randomised controlled
trials. JAMA 1996;275:1016–22.
Chalmers 1990
Chalmers I, Adams M, Dickersin K, Hetherington J,
Tarnow-Mordi W, Meinert C, et al.A cohort study of
summary reports of controlled trials. JAMA 1990;263:
1401–5.
Clarke 1997
Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary
lipids and blood cholesterol: quantitative meta-analysis of
metabolic ward studies. BMJ 1997;314:112–7.
Davey Smith 1993
Davey Smith G, Song F, Sheldon TA. Cholesterol lowering
and mortality: the importance of considering initial level of
risk. BMJ 1993;306:1367–73.
De Caterina 2010
De Caterina R, Scarano M, Marfisi RM, Lucisano G, Palma
F, Tatasciore A, et al.Cholesterol-lowering interventions and
stroke. Journal of the American College of Cardiology 2010;
55:198–211.
Denke 1995
Denke MA. Cholesterol-lowering diets. A review of the
evidence. Archives of Internal Medicine 1995;155:17–26.
DerSimonian 1986
DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7:177–88.
Ebrahim 1997
Ebrahim S, Davey Smith G. Systematic review of
randomised controlled trials of multiple risk factor
interventions for preventing coronary heart disease. BMJ
1997;314(7095):1666.
Egger 1997
Egger M, Davey Smith G, Schneider M, Minder C. Bias
in meta-analysis detected by a simple graphical test. BMJ
1997;315:629–34.
Fraker 2007
Fraker TD, Fihn SD. 2007 Chronic angina: focused update
of the ACC/AHA 2002 guidelines for the management of
patients with chronic stable angina. Circulation 2007;116:
2762–72.
Gofman 1949
Gofman JW, Lindgren FT, Elliott HA. Ultracentrifugal
studies of lipoproteins of human serum. Journal of Biological
Chemistry 1949;179:973–9.
Hasselblad 1995
Hasselblad V, McRory DC. Meta-analytic tools for medical
decision making: a practical guide. Medical Decision
Making 1995;15:81–96.
Hauck 1991
Hauck WW, Gilliss CL, Donner A, Gortner S.
Randomisation by cluster. Nursing Research 1991;40(6):
356–8.
Hegsted 1965
Hegsted DM, McGandy RB, Myers ML, Stare FJ.
Quantitative effects of dietary fat on serum cholesterol in
man. American Journal of Clinical Nutrition 1965;17(5):
281–95.
Hegsted 2000
Hegsted DM. From chick nutrition to nutrition policy.
Annual Review of Nutrition 2000;20:1–19.
Hession 2009
Hession M, Rolland C, Kulkarni U, Wise A, Broom
J. Systematic review of randomized controlled trials of
low-carbohydrate vs. low-fat/low-calorie diets in the
management of obesity and its comorbidities. Obesity
Reviews 2009;10:36–50.
Higgins 1999
Higgins JPT. ciplot: confidence interval plots using S-
PLUS. Manual version 2, London: Institute of Child
Health 1999.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
68Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2011. Available from www.cochrane-handbook.org. The
Cochrane Collaboration..
Kagan 1974
Kagan A, Harris BR, Winkelstein W Jr, Johnson KG,
Kato H, Syme SL, et al.Epidemiologic studies of coronary
heart disease and stroke in Japanese men living in Japan,
Hawaii and California: demographic, physical, dietary and
biochemical characteristics. Journal of Chronic Disease 1974;
27:345–64.
Keys 1950
Keys A, Mickelsen O, Miller EVO, Carleton B. The relation
in man between cholesterol levels in the diet and in the
blood. Science 1950;112:79–81.
Keys 1986
Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn
H, Buzina R, et al.The diet and 15-year death rate in the
seven countries study. American Journal of Epidemiology
1986;124:903–15.
Kodama 2009
Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Sato M,
et al.Influence of fat and carbohydrate proportions on the
metabolic profile in patients with type 2 diabetes: a meta-
analysis. Diabetes Care 2009;32(5):959–65.
Kristal 2005
Kristal AR, Peters U, Potter JD. Is it time to abandon
the food frequency questionnaire?. Cancer Epidemiology,
Biomarkers and Prevention 2005;14(12):2826–8.
Law 1991
Law MR, Frost CD, Wald NJ. By how much does dietary
salt restriction lower blood pressure?. BMJ 1991;302:
811–24.
Law 1994
Law MR, Wald NJ, Thompson SG. By how much and how
quickly does reduction in serum cholesterol concentration
lower risk of ischaemic heart disease?. BMJ 1994;308:
367–73.
Lenz 2007
Lenz M, Steckelberg A, Richter B, Mühlhauser I. Meta-
analysis does not allow appraisal of complex interventions
in diabetes and hypertension self-management:a
methodological review. Diabetologia 2007;50:1375-83.
Lichtenstein 2006
Lichtenstein AH, Appel LJ, Brands M, Carnethon
M, Daniels S, Franch HA, et al.Diet and lifestyle
recommendations revision 2006: a scientific statement from
the American Heart Association Nutrition Committee.
Circulation 2006;114:82–96.
Marchioli 1994
Marchioli R, Prieto JC, Tognoni G. Surrogate end-points:
the case of trials on coronary atherosclerotic plaque
regression. Clinical Trials and Meta-Analyses 1994;29:
139–76.
Mensink 1992
Mensink RP, Katan MB. Effect of dietary fatty acids on
serum lipids and lipoproteins: a meta-analysis of 27 trials.
Arteriosclerosis and Thrombosis 1992;12:911–9.
Michels 2009
Michels KB, Willett WC. The women’s health initiative
randomized controlled dietary modification trial: a post-
mortem. Breast Cancer Research and Treatment 2009;114:
1–6.
Mozaffarian 2010
Mozaffarian D, Micha R, Wallace S. Effects of coronary
heart disease of increasing polyunsaturated fat in place of
saturated fat: a systematic review and meta-analysis of
randomized controlled trials. PLOS Medicine 2010;7(3):
e1000252.
Ness 1997
Ness AR, Powles JW. Fruit and vegetables, and cardiovascular
disease: a review. International Journal of Epidemiology
1997;26:1–13.
NICE 2006
National Institute for Health and Clinical Excellence.
Technology Appraisal 94. Statins for the prevention of
cardiovascular events. NICE at: www.nice.org.uk/TA094
2006.
Oliver 1953
Oliver MF, Boyd GS. The plasma lipids in coronary artery
disease. British Heart Journal 1953;15:387–90.
Oliver 2000
Oliver MF. Pioneer research in Britain into atherosclerosis
and coronary heart disease - an historical review.
Atherosclerosis 2000;150:1–12.
Prentice 2007
Prentice RL. Observational studies, clinical trials, and the
women’s health initiative. Lifetime Data Analysis 2007;13:
449–62.
Rimm 1996
Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of
moderate alcohol consumption and reduced risk of coronary
heart disease: is the effect due to beer, wine or spirits?. BMJ
1996;312:731–6.
Robertson 1977
Robertson TL, Kato H, Rhoads GG, Kagan A, Marmot
M, Syme SL, et al.Epidemiologic studies of coronary heart
disease and stroke in Japanese men living in Japan, Hawaii
and California. Incidence of myocardial infarction and
death from coronary heart disease. American Journal of
Cardiology 1977;39:239–43.
Robinson 2009
Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-
analysis of the relationship between non-high-density
lipoprotein cholesterol reduction and coronary heart disease
risk. Journal of the American College of Cardiology 2009;53:
316–22.
Rubins 1995
Rubins HB. Cholesterol in patients with coronary heart
disease: how low should we go?. Journal of General Internal
Medicine 1995;10(8):464–71.
69Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ryle 1949
Ryle JA, Russell WT. The natural history of coronary
disease. A clinical and epidemiological study. British Heart
Journal 1949;11:370.
Schatzkin 2003
Schatzkin A, Kipnis V, Carroll RJ, et al.A comparison of
a food frequency questionnaire with a 24-hour recall for
use in an epidemiological cohort study: results from the
biomarker-based Observing Protein and EnergyNutrition
(OPEN) Study. International Journal of Epidemiology 2003;
32:1054–62.
Shafiq 2010
Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S. Dietary
treatment for familial hypercholesterolaemia. Cochrane
Database of Systematic Reviews 2010, Issue 1. [DOI:
10.1002/14651858.CD001918.pub2]
Shah 2007
Shah M, Adams-Huet B, Garg A. Effect of high-
carbohydrate or high-cis-monounsaturated fat diets on
blood pressure: a meta-analysis of intervention trials.
American Journal of Clinical Nutrition 2007;85:1251–6.
Sharp 1998
Sharp S. Meta-analysis regression. Stats Technical Bulletin
1998;42:16–22.
Sheppherd 2009
Shepperd S, Lewin S, Straus S, Clarke M, Eccles MP,
Fitzpatrick R, et al.Can we systematically review studies that
evaluate complex interventions?. PLoS Medicine / Public
Library of Science 2009;6(8):e1000086.
SIGN 1996
Scottish Intercollegiate Guidelines Network. Obesity in
Scotland, integratingpPrevention with weight management.
SIGN publication no. 8 1996:Edinburgh.
Siri-Tarino 2010
Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis
of prospective cohort studies evaluating the association of
saturated fat with cardiovascular disease. American Journal
of Clinical Nutrition 2010;91:535–46.
Skeaff 2009
Skeaff CM, Miller J. Dietary fat and coronary heart
disease: summary of evidence from prospective cohort
and randomised controlled trials. Annals of Nutrition and
Metabolism 2009;55:173–201.
Stein 2006
Stein K. After the media feeding frenzy: whither the
Women’s Health Initiative Dietary Modification Trial?.
Journal of the American Dietetic Association 2006;106(6):
794–800.
Sterne 2009
Sterne JAC. Meta-analysis in Stata: an updated collection
from the Stata journal. Texas, USA: STATA Press, 2009.
Sterne, Bradburn and Egger 2001
Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in
STATA. In: Egger M, Davey Smith G, Altman DG editor
(s). Systematic reviews in health care: meta-analysis in context.
London: BMJ Books, 2001.
Thorogood 1996
Thorogood M. Nutrition. In: Lawrence M, Neil A, Mant
D, Fowler G editor(s). Prevention of Cardiovascular Disease:
an evidence-based approach. Kings Lynn: Oxford University
Press, 1996:54–66.
Walsh 1995
Walsh JME, Grady D. Treatment of hyperlipidaemia in
women. JAMA 1995;274:1152–58.
Weggemans 2001
Weggemans RM, Zock PL, Katan MB. Dietary cholesterol
from eggs increases the ratio of total cholesterol to high-
density lipoprotein cholesterol in humans: a meta-analysis.
American Journal of Clinical Nutrition 2001;73:885–91.
Yngve 2006
Yngve A, Hambraeus L, Lissner L, Serra Majem L, Vaz de
Almeida MD, Berg C, et al.Invited Commentary. The
Women’s Health Initiative. What is on trial: nutrition and
chronic disease? Or misinterpreted science, media havoc
and the sound of silence from peers. Public Health Nutrition
2006;9(2):269–72.
Yu-Poth 1999
Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda
S, Kris-Etherton PM. Effects of the National Cholesterol
Education Program’s Step I and Step II dietary intervention
programs on cardiovascular disease risk factors: a meta-
analysis. American Journal of Clinical Nutrition 1999;69:
632–46.
References to other published versions of this review
Hooper 2000
Hooper L, Summerbell CD, Higgins JPT, Thompson RL,
Clements G, Capps N, et al.Reduced or modified dietary fat
for preventing of cardiovascular disease. Cochrane Database
of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/
14651858.CD002137]
Hooper 2001
Hooper L, Summerbell CD, Higgins JPT, Thompson RL,
Capps N, Davey Smith G, et al.Dietary fat intake and
prevention of cardiovascular disease: systematic review.
BMJ 2001;322:757–63.
∗ Indicates the major publication for the study
70Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anderson 1990
Methods RCT
Participants Moderately hypercholesterolaemic, non-obese Caucasian men and women aged 30-50
(USA)
CVD risk: moderate
Control: randomised 62, analysed 51
Intervention: randomised 56, analysed 47
Mean years in trial: control 0.91, intervention 0.92
% male: control 61, intervention 66
Age: mean control 40.3 (sd 5.4), intervention 40.7 (sd 5.2) (all 30-50)
Interventions Reduced fat diet vs usual diet
Control aims: no diet intervention
Intervention aims: 25%E from fats, 20%E from protein, 55%E from CHO, <200mg
chol /day
(Also an intervention arm with similar aims plus increased fibre intake)
Control methods: no intervention
Intervention methods: seminars and individual eating patterns taught, 10 weeks teaching
and 40 weeks maintenance
Total fat intake (at 1 year): low fat 30 (sd 7.5), cont 31 (sd 5.7)%E
Saturated fat intake (at 1 year): low fat 9 (sd 2.7), cont 10 (sd 2.9)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: diet composition, lipids
Data available on total mortality? yes (none)
Cardiovascular mortality? yes (none)
Events available for combined cardiovascular events: cardiovascular deaths, fatal and non-
fatal MI, stroke (none)
Secondary outcomes: total and non-fatal MI, stroke
Tertiary outcomes: total, LDL and HDL cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”matched on age, gender & cholesterol level, randomly assigned
to intervention group using systematic random procedure“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
71Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Anderson 1990 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of their dietary advice, researchers were
not
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Deaths, cancer and CV events are drop-outs, trialists asked for
data
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk See Control and Intervention Methods in Interventions section
of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk (As the high fibre arm has not been used in the data set). See
Control and Intervention Aims in Interventions section of the
Table of Characteristics of Included Studies
Azadbakht 2007
Methods RCT
Participants Overweight and obese people (Iran)
CVD risk: low
Modified fat diet: 50 randomised, 45 analysed
Low fat diet: 50 randomised, 44 analysed
Mean years in trial: both groups 1.1
% male: modified fat diet 32%, low fat diet 25%
Age: mean modified fat 45 (sd 5), low fat diet 46 (sd 6)
Interventions Reduced fat diet vs modified fat diet
Modified fat aims: 30%E from fat, SFA 5%E, MUFA 15%E, PUFA 10%E, protein
15%E, CHO 55%E, cholesterol <200mg/d, fibre 25g/d, 500kcal below energy needs
Low fat aims: 20%E from fat, SFA 5-6%E, MUFA 7%E, PUFA 7%E, protein 15%E,
CHO 65%E, cholesterol <200mg/d, fibre 25g/d, 500kcal below energy needs
Modified fat methods: monthly appointments, oral and written information on healthy
food choices, individual programmes
Low fat methods: monthly appointments, oral and written information on healthy food
choices, individual programmes
Total fat intake (at 14 months): low fat 20 (sd 10)%E, mod fat 30 (sd 7.2)%E
Saturated fat intake (at 14 months): low fat 6.8 (sd 4.2)%E, mod fat 7.0 (sd 3.6)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: weight, metabolic risk
Data available on total mortality? yes (none)
Cardiovascular mortality? yes (none)
Events available for combined cardiovascular events: MI, stroke (no events)
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Azadbakht 2007 (Continued)
Secondary outcomes: total MI, stroke, cancer diagnoses, cancer deaths (no events)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Program generated by a random number table (?)
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and nutritionist were not blinded, lab staff were
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Both groups given equivalent intervention intensity and dura-
tion. See Control and Intervention Methods in Interventions
section of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk Focus on fat and types of fat. See Control and Intervention




Participants Men who have recently recovered from their first MI (UK)
CVD risk: high
Control: unclear how many randomised, 129 analysed
Intervention: unclear how many randomised, 123 analysed
Mean years in trial: 3.0
% male: 100
Age: unclear (all <65)
Interventions Reduced fat intake vs. usual diet
Control aims: usual diet, overweight subjects given weight reduction advice (mainly
CHO reduction)
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Ball 1965 (Continued)
Intervention aims: reduce fat intake to 40g daily, overweight subjects given weight re-
ducing advice
Control methods: continued with normal diet, unclear if follow up for control group
was as for intervention group.
Intervention methods: unclear who gave dietary advice or how often, patient and wife
saw doctor and dietitian 2 weeks after hospital discharge, then every 2 weeks for 3
months, every 3 months for two years and six-monthly thereafter. Diet diaries checked
by dietitian at each visit and problems discussed.
Total fat intake (at 4 years): low fat 21.8 (sd unclear), cont 44.3 (sd unclear)%E
Saturated fat intake: unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: reinfarction, death
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI
Secondary outcomes: total MI
Tertiary outcomes: none (weight and total cholesterol reported but no variance info)
Notes At 3 years weight: control -3.6kg n=67, intervention -5.4kg n=68
total cholesterol: control -0.85mmol/L n=52, intervention -1.14mmol/L n=54
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”allocated at random to one of two groups at each hospital“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were not blinded, the researcher who assessed out-
comes was blinded to treatment arm
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if any lost to follow up
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Unclear risk See Control and Intervention Methods in Interventions section
of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
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BDIT Pilot Studies 1996
Methods RCT
Participants Women with mammographic dysplasia (Canada)
CVD risk: low
Control: 147 randomised, 110 analysed at over 8 years
Intervention: 148 randomised, 104 analysed at over 8 years
Mean years in trial: control 7.5, intervention 6.8
% male: 0
Age: mean control 45, intervention 44 (all >30)
Interventions Reduced fat intake vs usual diet
Control aims: healthy diet advice, no alteration in dietary fat advised, aim to maintain
weight
Intervention aims: total fat 15%E, replace fat by complex CHO, aim to maintain weight
Control methods: seen for advice once every 4 months for 12 months
Intervention methods: seen for advice once a month for 12 months
Total fat intake (at 9.2 years): low fat 31.7 (sd 7.3)%E, cont 35.3 (sd 5.6)%E
Saturated fat intake (at 9.2 years): low fat 10.6 (sd 4.6), cont 12.3 (sd 4.6)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: dietary fat, serum cholesterol
Data available on total mortality? yes, but not clear from which groups
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: weight, BMI, total and HDL cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomly allocated“
Allocation concealment (selection bias) Unclear risk Randomisation not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants not blinded, but outcome assessors blinded to in-
tervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
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BDIT Pilot Studies 1996 (Continued)
Other bias Low risk
Free of systematic difference in care? High risk Minor, women in intervention group seen more frequently. See
Control and Intervention Methods in Interventions section of
the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
beFIT 1997
Methods RCT
Participants Women and men with mild hypercholesterolemia (USA)
CVD risk: moderate
Control: unclear how many randomised, 192 analysed
Intervention: unclear how many randomised, 217 analysed
Mean years in trial: unclear (max duration 0.5 years)
% male: 52 (not divided by intervention group)
Age: mean 43.2 (not divided by intervention group) (all >30)
Interventions Reduced and modified fat vs usual diet
Control aims:asked to delay dietary changes (provided intervention after the randomised
trial)
Intervention aims: total fat <30%E, SFA <7%E, dietary chol<200mg/d
Control methods: usual intake
Intervention methods: 8 weekly classes with nutrition info and behaviour modification
with spouses, plus individual appointments at 3 and 6 months
Total fat intake (at 6 months): int 25.2 (sd unclear)%E, cont unclear - no significant
difference from baseline 34 (sd unclear)%E
Saturated fat intake (at 6months): int 7.6% (sd unclear)%E, cont unclear - no significant
difference from baseline 12 (sd unclear)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: lipids
Data available on total mortality? yes (no events)
Cardiovascular mortality? no
Events available for combined cardiovascular events: unclear but authors stated that there
were no CVD events
Secondary outcomes: none
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs (but variance data
only provided for the randomised comparison for LDL cholesterol)
Notes Weight: control ’no change’, intervention -2.7kg at 6 months
Risk of bias
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beFIT 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified random sampling scheme
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants knew their allocation, unclear for outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Intensive intervention for intervention group, but no interven-
tion during the 6 months of the randomised part of the study
for the control group. See Control and Intervention Methods in
Interventions section of the Table of Characteristics of Included
Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Black 1994
Methods RCT
Participants People with non-melanoma skin cancer (USA)
CVD risk: low
Control: randomised 67, analysed 58
Intervention: randomised 66, analysed 57
Mean years in trial: 1.9
% male: control 67%, intervention 54%
Age: mean control 52.3 (sd 13.2), intervention 50.6 (sd 9.7)
Interventions Reduced fat vs. usual diet
Control aims: no dietary advice
Intervention aims: total fat 20%E, protein 15%E, CHO 65%E
Control methods: no dietary change, 4 monthly clinic visits
Intervention methods: 8 weekly classes, with behavioural techniques, plus 4 monthly
clinic visits
Total fat intake (“during study” months 4-24): low fat 20.7 (sd 5.5), cont 37.8 (sd 4.1)
%E
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Black 1994 (Continued)




Outcomes Stated trial outcomes: incidence of actinic keratosis and non-melanoma skin cancer
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths
Secondary outcomes: cancer deaths (none)
Tertiary outcomes: none (weight data provided, but no variance info)
Notes At 2 years control -1.5kg n=50?, intervention -1kg n=51?
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”list of randomly generated numbers“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Physician blinding: adequate
Participant blinding: inadequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk For mortality. Unclear for other outcomes
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Minor, all have 4 monthly clinic visits, the intervention group
had 8 behavioural technique classes that the control group did
not have
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
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Boyd 1988
Methods RCT
Participants Women with severe cyclical mastopathy for at least 5 years (Canada)
CVD risk: low
Control: randomised 10, analysed 9
Intervention: randomised 11, analysed 10
Mean years in trial: control 0.45, intervention 0.45
% male: 0%
Age: mean control 36, intervention 38 (variances unclear)
Interventions Reduced fat vs usual diet
Control aims: given principles of healthy diet, not counselled to alter fat content
Intervention aims: total fat 15%E, CHO 65%E
Controlmethods: seen every 2months tomonitor symptoms, nutrition andbiochemistry
Intervention methods: seen monthly to monitor symptoms, nutrition and biochemistry,
teaching materials included food guide, recipes, product information and advice on
eating out
Total fat intake (at 6 months): low fat 22.8 (sd unclear), cont 33.4 (sd unclear)%E
Saturated fat intake (at 6 months): low fat 8.8 (sd unclear), cont 12.3 (sd unclear)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: mastopathy symptoms, plasma hormone and lipids
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: none
Secondary outcomes: cancer deaths (none)
Tertiary outcomes: total cholesterol (but variance data not provided)
Notes Total cholesterol rose by 0.09mmol/L in control group (from 4.5 to 4.59) and fell by
0.15mmol/L in intervention group (4.84 to 4.69)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomly allocated“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were not blinded, those assessing physical outcomes
were blinded, those assessing symptoms were not
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
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Boyd 1988 (Continued)
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Minor differences in follow up frequency. SeeControl and Inter-
vention Methods in Interventions section of the Table of Char-
acteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
BRIDGES 2001
Methods RCT
Participants Women diagnosed with stage I or II breast cancer over the past 2 years (USA)
CVD risk: low
Control: randomised unclear (at least 56), analysed 56
Intervention: randomised unclear (at least 50), analysed 50
Mean years in trial: unclear (1 year max follow up)
% male: 0
Age: mean control unclear (71% postmenopausal), intervention unclear (56% post-
menopausal) (all 20-65)
Interventions Reduced fat vs usual diet
Control aims: no formal intervention
Intervention diet aims: total fat 20%E, high fibre, plant based micronutrients
Intervention stress: separate parallel arm, stress reduction programme (data not used
here)
Control methods: no formal intervention
Intervention methods: nutrition intervention programme, 15 sessions (42 hours) over
15 weeks, group-based, dietitian led, 2 individual sessions using social cognitive theory
and patient centred counselling to increase self efficacy and confidence
Total fat intake (at 12 months): low fat 29.9 (sd unclear), cont 33.6 (sd unclear)%E
Saturated fat intake: unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: diet and BMI
Data available on total mortality? yes
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: cardiovascular deaths, non fatal MI,
stroke (no events)
Secondary outcomes: total and non-fatalMI, stroke, cancer deaths (events only for cancer
deaths)
Tertiary outcomes: weight
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomised“, stratified by medical centre, cancer stage and age,
randomised number/envelope method by project coordinator
Allocation concealment (selection bias) Low risk The project coordinator had contact with those from the Uni-
versity of Massachussets, but not those from the other 3 centres,
and allocation could not be altered later
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants not blinded, unclear about researchers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk High intensity programme for intervention group, nothing for
control group. See Control and Intervention Methods in In-
terventions section of the Table of Characteristics of Included
Studies
Free of dietary differences other than fat? High risk Intervention also focused on fibre and plant based micronutri-
ents. See Control and Intervention Aims in Interventions sec-
tion of the Table of Characteristics of Included Studies
CARMEN 2000
Methods RCT
Participants Healthy overweight people, BMI 26-34 (Europe, 5 centres)
CVD risk: low
Control: unclear how many randomised, 77 analysed (290 randomised over all 3 arms)
Intervention with simple CHO: unclear how many randomised, 76 analysed
Intervention with complex CHO: unclear how many randomised, 83 analysed
Mean years in trial: unclear (max duration 0.5 years)
% male: control 48%, simple CHO intervention 47%, complex CHO intervention
52%
Age: mean control 38 (sd 9), simple CHO intervention 41 (sd 9), complex CHO
intervention 38 (sd 9)
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CARMEN 2000 (Continued)
Interventions Reduced fat vs usual diet
Control aims: to attain national ”normal“ intake
Intervention aims: total fat reduced by 10%E with increases in simple or complex CHO
Control methods: trial shop provided local selection of a specific set of national ”normal“
intake foods
Intervention methods: trial shop provided local selection of a specific set of low fat and
high simple or complex CHO foods
Total fat intake (at 6 months): low fat complex CHO 27.8 (sd unclear)%E, low fat
simple CHO 25.5 (sd unclear)%E, cont 36.5 (sd unclear)%E
Saturated fat intake (at 6 months): low fat complex CHO 9.9 (sd unclear)%E, low fat
simple CHO 8.6 (sd unclear)%E, cont 12.7 (sd unclear)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: weight, body composition, lipids
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: CVD deaths, non-fatal MI, stroke,
heart failure, PVD (no events)
Secondary outcomes: cancer deaths and diagnoses (no events)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation
Allocation concealment (selection bias) Low risk Randomisation by 3rd party, independent of research centres.
Blind data were sent to him for computer randomisation
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were clear about whether they were in the control
or an intervention group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Trial shop used by both groups. See Control and Intervention
Methods in Interventions section of the Table of Characteristics
of Included Studies
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CARMEN 2000 (Continued)
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
CARMEN MS sub-study 2002
Methods RCT (data for this study excludes the 13 participants that were included in the main
CARMEN data set)
Participants People with at least 3 risk factors for metabolic syndrome (Europe, 5 centres)
CVD risk: moderate
Control: 12 randomised, 8 analysed
Intervention with simple CHO: 10 randomised, 9 analysed
Intervention with complex CHO: 11 randomised, 9 analysed
Mean years in trial: control 0.4, simple CHO 0.5, complex CHO 0.5
% male: control 0%, simple CHO 33%, complex CHO 22%
Age:mean control 47.5 (sd 3.9), simple CHO intervention 44.7 (sd 4.7), complex CHO
intervention 43.4 (sd 4.5)
Interventions Reduced fat vs usual diet
Control aims: to attain national ”normal“ intake
Intervention aims: total fat reduced by 10%E with increases in simple or complex CHO
Control methods: trial shop provided local selection of a specific set of national ”normal“
intake foods
Intervention methods: trial shop provided local selection of a specific set of low fat and
high simple or complex CHO foods
Total fat intake (at 6 months): low fat complex CHO 27.1 (sd 4.8), low fat simple CHO
20.6 (sd 6.6), cont 30.4 (sd 2.3)%E
Saturated fat intake: unclear
Style: food provided
Setting: community
Outcomes Stated trial outcomes: weight, body composition, lipids
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: CVD deaths, non-fatal MI, stroke,
heart failure, PVD (no events)
Secondary outcomes: cancer deaths and diagnoses (no events)
Tertiary outcomes: BMI, total, LDL and HDL cholesterol, TGs, diastolic BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation
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CARMEN MS sub-study 2002 (Continued)
Allocation concealment (selection bias) Low risk Randomisation by 3rd party, independent
of research centres. Blind data were sent to
him for computer randomisation
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were clear about whether they
were in the control or an intervention
group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
drop-outs, trialists asked for data - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary
outcomes as all trialists asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Trial shopused by both groups. SeeControl
and InterventionMethods in Interventions
section of the Table of Characteristics of
Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in In-
terventions section of the Table of Charac-
teristics of Included Studies
Curzio 1989
Methods RCT
Participants Hypertensives with cholesterol >6.5mmol/L (UK)
CVD risk: moderate
Control: randomised 72, analysed 63
Intervention: randomised 72, analysed 61
Mean years in trial: control 0.47, intervention 0.46
% male: control 54%, intervention 44%
Age: mean control 56, intervention 57
Interventions Unclear
Control aims: no dietary advice
Intervention aims: advice to reduce serum cholesterol (?)
Control methods: no advice at any visit (0, 1, 3 and 6 months)
Intervention methods: intensive and specific dietary advice, by dietitian at each visit (0,
1, 3 and 6 months)
Total fat intake: unclear
Saturated fat intake: unclear
Style: diet advice
Setting: community
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Curzio 1989 (Continued)
Outcomes Stated trial outcomes: blood pressure, weight, lipids
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: cardiovascular deaths (no events)
Secondary outcomes: cancer deaths (no events)
Tertiary outcomes: total, HDL and LDL cholesterol, TG (not used in analysis as unclear
whether reduced and/or modified fat intervention)
Notes Changes in lipid parameters from baseline to 6 months (control n=63, intervention n=
61), all mmol/L
Total cholesterol control -0.3 (sd 0.7), intervention -0.3 (sd 0.6)
LDL cholesterol control -0.1 (sd 0.7), intervention -0.3 (sd 0.7)
HDL cholesterol control -0.0 (sd 0.1), intervention 0.2 (sd 0.2)
TGs control -0.2 (sd 0.6), intervention -0.2 (sd 0.7)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”stratified by antihypertensive treatment, randomly allocated“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants not blinded, researchers unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Dietetic time for those on intervention only. See Control and
Intervention Methods in Interventions section of the Table of
Characteristics of Included Studies
Free of dietary differences other than fat? Unclear risk Dietary goals unclear.
85Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DART 1989
Methods RCT
Participants Men recovering from an MI (UK)
CVD risk: high
Control: randomised 1015, analysed unclear
Intervention: randomised 1018, analysed unclear
Mean years in trial: control 1.9, randomised 1.9
% male: 100%
Age: mean control 56.8, intervention 56.4 (all <70)
Interventions Reduced and modified fat vs usual diet
Control aims: no dietary advice on fat, weight reducing advice if BMI>30
Intervention aims: reduce fat intake to 30%E, increase P/S to 1.0, weight reducing advice
if BMI>30
Note: This was a factorial trial, and so some in each group were randomised to increased
fatty fish and/or increased cereal fibre.
Controlmethods: dietitians provided ’sensible eating’ advicewithout specific information
on fats
Intervention methods: dietitians provided the participants and their wives with initial
individual advice and a diet information sheet, participants were revisited for further
advice, recipes, encouragement at 1, 3, 6, 9, 12, 15, 18 and 21 months.
Total fat intake (through study): int 31 (sd 7), cont 35 (sd 6)%E
Saturated fat intake (through study): int 11 (sd 3), cont 15 (sd 3)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: mortality, reinfarction
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths (including
stroke deaths) plus non-fatal MI
Secondary outcomes: cancer deaths, total MI, non-fatal MI
Tertiary outcomes: total and HDL cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk randomised using sealed envelopes
Allocation concealment (selection bias) Unclear risk Unclear if envelopes were opaque
Blinding (performance bias and detection
bias)
All outcomes
High risk Physician blinding: yes
Participant blinding: unclear
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DART 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk GPs contacted for informationonmortality andmorbiditywhen
patients did not attend
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Different levels of advice appear to have been provided. See
Control and Intervention Methods in Interventions section of
the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk There were also other arms, testing fish and fibre interventions
(in a factorial design). See Control and Intervention Aims in




Participants Survivors of Oslo Diet Study who had hyperlipidaemia and high risk of CVD in the
1970s (Norway)
CVD risk: moderate (although 25% have CVD)
control: No n-3 control, 142 randomised, 117 analysed
With n-3 control, 140 randomised, 124 analysed
intervention: No n-3 intervention, 139 randomised, 122 analysed
With n-3 intervention, 142 randomised, 124 analysed
Mean years in trial: 3
% male: 100
Age: control groups median 70 years, intervention groups median 70
Interventions Reduced fat intake vs usual diet
Control aims: usual care (with n-3 capsules or corn oil capsules)
Intervention aims: 27-30%E from fat, protein 15-18%, CHO 50-55%E, increase fruit,
vegetables, fish, decrease meat, polyunsaturated margarine provided free (with n-3 cap-
sules or corn oil capsules)
Control methods: usual care, with either corn oil or omega-3 capsules
Intervention methods: dietary advice (30-45 mins initially plus 30 mins follow up at 3
months, then 6 monthly), polyunsaturated margarines provided free, plus either corn
oil or omega-3 capsules
Total fat intake (at 36 months): low fat 27.6 (sd 5.5), cont 29.5 (sd 5.4)%E
Saturated fat intake (at 36 months): low fat 9.2 (sd 3.6), cont 10.5 (sd 3.7)%E
Style: diet advice and supplement
Setting: community
Outcomes Stated trial outcomes: CVD
Data available on total mortality? yes
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DO IT 2006 (Continued)
Cardiovascular mortality? yes
Events available for combined cardiovascular events: total MI, verified cardiovascular
events
Secondary outcomes: cancer deaths and diagnoses, diabetes, total MI
Tertiary outcomes: BMI, total, HDL, LDL cholesterol, TG, systolic BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’randomly assigned’
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Not for dietary intervention.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Additional dietary appointments in the intervention groups. See
Control and Intervention Methods in Interventions section of
the Table of Characteristics of Included Studies
Free of dietary differences other than fat? High risk Also fruit, veg, fish and meat advice. See Control and Interven-
tion Aims in Interventions section of the Table of Characteristics
of Included Studies
Due Low fat 2008
Methods RCT
Participants Young overweight adults who had lost at least 8% of body weight (Denmark)
CVD risk: low
control: 25 randomised, 25 analysed (24 completed)
Intervention low fat: 48 randomised, 48 analysed (43 completed)
Mean years in trial: control 0.49, low fat 0.47
% male: control 42%, low fat 43%
Age: control group 27.6 (sd 5.1), low fat 27.3 (sd 4.9)
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Due Low fat 2008 (Continued)
Interventions Reduced fat intake vs usual diet
Control aims: 30-40%E from fat, SFA >15%E,MUFA5-15%E, PUFA0-10%E, protein
10-20%E, CHO45-55%E, added sugars 5-15%E, alcohol <5%E, glycaemic index high,
energy density high, energy intake ad libitum
Low fat aims: 20-30%E from fat, SFA <10%E, MUFA 5-15%E, PUFA 5-10%E, pro-
tein 10-20%E, CHO 55-65%E, added sugars <10%E, alcohol <5%E, glycaemic index
medium, energy density low, energy intake ad libitum
Control and intervention methods: supermarket model, all foods provided free, personal
shoppers helped participants collect appropriate foods, not allowed to leave shop until
dietary composition was correct, waste and leftovers returned to shop, minimum of 2
dietetic counselling sessions over 2 months.
Total fat intake (at 6 months): low fat 23.6 (sd 1.67)%E, cont 32.1 (sd 1.62)%E
Saturated fat intake (at 6 months): low fat 7.9 (sd 1.17)%E, cont 15.1 (sd 1.0)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: CVD risk, diabetes risk, weight
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: total MI, stroke (no events)
Secondary outcomes: cancer deaths and diagnoses, total and non-fatal MI, stroke (no
events in any group)
Tertiary outcomes: weight, BMI, total, HDL, LDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independently randomised by 2 study personnel, stratified by
sex and initial BMI
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of their own allocated diet, those assess-
ing outcomes unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for dropouts provided, ITTanalysis used for continuous
outcomes
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Yes, advice and shop system was the same across all groups
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Due Low fat 2008 (Continued)
Free of dietary differences other than fat? High risk No, there were also differences in sugary foods, legumes, dietary
glycaemic index etc
Due Low vs Mod 2008
Methods RCT
Participants Young overweight adults who had lost at least 8% of body weight (Denmark)
CVD risk: low
Intervention modified fat: 52 randomised, 52 analysed (39 completed)
Intervention low fat: 48 randomised, 48 analysed (43 completed)
Mean years in trial: moderate fat 0.44, low fat 0.47
% male: modified fat 41%, low fat 43%
Age: modified fat 29.2 (sd 4.5), low fat 27.3 (sd 4.9)
Baseline total fat intake: int cont
Baseline saturated fat intake: int cont
Interventions Reduced fat intake vs modified fat
Modified fat aims: 35-45%E from fat, SFA <10%E, MUFA >20%E, PUFA 5-10%E,
protein 10-20%E, CHO 40-50%E, added sugars <10%E, alcohol <5%E, glycaemic
index low, energy density high, energy intake ad libitum
Low fat aims: 20-30%E from fat, SFA <10%E, MUFA 5-15%E, PUFA 5-10%E, pro-
tein 10-20%E, CHO 55-65%E, added sugars <10%E, alcohol <5%E, glycaemic index
medium, energy density low, energy intake ad libitum
Control and intervention methods: supermarket model, all foods provided free, personal
shoppers helped participants collect appropriate foods, not allowed to leave shop until
dietary composition was correct, waste and leftovers returned to shop, minimum of 2
dietetic counselling sessions over 2 months.
Total fat intake (at 6 months): low fat 23.6 (sd 1.67)%E, mod fat 38.4 (sd 1.75)%E
Saturated fat intake (at 6 months): low fat 7.9 (sd 1.17)%E, mod fat 7.1 (sd 0.80)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: CVD risk, diabetes risk, weight
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: total MI, stroke (no events)
Secondary outcomes: cancer deaths and diagnoses, total and non-fatal MI, stroke (no
events in any group)
Tertiary outcomes: weight, BMI, total, HDL, LDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Due Low vs Mod 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Independently randomised by 2 study personnel, stratified by
sex and initial BMI
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of their own allocated diet, those assess-
ing outcomes unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for dropouts provided, ITTanalysis used for continuous
outcomes
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Yes, advice and shop system was the same across all groups
Free of dietary differences other than fat? High risk No, there were also differences in sugary foods, legumes, dietary
glycaemic index etc
Due Mod fat 2008
Methods RCT
Participants Young overweight adults who had lost at least 8% of body weight (Denmark)
CVD risk: low
control: 25 randomised, 25 analysed (24 completed)
Intervention modified fat: 52 randomised, 52 analysed (39 completed)
Mean years in trial: control 0.49, moderate fat 0.44
% male: control 42%, modified fat 41%
Age: control group 27.6 (sd 5.1), modified fat 29.2 (sd 4.5)
Baseline total fat intake: int cont
Baseline saturated fat intake: int cont
Interventions Modified fat vs usual diet
Control aims: 30-40%E from fat, SFA >15%E,MUFA5-15%E, PUFA0-10%E, protein
10-20%E, CHO45-55%E, added sugars 5-15%E, alcohol <5%E, glycaemic index high,
energy density high, energy intake ad libitum
Modified fat aims: 35-45%E from fat, SFA <10%E, MUFA >20%E, PUFA 5-10%E,
protein 10-20%E, CHO 40-50%E, added sugars <10%E, alcohol <5%E, glycaemic
index low, energy density high, energy intake ad libitum
Control and intervention methods: supermarket model, all foods provided free, personal
shoppers helped participants collect appropriate foods, not allowed to leave shop until
dietary composition was correct, waste and leftovers returned to shop, minimum of 2
dietetic counselling sessions over 2 months.
Total fat intake (at 6 months): mod fat 38.4 (sd 1.75)%E, cont 32.1 (sd 1.62)%E
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Due Mod fat 2008 (Continued)
Saturated fat intake (at 6 months): mod fat 7.1 (sd 0.80)%E, cont 15.1 (sd 1.0)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: CVD risk, diabetes risk, weight
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: total MI, stroke (no events)
Secondary outcomes: cancer deaths and diagnoses, total and non-fatal MI, stroke (no
events in any group)
Tertiary outcomes: weight, BMI, total, HDL, LDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independently randomised by 2 study personnel, stratified by
sex and initial BMI
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of their own allocated diet, those assess-
ing outcomes unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for dropouts provided, ITTanalysis used for continuous
outcomes
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Yes, advice and shop system was the same across all groups




Participants Type I diabetics with elevated urinary albumin (Netherlands)
Risk: moderate
Control: randomised 20, analysed 20
Intervention: randomised 18, analysed 16
Mean years in trial: control 2.0, intervention 1.9
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Dullaart 1992 (Continued)
% male: control 75%, intervention 81%
Age: mean control 41 (sd 14), intervention 44 (sd 12) (all 21-65)
Interventions Modified fat vs usual fat
Control aims: usual diet (urged not to alter fat or protein intake)
Intervention aims: replace SFA by linoleic acid to achieve P/S of 1.0, total fat and protein
intake to remain unchanged
Control methods: unclear
Interventionmethods: counselling by a dietitian (unclear howoften, but at least annually)
Total fat intake (at 2 years):mod fat 37 (sd 4), cont 40 (sd 7)%E
Saturated fat intake (at 2 years): mod fat 13 (sd 2), cont 16 (sd 3)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: albuminuria and serum lipoproteins
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI,
stroke (no events)
Secondary outcomes: stroke (no events), MI (no events), cancer deaths (no events)
Tertiary outcomes: weight, total, HDL and LDL cholesterol (data read off graph as data
files no longer exist, total and LDL cholesterol data not used as very different in control
and intervention arms at baseline)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”stratified according to gender, randomised in blocks of 6 using
opaque sealed envelopes“ by independent statistical investigator
with no contact with participants
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants could not be blinded, research blinding was unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
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Dullaart 1992 (Continued)
Free of systematic difference in care? Unclear risk Probably not, appears that the intervention group had more
time with dietitian. See Control and Intervention Methods in
Interventions section of the Table of Characteristics of Included
Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Frenkiel 1986
Methods RCT
Participants People with radiolucent gallstones taking ursodeoxycholic acid, UDCA (USA)
CVD risk: low
Control: randomised 17, analysed 16
Intervention: randomised 19, analysed 16
Mean years in trial: control 0.6, intervention 0.6
% male: control 35%, intervention 58%
Age: mean control 52.4, intervention 53.1
Interventions Modified fat vs average diet
Control aims: dietary advice for total fat 38-42%E, dietary cholesterol 500mg/day, pro-
tein 18-22%E, CHO 38-42%E, weight maintaining, low fibre
Intervention aims: as above but limit dietary cholesterol to 250mg/day, weight main-
taining, low fibre
Control methods: dietary advice from dietitian every 3 months
Intervention methods: dietary advice from dietitian every 3 months
Total fat intake (at 6 or 9 months): mod fat 32.5 (sd 6.2), cont 36.0 (sd 5.1)%E
Saturated fat intake: unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: bile acid kinetics
Data available on total mortality? yes (no events)
Cardiovascular mortality? no





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomly allocated“
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Frenkiel 1986 (Continued)
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants knew their allocation, unclear for researchers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar level and duration of advice. See Control and Interven-
tion Methods in Interventions section of the Table of Charac-
teristics of Included Studies
Free of dietary differences other than fat? Unclear risk Intervention unclear, aimwas tomaintain total fat intake in both
groups but reduce cholesterol intake - so fat modification must
have occurred. See Control and Intervention Aims in Interven-
tions section of the Table of Characteristics of Included Studies
Houtsmuller 1979
Methods RCT
Participants Adults with newly diagnosed diabetes (The Netherlands)
CVD risk: moderate
Control: 51 randomised, unclear how many analysed (all analysed re deaths)
Intervention: 51 randomised, unclear how many analysed (all re deaths)
Mean years in trial: unclear (max duration 6 years)
% male: 56% overall
Age: mean unclear
Baseline total fat intake: int cont
Baseline saturated fat intake: int cont
Interventions Modified fat vs usual diet
Control aims: SFA 35%E, CHO 50%E, protein 15%E
Intervention aims: total fat 40%E, 1/3 linoleic acid, CHO 45%E, protein 15%E
Control methods: unclear, surveyed by dietitian
Intervention methods: unclear, surveyed by dietitian
Total fat intake: mod fat unclear, cont unclear
Saturated fat intake: mod fat unclear, cont unclear
Style: diet advice?
Setting: community
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Houtsmuller 1979 (Continued)
Outcomes Stated trial outcomes: progression of diabetic retinopathy
Data available on total mortality? no
Cardiovascular mortality? no
Events available for combined cardiovascular events: total MI and angina
Secondary outcomes: none
Tertiary outcomes: total cholesterol, TGs (data read off graph)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants matched in pairs then randomised
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Neither participants nor physicians appear blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Unclear risk Level and type of intervention unclear. See Control and Inter-
vention Methods in Interventions section of the Table of Char-
acteristics of Included Studies
Free of dietary differences other than fat? Low risk State that fibre and dietary cholesterol were similar in control
and intervention. See Control and Intervention Aims in Inter-




Participants Healthy women, BMI >25 (UK)
CVD risk: low
Control: randomised 53, analysed 40
Intervention: randomised 57, analysed 42
Mean years in trial: control 0.42, intervention 0.43
96Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lean 1997 (Continued)
% male: 0
Age: mean control 50, intervention 51
Interventions Reduced fat vs usual diet
Control aims: advice - total fat 35%E, CHO 34.5%E, 1200kcal per day encouraged but
not prescribed
Intervention aims: total fat 20%E, CHO 58%E, 1200kcal/day encouraged but not
prescribed
Control methods: dietary advice supported by exchanges and recipes
Intervention methods: dietary advice supported by exchanges and recipes
Total fat intake: unclear
Saturated fat intake: unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: weight loss and cardiovascular risk factors
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: cardiovascular deaths, non fatal MI,
stroke (no events)
Secondary outcomes: total and non-fatal MI, stroke, cancer deaths (no events)
Tertiary outcomes: BMI, total, LDL and HDL cholesterol, TG, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”medical officer drew coloured straws from a box“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were not blinded, unclear about researchers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Deaths, cancer and CV events are drop-outs, trialists asked for
data
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar intervention in both groups. See Control and Interven-
tion Methods in Interventions section of the Table of Charac-
teristics of Included Studies
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Lean 1997 (Continued)
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Ley 2004
Methods RCT
Participants People with impaired glucose intolerance or high normal blood glucose (New Zealand)
CVD risk: moderate
Control: unclear how many randomised (176 between both groups), unclear how many
analysed (112 between both groups at 5 years)
Intervention: as above
Mean years in trial: 4.1 over whole trial
% male: control 80%, intervention 68%
Age: mean control 52.0 (SE 0.8), intervention 52.5 (SE 0.8)
Interventions Reduced fat vs usual diet
Control aims: usual diet
Intervention aims: reduced fat diet (no specific goal stated)
Control methods: usual intake
Intervention methods: monthlymeetings to follow a 1 year structured programme aimed
at reducing fat in the diet, includes education, personal goal setting, self-monitoring
Total fat intake (at 1 year): low fat 26.1 (sd 7.7), cont 33.6 (sd 7.8)%E
Saturated fat intake (at 1 year): low fat 10.0 (sd 4.2), cont 13.4 (sd 4.7)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: lipids, glucose, blood pressure
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: MI, angina, stroke, heart failure
Secondary outcomes: total MI, stroke, cancer diagnoses, cancer deaths
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Unmarked opaque envelopes were opened by the person recruit-
ing, unable to alter allocation later
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were not blinded, outcome assessors were
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Ley 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk See Control and Intervention Methods in Interventions section
of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
McAuley 2005
Methods RCT
Participants Overweight and insulin-resistant women (New Zealand)
CVD risk: low
Low fat: randomised 32, analysed 24 (at 1 year)
Modified fat: randomised 30, analysed 28 (at 1 year)
Mean years in trial: low fat 0.88, modified fat 0.97
% male: 0
Age: mean low fat 45 (sd 7.5), modified fat 47 (sd 7.9)
Interventions Reduced fat vs Modified fat diet
Modified fat aims: 30%E from fat, predominantly MUFA, protein 30%E, CHO low
glycaemic index 40%E, 5 meals/d, less than 5 hours between meals, ad libitum con-
sumption, 30mins activity 5 days/week advised
Low fat aims: total fat <30%E, SFA <8%, protein 15%E, CHO >55%E, advised to
reduce dietary fat, salt and sugar, national healthy eating guidelines plus at least 6 servings
of bread and whole-grains /d, at least 3 of vegetables, 2 of fruit, 2 of low fat dairy/d, ad
libitum consumption, 30mins activity 5 days/week advised
(Also a high fat Atkins-type arm)
Low fat methods: unclear how much dietary advice, or who delivered
Modified fat methods: unclear how much dietary advice or who delivered it
Total fat intake (at 6 months): low fat 28 (sd 7)%E, mod fat 35 (sd 7)%E
Saturated fat intake (at 6 months): low fat 10 (sd 4)%E, mod fat 11 (sd 3)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: weight loss, lipids
Data available on total mortality? yes (none)
Cardiovascular mortality? yes (none)
Events available for combined cardiovascular events: total MI, stroke (no CVD events)
Secondary outcomes: non-fatal and total MI, stroke, cancer deaths and diagnoses (no
events for any outcome)
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McAuley 2005 (Continued)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’randomised’
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants knew allocation, unclear whether researchers did
also
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Unclear risk Probably, as both groups were taught their diets. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
Free of dietary differences other than fat? High risk Differences in meal frequency, salt and sugar advice.
McKeown-Eyssen 1994
Methods RCT
Participants People after adenomatous colorectal polypectomy (Canada)
CVD risk: low
Control: randomised 102, unclear how many analysed
Intervention: randomised 99, unclear how many analysed
Mean years in trial: 2.0
% male: control 55%, intervention 57%
age: mean control 58, intervention 58 (all <85)
Interventions Reduced fat vs usual diet
Control aims: advice for nutritionally balanced diet (optional low fibre supplement with
added calcium and iron)
Intervention aims: total fat <20%E (or less than 50g fat/d), at least 50g fibre daily
(optional fibre supplement with added calcium and iron)
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McKeown-Eyssen 1994 (Continued)
Control methods: 4-monthly counselling to encourage a nutritionally balanced diet
Intervention methods: monthly counselling on diet to achieve fat goals
Total fat intake (at 24 months): low fat men 24.3 (sd 5.2), women 24.4 (sd 8.2), cont
men 31.6 (sd 5.9), women 31.3 (sd 6.5)%E
Saturated fat intake: unclear
Style: dietary advice & supplement (food)
Setting: community
Outcomes Stated trial outcomes: recurrence of neoplastic polyps
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnoses, cancer deaths (no deaths)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk ”stratification by physician, gender, age, randomisation by re-
search associate, centrally, using random numbers generated by
computer“
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants not blinded, physicians were
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing. ITT analysis performed.
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk More frequent visits for intervention group. See Control and
Intervention Methods in Interventions section of the Table of
Characteristics of Included Studies
Free of dietary differences other than fat? High risk Dietary fibre advice also in intervention group
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MeDiet 2002
Methods RCT
Participants Healthy postmenopausal women with above median serum testosterone (Italy)
CVD risk: low
Control: randomised 57, analysed at 6 months 55
Intervention: randomised 58, analysed at 6 months 51
Mean years in trial: control 4.38, intervention 4.28
% male: 0
Age: mean unclear (age range 48-69)
Interventions Reduced and modified fat vs usual diet
Control aims: advised to increase fruit and vegetable intake
Intervention aims: taught Sicilian diet including reduced total, saturated and omega-6
fats, increased blue fish (high in omega 3), increased whole cereals, legumes, seeds, fruit
and vegetables
Control methods: advice
Intervention methods: taught Sicilian diet and cooking by professional chefs, with a
weekly cooking course including social dinners
Total fat intake (at 6 months): low & mod fat 30.9 (sd 11.4), cont 34.0 (sd 11.8)%E
Saturated fat intake (at 6 months): low & mod fat 8.4 (sd 3.0), cont 11.2 (sd 5.0)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: breast cancer, weight, lipids, wellbeing
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: cardiovascular deaths, non fatal MI,
stroke, ventricular fibrillation, ventricular overload
Secondary outcomes: total and non-fatal MI, stroke, cancer diagnoses and deaths (events




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”individually randomised“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of assignment, researchers unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
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MeDiet 2002 (Continued)
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Intensive cookery course with social element compared with
brief advice. SeeControl and Intervention Methods in Interven-
tions section of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? High risk Both groups encouraged to increase fruit and vegetables, but
intervention group also encouraged to increase fish, pulses, seeds,
whole grains.
Minnesota Coron men 1989
Methods RCT
Participants Institutionalised men living in a mental hospital (USA)
CVD risk: low
Control: randomised 2196, analysed unclear
Intervention: randomised 2197, analysed unclear
Mean years in trial: control 1.0, intervention 1.1
% male: 100
Age: unclear, ranges from <30 to >70
Interventions Modified fat diet vs. usual diet
Control aims: usual institutional diet provided
Intervention aims: institutional diet modified to total fat 45%E, PUFA 18-20%E, P/S
2.5, less than 150mg/day dietary chol
Control methods: whole diet provided
Intervention methods: whole diet provided
Total fat intake (over 4 years): mod fat 37.8 (sd unclear)%E, cont 39.1 (sd unclear)%E




Outcomes Stated trial outcomes: MI, mortality, sudden deaths
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: total MI plus sudden death plus
stroke
Secondary outcomes: stroke, cancer deaths, total MI
Tertiary outcomes: none (data provided on total cholesterol and TGs but no variance
info)
Notes This was a 4.5 year institutional study, but as turnover of participants was very high
average time in trial per participant was actually around one year. Participants were
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Minnesota Coron men 1989 (Continued)
replaced as they left, and often left the institution and later returned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”stratified randomisation“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Physician blinding: adequate
Participant blinding: adequate
Incomplete outcome data (attrition bias)
All outcomes
High risk No, participants appear to have been lost on leaving the institu-
tion
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Whole diet provided for both groups. See Control and Inter-
vention Methods in Interventions section of the Table of Char-
acteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Minnesota Coron women1989
Methods
Participants Institutionalised women living in a mental hospital (USA)
CVD risk: low
Control: randomised 2320, analysed unclear
Intervention: randomised 2344, analysed unclear
Mean years in trial: control 1.0, intervention 1.1
% male: 0
Age: unclear, ranges from <30 to >70
Interventions Modified fat diet vs. usual diet
Control aims: usual institutional diet provided
Intervention aims: institutional diet modified to total fat 45%E, PUFA 18-20%E, P/S
2.5, less than 150mg/day dietary chol
Control methods: whole diet provided
Intervention methods: whole diet provided
Total fat intake (over 4 years): mod fat 37.8 (sd unclear)%E, cont 39.1 (sd unclear)%E
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Outcomes Stated trial outcomes: MI, mortality, sudden deaths
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: total MI plus sudden death plus
stroke
Secondary outcomes: stroke, cancer deaths, total MI
Tertiary outcomes: none (data provided on total cholesterol and TGs but no variance
info)
Notes This was a 4.5 year institutional study, but as turnover of participants was very high
average time in trial per participant was actually around one year. Participants were
replaced as they left, and often left the institution and later returned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”stratified randomisation“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Physician blinding: adequate
Participant blinding: adequate
Incomplete outcome data (attrition bias)
All outcomes
High risk No, participants appear to have been lost on leaving the institu-
tion
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Whole diet provided for both groups. See Control and Inter-
vention Methods in Interventions section of the Table of Char-
acteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
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Moy 2001
Methods RCT
Participants Middle-aged siblings of people with early CHD, with at least one CVD risk factor (USA)
CVD risk: moderate
Control: randomised 132, analysed 118
Intervention: randomised 135, analysed 117
Mean years in trial: 1.9
% male: control 49%, intervention 55%
Age: control mean 45.7 (sd 7), intervention 46.2 (sd 7)
Interventions Reduced fat intake vs. usual diet
Control: physician management (physicians informed on risk factor management).
Intervention: nurse management, aim total fat 40g/d or less
Control methods: physician management with risk factor management at 0, 1 and 2
years
Intervention methods: nurse management, appointments 6-8 weekly for 2 years
Total fat intake (at 2 years): low fat 34.1 (sd unclear), cont 38.0 (sd unclear)%E
Saturated fat intake (at 2 years): low fat 11.5 (sd unclear), cont 14.4 (sd unclear)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: dietary intake
Data available on total mortality? yes, no deaths
Cardiovascular mortality? yes, no deaths
Events available for combined cardiovascular events: total MI, stroke, unstable angina,
PVD and PTCA
Secondary outcomes: cancer diagnoses (no events), cancer deaths (none), stroke, total
and non-fatal MI
Tertiary outcomes: BMI, HDL and LDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned via computerised schema after all eligible
siblings from a family had been screened
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and trialists clear about their allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
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Moy 2001 (Continued)
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Differences in frequency of follow up, but unclear what differ-
ences in care occurred between the physician and nurse-led care.
See Control and Intervention Methods in Interventions section
of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Unclear risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
MRC 1968
Methods RCT
Participants Free-living men who have survived a first MI (UK)
CVD risk: high
Control: randomised 194, analysed 181 at 2 years
Intervention: randomised 199, analysed 172 at 2 years
Mean years in trial: control 3.7, intervention 3.8
% male: 100
Age: unclear (all <60)
Interventions Modified fat vs usual diet
Control aims: usual diet
Intervention aims: reduce dietary fat to 35g fat per day, add 84g soya oil per day
Control methods: usual diet
Intervention methods: unclear who gave dietary advice or how often
Total fat intake (at 3.5 years): mod fat 46 (sd unclear), cont 43 (sd unclear)%E
Saturated fat intake: unclear
Style: diet advice & supplement (soy oil)
Setting: community
Outcomes Stated trial outcomes: MI or sudden death
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths and fatal or
non-fatal MI
Secondary outcomes: total and non-fatal MI
Tertiary outcomes: none (data for weight, total cholesterol and BP, but no variance info)
Notes For all, data at 4 years, control n=89, intervention n=88
Weight change: control -3kg, intervention 0kg
Total cholesterol change: control -0.47mmol/L, intervention -1.11mmol/L
Systolic BP change: control 0mmHg, intervention +2mmHg
Diastolic BP change: control +3mmHg, intervention -1mmHg
107Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MRC 1968 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”using random numbers, by blocks within hospitals“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Physician blinding: adequate
Participant blinding: inadequate
Incomplete outcome data (attrition bias)
All outcomes
High risk Data collection was thorough, but some participants dropped
out and contact was lost
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Unlikely as control group continued diet as usual, intervention
group were likely to have had additional contact. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
MSFAT 1997
Methods RCT
Participants Healthy people aged 20-55 (Netherlands)
CVD risk: low
Control: randomised unclear (120?), analysed 103
Intervention: randomised unclear (120?), analysed 117
Mean years in trial: control 0.46, intervention 0.49
% male: control 50%, intervention 50%
Age: mean control men 35.6 (sd 10), control women 36.0 (sd 11), intervention men
35.5 (sd 11), intervention women 36.0 (sd 12) (all 19-55)
Interventions Reduced fat vs usual diet
Control aims: advised to use products from trial shop ad lib. (usual fat products provided)
Intervention aims: advised to use products from trial shop ad lib. (low fat products
provided)
Control methods: participants obtained foods in a study shop at least once a week
Intervention methods: participants obtained foods in a study shop at least once a week
Total fat intake (at 6 months): low fat 34.7 (sd unclear), cont 42.7 (sd unclear)%E
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MSFAT 1997 (Continued)
Saturated fat intake (at 6 months): low fat 14.2 (sd unclear), cont 18.2 (sd unclear)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: weight, vitamin and fatty acid intake, anti-oxidative capacity
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: MI, stroke and CVD deaths (no
events)
Secondary outcomes: stroke, MI, cancer diagnoses and deaths (no events for any out-
come)
Tertiary outcomes: weight (for subgroup), weight and lipids provided for larger group,
but without variance data
Notes Change from baseline to 6 months for whole group (control 103, intervention 117):
Weight, kg: 1.1, 0.4
total cholesterol, mmol/L: 0.07, -0.09
HDL cholesterol, mmol/L: -0.03, -0.06
LDL cholesterol, mmol/L: 0.15, 0.16
TGs, mmol/L: 0.04, -0.04
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”stratified randomisation (according to sex, age, QI index and
eating behaviour) by co-ordinating centre“, a statistician at
Unilever Research, SAS software, and allocation could not be
altered later
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants aware of allocation, those analysing biochemistry
were not
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Both groups used study shop. See Control and Intervention
Methods in Interventions section of the Table of Characteristics
of Included Studies
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Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
NDHS Faribault 1968
Methods RCT
Participants Men living in a mental health institute (USA)
CVD risk: low
Control: randomised 57, analysed 52
Interventions B, C, E combined: randomised 167, analysed 143
Mean years in trial: control 1.0, Interventions 0.9
% male: 100
Age: unclear (all 45-54)
Interventions Modified fat vs. usual diet
Control aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4
Intervention aims: B (C, E) total fat 30%E (40%E, 40%E), SFA <9%E (<9%E, not
stated), dietary chol 350-450mg/d (350-450mg/d, not stated), PUFA 15%E (18-20%E,
not stated), P/S 1.5 (2.0, 4.4)
Control methods: whole diet provided
Intervention methods: whole diet provided
Total fat intake (at 28 & 44 weeks combined): B (C, E) mod fat 29.2 (38.5, 37.1) (sds
unclear)%E, cont 39.4 (sd unclear)%E
Saturated fat intake (at 28 & 44 weeks combined): B (C, E) mod fat 6.6 (7.4, 4.9) (sds
unclear)%E, cont 15.6 (sd unclear)%E
Style: diet provided
Setting: residential institution
Outcomes Stated trial outcomes: lipid levels and dietary assessment
Data available on total mortality? yes
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: no cancer deaths or diagnoses occurred
Tertiary outcomes: total cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical centre
Allocation concealment (selection bias) Low risk
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NDHS Faribault 1968 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, facilitated by provision of the whole diet
Incomplete outcome data (attrition bias)
All outcomes
Low risk Institution so able to follow up all participants through study.
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Whole diet provided for both groups. See Control and Inter-
vention Methods in Interventions section of the Table of Char-
acteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
NDHS Open 1st L&M 1968
Methods RCT
Participants Free living men (USA)
CVD risk: low
Control: randomised 382, analysed 341
Intervention B: randomised 385, analysed 332
Intervention X: randomised 54, analysed 46
Mean years in trial: control 1.0, B 0.9, C 0.9, X 0.9
% male: 100
Age: unclear (all 45-54)
Interventions Reduced and modified fat diet vs. usual diet
Control aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4
Intervention B: total fat 30%E, SFA <9%E, dietary chol 350-450mg/d, PUFA 15%E,
P/S 1.5
Intervention X: total fat 30%E, SFA <9%E, dietary chol 350-450mg/d, PUFA 15%E,
P/S 1.5
Control methods: dietary advice to reduce saturated fat and cholesterol (plus 10 follow
up visits with nutritionist), purchase of ’usual fat’ items from a trial shop
Intervention B methods: dietary advice to reduce saturated fat and cholesterol (plus 10
follow up visits with nutritionist), plus purchase of appropriately reduced and modified
fat items from a trial shop
Intervention X methods: dietary advice but no trial shop
Total fat intake (through study): B 29.7 (sd unclear)%E, X 31.7 (sd unclear), cont 34.9
(sd unclear)%E
Saturated fat intake (through study): B 7.1 (sd unclear)%E, X 8.9 (sd unclear), cont 11.6
(sd unclear)%E
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NDHS Open 1st L&M 1968 (Continued)
Style: B diet provided, X - diet advice
Setting: community
Outcomes Stated trial outcomes: lipid levels and dietary assessment
Data available on total mortality? no
Cardiovascular mortality? yes (none occurred)
Events available for combined cardiovascular events: fatal and non-fatal MI, peripheral
vascular events
Secondary outcomes: no cancer diagnoses, total or non-fatal MI occurred
Tertiary outcomes: total cholesterol (some weight and BP data presented but no variance
info)
Notes At 52 weeks weight change in the control was not presented, weight change in B was -
2.4kg.
At 52 weeks diastolic BP change from baseline was -2.2 kg in control, -1.9 in B and -
5.8 in X.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical centre
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Intervention B: All reduced saturated fat and purchased blinded
foods from a trial shop, double blind.
Intervention X: No trial shop, so participants not blinded,
though those analysing blood samples etc were.
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts do not appear to have been followed for death or CV
events. Deaths, cancer and CV events for participants otherwise
still included in the study were collated as a reason for study
exclusion
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Yes for intervention B (as both intervention and control received
dietary advice and purchased food from trial shop). No for in-
tervention X (as it did not include a trial shop as in the control
group). See Control and Intervention Methods in Interventions
section of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
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NDHS Open 1st mod 1968
Methods RCT
Participants Free living men (USA)
CVD risk: low
Control: randomised 382, analysed 341
Intervention C: randomised 390, analysed 348
Mean years in trial: control 1.0, C 0.9
% male: 100
Age: unclear (all 45-54)
Interventions Modified fat diet vs. usual diet
Control aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4
Intervention C: total fat 40%E, SFA <9%E, dietary chol 350-450mg/d, PUFA 18-
20%E, P/S 2.0
Control methods: dietary advice to reduce saturated fat and cholesterol (plus 10 follow
up visits with nutritionist), purchase of ’usual fat’ items from a trial shop
Intervention C methods: dietary advice to reduce saturated fat and cholesterol (plus 10
follow up visits with nutritionist), plus purchase of appropriately reduced and modified
fat items from a trial shop
Total fat intake (through study): C 34.4 (sd unclear)%E, cont 34.9 (sd unclear)%E
Saturated fat intake (through study): C 7.4 (sd unclear)%E, cont 11.6 (sd unclear)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: lipid levels and dietary assessment
Data available on total mortality? no
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: fatal and non-fatal MI, peripheral
vascular events
Secondary outcomes: cancer diagnoses, total and non-fatal MI
Tertiary outcomes: none (total cholesterol and BP data presented but no variance info)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical centre
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk All reduced saturated fat and purchased blinded foods from a
trial shop, double blind.
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts do not appear to have been followed for death or CV
events. Deaths, cancer and CV events for participants otherwise
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NDHS Open 1st mod 1968 (Continued)
still included in the study were collated as a reason for study
exclusion
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Trial shop used by both groups, plus dietary advice. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
NDHS Open 2nd L&M 1968
Methods RCT
Participants Free living men who had participated in NDHS 1st studies (USA)
CVD risk: low
Control: randomised 304, analysed 280
Intervention BC: randomised 194, analysed 179
Mean years in trial: control 0.6, intervention BC 0.6
% male: 100
Age: unclear (all 45-54)
Interventions Reduced and modified fat vs usual diet
Control aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4, X -
advice to continue usual diet
Intervention aims: BC total fat 30-40%E, SFA reduced, dietary chol 350-450mg/d,
increased PUFA, P/S 1.5-2.0
Control methods: dietary advice to reduce saturated fat and cholesterol (plus 10 follow
up visits with nutritionist), purchase of ’usual fat’ items from a trial shop
Intervention BC methods: dietary advice to reduce saturated fat and cholesterol (plus 10
follow up visits with nutritionist), plus purchase of appropriately reduced and modified
fat items from a trial shop
Total fat intake (through study): BC 32.5 (sd unclear)%E, cont 35.5 (sd unclear)%E
Saturated fat intake (through study): BC 7.4 (sd unclear)%E, cont 12.0 (sd unclear)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: lipid levels and dietary assessment
Data available on total mortality? no
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: fatal and non-fatal MI, peripheral
vascular events
Secondary outcomes: cancer diagnoses (no events), total and non-fatal MI
Tertiary outcomes: none
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical centre
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Some participants continued with advice to reduce saturated fat
and purchased blinded foods from a trial shop, but half of the
participantswere instructed in their ownpurchase of appropriate
foods from normal shops to compile their own dietary regimen.
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts do not appear to have been followed for death or CV
events. Deaths, cancer and CV events for participants otherwise
still included in the study were collated as a reason for study
exclusion
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Trial shop used by both groups, plus dietary advice. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
NDHS Open 2nd Mod 1968
Methods RCT
Participants Free living men who had participated in NDHS 1st studies (USA)
CVD risk: low
Control: randomised 304, analysed 280
Intervention F: randomised 127, analysed 112
Mean years in trial: control 0.6, intervention 0.6
% male: 100
Age: unclear (all 45-54)
Interventions Modified fat vs usual diet
Control aims: total fat 40%E, SFA 16-18%E, dietary chol 650-750mg/d, P/S 0.4,
Intervention aims: F total fat 40%E, SFA no data, dietary chol 350-450mg/d, increased
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PUFA , P/S 3.0
Control methods: dietary advice to reduce saturated fat and cholesterol (plus 10 follow
up visits with nutritionist), purchase of ’usual fat’ items from a trial shop
Intervention F methods: dietary advice to reduce saturated fat and cholesterol (plus 10
follow up visits with nutritionist), plus purchase of appropriately reduced and modified
fat items from a trial shop
Total fat intake (through study): F 35.1 (sd unclear)%E, cont 35.5 (sd unclear)%E
Saturated fat intake (through study): F 7.8 (sd unclear)%E, cont 12.0 (sd unclear)%E
Style: food provided
Setting: community
Outcomes Stated trial outcomes: lipid levels and dietary assessment
Data available on total mortality? no
Cardiovascular mortality? yes (none)
Events available for combined cardiovascular events: fatal and non-fatal MI, peripheral
vascular events




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical centre
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Some participants continued with advice to reduce saturated fat
and purchased blinded foods from a trial shop, but half of the
participantswere instructed in their ownpurchase of appropriate
foods from normal shops to compile their own dietary regimen
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts do not appear to have been followed for death or CV
events. Deaths, cancer and CV events for participants otherwise
still included in the study were collated as a reason for study
exclusion
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Trial shop used by both groups, plus dietary advice. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
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Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Nutrition & Breast Health
Methods RCT
Participants Pre-menopausal women at increased risk of breast cancer (USA)
CVD risk: low
Control: randomised 53, analysed 50
Intervention: randomised 69, analysed 47
Mean years in trial: control 1.0, intervention 0.8
% male: control 0%, intervention 0%
Age: mean 38 (sd 7) - not provided by study arm (all 21-50)
Interventions Reduced fat vs usual diet
Control aims: followed usual diet, given daily food guide pyramid (half of this group
randomised to 9 portions/d of fruit and vegetables advice)
Intervention aims: total fat 15%E (half of this group randomised to 9 portions/d of fruit
and vegetables advice)
Control methods: no dietary counselling (offered this at the end of study), but those
given fruit and veg advice had support as below
Intervention methods: met dietitian every 2 weeks until compliant, monthly group
meetings, counselling on home diets, restaurants, parties, social support, eating at work,
exchange booklets, cookbook
Total fat intake (at 12 months): low fat 15.7 (sd 5.1)%E, cont 32.7 (sd 6.1)%E




Outcomes Stated trial outcomes: body weight, dietary compliance
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: total MI, stroke (no events)
Secondary outcomes: non-fatal and total MI, stroke, cancer diagnoses and deaths (no
events for any outcome)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TG, BMI (but variance
data not provided for any but weight)
Notes Change from baseline to 12 months for the control (n=23), control plus fruit & veg (n=
25), low fat (n=24), low fat plus fruit & veg (n=23):
Total cholesterol mg/dl: 9, 2, -8, 0
TGs mg/dl: -7, 1, 5, 8
HDL chol mg/dl: 0, 0, -4, 0
LDL chol mg/dl: 11, 2, -6, -2
BMI kg/m2: 0, 4, -13, 0
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The statistician made envelopes ahead of time, dietitians handed
out envelopes at first visit
Allocation concealment (selection bias) Low risk Allocation could not be altered once made
Blinding (performance bias and detection
bias)
All outcomes
High risk Paricipants were aware of allocation, researchers and those as-
sessing lipids were not
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk High levels of intervention for those on low fat or high fruit
and vegetable diets. See Control and Intervention Methods in
Interventions section of the Table of Characteristics of Included
Studies
Free of dietary differences other than fat? Low risk Randomisation to fruit and vegetable intervention was indepen-
dent of low fat allocation
Ole Study 2002
Methods RCT
Participants Moderately obese healthy men (USA)
CVD risk: low
Control: randomised 15, analysed 12
Intervention: randomised 15, analysed 13
Mean years in trial: control 0.68, intervention 0.70
% male: control 100%, intervention 100%
Age: mean control 37.0 (SE 2.54), intervention 36.1 (SE 2.49)
Interventions Reduced fat vs usual diet
Control aims: total fat 33%E, CHO 52%E, protein 15%E
Intervention aims: total fat 25%E, CHO 58%E, protein 17%E, provided with 11% less
energy than controls, but were allowed to ask for more
Also second intervention arm with Olestra added to
Control methods: 5 meals/week eaten in centre, other meals in takeout containers, asked
to return uneaten food, allowed to ask for more
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Ole Study 2002 (Continued)
Intervention methods: 5 meals/week eaten in centre, other meals in takeout containers,
asked to return uneaten food, allowed to ask for more
Total fat intake (at 6 months): low fat 26.2 (sd 2.8)%E, cont 34.1 (sd 2.7)%E
Saturated fat intake (at 6 months): low fat 6.2 (sd 0.7)%E, cont 7.6 (sd 0.9)%E
Style: diet provided
Setting: community
Outcomes Stated trial outcomes: body weight, body fat, lipids, glucose, insulin
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: total MI, stroke, angina, CABG,
angioplasty, peripheral vascular events (no events)
Secondary outcomes: non-fatal and total MI, stroke, cancer diagnoses and deaths (no
events for any outcome), Quality of Life
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TG, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer stratified and randomised by personnel not involved
with participants
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Workers in the dietary kitchen, who provided the meals, were
the only ones who knew the allocations
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Most food provided for both groups. See Control and Interven-
tion Methods in Interventions section of the Table of Charac-
teristics of Included Studies
Free of dietary differences other than fat? High risk Potential difference in energy intake, but unclear what effect this
had
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Oslo Diet-Heart 1966
Methods RCT
Participants Men with previous MI (Norway)
CVD risk: high
Control: randomised 206, analysed 148 (at 5 years)
Intervention: randomised 206, analysed 152 (at 5 years)
Mean years in trial: control 4.3, intervention 4.3
% male: 100
age: mean control 56.3, intervention 56.2 (all 30-67)
Interventions Modified fat diet vs control
Control aims: no dietary advice but direct questions answered, supplement = 1 vitamin
tablet daily
Intervention aims: reduce meat & dairy fats, increase fish, vegetables, supplement - 1
vitamin tablet daily, 0.5L soy bean oil per week (free to 25% of participants), sardines
in cod liver oil (free at certain times to encourage compliance)
Control methods: usual diet
Intervention methods: continuous instruction and supervision by dietitian, including
home visits, letters and phone calls
Total fat intake: mod fat unclear, cont unclear
Saturated fat intake: mod fat unclear, cont unclear
Style: diet advice & supplement (food)
Setting: community
Outcomes Stated trial outcomes: coronary heart disease morbidity and mortality
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: total MI, sudden death, stroke,
angina
Secondary outcomes: non-fatal and total MI, stroke
Tertiary outcomes: weight, total cholesterol, systolic and diastolic BP (but no variance
information is provided)
Notes Weight change from baseline was -0.5kg in the control group (n~155), -2.5kg in the
intervention group (n~160) to 51 months
Total cholesterol change from baseline was -0.46mmol/L in the control group and -
1.53mmol/L in the intervention group at 51 months.
Systolic BP at baseline was 153.8mmHg in control and 159.0 in intervention, and mean
sBP through trial was 154.3mmHg in control and 158.2mmHg in the intervention
group.
Diastolic BP at baseline was 93.5mmHg in control and 97.1mmHg in intervention,
through trial mean dBP was 95.5mmHg in control and 98.6mmHg in intervention
participants.
Risk of bias
Bias Authors’ judgement Support for judgement
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Oslo Diet-Heart 1966 (Continued)
Random sequence generation (selection
bias)
Low risk ”table of random numbers used“, by Prof Knut Westlund
Allocation concealment (selection bias) Low risk Randomisation appears to have occurred before medical exam-
ination within the study
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of their allocation as was the main trial-
ist. Outcomes were categorised by a diagnostic board, but their
blinded status was unclear.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The participants who could not be directly followed up for the
5 years were followed until death or study end through personal
interviews, or contact with their physicians or relatives.
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Dietetic input level very different, although medical care ap-
peared similar. See Control and Intervention Methods in In-
terventions section of the Table of Characteristics of Included
Studies
Free of dietary differences other than fat? High risk Differences in fruit and vegetables, fish etc. as above.
Oxford Retinopathy 1978
Methods RCT
Participants Newly diagnosed non-insulin dependant diabetics (UK)
CVD risk: moderate
Control: randomised unclear (249 split between the 2 groups, 125?), analysed for mor-
tality unclear (all but 2 overall at 16 years)
Intervention: randomised unclear (249 split between the 2 groups, 125?), analysed as
above
Mean years in trial: overall 9.3?
% male: overall 49
Age: mean overall 47.1 (all <65)
Interventions Reduced and modified dietary fat vs average diet
Control aims: total fat 40%E, PUFA 12%E, protein 20%E, CHO 40%E (reducing
simple sugars), 1500kcal/day
Intervention aims: total fat 26%E, PUFA 16%E, protein 20%E, CHO 54%E (reducing
simple sugars), 1500kcal/day
Control methods: dietary advice from diabetes dietitian
Intervention methods: dietary advice from diabetes dietitian
Total fat intake (at 7-9 years): low & mod fat 32 (sd unclear), cont 41 (sd unclear)%E
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Oxford Retinopathy 1978 (Continued)
Saturated fat intake (at 7-9 years): low&mod fat 10.7 (sd unclear), cont 20.4 (sd unclear)
%E
Style: diet advice
Setting: community (outpatients clinic)
Outcomes Stated trial outcomes: retinopathy
Data available on total mortality? yes, but unable to ascertain from which intervention
groups (34 deaths at 10 years)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: BMI, total cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”random number sequence, provided and allotted by a separate
agency“ (Prof Richard Peto)
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants not blinded, physicians unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Dietetic advice for both groups. See Control and Intervention
Methods in Interventions section of the Table of Characteristics
of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
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Polyp Prevention 1996
Methods RCT
Participants People with at least one adenomatous polyp of the large bowel removed (USA)
CVD risk: low
Control: 1042 randomised, 947 analysed
Intervention: 1037 randomised, 958 analysed
Mean years in trial: control 3.05, intervention 3.05
% male: control 64%, intervention 66%
Age: mean control 61.5, intervention 61.4 (all at least 35)
Interventions Low fat vs usual diet
Control: general dietary guidelines
Intervention: total fat 20%E, 18g fibre/1000kcal, 5-8 servings fruit and veg daily
Control methods: leaflet, no additional information or behaviour modification
Intervention methods: >50 hours of counselling over 4 years, included skill building,
behaviour modification, self monitoring and nutritional materials
Total fat intake (at 4 years): low fat 23.8 (sd 6.0), cont 33.9 (sd 5.9)%E
Saturated fat intake: unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: recurrence of polyps, prostate cancer
Data available on total mortality? yes
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnoses
Tertiary outcomes: weight, total cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomly assigned“
Allocation concealment (selection bias) Low risk Phone call to computer randomisation centre, stratified accord-
ing to centre
Blinding (performance bias and detection
bias)
All outcomes
High risk Outcome assessors blinded, participants not.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
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Polyp Prevention 1996 (Continued)
Other bias Low risk
Free of systematic difference in care? High risk 50 hours behaviour modification in intervention group, not in
control. See Control and Intervention Methods in Interventions
section of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? High risk Fibre, fruit and vegetable goals in intervention group
PREMIER 2003
Methods RCT
Participants Adults with above optimal BP or stage 1 hypertension (USA)
CVD risk: moderate
Control: 269 randomised, 269 analysed
Intervention: 268 randomised, 268 analysed
Mean years in trial: 1.5
% male: control 35.3%, intervention 42.8%
Age, years: control 50.2 mean (sd 8.6), intervention 50.2 (sd 9.3)
Interventions Reduced fat vs usual diet
Control: ’established’ goals weight loss of 6.8kg at 6months, 180 mins/week of moderate
physical activity, limited sodium intake, limited alcohol.
Intervention: ’established plusDASH’ goals as ’established’ plus saturated fat intake 7%E
or less, total fat intake 25%E or less, 2-3 portions low fat dairy foods/d, 9-12 portions
fruit and veg/d.
Other arms: Advice only standard care arm, data not used.
Control methods: 18 face to face contacts (14 group and 4 individual), food diaries,
physical activity records, calorie and sodium intake records
Intervention methods: 18 face to face contacts (14 group and 4 individual), food diaries,
physical activity records, calorie and sodium intake records
Total fat intake (at 6 months): low fat 23.8 (sd 8.6), cont 29.4 (sd 8.4)%E
Saturated fat intake (at 6 months): low fat 7.7 (sd 3.2), cont 9.4 (sd 3.5)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: blood pressure
Data available on total mortality? yes
Cardiovascular mortality? yes, none by 18 months
Events available for combined cardiovascular events: total MI, stroke.
Secondary outcomes: cancer deaths (none), cancer diagnoses, diabetes, stroke, total and
non-fatal MI
Tertiary outcomes: weight, BP
Notes
Risk of bias
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PREMIER 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out centrally by computer pro-
gramme, stratified by clinic and baseline BP, blocked
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were not blinded to the intervention, though efforts
were made to mask centre staff involved in outcome assessments
to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All those randomisedwere included in the analysis of both events
and blood pressure
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar style and duration of interventions. See Control and
Intervention Methods in Interventions section of the Table of
Characteristics of Included Studies
Free of dietary differences other than fat? High risk Differences in fruit and vegetable advice
Rivellese 1994
Methods RCT
Participants Adults with primary hyperlipoproteinaemia (Italy)
CVD risk: moderate
Intervention reduced fat: 33 randomised, 27 analysed
Intervention modified fat: 30 randomised, 17 analysed
Mean years in trial: reduced fat 0.4, modified fat 0.4
% male: reduced fat 82%, modified fat 63%
Age, years: reduced fat 47.4 mean (sd 10.3), modified fat 48.6 (sd 8.1)
Interventions Reduced fat vs Modified fat diet
Reduced fat aims: total fat 25%E, SFA 8%E, MUFA 15%, PUFA 2%, dietary chol
<300mg/d, CHO 58%, protein 17%E, soluble fibre 41g/d
Modified fat aims: total fat 38%E, SFA <10%E, MUFA 20%E, PUFA 10%E, dietary
chol<300mg/d, CHO 47%E, protein 15%E, soluble fibre 19g/d
Reduced fat methods:seen monthly by dietitian and doctor, feedback based on 7 day
food diary each time
Modified fat methods: seen monthly by dietitian and doctor, feedback based on 7 day
food diary each time
Total fat intake (at 5-6 months): low fat 27 (sd unclear)%E, mod fat 36 (sd unclear)%E
Saturated fat intake (at 5-6 months): low fat 6 (sd unclear)%E, mod fat 7 (sd unclear)
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Outcomes Stated trial outcomes: metabolic effects
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: total MI, cardiovascular deaths,
stroke (no events)
Secondary outcomes: stroke, total and non-fatal MI (no events for any outcomes)
Tertiary outcomes: total, LDL and HDL cholesterol, TGs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Following 3 or 6 weeks compliance with control diet run-in,
stratified block randomisation with tables of random numbers
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described




Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Identical follow up. See Control and Intervention Methods in
Interventions section of the Table of Characteristics of Included
Studies
Free of dietary differences other than fat? High risk Some differences in soluble fibre intake
Rose 1965
Methods RCT
Participants Men (?) with angina or following MI (UK)
CVD risk: high
Control: randomised 26, analysed 18
Intervention - olive: randomised 28, analysed 12
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Rose 1965 (Continued)
Intervention - corn: randomised 26, analysed 13
Mean years in trial: control 1.7, olive 1.5, corn 1.5
% male: unclear (100%?)
Age: mean control 58.8, olive 55.0, corn 52.6 (all <70)
Interventions Modified fat vs. usual diet
Control aims: usual diet
Intervention aims -olive: restrict dietary fat, plus 80g/day olive oil provided
Intervention aims - corn: restrict dietary fat, plus 80g/day corn oil provided
Control methods: usual physician care plus follow up clinic monthly, then every 2
months, no dietary fat advice or oil provided
Intervention methods: usual physician care plus follow up clinic monthly, then every 2
months, dietary fat advice plus oil provided
Total fat intake (at 18 months): corn 50.5 (sd unclear), olive 46.2 (sd unclear), cont 32.6
(sd unclear)%E
Saturated fat intake: unclear
Style: diet advice & supplement (oil)
Setting: community
Outcomes Stated trial outcomes: cardiac events
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI,
angina, stroke
Secondary outcomes: stroke (none), non-fatal and total MI
Tertiary outcomes: total cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”sealed envelopes“
Allocation concealment (selection bias) Unclear risk Unclear if envelopes were opaque
Blinding (performance bias and detection
bias)
All outcomes
High risk Physician blinding: inadequate
Participant blinding: inadequate
Incomplete outcome data (attrition bias)
All outcomes
High risk Some lost to follow up by 2 years
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
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Rose 1965 (Continued)
Free of systematic difference in care? Low risk All received conventional treatments at the discretion of the
physicians, all attended a special follow up clinic. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Sacks high protein 2009
Methods RCT
Participants Overweight or obese adults (USA)
CVD risk: low
Intervention reduced fat: 202 randomised, 202 analysed
Intervention modified fat: 201 randomised, 201 analysed
Mean years in trial: reduced fat 1.78, modified fat 1.84
% male: reduced fat 33%, modified fat 36%
Age, years: reduced fat 50 (SD 10), modified fat 51 (9)
Interventions Reduced fat vs Modified fat diet
Reduced fat aims: total fat 20%E, SFA ≤8%E, MUFA 6%, PUFA 6%, dietary chol
150mg/1000kcal, CHO 55%, protein 25%E, dietary fibre 20g/d
Modified fat aims: total fat 40%E, SFA ≤8%E, MUFA 22%E, PUFA 10%E, dietary
chol 150mg/1000kcal, CHO 35%E, protein 25%E, dietary fibre 20g/d
Reduced fat methods: 18 group sessions in first 6 months, then 2 group sessions per
month to 2 years, plus individual sessions every 8 weeks for 2 years. All sessions included
behavioural counselling, daily meal plans provided, food diary and web-based self-mon-
itoring tool provided, 90 mins/week of moderate exercise encouraged.
Modified fat methods: 18 group sessions in first 6 months, then 2 group sessions per
month to 2 years, plus individual sessions every 8 weeks for 2 years. All sessions included
behavioural counselling, daily meal plans provided, food diary and web-based self-mon-
itoring tool provided, 90 mins/week of moderate exercise encouraged.
Total fat intake (at 2 years): low fat 28.4 (sd 8.1)%E, mod fat 35.1 (sd 7.0)%E
Saturated fat intake (at 2 years): low fat 8.9 (sd 3.8)%E, mod fat 10.5 (sd 2.7)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: weight
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: unclear
Secondary outcomes: cancer deaths (no events) and cancer diagnoses
Tertiary outcomes: weight; total, LDL and HDL cholesterol; TGs; systolic and diastolic
blood pressure, QoL (QoL outcomes not reported)
Notes This was a factorial trial, so there were also 2 arms with lower protein intake (see Sacks
low protein 2009)
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Sacks high protein 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization assignments to one of 4 diet groups were gen-
erated by the data manager at the coordinating center... after
confirming, by computer program, that all screening activities
had occurred... Diet group assignments were stratified by site
with varying block sizes to ensure a balance at each site.’
Allocation concealment (selection bias) Low risk As above
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Blinding was established by naming each diet with colors, and
using the same foods for each diet. Blinding and equipoise were
strictly maintained by emphasizing to intervention staff and par-
ticipants that each diet adheres to healthy principles, and each is
advocated by certain experts to be superior for long-termweight-
loss. Except for interventionists ... investigators and staff were
kept blind to diet assignment of the participants. The trial ad-
hered to established procedures to maintain separation between
staff that take outcome measurements and staff that deliver the
intervention. Staff members who obtained outcome measure-
ments were not informed of the diet group assignment.... All in-
vestigators, staff and participants were kept masked to outcome
measurements and trial results.’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear for cardiovascular events. Yes for tertiary outcomes -
intention to treat analysis, imputing zero change from baseline
for missing data (except for weight which was more complex,
assuming weight regain for missing data following weight loss,
and zero change for those who had previously gained weight).
Selective reporting (reporting bias) Low risk ClinicalTrials.gov number NCT00072995. Protocol secondary
outcomes (hepatic and skeletal muscle, visceral fat, and quality
of life) not yet reported in full
Other bias Low risk
Free of systematic difference in care? Low risk Identical follow up for all groups
Free of dietary differences other than fat? Low risk Clear dietary goal similarities across saturated fat, fibre, choles-
terol etc.
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Sacks low protein 2009
Methods RCT
Participants Overweight or obese adults (USA)
CVD risk: low
Intervention reduced fat: 204 randomised, 204 analysed
Intervention modified fat: 204 randomised, 204 analysed
Mean years in trial: reduced fat 1.83, modified fat 1.74
% male: reduced fat 38%, modified fat 39%
Age, years: reduced fat 51 (SD 9), modified fat 52 (9)
Interventions Reduced fat vs Modified fat diet
Reduced fat aims: total fat 20%E, SFA ≤8%E, MUFA 6%, PUFA 6%, dietary chol
150mg/1000kcal, CHO 65%, protein 15%E, dietary fibre 20g/d
Modified fat aims: total fat 40%E, SFA ≤8%E, MUFA 22%E, PUFA 10%E, dietary
chol 150mg/1000kcal, CHO 45%E, protein 15%E, dietary fibre 20g/d
Reduced fat methods: 18 group sessions in first 6 months, then 2 group sessions per
month to 2 years, plus individual sessions every 8 weeks for 2 years. All sessions included
behavioural counselling, daily meal plans provided, food diary and web-based self-mon-
itoring tool provided, 90 mins/week of moderate exercise encouraged.
Modified fat methods: 18 group sessions in first 6 months, then 2 group sessions per
month to 2 years, plus individual sessions every 8 weeks for 2 years. All sessions included
behavioural counselling, daily meal plans provided, food diary and web-based self-mon-
itoring tool provided, 90 mins/week of moderate exercise encouraged.
Total fat intake (at 2 years): low fat 26.5 (sd 8.0)%E, mod fat 33.3 (sd 8.2)%E
Saturated fat intake (at 2 years): low fat 8.0 (sd 3.1)%E, mod fat 9.8 (sd 3.3)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: weight
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: unclear
Secondary outcomes: cancer deaths (no events) and cancer diagnoses
Tertiary outcomes: weight; total, LDL and HDL cholesterol; TGs; systolic and diastolic
blood pressure, QoL (QoL outcomes not reported)
Notes This was a factorial trial, so there were also 2 arms with higher protein intake (see Sacks
high protein 2009)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomization assignments to one of 4 diet groups were gen-
erated by the data manager at the coordinating center... after
confirming, by computer program, that all screening activities
had occurred... Diet group assignments were stratified by site
with varying block sizes to ensure a balance at each site.’
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Sacks low protein 2009 (Continued)
Allocation concealment (selection bias) Low risk As above.
Blinding (performance bias and detection
bias)
All outcomes
Low risk ’Blinding was established by naming each diet with colors, and
using the same foods for each diet. Blinding and equipoise were
strictly maintained by emphasizing to intervention staff and par-
ticipants that each diet adheres to healthy principles, and each is
advocated by certain experts to be superior for long-termweight-
loss. Except for interventionists ... investigators and staff were
kept blind to diet assignment of the participants. The trial ad-
hered to established procedures to maintain separation between
staff that take outcome measurements and staff that deliver the
intervention. Staff members who obtained outcome measure-
ments were not informed of the diet group assignment.... All in-
vestigators, staff and participants were kept masked to outcome
measurements and trial results.’
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear for cardiovascular events. Yes for tertiary outcomes -
intention to treat analysis, imputing zero change from baseline
for missing data (except for weight which was more complex,
assuming weight regain for missing data following weight loss,
and zero change for those who had previously gained weight).
Selective reporting (reporting bias) Low risk ClinicalTrials.gov number NCT00072995. Protocol secondary
outcomes (hepatic and skeletal muscle, visceral fat, and quality
of life) not yet reported in full
Other bias Low risk
Free of systematic difference in care? Low risk Identical follow up for all groups
Free of dietary differences other than fat? Low risk Clear dietary goal similarities across saturated fat, fibre, choles-
terol etc.
Sarkkinen Fat Mod 1995
Methods RCT (the 3 Kuopio trials share a common control group)
Participants Free-living people aged 30-60 with serum total cholesterol levels 6.5-8.0mmol/L (Fin-
land)
CVD risk: moderate
Control: randomised 37, analysed 37
Intervention Mono: randomised 41, analysed 41
Mean years in trial: for both groups 0.5
% male: control 46, Mono 46
Age: mean control 43.2, Mono 46.4 (all 30-60)
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Sarkkinen Fat Mod 1995 (Continued)
Interventions Modified fat vs usual diet
Control aims: advised total fat 38%E, SFA <18%E, MUFA 15%E, PUFA <5%E, rape-
seed oil, butter and semi-skimmed milk provided
Intervention aims Mono: total fat 38%E, SFA <14%E, MUFA 18%E, PUFA <6%E,
rapeseed oil, rapeseed spread and skimmed milk provided
Control and intervention methods: given written dietary instructions and a diet plan
with checking and reinforcement for 3 visits, then at 2, 6, 12, 18 and 26 weeks
Total fat intake (weeks 14-28): mod fat 35 (sd 5), cont 36 (sd 5)%E
Saturated fat intake (weeks 14-28): mod fat 11 (sd 2), cont 15 (sd 2)%E
Style: dietary advice & supplement (food)
Setting: community
Outcomes Stated trial outcomes: lipids and blood pressure
Data available on total mortality? yes (no events)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: BMI, total, LDL and HDL cholesterol, TG, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomisation stratified for men and
women, singles and couples, random num-
ber tables“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and researchers knew alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
drop-outs, trialists asked for data - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary
outcomes as all trialists asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar intensity and duration for both
groups. See Control and Intervention
Methods in Interventions section of the Ta-
ble of Characteristics of Included Studies.
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Sarkkinen Fat Mod 1995 (Continued)
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in In-
terventions section of the Table of Charac-
teristics of Included Studies
Sarkkinen Red & Mod 1995
Methods RCT (the 3 Kuopio trials share a common control group)
Participants Free-living people aged 30-60 with serum total cholesterol levels 6.5-8.0mmol/L (Fin-
land)
CVD risk: moderate
Control: randomised 37, analysed 37
Intervention AHA: randomised 41, analysed 41
Mean years in trial: for all 4 groups 0.5
% male: control 46, AHA 46
Age: mean control 43.2, AHA 47.3 (all 30-60)
Interventions Reduced and modified fat vs usual diet
Control aims: advised total fat 38%E, SFA <18%E, MUFA 15%E, PUFA <5%E, rape-
seed oil, butter and semi-skimmed milk provided
Intervention aims AHA: total fat 30%E, SFA <10%E, MUFA 10%E, PUFA 10%E,
sunflower oil, sunflower spread and skimmed milk provided
Control and intervention methods: given written dietary instructions and a diet plan
with checking and reinforcement for 3 visits, then at 2, 6, 12, 18 and 26 weeks
Total fat intake (weeks 14-28): low & mod fat 34 (sd 4), cont 36 (sd 5)%E
Saturated fat intake (weeks 14-28): low & mod fat 11 (sd 2), cont 15 (sd 2)%E
Style: dietary advice & supplement (food)
Setting: community
Outcomes Stated trial outcomes: lipids and blood pressure
Data available on total mortality? yes (no events)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: BMI, total, LDL and HDL cholesterol, TG, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomisation stratified for men and
women, singles and couples, random num-
ber tables“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
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Sarkkinen Red & Mod 1995 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and researchers knew alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
drop-outs, trialists asked for data - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary
outcomes as all trialists asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar intensity and duration in both
groups. See Control and Intervention
Methods in Interventions section of the Ta-
ble of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in In-
terventions section of the Table of Charac-
teristics of Included Studies
Sarkkinen Red Fat 1995
Methods RCT (the 3 Kuopio trials share a common control group)
Participants Free-living people aged 30-60 with serum total cholesterol levels 6.5-8.0mmol/L (Fin-
land)
CVD risk: moderate
Control: randomised 37, analysed 37
Intervention low fat: randomised 40, analysed 40
Mean years in trial: for both groups 0.5
% male: control 46, low fat 48
Age: mean control 43.2, low fat 45.8 (all 30-60)
Interventions Reduced fat vs usual diet (low fat vs control)
Control aims: advised total fat 38%E, SFA <18%E, MUFA 15%E, PUFA <5%E, rape-
seed oil, butter and semi-skimmed milk provided
Intervention aims low fat: total fat 28-30%E, SFA <14%E, MUFA 10%E, PUFA 4%E,
butter and rapeseed spread and skimmed milk provided
Control and intervention methods: given written dietary instructions and a diet plan
with checking and reinforcement for 3 visits, then at 2, 6, 12, 18 and 26 weeks
Total fat intake (weeks 14-28): low fat 31 (sd 5), cont 36 (sd 5)%E
Saturated fat intake (weeks 14-28): low fat 12 (sd 2), cont 15 (sd 2)%E
Style: dietary advice & supplement (food)
Setting: community
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Sarkkinen Red Fat 1995 (Continued)
Outcomes Stated trial outcomes: lipids and blood pressure
Data available on total mortality? yes (no events)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: BMI, total, LDL and HDL cholesterol, TG, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomisation stratified for men and
women, singles and couples, random num-
ber tables“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and researchers knew alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
drop-outs, trialists asked for data - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary
outcomes as all trialists asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar intensity and duration in both
groups. See Control and Intervention
Methods in Interventions section of the Ta-
ble of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in In-
terventions section of the Table of Charac-
teristics of Included Studies
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Sarkkinen Red vs Mod1995
Methods RCT
Participants Free-living people aged 30-60 with serum total cholesterol levels 6.5-8.0mmol/L (Fin-
land)
CVD risk: moderate
Intervention Mono: randomised 41, analysed 41
Intervention low fat: randomised 40, analysed 40
Mean years in trial: for both groups 0.5
% male: mono 46, low fat 48
Age: mean Mono 46.4 (all 30-60), low fat 45.8 (all 30-60)
Interventions Reduced fat vs modified fat (low fat vs Mono)
Intervention aims Mono: total fat 38%E, SFA <14%E, MUFA 18%E, PUFA <6%E,
rapeseed oil, rapeseed spread and skimmed milk provided
Intervention aims low fat: total fat 28-30%E, SFA <14%E, MUFA 10%E, PUFA 4%E,
butter and rapeseed spread and skimmed milk provided
Both intervention methods: given written dietary instructions and a diet plan with
checking and reinforcement for 3 visits, then at 2, 6, 12, 18 and 26 weeks
Total fat intake (weeks 14-28): mod fat 35 (sd 5), low fat 31 (sd 5)%E
Saturated fat intake (weeks 14-28): mod fat 11 (sd 2), low fat 12 (sd 2)%E
Style: dietary advice & supplement (food)
Setting: community
Outcomes Stated trial outcomes: lipids and blood pressure
Data available on total mortality? yes (no events)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: BMI, total, LDL and HDL cholesterol, TG, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomisation stratified for men and women, singles and cou-
ples, random number tables“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and researchers knew allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
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Sarkkinen Red vs Mod1995 (Continued)
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Similar intensity and duration in both groups. See Control and
Intervention Methods in Interventions section of the Table of
Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Seppelt 1996
Methods RCT
Participants Women with BMI 24-29 (Germany)
CVD risk: low
Control: randomised 35, analysed 32
Intervention: randomised 35, analysed 35
Mean years in trial: control 0.7, intervention 0.8
% male: 0
Age: mean control 46, intervention 48 (all 40-60)
Interventions Reduced fat vs usual diet
Control aims: advice to buy foods from trial shop, usual fat foods supplied
Intervention aims: advice to buy foods from trial shop, low fat foods supplied
Control methods: trial shop provided ad libitum usual fat foods
Intervention methods: trial shop provided ad libitum low fat foods
Total fat intake (at 9 months): low fat 35.1 (sd unclear), cont 35.5 (sd unclear)%E
Saturated fat intake: unclear
Style: food provided
Setting: community
Outcomes Stated trial outcomes: weight
Data available on total mortality? yes (no events)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI,
stroke (no events)
Secondary outcomes: total and non-fatal MI, stroke, cancer deaths (no events for any
outcomes)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Seppelt 1996 (Continued)
Random sequence generation (selection
bias)
Low risk ”participants assigned to a randomnumber, later numbers sorted
& assigned“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding unclear for participants and researchers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs, trialists
asked for data - unclear if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Trial shop for both groups. See Control and Intervention Meth-
ods in Interventions section of the Table of Characteristics of
Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Simon 1997
Methods RCT
Participants Women with a high risk of breast cancer (USA)
CVD risk: low
Control: randomised 96, analysed 75
Intervention: randomised 98, analysed 72
Mean years in trial: control 1.8, intervention 1.7
% male: 0
Age: mean control 46, intervention 46
Interventions Reduced fat vs usual diet
Control aims: usual diet
Intervention aims: total fat 15%E
Control methods: continued usual diet
Intervention methods: Biweekly individual dietetic appointments over 3 months fol-
lowed by monthly individual or group appointments, including education, goal setting,
evaluation, feedback and self-monitoring
Total fat intake (at 12 months): low fat 18.0 (sd 5.6), cont 33.8 (sd 7.4)%E
Saturated fat intake (at 12 months): low fat 6.0 (sd unclear), cont 11.3 (sd unclear)%E
Style: diet advice
Setting: community
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Simon 1997 (Continued)
Outcomes Stated trial outcomes: intervention feasibility
Data available on total mortality? yes (2 deaths, but not clear in which arms)
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnosis (8 diagnoses, but not clear in which arms)
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TGs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by age and randomised (block size 2)
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants knew their allocation, unclear whether physicians
did
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Very different contact time with dietitian, but medical appoint-
ments same in both groups. SeeControl and InterventionMeth-
ods in Interventions section of the Table of Characteristics of
Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Sondergaard 2003
Methods RCT
Participants People with IHD plus total cholesterol at least 5mmol/L (Denmark)
CVD risk: high
Control: 63 randomised, 52 analysed
Intervention: 68 randomised, 63 analysed
Mean years in trial: 1.0
% male: control 79%, intervention 62%
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Sondergaard 2003 (Continued)
age: control mean 62.8 (sd 10.5), intervention mean 62.1 (sd 9.3)
Interventions Reduced and modified fat intake vs. usual diet
Control: aims unclear
Intervention: aims reductions in total and saturated fat, replace fats with oils, 600g fruit
and vegetables/d, fatty fish at least once a week, eat plenty of bread and cereals
Control methods: booklets plus one dietetic interview, and 3 monthly clinical review
Interventionmethods: 1 hour nutrition interview every 3months, plus 3monthly clinical
review
Total fat intake (at 12 months): low & mod fat 26.2 (sd 5.1), cont 28.9 (sd 7.9)%E
Saturated fat intake (at 12 months): unclear
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: endothelial function
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: total MI, cardiovascular deaths,
stroke, angina, heart failure, CABG, PCI and atrial fibrillation.
Secondary outcomes: cancer diagnoses and deaths, stroke, total MI
Tertiary outcomes: total, LDL and HDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk ”randomised in unblinded 1:1 fashion“
Allocation concealment (selection bias) High risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants aware of allocation, unclear about others
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Additional dietetic time for intervention group. See Control and
Intervention Methods in Interventions section of the Table of
Characteristics of Included Studies
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Sondergaard 2003 (Continued)




Participants Men with angina referred for angiography (UK)
CVD risk: high
Control: unclear randomised (30?), analysed 24
Intervention: unclear how many randomised (30?), analysed 26
Mean years in trial: control 2.9, intervention 3.0
% male: 100
age: mean control 53.9, intervention 48.9 (all <66)
Interventions Reduced and modified fat diet vs usual diet
Control aims: no diet intervention but advised to lose weight if BMI>25
Intervention aims: total fat 27%E, SFA 8-10%E, omega-3 and omega-6 PUFA 8%E,
increase in plant-derived soluble fibre, dietary cholesterol 100mg/1000kcal, advised to
lose weight if BMI>25
Control methods: usual care but no formal dietetic counselling
Intervention methods: Usual care plus dietetic assessment of diet and advice
Total fat intake (through study): int 27 (sd unclear), cont 37 (sd unclear)%E
Saturated fat intake (through study): int 9 (sd unclear), cont 17 (sd unclear)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: angiography
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: cardiovascular deaths, non-fatal MI,
angina, stroke, CABG, angioplasty
Secondary outcomes: cancer deaths (none), stroke, total MI
Tertiary outcomes: total,HDL, LDLcholesterol, TGs (weight andBP ”remained similar“
but were not reported)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”blinded random cards issued centrally by statistician advisor“
Allocation concealment (selection bias) Low risk
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STARS 1992 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk Physician blinding: unclear
Participant blinding: inadequate
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are drop-outs - unclear
if any data missing
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Usual care in both groups, dietetic counselling only in the in-
tervention group. See Control and Intervention Methods in In-
terventions section of the Table of Characteristics of Included
Studies




Participants People with well controlled type I diabetes mellitus (Canada)
CVD risk: moderate
Intervention reduced fat: 18 randomised, 15 analysed
Intervention modified fat: 17 randomised, 15 analysed
Mean years in trial: reduced fat 0.46, modified fat 0.47
% male: reduced fat unclear, modified fat unclear
Age, years: 37.9 (8.1 SD) (not specified by study arm)
Interventions Reduced fat vs Modified fat diet
Reduced fat aims: total fat 27-30%E, SFA ≤10%E, MUFA 10%, CHO 54-57%
Modified fat aims: total fat 37-40%E, SFA ≤10%E, MUFA 20%E, CHO 43-46%E
Reduced fatmethods: after initial dietary advicemonitoredweekly by phone by a dietitian
(24 hour food recall). Glycaemia, insulin doses, CHO at meals, hypoglycaemic attacks
all self-monitored daily and reported weekly.
Modified fat methods: after initial dietary advice monitored weekly by phone by a
dietitian (24 hour food recall). Glycaemia, insulin doses, CHO at meals, hypoglycaemic
attacks all self-monitored daily and reported weekly.
Total fat intake (at 6 months): not stated
Saturated fat intake (at 6 months): not stated
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: Triglycerides and other CVD risk factors
Data available on total mortality? yes (no events)
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Strychar 2009 (Continued)
Cardiovascular mortality? yes (no events)
Events available for combined cardiovascular events: none
Secondary outcomes: cancer deaths (no events) and cancer diagnoses (no events)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”randomly assigned“
Allocation concealment (selection bias) Unclear risk No details provided
Blinding (performance bias and detection
bias)
All outcomes
High risk No details provided, but participants had to make decisions
about what they ate
Incomplete outcome data (attrition bias)
All outcomes
High risk Data reported for those who completed
Selective reporting (reporting bias) Unclear risk Unclear
Other bias Low risk
Free of systematic difference in care? Low risk Similar intervention in both groups
Free of dietary differences other than fat? Low risk Focus on fat and CHO intake
Sydney Diet-Heart 1978
Methods RCT
Participants Men with previous MI (Australia)
CVD risk: high
Control: randomised 237, analysed 221 at 2 years
Intervention: randomised 221, analysed 205 at 2 years
Mean years in trial: control 4.3, intervention 4.3
% male: 100
Age: mean control 49.1 (sd 6.5), intervention 48.7 (sd 6.8)
Interventions Modified fat diet vs usual diet
Control aims: reduction in energy if overweight, no other specific dietary advice, allowed
to use PUFA margarine instead of butter
Intervention aims: SFA 10%E, PUFA 15%E, reduction in energy if overweight, dietary
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Sydney Diet-Heart 1978 (Continued)
chol <300mg/day
Control methods: no specific dietary instruction (except re weight)
Intervention methods: advised and tutored individually, diet assessed 3 times in first year
and twice annually thereafter
Total fat intake (”during follow up“): mod fat 38.3 (sd 5.9), cont 38.1 (sd 5.4)%E
Saturated fat intake (”during follow up“): mod fat 9.8 (sd 2.6), cont 13.5 (sd 3.2)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: cardiovascular mortality and morbidity
Data available on total mortality? yes
Cardiovascular mortality? no (overall number given, but not by intervention group)
Events available for combined cardiovascular events: none
Secondary outcomes: none
Tertiary outcomes: total cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”random numbers“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
High risk Physician blinding: adequate
participant blinding: inadequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Survival analysis used
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Advice and follow up in intervention group, not in control. See
Control and Intervention Methods in Interventions section of
the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
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THIS DIET 2008
Methods RCT
Participants People following a first MI (USA)
CVD risk: high
Intervention 1 low fat: 50 randomised, 50 analysed
Intervention 2 modified fat: 51 randomised, 51 analysed
Mean years in trial: 2
% male: low fat 68%, modified fat 80%
Age, years: low fat 58 (sd 9), modified fat 58 (sd 10)
Interventions Low fat vs modified fat
Low fat aims: <30%E from fat, 7%E or less from SFA, 10-15%E MUFA, 200mg/d or
less cholesterol, 0.3 to 0.45%E from n-3
Modified fat aims: 30-40%E from fat, 7%E or less from SFA, 20-25%EMUFA, 200mg/
d or less cholesterol, >0.75%E from n-3
Control methods: 6+ classes plus individual dietetic appointments (2 in first month,
then at 3, 6, 12, 18 and 24 months)
Intervention methods: 6+ classes plus individual dietetic appointments (2 in first month,
then at 3, 6, 12, 18 and 24 months)
Total fat intake (at 12 months): low fat 27.9 (sd 7.0), mod fat 30.1 (sd 8.6)%E
Saturated fat intake (at 12 months): low fat 7.5 (sd 2.7), mod fat 7.9 (sd 3.4)%E
Style: diet advice
Setting: community
Outcomes Stated trial outcomes: mortality and morbidity
Data available on total mortality? yes, none
Cardiovascular mortality? yes, none
Events available for combined cardiovascular events: MI, unstable angina, stroke
Secondary outcomes: cancer deaths (none), stroke, total and non-fatal MI
Tertiary outcomes: HDL and LDL cholesterol, TG, BMI, BP
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes, stratified by diabetes, 10 envelope blocks, se-
lected in prepared order from locked drawer by study dietitian.
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were aware of allocation as taught the diet.
Incomplete outcome data (attrition bias)
All outcomes
Low risk For primary outcomes
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THIS DIET 2008 (Continued)
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk Same number of individual dietetic appointments and group
sessions in both arms. See Control and Intervention Methods in
Interventions section of the Table of Characteristics of Included
Studies




Participants Men living at the Veterans Administration Centre (USA)
CVD risk: low
Control: randomised 422, analysed 422
Intervention: randomised 424, analysed 424
Mean years in trial: control 3.7, intervention 3.7
% male: 100
age: mean control 65.6, intervention 65.4 (all 54-88)
Interventions Modified fat vs. usual diet
Control aims: provided, total fat 40%E
Intervention aims: total fat 40%E, 2/3 of SFA replaced by unsaturated fats, dietary chol
reduced
Control methods: whole diet provided
Intervention methods: whole diet provided
Total fat intake (during trial): mod fat 38.9 (sd unclear), cont 40 (sd unclear)%E
Saturated fat intake (during trial): mod fat 8.3 (sd unclear), cont 18.5 (sd unclear)%E
Style: diet provided
Setting: residential institution
Outcomes Stated trial outcomes: mortality, heart disease
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: sudden death, definite MI, definite
stroke, angina, PV events
Secondary outcomes: cancer deaths, cancer diagnoses, stroke, non-fatal MI, total MI
Tertiary outcomes: none (some data on total cholesterol, but no variance info)
Notes
Risk of bias
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Veterans Admin 1969 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”table of random numbers used“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly described
Blinding (performance bias and detection
bias)
All outcomes
Low risk physician blinding: adequate
participant blinding: adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk All followed up via Veterans Admin system
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? Low risk All ate centre food as usual. See Control and Intervention Meth-
ods in Interventions section of the Table of Characteristics of
Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
WHEL 2007
Methods RCT
Participants Women with previously treated early breast cancer (USA)
CVD risk: low
Control: randomised 1561, analysed 1551
Intervention: randomised 1546, analysed 1537
Mean years in trial: unclear, 11 years max, around 11 years mean?
% male: 0
Age: control mean 53.0 (sd 9.0), intervention mean 53.3 (sd 8.9)
Interventions Reduced fat intake vs usual diet
Control: aim 30%E from fat
Intervention: aim 15-20%E from fat, 5veg/d, 3 fruit/d, 16oz veg juice and 30g/d fibre
Control methods: given print materials only
Interventionmethods: telephone counselling programme (31 calls by study end), cooking
classes (12 offered in first year, 4 attended on average) and monthly newsletters (48 by
study end), all focused on self-efficacy, self-monitoring and barriers, retaining motivation
Total fat intake (at 72 months): low fat 28.9 (sd 9.0), cont 32.4 (sd 8.0)%E
Saturated fat intake (at 72 months): low fat 7.2 (sd unclear), cont 8.9 (sd unclear)%E
Style: diet advice
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WHEL 2007 (Continued)
Setting: community
Outcomes Stated trial outcomes: mortality, invasive breast cancer
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnoses and deaths
Tertiary outcomes: weight, total, LDL and HDL cholesterol, TG
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation via computer programme
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants aware of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Monitoring of national death register and medical records
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk High intensity intervention compared with leaflets. See Control
and Intervention Methods in Interventions section of the Table
of Characteristics of Included Studies
Free of dietary differences other than fat? High risk Fruit and veg intervention in low fat arm, not in control.
WHI with CVD 2006
Methods RCT
Participants Post-menopausal women aged 50-79 with CVD at baseline (USA)
CVD risk: high
Control: randomised 1369, analysed 1369
Intervention: randomised 908, analysed 908
Mean years in trial: control 8.1, intervention 8.1
% male: 0
Age: mean (women both with and without CVD at baseline) int 62.3 (sd 6.9), control
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WHI with CVD 2006 (Continued)
62.3 (sd 6.9)
Interventions Reduced fat vs. usual diet
Control: diet-related education materials
Intervention: low fat diet (20% E from fat) with increased fruit and vegetables
Control methods: given copy of ’Dietary Guidelines for Americans’
Intervention methods: 18 group sessions with trained and certified nutritionists in the
first year, quarterly maintenance sessions thereafter, focusing on diet and behaviour
modification
Total fat intake (at 6 years): int 28.8 (sd 8.4)%E, cont 37.0 (sd 7.3)%E
Saturated fat intake (at 6 years): int 9.5 (sd 3.2)%E, cont 12.4 (sd 3.1)%E
Style: dietary advice
Setting: community
Outcomes Stated trial outcomes: breast cancer, mortality, other cancers, cardiovascular events, dia-
betes
Data available on total mortality? yes
Cardiovascular mortality? yes
Events available for combined cardiovascular events: CHD, stroke, heart failure, angina,
peripheral vascular disease, revascularization, pulmonary embolism, DVT
Secondary outcomes: cancer deaths*, cancer diagnoses*, stroke, non-fatal MI
Tertiary outcomes: weight, BMI, total, LDL and HDL cholesterol, TGs, systolic and
diastolic BP




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer algorithm
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants aware of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
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WHI with CVD 2006 (Continued)
Free of systematic difference in care? High risk Intervention participants received 18 group sessions with be-
havioural modification plus quarterly maintenance sessions
thereafter, control groups received a leaflet. See Control and
Intervention Methods in Interventions section of the Table of
Characteristics of Included Studies
Free of dietary differences other than fat? High risk Also fruit and vegetable intervention. See Control and Interven-
tion Aims in Interventions section of the Table of Characteristics
of Included Studies
WHI without CVD 2006
Methods RCT
Participants Post-menopausal women aged 50-79 without CVD at baseline (USA)
CVD risk: low
Control: randomised 29294, analysed 29294
Intervention: randomised 19541, analysed 19541
Mean years in trial: control 8.1, intervention 8.1
% male: 0
Age: mean (both with and without CVD at baseline) int 62.3 (sd 6.9), control 62.3 (sd
6.9)
Interventions Reduced fat vs. usual diet
Control: diet-related education materials
Intervention: low fat diet (20% E from fat) with increased fruit and vegetables
Control methods: given copy of ’Dietary Guidelines for Americans’
Intervention methods: 18 group sessions with trained and certified nutritionists in the
first year, quarterly maintenance sessions thereafter, focusing on diet and behaviour
modification
Total fat intake (at 6 years): int 28.8 (sd 8.4)%E, cont 37.0 (sd 7.3)%E
Saturated fat intake (at 6 years): int 9.5 (sd 3.2)%E, cont 12.4 (sd 3.1)%E
Style: dietary advice
Setting: community
Outcomes Stated trial outcomes: breast cancer, mortality, other cancers, cardiovascular events, dia-
betes
Data available on total mortality? yes*
Cardiovascular mortality? yes
Events available for combined cardiovascular events: CHD, stroke, heart failure, angina,
peripheral vascular disease, revascularization, pulmonary embolism, DVT
Secondary outcomes: cancer deaths*, cancer diagnoses*, stroke, non-fatal MI, diabetes
diagnosis*
Tertiary outcomes: weight, BMI, total, LDL and HDL cholesterol, TGs, systolic and
diastolic BP
* these are only available for the whole cohort, not split between low and high CVD risk
groups
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WHI without CVD 2006 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer algorithm
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants aware of allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Intervention participants received 18 group sessions with be-
havioural modification plus quarterly maintenance sessions
thereafter. See Control and Intervention Methods in Interven-
tions section of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? High risk Also fruit and vegetable intervention. See Control and Interven-




Participants Women with localised re-sected breast cancer (USA)
CVD risk: low
Control: 1462 randomised, 1462 analysed
Intervention: 975 randomised, 975 analysed
Mean years in trial: overall 5.0
% men: 0
Age: control mean 58.5 (95% CI 43.6 to 73.4), intervention mean 58.6 (95% CI 44.4
to 72.8) (all post-menopausal)
Interventions Reduced fat intake vs. usual diet
Control aims: minimal nutritional counselling focused on nutritional adequacy
Intervention aims: total fat 15-20%E
Control methods: 1 baseline dietetic session plus 3-monthly sessions
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WINS 2006 (Continued)
Intervention methods: 8 bi-weekly individual dietetic sessions, then optional monthly
group sessions, incorporating individual fat gram goals, social cognitive theory, self-mon-
itoring, goal setting, modelling, social support and relapse prevention and management
Total fat intake (at 1 year): low fat 20.3 (sd 8.1), cont 29.2 (sd 7.4)%E
Saturated fat intake (at 1 year): low fat 10.4 (sd 6.7), cont 16.6 (sd 9.3)%E
Style: dietary advice
Setting: community
Outcomes Stated trial outcomes: dietary fat intake, total cholesterol, weight and waist
Data available on total mortality? yes
Cardiovascular mortality? no
Events available for combined cardiovascular events: none
Secondary outcomes: cancer diagnoses
Tertiary outcomes: weight, BMI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk random stratified permuted block design, carried out at the sta-
tistical co-ordinating centre of WINS
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants not blinded, not relevant for assessment ofmortality
by researchers
Incomplete outcome data (attrition bias)
All outcomes
Low risk All assessed.
Selective reporting (reporting bias) Low risk Not relevant for primary and secondary outcomes as all trialists
asked for data
Other bias Low risk
Free of systematic difference in care? High risk Differences in attention - more time for those in intervention
group. See Control and Intervention Methods in Interventions
section of the Table of Characteristics of Included Studies
Free of dietary differences other than fat? Low risk See Control and Intervention Aims in Interventions section of
the Table of Characteristics of Included Studies
Abreviations:
CHO = carbohydrates,
%E = percent of total energy intake,
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P/S = polyunsaturated / saturated fat ratio,
chol = cholesterol,
CVD = cardiovascular disease,
MI = myocardial infarction
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agewall 2001 Multifactorial intervention
Ammerman 2003 No appropriate control group (and not low fat vs modified fat)
Anti-Coronary C 1966 Not randomised
Aquilani 2000 No appropriate control group (and not low fat vs modified fat)
Arntzenius 1985 No appropriate control group (and not low fat vs modified fat)
Aro 1990 Intervention and randomised follow up less than 6 months
ASSIST 2001 Intervention is not dietary fat modification or low fat diet
Australian Polyp Prev 95 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Baer 1993 Not randomised
Bakx 1997 Multifactorial intervention
Barnard 2009 Weight reduction encouraged in the conventional diet, but not in the vegan diet arm
Barndt 1977 No appropriate control group (and not low fat vs modified fat)
Baron 1990 Multifactorial intervention
Barr 1990 Intervention and randomised follow up less than 6 months
Baumann 1982 Intervention and randomised follow up less than 6 months
Beckmann 1988 Not randomised
Beckmann 1995 Intervention is not dietary fat modification or low fat diet
Beresford 1992 Intervention and randomised follow up less than 6 months
Bergstrom 1967 Intervention and randomised follow up less than 6 months
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(Continued)
Bierenbaum 1963 No appropriate control group (and not low fat vs modified fat)
Bloemberg 1991 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Bloomgarden 1987 Multifactorial intervention
Bonnema 1995 No appropriate control group (and not low fat vs modified fat)
Bosaeus 1992 Intervention and randomised follow up less than 6 months
Boyar 1988 Not randomised
Brensike 1982 No appropriate control group (and not low fat vs modified fat)
Broekmans 2003 Intervention is not dietary fat modification or low fat diet
Brown 1984 No appropriate control group (and not low fat vs modified fat)
Bruce 1994 No appropriate control group (and not low fat vs modified fat)
Bruno 1983 Multifactorial intervention
Butcher 1990 Intervention and randomised follow up less than 6 months
Butowski 1998 Not randomised
Byers 1995 No appropriate control group (and not low fat vs modified fat)
Caggiula 1996 No appropriate control group (and not low fat vs modified fat)
Cerin 1993 Intervention and randomised follow up less than 6 months
Chan 1993 Intervention and randomised follow up less than 6 months
Chapman 1950 Intervention and randomised follow up less than 6 months
Charbonnier 1975 Intervention and randomised follow up less than 6 months
Cheng 2004 Intervention and randomised follow up less than 6 months
Chicago CPEP 1977 Not randomised
Chiostri 1988 Intervention and randomised follow up less than 6 months
Choudhury 1984 Intervention and randomised follow up less than 6 months
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Clark 1997 Multifactorial intervention
Clifton 1992 Intervention and randomised follow up less than 6 months
Cobb 1991 Intervention and randomised follow up less than 6 months
Cohen 1991 Intervention is not dietary fat modification or low fat diet
Cole 1988 Intervention and randomised follow up less than 6 months
Colquhoun 1990 Intervention and randomised follow up less than 6 months
Consolazio 1946 Intervention and randomised follow up less than 6 months
Cox 1996 Multifactorial intervention
Croft 1986 Intervention is not dietary fat modification or low fat diet
Crouch 1986 Not randomised
Da Qing IGT 1997 Intervention is not dietary fat modification or low fat diet
Dalgard 2001 No appropriate control group (and not low fat vs modified fat)
DAS 2000 No appropriate control group (and not low fat vs modified fat)
DASH 1997 Intervention and randomised follow up less than 6 months
Davey Smith 2005 Multifactorial intervention
de Boer 1983 Intervention and randomised follow up less than 6 months
de Bont 1981 Neither mortality nor cardiovascular morbidity data available as study data have been lost
DeBusk 1994 Multifactorial intervention
Delahanty 2001 No appropriate control group (and not low fat vs modified fat)
Delius 1969 Intervention is not dietary fat modification or low fat diet
Demark 1990 Intervention and randomised follow up less than 6 months
Dengel 1995 No appropriate control group (and not low fat vs modified fat)
Denke 1994 Intervention and randomised follow up less than 6 months
Diabetes CCT 1995 Intervention is not dietary fat modification or low fat diet
155Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
DIET 1998 Multifactorial intervention
Ding 1992 Intervention and randomised follow up less than 6 months
Dobs 1991 No appropriate control group (and not low fat vs modified fat)
Duffield 1982 Multifactorial intervention
Dullaart 1997 Not randomised
Eating Patterns 1997 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Ehnholm 1982 Intervention and randomised follow up less than 6 months
Ehnholm 1984 Intervention and randomised follow up less than 6 months
Eisenberg 1990 Intervention and randomised follow up less than 6 months
Elder 2000 No appropriate control group (and not low fat vs modified fat)
Ellegard 1991 Intervention and randomised follow up less than 6 months
Esposito 2003 No appropriate control group (and not low fat vs modified fat)
EUROACTION 2008 Multifactorial intervention
FARIS 1997 Multifactorial intervention
Fasting HGS 1997 No appropriate control group (and not low fat vs modified fat)
Ferrara 2000 No appropriate control group (and not low fat vs modified fat)
Fielding 1995 Intervention and randomised follow up less than 6 months
Finckenor 2000 Not randomised
Finnish Diabet Prev 2000 Multifactorial intervention
Finnish Mental Hosp 1972 Not randomised (cluster randomised, but <6 clusters)
Fisher 1981 Intervention and randomised follow up less than 6 months
Fleming 2002 No appropriate control group (and not low fat vs modified fat)
Fortmann 1988 Intervention is not dietary fat modification or low fat diet
Foster 2003 Weight reduction in one arm but not the other
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FRESH START 2007 Participants were newly diagnosed with cancer
Gambera 1995 Intervention and randomised follow up less than 6 months
Gaullier 2007 No appropriate control group (and not low fat vs modified fat)
Ginsberg 1988 Intervention and randomised follow up less than 6 months
Gjone 1972 Intervention and randomised follow up less than 6 months
Glatzel 1966 No appropriate control group (and not low fat vs modified fat)
Goodpaster 1999 No appropriate control group (and not low fat vs modified fat)
Grundy 1986 Intervention and randomised follow up less than 6 months
Hardcastle 2008 Multifactorial intervention
Harris 1990 Intervention and randomised follow up less than 6 months
Hartman 1993 No appropriate control group (and not low fat vs modified fat)
Hartwell 1986 No appropriate control group (and not low fat vs modified fat)
Hashim 1960 Intervention and randomised follow up less than 6 months
Haynes 1984 Intervention is not dietary fat modification or low fat diet
Heber 1991 Intervention and randomised follow up less than 6 months
Heine 1989 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Hellenius Diet & Ex 95 The study aimed for weight loss in one arm and not in the comparison arm
Hellenius Diet 1995 The study aimed for weight loss in one arm and not in the comparison arm
Heller 1993 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Hildreth 1951 No appropriate control group (and not low fat vs modified fat)
Holm 1990 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Hood 1965 Not randomised
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Horlick 1957 Intervention and randomised follow up less than 6 months
Horlick 1960 Intervention and randomised follow up less than 6 months
Howard 1977 Intervention and randomised follow up less than 6 months
Hunninghake 1990 Intervention and randomised follow up less than 6 months
Hutchison 1983 No appropriate control group (and not low fat vs modified fat)
Hyman 1998 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Iacono 1981 Not randomised, Intervention and randomised follow up less than 6 months
IMPACT 1995 Multifactorial intervention
Ishikawa 1995 Not randomised
Iso 1991 No appropriate control group (and not low fat vs modified fat)
Ives 1993 Multifactorial intervention
Jalkanen 1991 Multifactorial intervention
Jepson 1969 Not randomised
Jerusalem Nut 1992 Intervention and randomised follow up less than 6 months
Jula 1990 Multifactorial intervention
Junker 2001 Intervention and randomised follow up less than 6 months
Karmally 1990 Intervention and randomised follow up less than 6 months
Karvetti 1992 Multifactorial intervention
Kastarinen 2002 Multifactorial intervention
Kather 1985 Intervention and randomised follow up less than 6 months
Katzel 1995a Not randomised
Katzel 1995b Intervention is not dietary fat modification or low fat diet
Kawamura 1993 Intervention and randomised follow up less than 6 months
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Keidar 1988 Intervention and randomised follow up less than 6 months
Kempner 1948 No appropriate control group (and not low fat vs modified fat)
Keys 1952 Not randomised
Keys 1957a Intervention and randomised follow up less than 6 months
Keys 1957b Intervention and randomised follow up less than 6 months
Keys 1957c Intervention and randomised follow up less than 6 months
Khan 2003 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
King 2000 Intervention and randomised follow up less than 6 months
Kingsbury 1961 Intervention and randomised follow up less than 6 months
Kohler 1986 Not randomised
Koopman 1990 Intervention and randomised follow up less than 6 months
Korhonen 2003 Multifactorial intervention
Kriketos 2001 Intervention and randomised follow up less than 6 months
Kris 1994 Intervention and randomised follow up less than 6 months
Kristal 1997 Multifactorial intervention
Kromhout 1987 No appropriate control group (and not low fat vs modified fat)
Kummel 2008 Intervention is not dietary fat modification or low fat diet
Laitinen 1993 Multifactorial intervention
Laitinen 1994 Multifactorial intervention
Leduc 1994 Multifactorial intervention
Lewis 1958 Intervention and randomised follow up less than 6 months
Lewis 1981 Intervention and randomised follow up less than 6 months
Lewis 1985 Multifactorial intervention
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Lichtenstein 2002 Intervention and randomised follow up less than 6 months
Linko 1957 Intervention and randomised follow up less than 6 months
Lipid Res Clinic 1984 No appropriate control group (and not low fat vs modified fat)
Little 1990 Intervention and randomised follow up less than 6 months
Little 1991 Not randomised
Little 2004 Intervention is not dietary fat modification or low fat diet
Lottenberg 1996 Intervention and randomised follow up less than 6 months
Luszczynska 2007 No appropriate control group (and not low fat vs modified fat)
Lyon Diet Heart 1994 Intervention is not dietary fat modification or low fat diet
Lysikova 2003 Intervention and randomised follow up less than 6 months
Macdonald 1972 Intervention and randomised follow up less than 6 months
Mansel 1990 Intervention is not dietary fat modification or low fat diet
Marckmann 1993 Not randomised
MARGARIN 2002 No appropriate control group (and not low fat vs modified fat)
Marniemi 1990 Both intervention groups aimed to lose weight, while the control group did not.
Mattson 1985 Intervention and randomised follow up less than 6 months
McCarron 1997 Intervention and randomised follow up less than 6 months
McCarron 2001 Intervention is not dietary fat modification or low fat diet
McManus 2001 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
McNamara 1981 Intervention and randomised follow up less than 6 months
Medi-RIVAGE 2004 Weight reduction for some low fat diet participants (those with BMI >25) but not in Mediterranean
group
Mensink 1987 Intervention and randomised follow up less than 6 months
Mensink 1989 Intervention and randomised follow up less than 6 months
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Mensink 1990a Intervention and randomised follow up less than 6 months
Mensink 1990b Intervention and randomised follow up less than 6 months
Michalsen 2006 Diet plus stress management vs no intervention
Miettinen 1994 Intervention and randomised follow up less than 6 months
Millar 1973 No appropriate control group (and not low fat vs modified fat)
Miller 1998 Intervention and randomised follow up less than 6 months
Miller 2001 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Milne 1994 No appropriate control group (and not low fat vs modified fat) - the high CHO diet is neither ’usual’
or ’low fat’ to compare with the modified fat diet
Minnesota HHP 1990 No appropriate control group (and not low fat vs modified fat)
Mokuno 1988 Intervention and randomised follow up less than 6 months
Moreno 1994 Not randomised
Morrison 1950 Not randomised
Morrison 1951 Not randomised
Morrison 1960 Not randomised
Mortensen 1983 Intervention and randomised follow up less than 6 months
MRFIT substudy 1986 Intervention and randomised follow up less than 6 months
MSDELTA 1995 Intervention and randomised follow up less than 6 months
Mujeres Felices 2003 Diet and breast self examination vs no intervention
Mutanen 1997 Intervention and randomised follow up less than 6 months
Muzio 2007 Intervention and randomised follow up less than 6 months
NAS 1987 Intervention and randomised follow up less than 6 months
NCEP weight 1991 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
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Neil 1995 No appropriate control group (and not low fat vs modified fat)
Neverov 1997 Multifactorial intervention
Next Step 1995 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Nordoy 1971 Intervention and randomised follow up less than 6 months
Norway Veg Oil 1968 No appropriate control group (and not low fat vs modified fat)
O’Brien 1976 Intervention and randomised follow up less than 6 months
ODES 2006 The study aimed for weight loss in one arm and not in the other arm
Oldroyd 2001 Multifactorial intervention
ORIGIN 2008 Intervention is not dietary fat modification or low fat diet
Oslo Study 2004 Multifactorial intervention
Pascale 1995 Multifactorial intervention
PEP 2001 Multifactorial intervention
PHYLLIS 1993 No appropriate control group (and not low fat vs modified fat)
Pilkington 1960 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Pritchard 2002 The study aimed for weight loss in one arm and not in the comparison arm
Puget Sound EP 2000 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Rabast 1979 Intervention and randomised follow up less than 6 months
Rabkin 1981 Intervention and randomised follow up less than 6 months
Radack 1990 Intervention and randomised follow up less than 6 months
Rasmussen 1995 Intervention and randomised follow up less than 6 months
Reaven 2001 Intervention and randomised follow up less than 6 months
Reid 2002 No appropriate control group (and not low fat vs modified fat)
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Renaud 1986 Not randomised
Rivellese 2003 Intervention and randomised follow up less than 6 months
Roderick 1997 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Roman CHD prev 1986 Multifactorial intervention
Rose 1987 No appropriate control group (and not low fat vs modified fat)
Sandstrom 1992 Not randomised
Sasaki 2000 Not randomised
Schaefer 1995a Intervention and randomised follow up less than 6 months
Schaefer 1995b Intervention and randomised follow up less than 6 months
Schectman 1996 Multifactorial intervention
Schlierf 1995 Multifactorial intervention
Seppanen-Laakso 1992 Intervention and randomised follow up less than 6 months
Singh 1990 Not randomised
Singh 1991 Multifactorial intervention
Singh 1992 No appropriate control group (and not low fat vs modified fat)
Sirtori 1992 Intervention and randomised follow up less than 6 months
SLIM 2008 Multifactorial intervention
Sopotsinskaia 1992 The study aimed for weight loss in one arm and not in the comparison arm
Staff HHP 1994 Not randomised
Stanford NAP 1997 Intervention and randomised follow up less than 6 months
Stanford Weight 1994 The study aimed for weight loss in one arm and not in the comparison arm
Starmans 1995 Intervention and randomised follow up less than 6 months
Steinbach 1996 Multifactorial intervention
Steptoe 2001 No appropriate control group (and not low fat vs modified fat)
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Stevens 2002 Diet plus breast self-examination vs no intervention
Stevenson 1988 No appropriate control group (and not low fat vs modified fat)
Sweeney 2004 Intervention is not dietary fat modification or low fat diet
TAIM 1992 Intervention is not dietary fat modification or low fat diet
Take Heart II 1997 Not randomised
Taylor 1991 Not randomised
TOHP I 1992 Multifactorial intervention
TONE 1997 Intervention is not dietary fat modification or low fat diet
Toobert 2003 Multifactorial intervention
Towle 1994 Intervention and randomised follow up less than 6 months
TRANSFACT 2006 Intervention and randomised follow up less than 6 months
Treatwell 1992 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Tromso Heart 1989 Multifactorial intervention
Turpeinen 1960 Not randomised
UK PDS 1996 No appropriate control group (and not low fat vs modified fat)
Urbach 1952 No appropriate control group (and not low fat vs modified fat)
Uusitupa 1993 Multifactorial intervention
Vavrikova 1958 Intervention and randomised follow up less than 6 months
Wass 1981 Intervention and randomised follow up less than 6 months
Wassertheil 1985 Intervention is not dietary fat modification or low fat diet
WATCH 1999 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Watts 1988 Intervention and randomised follow up less than 6 months
Weintraub 1992 No appropriate control group (and not low fat vs modified fat)
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Westman 2006 Intervention is not dietary fat modification or low fat diet
Weststrate 1998 Intervention and randomised follow up less than 6 months
WHO primary prev 1979 Multifactorial intervention
WHT 1990 Neither mortality nor cardiovascular morbidity data available as such data were not collected in the
study
WHT Feasibility 2003 Neither mortality nor cardiovascular morbidity data available (only decided after contact with at least
one author)
Wilke 1974 Intervention and randomised follow up less than 6 months
Williams 1990 Intervention is not dietary fat modification or low fat diet
Williams 1992 Intervention is not dietary fat modification or low fat diet
Williams 1994 Intervention is not dietary fat modification or low fat diet
Wilmot 1952 No appropriate control group (and not low fat vs modified fat)
Wing 1998 No appropriate control group (and not low fat vs modified fat)
WOMAN 2007 Lifestyle intervention includes exercise and weight as well as diet
Wood 1988 Intervention is not dietary fat modification or low fat diet
Woollard 2003 Multifactorial intervention including smoking, weight, exercise and alcohol components
Working Well 1996 Multifactorial intervention
Zock 1995 Intervention and randomised follow up less than 6 months
The figure in brackets following the Study ID of each reference is a code for “reason for exclusion”. The code is given in full in
“Description of Studies section of the text.
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Characteristics of studies awaiting assessment [ordered by study ID]
Barsotti 1991
Methods RCT
Participants 356 people with hyperlipidaemia
Interventions Allocated to bezafibrate, not bezafibrate, simvastatin or low fat low cholesterol diet for 4 years
Outcomes Plaque progression
Notes Complex paper in Italian, unclear whether cardiovascular events occurred
Bonk 1975
Methods Trial, unclear if randomised
Participants 300 people who have had a myocardial infarction (Germany)
Interventions Intensive change of nutrition vs. usual diet (both with comprehensive medical care)
Outcomes Return to work
Notes No answer to requests to clarify the way that participants were allocated to intervention or control
Brehm 2009
Methods RCT
Participants 124 overweight or obese people with type 2 diabetes
Interventions Low fat vs modified fat diet
Outcomes Weight and glycaemic control
Notes LH has recently contacted the authors about whether any deaths or CV events occurred
Canadian DBCP 1997
Methods RCT
Participants 4690 women with mammographic densities >50% breast area (Canada)
Interventions Control: self-selected diet (no advice) vs intervention: total fat 15%E, protein 20%E, CHO 65%E, followed up for
10 years
style: diet advice
Outcomes Stated trial outcomes: incidence of breast cancer
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Canadian DBCP 1997 (Continued)
Notes No answer to requests for data on deaths or health events
DEER 1998
Methods RCT
Participants 180 Postmenopausal women and 197 men with low HDL and raised LDL
Interventions NCEP step 2 diet vs aerobic exercise vs diet and exercise vs no intervention, all for 1 year
Outcomes lipids and diet
Notes No answer to requests for data on deaths or health events
Diet & Hormone Study 2003
Methods RCT
Participants 213 healthy women aged 20-40 years (USA)
Interventions Low fat, high fruit, vegetable and fibre diet vs usual diet, for 1 year
Outcomes Hormone levels
Notes No answer to requests for data on deaths or health events
DIRECT 2009
Methods RCT
Participants 322 moderately obese people
Interventions Low fat restricted-calorie diet vs modified fat restricted-calorie diet, for 24 months
Outcomes Weight and safety
Notes LH has recently contacted the authors about whether any deaths or CV events occurred
Esposito 2004
Methods RCT
Participants 180 men and women with metabolic syndrome (Italy)
Interventions Mediterranean style diet vs low fat diet, for 2 years
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Esposito 2004 (Continued)
Outcomes Remaining metabolic syndrome, inflammatory markers
Notes No answer to requests for data on deaths or health events
Koranyi 1963
Methods Intervention study, unclear if randomised
Participants Nearly 250 people with severe coronary stenosis (mostly post MI) acrued since 1957 (Hungary)
Interventions Low fat diet (35-40g fat/d) vs Modified fat (50g edible oil but no butter, lard etc/d) vs Modified fat 2 (50g fat/d
made up of both edible oil and butter, lard etc) vs control (no intervention)





Participants 403 middle class urban households (Pakistan)
Interventions Counselling on changing cooking fats and reducing salt vs. usual diet
Outcomes Dietary intake
Notes No answer to requests for data on deaths or health events
Mojonnier 1980
Methods RCT
Participants 418 people with hypercholesterolaemia (USA)
Interventions Self-teaching vs group-teaching vs individual teaching vs mixed teaching (all teaching eating with reduced and
modified dietary fat) vs usual care, for 9 months
Outcomes Dietary intake and total cholesterol
Notes No answer to requests for data on deaths or health events
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Naglak 2000
Methods RCT
Participants 153 people within 16 primary care practices - cluster randomised by practice (USA)
Interventions Home based healthy heart programme vs usual care
Outcomes Dietary intake
Notes Have written to ask whether any deaths or CV events occurred, but no reply
OLIVE 1997
Methods RCT
Participants 180 people with CHD documented by angiography
Interventions Mediterranean diet vs low fat diet, for 2.5 years
Outcomes Angiographic endpoints
Notes No answer to requests for data on deaths or health events
Tapsell 2004
Methods RCT
Participants 86 people with type II diabetes (Australia)
Interventions Low fat diet vs modified fat diet, for 1 year
Outcomes Uptake of advice
Notes No answer to questions about whether any deaths or CV events occurred.
Verheiden 2003
Methods RCT
Participants 143 patients at risk of CVD in Dutch general practices (Netherlands)
Interventions 9 family practices were randomised to dietary advice according to stages of change vs. usual care for 12 months
Outcomes Fat intake and lipids
Notes No answer to requests for data on deaths or health events
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Characteristics of ongoing studies [ordered by study ID]
PREDIMED 2008
Trial name or title PREDIMED
Methods RCT
Participants 372 people at high cardiovascular risk
Interventions Low fat diet vs. modified fat diets (2), for 4 years
Outcomes Various CVD risk factors
Starting date 2003
Contact information Professor Ramon Estruch, Department of Internal Medicine, University of Barcelona
Notes Authors replied that mortality and morbidity data will not be analysed until 2011
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D A T A A N D A N A L Y S E S
Comparison 1. fat modification or reduction vs usual diet - primary outcomes




participants Statistical method Effect size
1 Total mortality 21 71790 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.93, 1.04]
1.1 Modified fat intake 8 11441 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.88, 1.18]
1.2 Reduced fat intake 10 58130 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.04]
1.3 Reduced and modified fat
intake
3 2219 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.76, 1.23]
2 Cardiovascular mortality 16 65978 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.85, 1.04]
2.1 Modified fat intake 6 10788 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.15]
2.2 Reduced fat intake 7 52971 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.82, 1.13]
2.3 Reduced and modified fat
intake
3 2219 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.76, 1.27]
3 Combined cardiovascular events 23 65508 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.77, 0.96]
3.1 Modified fat intake 9 11660 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.66, 1.02]
3.2 Reduced fat intake 8 50655 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.87, 1.08]
3.3 Reduced and modified fat
intake
6 3193 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.57, 1.03]
Comparison 2. fat modification or reduction vs usual diet - secondary outcomes




participants Statistical method Effect size
1 Myocardial infarctions 19 64891 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.02]
1.1 Modified fat intake 9 11831 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.72, 1.16]
1.2 Reduced fat intake 6 50522 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.08]
1.3 Reduced and modified fat
intake
4 2538 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.11]
2 Stroke 11 59853 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.11]
2.1 Modified fat intake 4 10315 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.36, 1.34]
2.2 Reduced fat intake 4 49246 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.90, 1.13]
2.3 Reduced and modified fat
intake
3 292 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.08, 2.04]
3 Cancer deaths 10 64759 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.91, 1.06]
3.1 Modified fat intake 3 9903 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.96, 2.21]
3.2 Reduced fat intake 5 52692 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
3.3 Reduced and modified fat
intake
2 2164 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.25, 2.61]
4 Cancer diagnoses 12 58847 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.91, 1.01]
4.1 Modified fat intake 2 1535 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.85, 1.60]
4.2 Reduced fat intake 8 57075 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.02]
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4.3 Reduced and modified
intake
2 237 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.06, 9.03]
5 Diabetes diagnoses 3 49859 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.02]
5.1 Modified fat intake 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Reduced fat intake 3 49859 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.90, 1.02]
5.3 Reduced and modified
intake
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Non-fatal MI 13 54883 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.81, 1.12]
6.1 Modified fat intake 6 2672 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.64, 1.16]
6.2 Reduced fat intake 5 49859 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.80, 1.40]
6.3 Reduced and modified
intake
2 2352 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.47, 1.10]
Comparison 3. fat modification or reduction vs usual diet - tertiary outcomes




participants Statistical method Effect size
1 Weight, kg 18 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Modified fat intake 2 99 Mean Difference (IV, Random, 95% CI) -1.10 [-3.14, 0.93]
1.2 Reduced fat intake 16 11058 Mean Difference (IV, Random, 95% CI) -0.83 [-1.37, -0.30]
1.3 Reduced and modified fat
intake
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 BMI, kg/m2 14 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Modified fat intake 2 116 Mean Difference (IV, Random, 95% CI) -0.34 [-0.99, 0.31]
2.2 Reduced fat intake 10 5972 Mean Difference (IV, Random, 95% CI) -0.47 [-0.72, -0.23]
2.3 Reduced and modified fat
intake
2 111 Mean Difference (IV, Random, 95% CI) -0.20 [-1.30, 0.91]
3 LDL cholesterol, mmol/L 20 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Modified fat intake 2 116 Mean Difference (IV, Random, 95% CI) -0.20 [-0.47, 0.07]
3.2 Reduced fat intake 14 6971 Mean Difference (IV, Random, 95% CI) -0.10 [-0.14, -0.05]
3.3 Reduced and modified fat
intake
4 627 Mean Difference (IV, Random, 95% CI) -0.21 [-0.35, -0.08]
4 HDL cholesterol, mmol/Lkg 22 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Modified fat intake 3 152 Mean Difference (IV, Random, 95% CI) -0.04 [-0.18, 0.09]
4.2 Reduced fat intake 15 7082 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
4.3 Reduced and modified fat
intake
4 2073 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.01]
5 Total cholesterol, mmol/L 28 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Modified fat intake 8 2280 Mean Difference (IV, Random, 95% CI) -0.44 [-0.60, -0.28]
5.2 Reduced fat intake 15 7602 Mean Difference (IV, Random, 95% CI) -0.10 [-0.14, -0.05]
5.3 Reduced and modified fat
intake
5 2131 Mean Difference (IV, Random, 95% CI) -0.26 [-0.47, -0.04]
6 Triglycerides, mmol/L 21 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Modified fat intake 5 706 Mean Difference (IV, Random, 95% CI) -0.11 [-0.22, -0.00]
6.2 Reduced fat intake 13 6875 Mean Difference (IV, Random, 95% CI) -5.09 [-3.25, 3.24]
6.3 Reduced and modified fat
intake
3 218 Mean Difference (IV, Random, 95% CI) -0.27 [-0.53, -0.00]
7 Systolic Blood Pressure, mmHg 7 4059 Mean Difference (IV, Random, 95% CI) -0.67 [-1.61, 0.28]
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7.1 Modified fat intake 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Reduced fat intake 6 3981 Mean Difference (IV, Random, 95% CI) -0.56 [-1.52, 0.40]
7.3 Reduced and modified fat
intake
1 78 Mean Difference (IV, Random, 95% CI) -5.08 [-11.22, 1.06]
8 Diastolic Blood Pressure, mmHg 7 3621 Mean Difference (IV, Random, 95% CI) -0.40 [1.00, 0.20]
8.1 Modified fat intake 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Reduced fat intake 6 3543 Mean Difference (IV, Random, 95% CI) -0.35 [-0.96, 0.26]
8.3 Reduced and modified fat
intake
1 78 Mean Difference (IV, Random, 95% CI) -2.31 [-6.20, 1.58]
Comparison 4. fat reduction vs fat modification - primary outcomes




participants Statistical method Effect size
1 Total mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Cardiovascular mortality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Combined cardiovascular events 3 912 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.41, 3.06]
Comparison 5. fat reduction vs fat modification - secondary outcomes




participants Statistical method Effect size
1 Myocardial infarction 1 101 Risk Ratio (M-H, Random, 95% CI) 3.06 [0.33, 28.44]
2 Stroke 1 101 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.04, 3.16]
3 Cancer deaths 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Cancer diagnoses 2 811 Risk Ratio (M-H, Random, 95% CI) 2.07 [0.27, 15.98]
5 Diabetes diagnoses 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Non-fatal MI 1 101 Risk Ratio (M-H, Random, 95% CI) 3.06 [0.33, 28.44]
Comparison 6. fat reduction vs fat modification - tertiary outcomes




participants Statistical method Effect size
1 Weight, kg 6 1057 Mean Difference (IV, Random, 95% CI) -0.25 [-1.88, 1.39]
2 BMI, kg/m2 5 345 Mean Difference (IV, Random, 95% CI) 0.06 [-0.79, 0.92]
3 LDL cholesterol, mmol/L 9 1275 Mean Difference (IV, Random, 95% CI) -0.01 [-0.13, 0.12]
4 HDL cholesterol, mmol/Lkg 9 1275 Mean Difference (IV, Random, 95% CI) -0.02 [-0.06, 0.02]
5 Total cholesterol, mmol/L 7 1130 Mean Difference (IV, Random, 95% CI) -0.04 [-0.18, 0.09]
6 Triglycerides, mmol/L 9 1275 Mean Difference (IV, Random, 95% CI) 0.05 [-0.02, 0.12]
7 Systolic Blood Pressure, mmHg 6 1068 Mean Difference (IV, Random, 95% CI) -0.13 [-2.16, 1.90]
8 Diastolic Blood Pressure, mmHg 6 1068 Mean Difference (IV, Random, 95% CI) -0.23 [-1.90, 1.43]
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9 Dropouts 9 1353 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.58, 1.22]
Analysis 1.1. Comparison 1 fat modification or reduction vs usual diet - primary outcomes, Outcome 1
Total mortality.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 1 fat modification or reduction vs usual diet - primary outcomes
Outcome: 1 Total mortality
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Veterans Admin 1969 174/424 177/422 12.7 % 0.98 [ 0.83, 1.15 ]
Rose 1965 8/54 1/26 0.1 % 3.85 [ 0.51, 29.20 ]
Oslo Diet-Heart 1966 48/206 65/206 3.2 % 0.74 [ 0.54, 1.02 ]
MRC 1968 28/199 31/194 1.5 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/143 0/52 0.0 % 3.31 [ 0.18, 60.49 ]
Minnesota Coron men 1989 158/2197 153/2196 7.1 % 1.03 [ 0.83, 1.28 ]
Minnesota Coron women1989 111/2344 95/2320 4.5 % 1.16 [ 0.88, 1.51 ]
Sydney Diet-Heart 1978 39/221 28/237 1.6 % 1.49 [ 0.95, 2.34 ]
Subtotal (95% CI) 5788 5653 30.8 % 1.02 [ 0.88, 1.18 ]
Total events: 570 (reduced or modified fat), 550 (usual diet)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.53, df = 7 (P = 0.16); I2 =34%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Reduced fat intake
Ball 1965 20/123 24/129 1.1 % 0.87 [ 0.51, 1.50 ]
WINS 2006 15/975 19/1462 0.7 % 1.18 [ 0.60, 2.32 ]
Black 1994 1/66 2/67 0.1 % 0.51 [ 0.05, 5.46 ]
Polyp Prevention 1996 42/1037 46/1042 1.9 % 0.92 [ 0.61, 1.38 ]
Ley 2004 2/88 6/88 0.1 % 0.33 [ 0.07, 1.61 ]
BRIDGES 2001 0/50 1/56 0.0 % 0.37 [ 0.02, 8.94 ]
PREMIER 2003 0/269 1/268 0.0 % 0.33 [ 0.01, 8.12 ]
DO IT 2006 17/246 21/241 0.9 % 0.79 [ 0.43, 1.47 ]
WHI without CVD 2006 950/19541 1454/29294 51.3 % 0.98 [ 0.90, 1.06 ]
WHEL 2007 155/1537 160/1551 7.4 % 0.98 [ 0.79, 1.21 ]
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Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Subtotal (95% CI) 23932 34198 63.6 % 0.97 [ 0.90, 1.04 ]
Total events: 1202 (reduced or modified fat), 1734 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.86, df = 9 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
3 Reduced and modified fat intake
DART 1989 111/1018 113/1015 5.3 % 0.98 [ 0.76, 1.25 ]
STARS 1992 1/27 3/28 0.1 % 0.35 [ 0.04, 3.12 ]
Sondergaard 2003 4/68 4/63 0.2 % 0.93 [ 0.24, 3.55 ]
Subtotal (95% CI) 1113 1106 5.6 % 0.97 [ 0.76, 1.23 ]
Total events: 116 (reduced or modified fat), 120 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.78)
Total (95% CI) 30833 40957 100.0 % 0.98 [ 0.93, 1.04 ]
Total events: 1888 (reduced or modified fat), 2404 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 15.52, df = 20 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 1.2. Comparison 1 fat modification or reduction vs usual diet - primary outcomes, Outcome 2
Cardiovascular mortality.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 1 fat modification or reduction vs usual diet - primary outcomes
Outcome: 2 Cardiovascular mortality
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Veterans Admin 1969 57/424 81/422 10.8 % 0.70 [ 0.51, 0.96 ]
Rose 1965 8/54 1/26 0.3 % 3.85 [ 0.51, 29.20 ]
Oslo Diet-Heart 1966 38/206 52/206 7.6 % 0.73 [ 0.50, 1.06 ]
MRC 1968 27/199 25/194 4.1 % 1.05 [ 0.63, 1.75 ]
Minnesota Coron men 1989 92/2197 94/2196 13.2 % 0.98 [ 0.74, 1.30 ]
Minnesota Coron women1989 65/2344 53/2320 8.1 % 1.21 [ 0.85, 1.74 ]
Subtotal (95% CI) 5424 5364 44.0 % 0.92 [ 0.73, 1.15 ]
Total events: 287 (reduced or modified fat), 306 (usual diet)
Heterogeneity: Tau2 = 0.03; Chi2 = 9.13, df = 5 (P = 0.10); I2 =45%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Reduced fat intake
Ball 1965 17/123 20/129 2.9 % 0.89 [ 0.49, 1.62 ]
Black 1994 0/66 2/67 0.1 % 0.20 [ 0.01, 4.15 ]
Ley 2004 1/88 4/88 0.2 % 0.25 [ 0.03, 2.19 ]
DO IT 2006 8/246 10/241 1.3 % 0.78 [ 0.31, 1.95 ]
WHI without CVD 2006 170/18633 258/27925 28.1 % 0.99 [ 0.81, 1.20 ]
WHI with CVD 2006 43/908 62/1369 7.2 % 1.05 [ 0.72, 1.53 ]
WHEL 2007 2/1537 5/1551 0.4 % 0.40 [ 0.08, 2.08 ]
Subtotal (95% CI) 21601 31370 40.2 % 0.96 [ 0.82, 1.13 ]
Total events: 241 (reduced or modified fat), 361 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.10, df = 6 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
3 Reduced and modified fat intake
DART 1989 101/1018 100/1015 15.1 % 1.01 [ 0.77, 1.31 ]
STARS 1992 1/27 3/28 0.2 % 0.35 [ 0.04, 3.12 ]
Sondergaard 2003 3/68 4/63 0.5 % 0.69 [ 0.16, 2.98 ]
Subtotal (95% CI) 1113 1106 15.8 % 0.98 [ 0.76, 1.27 ]
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Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Total events: 105 (reduced or modified fat), 107 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 28138 37840 100.0 % 0.94 [ 0.85, 1.04 ]
Total events: 633 (reduced or modified fat), 774 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.72, df = 15 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
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Analysis 1.3. Comparison 1 fat modification or reduction vs usual diet - primary outcomes, Outcome 3
Combined cardiovascular events.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 1 fat modification or reduction vs usual diet - primary outcomes
Outcome: 3 Combined cardiovascular events
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Rose 1965 26/54 11/26 3.4 % 1.14 [ 0.67, 1.93 ]
Veterans Admin 1969 97/424 122/422 8.8 % 0.79 [ 0.63, 1.00 ]
Oslo Diet-Heart 1966 64/206 90/206 8.1 % 0.71 [ 0.55, 0.92 ]
NDHS Open 2nd Mod 1968 1/112 2/140 0.2 % 0.63 [ 0.06, 6.80 ]
NDHS Open 1st mod 1968 4/348 1/170 0.3 % 1.95 [ 0.22, 17.35 ]
MRC 1968 62/199 74/194 7.6 % 0.82 [ 0.62, 1.07 ]
Minnesota Coron women1989 67/2344 51/2320 5.7 % 1.30 [ 0.91, 1.86 ]
Minnesota Coron men 1989 67/2197 78/2196 6.5 % 0.86 [ 0.62, 1.18 ]
Houtsmuller 1979 8/51 30/51 2.3 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 5935 5725 42.7 % 0.82 [ 0.66, 1.02 ]
Total events: 396 (reduced or modified fat), 459 (usual diet)
Heterogeneity: Tau2 = 0.06; Chi2 = 20.43, df = 8 (P = 0.01); I2 =61%
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Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Test for overall effect: Z = 1.79 (P = 0.073)
2 Reduced fat intake
Ball 1965 38/123 42/129 5.6 % 0.95 [ 0.66, 1.36 ]
Black 1994 0/66 2/67 0.1 % 0.20 [ 0.01, 4.15 ]
Ley 2004 11/88 16/88 2.1 % 0.69 [ 0.34, 1.40 ]
Moy 2001 5/117 3/118 0.6 % 1.68 [ 0.41, 6.87 ]
PREMIER 2003 0/269 2/268 0.1 % 0.20 [ 0.01, 4.13 ]
DO IT 2006 28/246 40/241 4.3 % 0.69 [ 0.44, 1.07 ]
WHI without CVD 2006 1132/18633 1777/27925 13.2 % 0.95 [ 0.89, 1.03 ]
WHI with CVD 2006 225/908 311/1369 11.2 % 1.09 [ 0.94, 1.27 ]
Subtotal (95% CI) 20450 30205 37.3 % 0.97 [ 0.87, 1.08 ]
Total events: 1439 (reduced or modified fat), 2193 (usual diet)
Heterogeneity: Tau2 = 0.00; Chi2 = 8.44, df = 7 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.60 (P = 0.55)
3 Reduced and modified fat intake
NDHS Open 2nd L%M 1968 0/179 2/140 0.1 % 0.16 [ 0.01, 3.24 ]
NDHS Open 1st L%M 1968 1/378 1/171 0.2 % 0.45 [ 0.03, 7.19 ]
DART 1989 136/1018 147/1015 9.2 % 0.92 [ 0.74, 1.15 ]
STARS 1992 8/27 20/28 2.6 % 0.41 [ 0.22, 0.78 ]
Sondergaard 2003 40/68 42/63 7.8 % 0.88 [ 0.68, 1.15 ]
MeDiet 2002 0/51 3/55 0.1 % 0.15 [ 0.01, 2.91 ]
Subtotal (95% CI) 1721 1472 20.0 % 0.77 [ 0.57, 1.03 ]
Total events: 185 (reduced or modified fat), 215 (usual diet)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.36, df = 5 (P = 0.14); I2 =40%
Test for overall effect: Z = 1.77 (P = 0.077)
Total (95% CI) 28106 37402 100.0 % 0.86 [ 0.77, 0.96 ]
Total events: 2020 (reduced or modified fat), 2867 (usual diet)
Heterogeneity: Tau2 = 0.02; Chi2 = 44.30, df = 22 (P = 0.003); I2 =50%
Test for overall effect: Z = 2.71 (P = 0.0068)
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Analysis 2.1. Comparison 2 fat modification or reduction vs usual diet - secondary outcomes, Outcome 1
Myocardial infarctions.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 2 fat modification or reduction vs usual diet - secondary outcomes
Outcome: 1 Myocardial infarctions
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Houtsmuller 1979 0/51 6/51 0.1 % 0.08 [ 0.00, 1.33 ]
Minnesota Coron men 1989 69/2197 74/2196 8.6 % 0.93 [ 0.68, 1.29 ]
Minnesota Coron women1989 62/2344 47/2320 6.5 % 1.31 [ 0.90, 1.90 ]
MRC 1968 39/199 40/194 5.9 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st mod 1968 4/348 1/341 0.2 % 3.92 [ 0.44, 34.89 ]
NDHS Open 2nd Mod 1968 1/112 2/140 0.2 % 0.63 [ 0.06, 6.80 ]
Oslo Diet-Heart 1966 34/206 54/206 6.3 % 0.63 [ 0.43, 0.92 ]
Rose 1965 16/54 5/26 1.2 % 1.54 [ 0.63, 3.75 ]
Veterans Admin 1969 54/424 71/422 8.4 % 0.76 [ 0.55, 1.05 ]
Subtotal (95% CI) 5935 5896 37.4 % 0.91 [ 0.72, 1.16 ]
Total events: 279 (reduced or modified fat), 300 (usual diet)
Heterogeneity: Tau2 = 0.05; Chi2 = 14.42, df = 8 (P = 0.07); I2 =45%
Test for overall effect: Z = 0.73 (P = 0.46)
2 Reduced fat intake
Ball 1965 31/123 34/129 5.3 % 0.96 [ 0.63, 1.45 ]
DO IT 2006 8/246 12/241 1.3 % 0.65 [ 0.27, 1.57 ]
Ley 2004 4/88 3/88 0.5 % 1.33 [ 0.31, 5.78 ]
Moy 2001 2/117 1/118 0.2 % 2.02 [ 0.19, 21.94 ]
PREMIER 2003 0/269 2/268 0.1 % 0.20 [ 0.01, 4.13 ]
WHI without CVD 2006 435/19541 671/29294 38.1 % 0.97 [ 0.86, 1.09 ]
Subtotal (95% CI) 20384 30138 45.4 % 0.97 [ 0.86, 1.08 ]
Total events: 480 (reduced or modified fat), 723 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.37, df = 5 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
3 Reduced and modified fat intake
DART 1989 132/1018 144/1015 16.6 % 0.91 [ 0.73, 1.14 ]
NDHS Open 2nd L%M 1968 0/179 2/140 0.1 % 0.16 [ 0.01, 3.24 ]
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Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Sondergaard 2003 2/68 3/63 0.3 % 0.62 [ 0.11, 3.58 ]
STARS 1992 1/27 2/28 0.2 % 0.52 [ 0.05, 5.39 ]
Subtotal (95% CI) 1292 1246 17.2 % 0.90 [ 0.72, 1.11 ]
Total events: 135 (reduced or modified fat), 151 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 27611 37280 100.0 % 0.93 [ 0.84, 1.02 ]
Total events: 894 (reduced or modified fat), 1174 (usual diet)
Heterogeneity: Tau2 = 0.00; Chi2 = 19.19, df = 18 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 2.2. Comparison 2 fat modification or reduction vs usual diet - secondary outcomes, Outcome 2
Stroke.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 2 fat modification or reduction vs usual diet - secondary outcomes
Outcome: 2 Stroke
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Minnesota Coron men 1989 0/2197 4/2196 0.1 % 0.11 [ 0.01, 2.06 ]
Minnesota Coron women1989 5/2344 4/2320 0.7 % 1.24 [ 0.33, 4.60 ]
Oslo Diet-Heart 1966 2/206 1/206 0.2 % 2.00 [ 0.18, 21.89 ]
Veterans Admin 1969 13/424 22/422 2.7 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 5171 5144 3.8 % 0.70 [ 0.36, 1.34 ]
Total events: 20 (reduced or modified fat), 31 (usual diet)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.26, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Reduced fat intake
Ley 2004 1/88 5/88 0.3 % 0.20 [ 0.02, 1.68 ]
0.005 0.1 1 10 200
Favours altered fat diet Favours control
(Continued . . . )
180Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Moy 2001 1/117 1/118 0.2 % 1.01 [ 0.06, 15.93 ]
WHI with CVD 2006 206/908 308/1369 51.2 % 1.01 [ 0.86, 1.18 ]
WHI without CVD 2006 228/18633 334/27925 44.1 % 1.02 [ 0.87, 1.21 ]
Subtotal (95% CI) 19746 29500 95.7 % 1.01 [ 0.90, 1.13 ]
Total events: 436 (reduced or modified fat), 648 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.25, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
3 Reduced and modified fat intake
MeDiet 2002 0/51 1/55 0.1 % 0.36 [ 0.01, 8.62 ]
Sondergaard 2003 1/68 2/63 0.2 % 0.46 [ 0.04, 4.98 ]
STARS 1992 0/27 1/28 0.1 % 0.35 [ 0.01, 8.12 ]
Subtotal (95% CI) 146 146 0.5 % 0.40 [ 0.08, 2.04 ]
Total events: 1 (reduced or modified fat), 4 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 25063 34790 100.0 % 0.99 [ 0.89, 1.11 ]
Total events: 457 (reduced or modified fat), 683 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.51, df = 10 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
0.005 0.1 1 10 200
Favours altered fat diet Favours control
181Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 fat modification or reduction vs usual diet - secondary outcomes, Outcome 3
Cancer deaths.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 2 fat modification or reduction vs usual diet - secondary outcomes
Outcome: 3 Cancer deaths
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Minnesota Coron men 1989 16/2197 12/2196 1.0 % 1.33 [ 0.63, 2.81 ]
Minnesota Coron women1989 7/2344 8/2320 0.5 % 0.87 [ 0.31, 2.38 ]
Veterans Admin 1969 31/424 17/422 1.6 % 1.81 [ 1.02, 3.23 ]
Subtotal (95% CI) 4965 4938 3.1 % 1.46 [ 0.96, 2.21 ]
Total events: 54 (reduced or modified fat), 37 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
2 Reduced fat intake
BRIDGES 2001 0/50 1/56 0.1 % 0.37 [ 0.02, 8.94 ]
DO IT 2006 9/246 10/241 0.7 % 0.88 [ 0.36, 2.13 ]
Ley 2004 1/88 2/88 0.1 % 0.50 [ 0.05, 5.41 ]
WHEL 2007 139/1537 150/1551 11.1 % 0.94 [ 0.75, 1.16 ]
WHI without CVD 2006 950/19541 1454/29294 84.5 % 0.98 [ 0.90, 1.06 ]
Subtotal (95% CI) 21462 31230 96.5 % 0.97 [ 0.90, 1.05 ]
Total events: 1099 (reduced or modified fat), 1617 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 4 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Reduced and modified fat intake
DART 1989 4/1018 6/1015 0.3 % 0.66 [ 0.19, 2.35 ]
Sondergaard 2003 1/68 0/63 0.1 % 2.78 [ 0.12, 67.08 ]
Subtotal (95% CI) 1086 1078 0.4 % 0.81 [ 0.25, 2.61 ]
Total events: 5 (reduced or modified fat), 6 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 27513 37246 100.0 % 0.98 [ 0.91, 1.06 ]
Total events: 1158 (reduced or modified fat), 1660 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.77, df = 9 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
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Analysis 2.4. Comparison 2 fat modification or reduction vs usual diet - secondary outcomes, Outcome 4
Cancer diagnoses.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 2 fat modification or reduction vs usual diet - secondary outcomes
Outcome: 4 Cancer diagnoses
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
NDHS Open 1st mod 1968 0/348 1/341 0.0 % 0.33 [ 0.01, 7.99 ]
Veterans Admin 1969 70/424 59/422 2.7 % 1.18 [ 0.86, 1.62 ]
Subtotal (95% CI) 772 763 2.8 % 1.17 [ 0.85, 1.60 ]
Total events: 70 (reduced or modified fat), 60 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Reduced fat intake
DO IT 2006 8/246 16/241 0.4 % 0.49 [ 0.21, 1.12 ]
Ley 2004 3/88 3/88 0.1 % 1.00 [ 0.21, 4.82 ]
McKeown-Eyssen 1994 17/78 16/87 0.7 % 1.19 [ 0.64, 2.18 ]
Polyp Prevention 1996 32/689 23/661 1.0 % 1.33 [ 0.79, 2.26 ]
PREMIER 2003 2/269 3/268 0.1 % 0.66 [ 0.11, 3.94 ]
WHEL 2007 256/1537 262/1551 11.0 % 0.99 [ 0.84, 1.15 ]
WHI without CVD 2006 1946/19541 3040/29294 77.1 % 0.96 [ 0.91, 1.01 ]
WINS 2006 124/975 231/1462 6.7 % 0.80 [ 0.66, 0.99 ]
Subtotal (95% CI) 23423 33652 97.2 % 0.95 [ 0.88, 1.02 ]
Total events: 2388 (reduced or modified fat), 3594 (usual diet)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.61, df = 7 (P = 0.37); I2 =8%
Test for overall effect: Z = 1.44 (P = 0.15)
3 Reduced and modified intake
MeDiet 2002 0/51 2/55 0.0 % 0.22 [ 0.01, 4.38 ]
Sondergaard 2003 1/68 0/63 0.0 % 2.78 [ 0.12, 67.08 ]
Subtotal (95% CI) 119 118 0.1 % 0.73 [ 0.06, 9.03 ]
Total events: 1 (reduced or modified fat), 2 (usual diet)
Heterogeneity: Tau2 = 0.78; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 24314 34533 100.0 % 0.96 [ 0.91, 1.01 ]
Total events: 2459 (reduced or modified fat), 3656 (usual diet)
Heterogeneity: Tau2 = 0.00; Chi2 = 11.10, df = 11 (P = 0.43); I2 =1%
Test for overall effect: Z = 1.59 (P = 0.11)
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Analysis 2.5. Comparison 2 fat modification or reduction vs usual diet - secondary outcomes, Outcome 5
Diabetes diagnoses.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 2 fat modification or reduction vs usual diet - secondary outcomes
Outcome: 5 Diabetes diagnoses
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (reduced or modified fat), 0 (usual diet)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Reduced fat intake
DO IT 2006 10/246 10/241 0.6 % 0.98 [ 0.42, 2.31 ]
PREMIER 2003 2/269 3/268 0.1 % 0.66 [ 0.11, 3.94 ]
WHI without CVD 2006 1303/19541 2039/29294 99.3 % 0.96 [ 0.90, 1.02 ]
Subtotal (95% CI) 20056 29803 100.0 % 0.96 [ 0.90, 1.02 ]
Total events: 1315 (reduced or modified fat), 2052 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
3 Reduced and modified intake
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (reduced or modified fat), 0 (usual diet)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 20056 29803 100.0 % 0.96 [ 0.90, 1.02 ]
Total events: 1315 (reduced or modified fat), 2052 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 2.6. Comparison 2 fat modification or reduction vs usual diet - secondary outcomes, Outcome 6
Non-fatal MI.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 2 fat modification or reduction vs usual diet - secondary outcomes
Outcome: 6 Non-fatal MI
Study or subgroup reduced or modified fat usual diet Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Modified fat intake
MRC 1968 25/199 25/194 8.3 % 0.97 [ 0.58, 1.64 ]
NDHS Open 1st mod 1968 4/348 1/341 0.6 % 3.92 [ 0.44, 34.89 ]
NDHS Open 2nd Mod 1968 1/112 2/140 0.5 % 0.63 [ 0.06, 6.80 ]
Oslo Diet-Heart 1966 24/206 31/206 8.8 % 0.77 [ 0.47, 1.27 ]
Rose 1965 13/54 5/26 3.0 % 1.25 [ 0.50, 3.14 ]
Veterans Admin 1969 13/424 21/422 5.2 % 0.62 [ 0.31, 1.21 ]
Subtotal (95% CI) 1343 1329 26.3 % 0.86 [ 0.64, 1.16 ]
Total events: 80 (reduced or modified fat), 85 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.88, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
2 Reduced fat intake
Ball 1965 21/123 22/129 7.6 % 1.00 [ 0.58, 1.73 ]
Moy 2001 2/117 1/118 0.5 % 2.02 [ 0.19, 21.94 ]
PREMIER 2003 0/269 2/268 0.3 % 0.20 [ 0.01, 4.13 ]
WHI with CVD 2006 82/908 90/1369 19.0 % 1.37 [ 1.03, 1.83 ]
WHI without CVD 2006 353/18633 581/27925 35.0 % 0.91 [ 0.80, 1.04 ]
Subtotal (95% CI) 20050 29809 62.3 % 1.06 [ 0.80, 1.40 ]
Total events: 458 (reduced or modified fat), 696 (usual diet)
Heterogeneity: Tau2 = 0.04; Chi2 = 7.95, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 0.41 (P = 0.68)
3 Reduced and modified intake
DART 1989 35/1018 47/1015 11.1 % 0.74 [ 0.48, 1.14 ]
NDHS Open 2nd L%M 1968 0/179 2/140 0.3 % 0.16 [ 0.01, 3.24 ]
Subtotal (95% CI) 1197 1155 11.4 % 0.72 [ 0.47, 1.10 ]
Total events: 35 (reduced or modified fat), 49 (usual diet)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 22590 32293 100.0 % 0.95 [ 0.81, 1.12 ]
Total events: 573 (reduced or modified fat), 830 (usual diet)
Heterogeneity: Tau2 = 0.02; Chi2 = 15.11, df = 12 (P = 0.24); I2 =21%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 3.1. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 1
Weight, kg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 1 Weight, kg
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Due Mod fat 2008 39 2.5 (4.46) 24 3.8 (4) 91.4 % -1.30 [ -3.43, 0.83 ]
Dullaart 1992 16 77 (10) 20 76 (11.2) 8.6 % 1.00 [ -5.94, 7.94 ]
Subtotal (95% CI) 55 44 100.0 % -1.10 [ -3.14, 0.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Reduced fat intake
BDIT Pilot Studies 1996 76 64.9 (11.2) 81 64.1 (9.6) 2.3 % 0.80 [ -2.47, 4.07 ]
BRIDGES 2001 48 0.1 (4.85) 46 0.5 (4.07) 5.7 % -0.40 [ -2.21, 1.41 ]
CARMEN 2000 159 -1.37 (3.416) 77 0.8 (4.1) 9.7 % -2.17 [ -3.23, -1.11 ]
Due Low fat 2008 43 2.2 (4.35) 24 3.8 (4) 4.7 % -1.60 [ -3.66, 0.46 ]
Lean 1997 42 -5.6 (4.96) 40 -6.8 (5.16) 4.4 % 1.20 [ -0.99, 3.39 ]
Ley 2004 51 1.06 (4.57) 52 1.26 (4.9) 5.6 % -0.20 [ -2.03, 1.63 ]
MSFAT 1997 40 -0.08 (2.36) 36 0.46 (2.18) 10.0 % -0.54 [ -1.56, 0.48 ]
Nutrition % Breast Health 47 67.3 (13.8) 50 66.4 (12) 1.0 % 0.90 [ -4.26, 6.06 ]
Ole Study 2002 14 -2.54 (2.96) 14 -3.9 (3.29) 4.0 % 1.36 [ -0.96, 3.68 ]
Polyp Prevention 1996 943 -0.65 (5.22) 943 0.31 (5.22) 13.9 % -0.96 [ -1.43, -0.49 ]
PREMIER 2003 241 -4.3 (7.4) 235 -3.8 (6.1) 8.7 % -0.50 [ -1.72, 0.72 ]
Seppelt 1996 35 70.3 (7.4) 32 71.9 (10) 1.5 % -1.60 [ -5.84, 2.64 ]
Simon 1997 34 63.4 (11.1) 38 71.9 (11.7) 1.0 % -8.50 [ -13.77, -3.23 ]
WHEL 2007 1308 74.1 (19.53) 1313 73.7 (19.205) 7.1 % 0.40 [ -1.08, 1.88 ]
WHI without CVD 2006 1133 -0.7 (9) 1699 0.6 (9.2) 12.4 % -1.30 [ -1.98, -0.62 ]
WINS 2006 854 70.6 (14.91) 1310 72.8 (15.696) 8.1 % -2.20 [ -3.51, -0.89 ]
Subtotal (95% CI) 5068 5990 100.0 % -0.83 [ -1.37, -0.30 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 32.37, df = 15 (P = 0.01); I2 =54%
Test for overall effect: Z = 3.03 (P = 0.0024)
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(. . . Continued)
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Reduced and modified fat intake
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.2. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 2 BMI,
kg/m2.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 2 BMI, kg/m2
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Due Mod fat 2008 39 0.8 (1.43) 24 1.2 (1.25) 93.8 % -0.40 [ -1.07, 0.27 ]
Sarkkinen Fat Mod 1995 41 26.3 (3.6) 12 25.7 (4.2) 6.2 % 0.60 [ -2.02, 3.22 ]
Subtotal (95% CI) 80 36 100.0 % -0.34 [ -0.99, 0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Reduced fat intake
BDIT Pilot Studies 1996 76 24.3 (3.8) 81 24.3 (3.6) 3.8 % 0.0 [ -1.16, 1.16 ]
CARMEN MS sub-study 2002 18 -0.765 (1.42) 8 0.41 (0.88) 5.8 % -1.18 [ -2.07, -0.28 ]
DO IT 2006 233 -0.19 (1.3) 231 0.18 (1.3) 21.6 % -0.37 [ -0.61, -0.13 ]
Due Low fat 2008 43 0.7 (1.34) 24 1.2 (1.25) 9.5 % -0.50 [ -1.14, 0.14 ]
Lean 1997 42 -2.2 (1.82) 40 -2.6 (2.1) 6.3 % 0.40 [ -0.45, 1.25 ]
Moy 2001 117 -0.1 (1) 118 0.21 (2) 15.5 % -0.31 [ -0.71, 0.09 ]
Sarkkinen Red Fat 1995 40 26.2 (3.2) 12 25.7 (4.2) 0.9 % 0.50 [ -2.07, 3.07 ]
Simon 1997 34 23.8 (4.7) 38 27.4 (4.9) 1.2 % -3.60 [ -5.82, -1.38 ]
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(. . . Continued)
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WHI without CVD 2006 1133 -0.2 (2.7) 1699 0.3 (2.7) 22.8 % -0.50 [ -0.70, -0.30 ]
WINS 2006 755 26.8 (5.608) 1230 27.6 (5.368) 12.7 % -0.80 [ -1.30, -0.30 ]
Subtotal (95% CI) 2491 3481 100.0 % -0.47 [ -0.72, -0.23 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 18.21, df = 9 (P = 0.03); I2 =51%
Test for overall effect: Z = 3.78 (P = 0.00015)
3 Reduced and modified fat intake
Oxford Retinopathy 1978 29 -1 (2.8) 29 -0.7 (1.8) 83.0 % -0.30 [ -1.51, 0.91 ]
Sarkkinen Red % Mod 1995 41 26 (4) 12 25.7 (4.2) 17.0 % 0.30 [ -2.37, 2.97 ]
Subtotal (95% CI) 70 41 100.0 % -0.20 [ -1.30, 0.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
-4 -2 0 2 4
Favours altered fat Favours control
Analysis 3.3. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 3 LDL
cholesterol, mmol/L.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 3 LDL cholesterol, mmol/L
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Due Mod fat 2008 39 -0.08 (0.48) 24 0.14 (0.63) 81.7 % -0.22 [ -0.51, 0.07 ]
Sarkkinen Fat Mod 1995 41 4.25 (0.95) 12 4.36 (0.97) 18.3 % -0.11 [ -0.73, 0.51 ]
Subtotal (95% CI) 80 36 100.0 % -0.20 [ -0.47, 0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
2 Reduced fat intake
Anderson 1990 47 -0.56 (0.55) 51 -0.4 (0.43) 5.3 % -0.16 [ -0.36, 0.04 ]
CARMEN 2000 159 -0.053 (0.545) 77 -0.03 (0.65) 7.3 % -0.02 [ -0.19, 0.15 ]
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(. . . Continued)
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
CARMEN MS sub-study 2002 18 -0.145 (0.498) 8 0.16 (0.86) 0.5 % -0.31 [ -0.94, 0.33 ]
DO IT 2006 233 -0.035 (0.83) 231 0.01 (0.91) 8.2 % -0.05 [ -0.20, 0.11 ]
Due Low fat 2008 43 0.01 (0.5) 24 0.14 (0.63) 2.4 % -0.13 [ -0.42, 0.16 ]
Lean 1997 37 -0.17 (0.59) 34 -0.03 (0.79) 1.9 % -0.14 [ -0.47, 0.19 ]
Ley 2004 51 -0.32 (0.64) 52 -0.16 (1.15) 1.6 % -0.16 [ -0.52, 0.20 ]
Moy 2001 117 -0.69 (1.1) 118 -0.4 (0.8) 3.4 % -0.29 [ -0.54, -0.04 ]
Ole Study 2002 14 -0.03 (0.45) 14 0.09 (0.52) 1.6 % -0.12 [ -0.48, 0.24 ]
Sarkkinen Red Fat 1995 40 4.26 (1.03) 12 4.36 (0.97) 0.5 % -0.10 [ -0.73, 0.53 ]
Seppelt 1996 35 -0.08 (0.61) 32 0.01 (0.6) 2.4 % -0.09 [ -0.38, 0.20 ]
Simon 1997 34 2.79 (0.82) 37 3.09 (0.99) 1.2 % -0.30 [ -0.72, 0.12 ]
WHEL 2007 1308 2.92 (11.902) 1313 2.95 (11.277) 0.3 % -0.03 [ -0.92, 0.86 ]
WHI without CVD 2006 1133 -0.251 (0.758) 1699 -0.16 (0.753) 63.5 % -0.09 [ -0.15, -0.03 ]
Subtotal (95% CI) 3269 3702 100.0 % -0.10 [ -0.14, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.52, df = 13 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.31 (P = 0.000017)
3 Reduced and modified fat intake
beFIT 1997 217 4.2 (0.94) 192 4.42 (0.88) 60.4 % -0.22 [ -0.40, -0.04 ]
Sarkkinen Red % Mod 1995 41 4.21 (0.89) 12 4.36 (0.97) 5.0 % -0.15 [ -0.76, 0.46 ]
Sondergaard 2003 63 2.98 (0.7) 52 3.07 (0.81) 24.0 % -0.09 [ -0.37, 0.19 ]
STARS 1992 26 4.19 (0.51) 24 4.67 (0.931) 10.6 % -0.48 [ -0.90, -0.06 ]
Subtotal (95% CI) 347 280 100.0 % -0.21 [ -0.35, -0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.33, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.04 (P = 0.0023)
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Analysis 3.4. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 4 HDL
cholesterol, mmol/Lkg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 4 HDL cholesterol, mmol/Lkg
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Due Mod fat 2008 39 0.09 (0.32) 24 0.09 (0.38) 54.4 % 0.0 [ -0.18, 0.18 ]
Dullaart 1992 16 1.31 (0.52) 20 1.27 (0.58) 13.9 % 0.04 [ -0.32, 0.40 ]
Sarkkinen Fat Mod 1995 41 1.38 (0.3) 12 1.53 (0.39) 31.6 % -0.15 [ -0.39, 0.09 ]
Subtotal (95% CI) 96 56 100.0 % -0.04 [ -0.18, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.19, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Reduced fat intake
Anderson 1990 47 0.01 (0.14) 51 0.01 (0.14) 6.8 % 0.0 [ -0.06, 0.06 ]
BDIT Pilot Studies 1996 53 1.62 (0.41) 57 1.56 (0.38) 1.0 % 0.06 [ -0.09, 0.21 ]
CARMEN 2000 159 -0.104 (0.203) 77 -0.07 (0.23) 5.8 % -0.03 [ -0.09, 0.03 ]
CARMEN MS sub-study 2002 18 -0.11 (0.168) 8 -0.13 (0.17) 1.1 % 0.02 [ -0.12, 0.16 ]
DO IT 2006 233 0.11 (0.24) 231 0.07 (0.28) 9.4 % 0.04 [ -0.01, 0.09 ]
Due Low fat 2008 43 0.05 (0.34) 24 0.09 (0.38) 0.6 % -0.04 [ -0.22, 0.14 ]
Lean 1997 37 -0.02 (0.2) 34 0.05 (0.25) 1.9 % -0.07 [ -0.18, 0.04 ]
Ley 2004 51 0.01 (0.14) 52 0.06 (0.36) 1.9 % -0.05 [ -0.16, 0.06 ]
Moy 2001 117 0.044 (0.3) 118 0.01 (0.2) 5.0 % 0.04 [ -0.03, 0.10 ]
Ole Study 2002 14 0.04 (0.11) 14 0.06 (0.07) 4.5 % -0.02 [ -0.09, 0.05 ]
Sarkkinen Red Fat 1995 40 1.38 (0.34) 12 1.53 (0.39) 0.4 % -0.15 [ -0.39, 0.09 ]
Seppelt 1996 35 0.03 (0.17) 32 0.1 (0.22) 2.3 % -0.07 [ -0.16, 0.02 ]
Simon 1997 34 1.44 (0.58) 38 1.56 (0.55) 0.3 % -0.12 [ -0.38, 0.14 ]
WHEL 2007 1308 1.45 (4.705) 1313 1.53 (4.345) 0.2 % -0.08 [ -0.43, 0.27 ]
WHI without CVD 2006 1133 -0.018 (0.243) 1699 -0.01 (0.264) 58.9 % -0.01 [ -0.03, 0.01 ]
Subtotal (95% CI) 3322 3760 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 13.45, df = 14 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
3 Reduced and modified fat intake
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Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
DART 1989 924 1.04 (0.31) 931 1.05 (0.3) 90.8 % -0.01 [ -0.04, 0.02 ]
Sarkkinen Red % Mod 1995 41 1.43 (0.28) 12 1.53 (0.39) 1.2 % -0.10 [ -0.34, 0.14 ]
Sondergaard 2003 63 1.25 (0.36) 52 1.23 (0.37) 3.9 % 0.02 [ -0.11, 0.15 ]
STARS 1992 26 1.14 (0.153) 24 1.21 (0.294) 4.0 % -0.07 [ -0.20, 0.06 ]
Subtotal (95% CI) 1054 1019 100.0 % -0.01 [ -0.04, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.52, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
-0.2 -0.1 0 0.1 0.2
Favours control Favours altered fat
Analysis 3.5. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 5
Total cholesterol, mmol/L.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 5 Total cholesterol, mmol/L
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Due Mod fat 2008 39 -0.06 (0.8) 24 0.17 (0.63) 11.4 % -0.23 [ -0.59, 0.13 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 13.8 % -0.47 [ -0.76, -0.18 ]
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 15.4 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st mod 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 23.5 % -0.45 [ -0.55, -0.35 ]
Rose 1965 28 -0.309 (1.643) 18 -0.2 (1.031) 3.7 % -0.11 [ -0.88, 0.66 ]
Sarkkinen Fat Mod 1995 41 6.3 (1.11) 12 6.51 (1.07) 4.4 % -0.21 [ -0.90, 0.48 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 17.9 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 10.0 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 1161 1119 100.0 % -0.44 [ -0.60, -0.28 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 16.88, df = 7 (P = 0.02); I2 =59%
Test for overall effect: Z = 5.41 (P < 0.00001)
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Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Reduced fat intake
Anderson 1990 47 -0.59 (0.62) 51 -0.42 (0.57) 3.6 % -0.17 [ -0.41, 0.07 ]
BDIT Pilot Studies 1996 54 5.14 (0.84) 61 5.38 (0.81) 2.2 % -0.24 [ -0.54, 0.06 ]
CARMEN 2000 159 -0.23 (0.634) 77 -0.14 (0.63) 6.7 % -0.09 [ -0.26, 0.08 ]
CARMEN MS sub-study 2002 18 -0.21 (0.694) 8 -0.11 (0.83) 0.5 % -0.10 [ -0.76, 0.56 ]
DO IT 2006 233 -0.09 (0.9) 231 -0.03 (1) 6.6 % -0.06 [ -0.23, 0.11 ]
Due Low fat 2008 43 0.01 (0.67) 24 0.17 (0.63) 1.9 % -0.16 [ -0.48, 0.16 ]
Lean 1997 40 -0.34 (0.69) 37 -0.12 (0.39) 3.2 % -0.22 [ -0.47, 0.03 ]
Ley 2004 51 -0.2 (0.79) 52 -0.15 (1.3) 1.2 % -0.05 [ -0.46, 0.36 ]
Ole Study 2002 14 0.11 (0.56) 14 0.19 (0.56) 1.2 % -0.08 [ -0.49, 0.33 ]
Polyp Prevention 1996 370 -0.13 (0.77) 374 -0.07 (0.77) 16.3 % -0.06 [ -0.17, 0.05 ]
Sarkkinen Red Fat 1995 40 6.35 (1.18) 12 6.51 (1.07) 0.4 % -0.16 [ -0.87, 0.55 ]
Seppelt 1996 35 -0.01 (0.64) 32 0.16 (0.6) 2.3 % -0.17 [ -0.47, 0.13 ]
Simon 1997 34 4.87 (0.87) 38 5.21 (0.18) 2.2 % -0.34 [ -0.64, -0.04 ]
WHEL 2007 1308 5.07 (11.902) 1313 4.99 (11.924) 0.2 % 0.08 [ -0.83, 0.99 ]
WHI without CVD 2006 1133 -0.264 (0.828) 1699 -0.18 (0.825) 51.5 % -0.09 [ -0.15, -0.02 ]
Subtotal (95% CI) 3579 4023 100.0 % -0.10 [ -0.14, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.05, df = 14 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 4.37 (P = 0.000012)
3 Reduced and modified fat intake
DART 1989 924 6.31 (1.14) 931 6.57 (1.16) 38.7 % -0.26 [ -0.36, -0.16 ]
Oxford Retinopathy 1978 29 4.94 (0.82) 29 4.87 (0.79) 16.4 % 0.07 [ -0.34, 0.48 ]
Sarkkinen Red % Mod 1995 41 6.24 (1.06) 12 6.51 (1.07) 7.9 % -0.27 [ -0.96, 0.42 ]
Sondergaard 2003 63 4.96 (0.77) 52 5.09 (0.99) 21.2 % -0.13 [ -0.46, 0.20 ]
STARS 1992 26 6.17 (0.459) 24 6.93 (0.98) 15.7 % -0.76 [ -1.19, -0.33 ]
Subtotal (95% CI) 1083 1048 100.0 % -0.26 [ -0.47, -0.04 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 8.22, df = 4 (P = 0.08); I2 =51%
Test for overall effect: Z = 2.36 (P = 0.018)
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Analysis 3.6. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 6
Triglycerides, mmol/L.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 6 Triglycerides, mmol/L
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Due Mod fat 2008 39 -0.15 (0.48) 24 -0.11 (0.25) 34.4 % -0.04 [ -0.22, 0.14 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.9 % -0.50 [ -1.64, 0.64 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 19.5 % -0.26 [ -0.50, -0.02 ]
Sarkkinen Fat Mod 1995 41 1.4 (0.84) 12 1.38 (0.84) 3.9 % 0.02 [ -0.52, 0.56 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 41.4 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 365 341 100.0 % -0.11 [ -0.22, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.76, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
2 Reduced fat intake
CARMEN 2000 159 -0.079 (0.578) 77 -0.13 (0.57) 0.0 % 0.05 [ -0.10, 0.21 ]
CARMEN MS sub-study 2002 18 0.095 (0.824) 8 -0.4 (0.95) 0.0 % 0.50 [ -0.27, 1.26 ]
DO IT 2006 233 -0.365 (0.663) 231 -0.22 (0.95) 0.0 % -0.14 [ -0.29, 0.01 ]
Due Low fat 2008 43 -0.15 (0.5) 24 -0.11 (0.25) 0.0 % -0.04 [ -0.22, 0.14 ]
Lean 1997 39 -0.27 (0.56) 34 -0.25 (0.57) 0.0 % -0.02 [ -0.28, 0.24 ]
Ley 2004 51 0.37 (0.71) 52 0.12 (1.59) 0.0 % 0.25 [ -0.22, 0.72 ]
Moy 2001 117 -0.4 (2) 118 -0.06 (1.9) 0.0 % -0.34 [ -0.84, 0.16 ]
Ole Study 2002 14 0.21 (0.38) 14 0.19 (0.86) 0.0 % 0.02 [ -0.47, 0.51 ]
Sarkkinen Red Fat 1995 40 1.44 (0.79) 12 1.38 (0.84) 0.0 % 0.06 [ -0.47, 0.59 ]
Seppelt 1996 35 0.09 (0.48) 32 0.13 (0.4) 0.0 % -0.04 [ -0.25, 0.17 ]
Simon 1997 34 1.35 (1.05) 37 1.25 (0.61) 0.0 % 0.10 [ -0.30, 0.50 ]
WHEL 2007 1308 1.17 (7.842) 1313 1.02 (9.983) 0.0 % 0.15 [ -0.54, 0.84 ]
WHI without CVD 2006 1133 0.011 (0.005) 1699 0.01 (0.003) 100.0 % 0.0 [ 0.00, 0.00 ]
Subtotal (95% CI) 3224 3651 100.0 % 0.00 [ 0.00, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.15, df = 12 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
3 Reduced and modified fat intake
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Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sarkkinen Red % Mod 1995 41 1.24 (0.6) 12 1.38 (0.84) 26.7 % -0.14 [ -0.65, 0.37 ]
Sondergaard 2003 63 1.53 (1.04) 52 1.76 (0.98) 50.7 % -0.23 [ -0.60, 0.14 ]
STARS 1992 26 1.85 (1.02) 24 2.35 (0.98) 22.6 % -0.50 [ -1.05, 0.05 ]
Subtotal (95% CI) 130 88 100.0 % -0.27 [ -0.53, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.047)
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Analysis 3.7. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 7
Systolic Blood Pressure, mmHg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 7 Systolic Blood Pressure, mmHg
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Reduced fat intake
Ley 2004 51 -3.5 (17.71) 52 1.31 (24.37) 1.3 % -4.81 [ -13.03, 3.41 ]
DO IT 2006 233 -7.5 (17.3) 231 -5.5 (16.7) 9.4 % -2.00 [ -5.09, 1.09 ]
PREMIER 2003 243 -9.5 (10.8) 237 -8.6 (11.6) 22.3 % -0.90 [ -2.91, 1.11 ]
Lean 1997 38 -1.1 (17.3) 36 -0.3 (17.91) 1.4 % -0.80 [ -8.83, 7.23 ]
Ole Study 2002 14 -2.34 (7.07) 14 -1.76 (5.76) 3.9 % -0.58 [ -5.36, 4.20 ]
WHI without CVD 2006 1133 -2.2 (16.3) 1699 -2.1 (16.4) 59.4 % -0.10 [ -1.33, 1.13 ]
Subtotal (95% CI) 1712 2269 97.6 % -0.56 [ -1.52, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 5 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
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Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Reduced and modified fat intake
Sarkkinen Red % Mod 1995 41 -2.59 (11.19) 37 2.49 (15.8) 2.4 % -5.08 [ -11.22, 1.06 ]
Subtotal (95% CI) 41 37 2.4 % -5.08 [ -11.22, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
Total (95% CI) 1753 2306 100.0 % -0.67 [ -1.61, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.55, df = 6 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
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Analysis 3.8. Comparison 3 fat modification or reduction vs usual diet - tertiary outcomes, Outcome 8
Diastolic Blood Pressure, mmHg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 3 fat modification or reduction vs usual diet - tertiary outcomes
Outcome: 8 Diastolic Blood Pressure, mmHg
Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Modified fat intake
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Reduced fat intake
CARMEN MS sub-study 2002 18 0.45 (10.289) 8 4.7 (3.9) 1.2 % -4.25 [ -9.72, 1.22 ]
Lean 1997 38 -2.7 (11.79) 36 -2.3 (11.63) 1.3 % -0.40 [ -5.74, 4.94 ]
Ley 2004 51 -7.16 (12) 52 -4.2 (13.85) 1.4 % -2.96 [ -7.96, 2.04 ]
Ole Study 2002 14 -4.4 (6.02) 14 -5.26 (7.22) 1.5 % 0.86 [ -4.06, 5.78 ]
PREMIER 2003 243 -6.2 (7.8) 237 -6 (7.3) 19.8 % -0.20 [ -1.55, 1.15 ]
WHI without CVD 2006 1133 -2.6 (9.4) 1699 -2.3 (9.4) 72.4 % -0.30 [ -1.01, 0.41 ]
Subtotal (95% CI) 1497 2046 97.6 % -0.35 [ -0.96, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.30, df = 5 (P = 0.65); I2 =0.0%
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Study or subgroup Reduced or modified fat Control or usual diet Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.13 (P = 0.26)
3 Reduced and modified fat intake
Sarkkinen Red % Mod 1995 41 -0.93 (7.13) 37 1.38 (10) 2.4 % -2.31 [ -6.20, 1.58 ]
Subtotal (95% CI) 41 37 2.4 % -2.31 [ -6.20, 1.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
Total (95% CI) 1538 2083 100.0 % -0.40 [ -1.00, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.25, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
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Analysis 4.3. Comparison 4 fat reduction vs fat modification - primary outcomes, Outcome 3 Combined
cardiovascular events.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 4 fat reduction vs fat modification - primary outcomes
Outcome: 3 Combined cardiovascular events
Study or subgroup Fat reduction Fat modification Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Sacks high protein 2009 2/202 4/201 26.1 % 0.50 [ 0.09, 2.69 ]
Sacks low protein 2009 5/204 1/204 18.0 % 5.00 [ 0.59, 42.42 ]
THIS DIET 2008 8/50 8/51 55.9 % 1.02 [ 0.42, 2.51 ]
Total (95% CI) 456 456 100.0 % 1.13 [ 0.41, 3.06 ]
Total events: 15 (Fat reduction), 13 (Fat modification)
Heterogeneity: Tau2 = 0.25; Chi2 = 2.85, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 5.1. Comparison 5 fat reduction vs fat modification - secondary outcomes, Outcome 1 Myocardial
infarction.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 5 fat reduction vs fat modification - secondary outcomes
Outcome: 1 Myocardial infarction
Study or subgroup Fat reduction Fat modification Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
THIS DIET 2008 3/50 1/51 100.0 % 3.06 [ 0.33, 28.44 ]
Total (95% CI) 50 51 100.0 % 3.06 [ 0.33, 28.44 ]
Total events: 3 (Fat reduction), 1 (Fat modification)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 5.2. Comparison 5 fat reduction vs fat modification - secondary outcomes, Outcome 2 Stroke.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 5 fat reduction vs fat modification - secondary outcomes
Outcome: 2 Stroke
Study or subgroup Fat reduction Fat modification Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
THIS DIET 2008 1/50 3/51 100.0 % 0.34 [ 0.04, 3.16 ]
Total (95% CI) 50 51 100.0 % 0.34 [ 0.04, 3.16 ]
Total events: 1 (Fat reduction), 3 (Fat modification)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
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Analysis 5.4. Comparison 5 fat reduction vs fat modification - secondary outcomes, Outcome 4 Cancer
diagnoses.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 5 fat reduction vs fat modification - secondary outcomes
Outcome: 4 Cancer diagnoses
Study or subgroup Fat reduction Fat modification Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Sacks high protein 2009 2/202 0/201 45.4 % 4.98 [ 0.24, 102.99 ]
Sacks low protein 2009 1/204 1/204 54.6 % 1.00 [ 0.06, 15.88 ]
Total (95% CI) 406 405 100.0 % 2.07 [ 0.27, 15.98 ]
Total events: 3 (Fat reduction), 1 (Fat modification)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
0.005 0.1 1 10 200
Favours experimental Favours control
Analysis 5.6. Comparison 5 fat reduction vs fat modification - secondary outcomes, Outcome 6 Non-fatal
MI.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 5 fat reduction vs fat modification - secondary outcomes
Outcome: 6 Non-fatal MI
Study or subgroup Fat reduction Fat modification Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
THIS DIET 2008 3/50 1/51 100.0 % 3.06 [ 0.33, 28.44 ]
Total (95% CI) 50 51 100.0 % 3.06 [ 0.33, 28.44 ]
Total events: 3 (Fat reduction), 1 (Fat modification)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
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Analysis 6.1. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 1 Weight, kg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 1 Weight, kg
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 -1.2 (7.3) 45 -5 (16.77) 7.5 % 3.80 [ -1.55, 9.15 ]
Due Low vs Mod 2008 43 2.2 (4.35) 39 2.5 (4.46) 25.5 % -0.30 [ -2.21, 1.61 ]
McAuley 2005 24 93.2 (15.1) 28 87.1 (15.6) 3.5 % 6.10 [ -2.26, 14.46 ]
Sacks high protein 2009 201 -3.8 (14.2) 201 -3.5 (14.2) 18.4 % -0.30 [ -3.08, 2.48 ]
Sacks low protein 2009 201 -3 (14.2) 201 -3.2 (14.2) 18.4 % 0.20 [ -2.58, 2.98 ]
Strychar 2009 15 -0.83 (3) 15 1.6 (1.8) 26.8 % -2.43 [ -4.20, -0.66 ]
Total (95% CI) 528 529 100.0 % -0.25 [ -1.88, 1.39 ]
Heterogeneity: Tau2 = 1.79; Chi2 = 9.57, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 0.30 (P = 0.77)
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Analysis 6.2. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 2 BMI, kg/m2.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 2 BMI, kg/m2
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Due Low vs Mod 2008 43 0.7 (1.34) 39 0.8 (1.43) 31.9 % -0.10 [ -0.70, 0.50 ]
McAuley 2005 30 34.9 (5.6) 29 31.5 (5.1) 7.8 % 3.40 [ 0.67, 6.13 ]
Sarkkinen Red vs Mod1995 40 26.2 (3.2) 41 26.3 (3.6) 17.7 % -0.10 [ -1.58, 1.38 ]
Strychar 2009 15 -0.24 (1) 15 0.56 (0.6) 32.1 % -0.80 [ -1.39, -0.21 ]
THIS DIET 2008 46 29 (6) 47 28 (5) 10.5 % 1.00 [ -1.25, 3.25 ]
Total (95% CI) 174 171 100.0 % 0.06 [ -0.79, 0.92 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 11.59, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.15 (P = 0.88)
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Analysis 6.3. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 3 LDL
cholesterol, mmol/L.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 3 LDL cholesterol, mmol/L
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 -0.1 (0.99) 45 -0.18 (0.8) 8.5 % 0.08 [ -0.29, 0.45 ]
Due Low vs Mod 2008 43 0.01 (0.5) 39 -0.08 (0.48) 16.7 % 0.09 [ -0.12, 0.30 ]
McAuley 2005 24 3.8 (0.7) 28 3.5 (0.7) 8.3 % 0.30 [ -0.08, 0.68 ]
Rivellese 1994 27 4.82 (0.94) 17 4.85 (0.87) 4.7 % -0.03 [ -0.57, 0.51 ]
Sacks high protein 2009 201 3.13 (0.85) 201 3.21 (0.8) 20.7 % -0.08 [ -0.24, 0.08 ]
Sacks low protein 2009 201 3.03 (0.8) 201 3.28 (0.85) 20.7 % -0.25 [ -0.41, -0.09 ]
Sarkkinen Red vs Mod1995 40 4.26 (1.03) 41 4.25 (0.95) 6.9 % 0.01 [ -0.42, 0.44 ]
Strychar 2009 15 -0.25 (0.7) 15 -0.21 (0.57) 6.3 % -0.04 [ -0.50, 0.42 ]
THIS DIET 2008 46 2.77 (1.18) 47 2.51 (0.82) 7.3 % 0.26 [ -0.15, 0.67 ]
Total (95% CI) 641 634 100.0 % -0.01 [ -0.13, 0.12 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.64, df = 8 (P = 0.09); I2 =41%
Test for overall effect: Z = 0.09 (P = 0.93)
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Analysis 6.4. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 4 HDL
cholesterol, mmol/Lkg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 4 HDL cholesterol, mmol/Lkg
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 0.1 (0.6) 45 0.17 (0.54) 2.6 % -0.07 [ -0.31, 0.17 ]
Due Low vs Mod 2008 43 0.05 (0.34) 39 0.09 (0.32) 7.2 % -0.04 [ -0.18, 0.10 ]
McAuley 2005 24 1.14 (0.29) 28 1.26 (0.29) 5.9 % -0.12 [ -0.28, 0.04 ]
Rivellese 1994 27 1.22 (0.31) 17 1.12 (0.16) 7.6 % 0.10 [ -0.04, 0.24 ]
Sacks high protein 2009 201 1.37 (0.39) 201 1.42 (0.44) 22.3 % -0.05 [ -0.13, 0.03 ]
Sacks low protein 2009 201 1.32 (0.39) 201 1.32 (0.34) 28.8 % 0.0 [ -0.07, 0.07 ]
Sarkkinen Red vs Mod1995 40 1.38 (0.34) 41 1.38 (0.3) 7.6 % 0.0 [ -0.14, 0.14 ]
Strychar 2009 15 0.06 (0.27) 15 -0.01 (0.22) 4.7 % 0.07 [ -0.11, 0.25 ]
THIS DIET 2008 46 1.05 (0.26) 47 1.1 (0.26) 13.2 % -0.05 [ -0.16, 0.06 ]
Total (95% CI) 641 634 100.0 % -0.02 [ -0.06, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.83, df = 8 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
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Analysis 6.5. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 5 Total
cholesterol, mmol/L.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 5 Total cholesterol, mmol/L
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 -0.15 (0.53) 45 -0.26 (0.74) 16.6 % 0.11 [ -0.16, 0.38 ]
Due Low vs Mod 2008 43 0.01 (0.67) 39 -0.06 (0.8) 12.8 % 0.07 [ -0.25, 0.39 ]
Rivellese 1994 27 6.78 (0.78) 17 6.63 (0.58) 9.0 % 0.15 [ -0.25, 0.55 ]
Sacks high protein 2009 201 5.09 (1.03) 201 5.22 (0.98) 24.0 % -0.13 [ -0.33, 0.07 ]
Sacks low protein 2009 201 4.96 (0.96) 201 5.22 (1.01) 24.5 % -0.26 [ -0.45, -0.07 ]
Sarkkinen Red vs Mod1995 40 6.35 (1.18) 41 6.3 (1.11) 6.2 % 0.05 [ -0.45, 0.55 ]
Strychar 2009 15 -0.12 (0.66) 15 -0.24 (0.66) 6.9 % 0.12 [ -0.35, 0.59 ]
Total (95% CI) 571 559 100.0 % -0.04 [ -0.18, 0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.56, df = 6 (P = 0.20); I2 =30%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 6.6. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 6 Triglycerides,
mmol/L.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 6 Triglycerides, mmol/L
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 -0.03 (0.13) 45 -0.11 (0.4) 29.7 % 0.08 [ -0.04, 0.20 ]
Due Low vs Mod 2008 43 -0.15 (0.5) 39 -0.15 (0.48) 11.3 % 0.0 [ -0.21, 0.21 ]
McAuley 2005 24 1.57 (0.79) 28 1.16 (0.55) 3.7 % 0.41 [ 0.03, 0.79 ]
Rivellese 1994 27 1.5 (0.68) 17 1.57 (0.7) 3.0 % -0.07 [ -0.49, 0.35 ]
Sacks high protein 2009 201 1.35 (0.76) 201 1.33 (0.8) 20.5 % 0.02 [ -0.13, 0.17 ]
Sacks low protein 2009 201 1.35 (0.94) 201 1.46 (1) 13.9 % -0.11 [ -0.30, 0.08 ]
Sarkkinen Red vs Mod1995 40 1.44 (0.79) 41 1.4 (0.84) 4.2 % 0.04 [ -0.32, 0.40 ]
Strychar 2009 15 0.14 (0.46) 15 -0.03 (0.22) 7.8 % 0.17 [ -0.09, 0.43 ]
THIS DIET 2008 46 1.52 (0.76) 47 1.36 (0.7) 5.9 % 0.16 [ -0.14, 0.46 ]
Total (95% CI) 641 634 100.0 % 0.05 [ -0.02, 0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.52, df = 8 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 6.7. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 7 Systolic Blood
Pressure, mmHg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 7 Systolic Blood Pressure, mmHg
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 -3.3 (7.96) 45 -7.4 (15.43) 12.9 % 4.10 [ -0.98, 9.18 ]
McAuley 2005 24 120 (12) 28 121 (9) 10.2 % -1.00 [ -6.84, 4.84 ]
Sacks high protein 2009 201 118 (13) 201 120 (14) 31.3 % -2.00 [ -4.64, 0.64 ]
Sacks low protein 2009 201 117 (12) 201 118 (12) 35.2 % -1.00 [ -3.35, 1.35 ]
Strychar 2009 15 3.9 (14.4) 15 -0.2 (21.1) 2.4 % 4.10 [ -8.83, 17.03 ]
THIS DIET 2008 46 124 (16) 47 120 (17) 8.1 % 4.00 [ -2.71, 10.71 ]
Total (95% CI) 531 537 100.0 % -0.13 [ -2.16, 1.90 ]
Heterogeneity: Tau2 = 1.63; Chi2 = 6.80, df = 5 (P = 0.24); I2 =26%
Test for overall effect: Z = 0.13 (P = 0.90)
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Analysis 6.8. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 8 Diastolic
Blood Pressure, mmHg.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 8 Diastolic Blood Pressure, mmHg
Study or subgroup Reduced fat Modified fat Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Azadbakht 2007 44 -1.3 (7.3) 45 -2.9 (8.05) 16.4 % 1.60 [ -1.59, 4.79 ]
McAuley 2005 24 78 (10) 28 78 (8) 8.8 % 0.0 [ -4.98, 4.98 ]
Sacks high protein 2009 201 74 (9) 201 76 (9) 28.1 % -2.00 [ -3.76, -0.24 ]
Sacks low protein 2009 201 74 (9) 201 75 (9) 28.1 % -1.00 [ -2.76, 0.76 ]
Strychar 2009 15 4.7 (11) 15 -2.6 (8.9) 4.8 % 7.30 [ 0.14, 14.46 ]
THIS DIET 2008 46 73 (9) 47 73 (9) 13.8 % 0.0 [ -3.66, 3.66 ]
Total (95% CI) 531 537 100.0 % -0.23 [ -1.90, 1.43 ]
Heterogeneity: Tau2 = 1.76; Chi2 = 9.20, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 0.27 (P = 0.78)
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Analysis 6.9. Comparison 6 fat reduction vs fat modification - tertiary outcomes, Outcome 9 Dropouts.
Review: Reduced or modified dietary fat for preventing cardiovascular disease
Comparison: 6 fat reduction vs fat modification - tertiary outcomes
Outcome: 9 Dropouts
Study or subgroup Reduced fat Modified fat Risk Ratio Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Azadbakht 2007 6/50 5/50 1.20 [ 0.39, 3.68 ]
Due Low vs Mod 2008 8/48 15/52 0.58 [ 0.27, 1.24 ]
McAuley 2005 2/32 3/30 0.63 [ 0.11, 3.48 ]
Rivellese 1994 6/33 13/30 0.42 [ 0.18, 0.96 ]
Sacks high protein 2009 45/202 33/201 1.36 [ 0.91, 2.03 ]
Sacks low protein 2009 35/204 53/204 0.66 [ 0.45, 0.97 ]
Sarkkinen Red vs Mod1995 0/40 0/41 0.0 [ 0.0, 0.0 ]
Strychar 2009 3/18 2/17 1.42 [ 0.27, 7.46 ]
THIS DIET 2008 5/50 3/51 1.70 [ 0.43, 6.74 ]
Total (95% CI) 677 676 0.84 [ 0.58, 1.22 ]
Total events: 110 (Reduced fat), 127 (Modified fat)
Heterogeneity: Tau2 = 0.11; Chi2 = 12.40, df = 7 (P = 0.09); I2 =44%
Test for overall effect: Z = 0.92 (P = 0.36)
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A P P E N D I C E S
Appendix 1. MEDLINE search strategies 1998
MEDLINE on SilverPlatter - diet and cardiovascular disease or mortality - from 1966 to May 1998
explode ”NUTRITION“/adverse-effects , classification , contraindications , drug-effects , education , mortality , methods , nursing ,
physiology , utilization
explode ”DIET“/ adverse-effects , blood , contraindications , drug-effects , metabolism , mortality , methods , nursing , physiology ,
utilization
explode ”DIET-THERAPY“/ all subheadings
explode ”LIPIDS“/ administration-and-dosage , adverse-effects , therapeutic-use
explode ”FOOD“/administration-and-dosage , adverse-effects , drug-effects , therapeutic-use
explode ”VITAMINS“/administration-and-dosage , adverse-effects , therapeutic-use
”SELENIUM“/administration-and-dosage , adverse-effects , therapeutic-use
”CALCIUM“/administration-and-dosage , adverse-effects , therapeutic-use
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explode ”CHLORIDES“/administration-and-dosage , adverse-effects , therapeutic-use
”MAGNESIUM“/administration-and-dosage , adverse-effects , therapeutic-use
”PHOSPHORUS,-DIETARY“/ all subheadings
”POTASSIUM,-DIETARY“/ all subheadings
explode ”SODIUM-CHLORIDE“/ all subheadings
explode ”TRACE-ELEMENTS“/administration-and-dosage , adverse-effects , therapeutic-use
explode ”FLUORIDES“/administration-and-dosage , adverse-effects , therapeutic-use
MEDITERRAN* in TI,AB
explode ”ANTIOXIDANTS“/administration-and-dosage , adverse-effects , therapeutic-use
#1 or #2 or #3 or #4 or #5 or #6 or #7
#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
#18 or #19
LIPID* near (LOW* or REDUC* or MODIFI*)
DIET* in TI,AB
FAT* near (LOW* or MODIFI* or ANIMAL* or VEGETABLE* or ACID* or MONO?UNSAT* or POLY?UNSAT* or SATURAT*
or UNSATUR*)
OIL* near (VEGETABLE* or OLIVE* or RAPE* or SUNFLOW* or LINSEED* or MONO?UNSAT* or POLY?UNSAT* or SAT-
URAT* or UNSATUR*)
MEAT* in TI,AB







SODIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
VEGETABLE* in TI,AB
FRUIT* in TI,AB
POTASSIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
LEGUM* in TI,AB
SOY* in TI,AB
#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30

















CALCIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
SELENIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
MAGNESIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
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PHOSPHORUS* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
CHROMIUM* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
COBALT* in TI,AB
IODINE* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
GARLIC* in TI, AB
ZINC* near (ORAL* or SUPPLEMEN* or ADD* or CAPSUL* or TABLET* or HIGH* or LOW* or ENRICH*)
#42 or #43 or #44 or #45 or #46 or #47
#48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57
#58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67
#68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77
#78 or #79 or #80 or #81 or #82
#20 or #41 or #83 or #84 or #85 or #86 or #87
explode ”CARDIOVASCULAR-DISEASES“/ complications , diet-therapy , epidemiology , etiology , mortality , prevention-and-
control , rehabilitation , secondary , therapy
explode ”CEREBROVASCULAR-DISORDERS“/ complications , diet-therapy , epidemiology , etiology , mortality , prevention-and-
control , rehabilitation , therapy
explode ”NEOPLASMS“/ diet-therapy , mortality , prevention-and-control
CORONARY* near (BYPAS* or GRAFT* or DISEASE* or EVENT*)
CEREBRO?VASCULA*
CARDIO?VASC*
MYOCARDIAL* near (INFARCT* or RE?VASCULAR* or ISCH?EMI*)
MORTAL*
MORBID* near (HEART* or CORONARY* or ISCH?EM* or MYOCARD*)
VASCULAR* near (PERIPHERAL* or DISEASE* or COMPLICATION*)
ANGINA*
STROKE*
HEART* near (DISEASE* or ATTACK* or BYPASS*)
#91 or #92 or #93 or #94 or #95 or #96 or #97 or #98 or #99 or #100 or #101 or #89 or #90
#102 and #88
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#107 or #108 or #109 or #110 or #105 or #106
#103 not #104
explode ”CHILD“/ all subheadings










explode ”Fats“/ all subheadings
explode ”Fatty-Acids“/ all subheadings
explode ”Oils“/ all subheadings
explode ”Dairy-Products“/ all subheadings
explode ”Dietary-Fats“/ all subheadings
”Dietary-Fiber“/ all subheadings
”Food,-Fortified“/ all subheadings
explode ”Nuts“/ all subheadings
lipid* near (low* or reduc* or modif*)
fat* near (diet* or low* or modifi* or animal* or vegetable* or acid* or mono?unsat* or poly?unsat* or saturat* or unsatur*)








#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or
#21 or #22
explode ”Lipoproteins“/ all subheadings







#24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#23 and #32







#35 or #36 or #37 or #38 or #39 or #40
209Reduced or modified dietary fat for preventing cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#33 not #34
explode ”Child“/ all subheadings





Appendix 2. Search strategies June 2010
CENTRAL
#1lipid near (low* or reduc* or modifi*)
#2cholesterol* near (low* or modifi* or reduc*)
#3(#1 OR #2)
#4MeSH descriptor Nutrition Therapy explode all trees
#5diet* or food* or nutrition*
#6(#4 OR #5)
#7(#3 AND #6)
#8fat* near (low* or reduc* or modifi* or animal* or saturat* or unsaturat*)
#9MeSH descriptor Diet, Atherogenic explode all trees
#10MeSH descriptor Diet Therapy explode all trees
#11(#7 OR #8 OR #9 OR #10)
#12MeSH descriptor Cardiovascular Diseases, this term only
#13MeSH descriptor Heart Diseases explode all trees
#14MeSH descriptor Vascular Diseases explode all trees
#15MeSH descriptor Cerebrovascular Disorders, this term only
#16MeSH descriptor Brain Ischemia explode all trees
#17MeSH descriptor Carotid Artery Diseases explode all trees
#18MeSH descriptor Dementia, Vascular explode all trees
#19MeSH descriptor Intracranial Arterial Diseases explode all trees
#20MeSH descriptor Intracranial Embolism and Thrombosis explode all trees
#21MeSH descriptor Intracranial Hemorrhages explode all trees
#22MeSH descriptor Stroke explode all trees
#23coronar* near (bypas* or graft* or disease* or event*)
#24cerebrovasc* or cardiovasc* or mortal* or angina* or stroke or strokes or tia or ischaem* or ischem*
#25myocardi* near (infarct* or revascular* or ischaem* or ischem*)
#26morbid* near (heart* or coronar* or ischaem* or ischem* or myocard*)
#27vascular* near (peripheral* or disease* or complication*)
#28heart* near (disease* or attack* or bypas*)
#29(#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26
OR #27 OR #28)
#30(#11 AND #29)
Ovid MEDLINE
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 Randomized Controlled Trials/
4 Random Allocation/
5 Double-Blind Method/
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6 Single-Blind Method/
7 or/1-6
8 Animal/ not Human/
9 7 not 8 (419534)
10 (lipid$ adj5 (low$ or reduc$ or modifi$)).mp.
11 (cholesterol$ adj5 (low$ or modific$ or reduc$)).mp.
12 11 or 10
13 exp Nutrition Therapy/
14 (diet$ or food$ or nutrition$).mp.
15 14 or 13
16 12 and 15
17 (fat adj5 (low$ or reduc$ or modifi$ or animal$ or saturat$ or unsatur$)).mp.
18 exp Diet, Atherogenic/
19 exp Diet Therapy/
20 17 or 18 or 19 or 16
21 cardiovascular diseases/ or exp heart diseases/ or exp vascular diseases/
22 cerebrovascular disorders/ or exp brain ischemia/ or exp carotid artery diseases/ or exp dementia, vascular/ or exp intracranial arterial
diseases/ or exp ”intracranial embolism and thrombosis“/ or exp intracranial hemorrhages/ or exp stroke/
23 (coronar$ adj5 (bypas$ or graft$ or disease$ or event$)).mp.
24 (cerebrovasc$ or cardiovasc$ or mortal$ or angina$ or stroke or strokes).mp.
25 (myocardi$ adj5 (infarct$ or revascular$ or ischaemi$ or ischemi$)).mp. (190649)
26 (morbid$ adj5 (heart$ or coronar$ or ischaem$ or ischem$ or myocard$)).mp.
27 (vascular$ adj5 (peripheral$ or disease$ or complication$)).mp.
28 (heart$ adj5 (disease$ or attack$ or bypass$)).mp.
29 27 or 26 or 21 or 25 or 28 or 24 or 22 or 23
30 9 and 29 and 20
31 limit 30 to yr=”1998 - current“
EMBASE <1980 to 2010 Week 23>
1 cardiovascular diseases/ or exp heart diseases/ or exp vascular diseases/ (1304100)
2 cerebrovascular disorders/ or exp brain ischemia/ or exp carotid artery diseases/ or exp dementia, vascular/ or exp intracranial arterial
diseases/ or exp ”intracranial embolism and thrombosis“/ or exp intracranial hemorrhages/ or exp stroke/ (320121)
3 (coronar$ adj5 (bypas$ or graft$ or disease$ or event$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name] (149449)
4 (cerebrovasc$ or cardiovasc$ or mortal$ or angina$ or stroke or strokes).mp. [mp=title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug manufacturer name] (838125)
5 (myocardi$ adj5 (infarct$ or revascular$ or ischaemi$ or ischemi$)).mp. [mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug manufacturer name] (119244)
6 (morbid$ adj5 (heart$ or coronar$ or ischaem$ or ischem$ or myocard$)).mp. [mp=title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug manufacturer name] (20403)
7 (vascular$ adj5 (peripheral$ or disease$ or complication$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name] (160186)
8 (heart$ adj5 (disease$ or attack$ or bypass$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original




12 (doubl$ adj blind$).ti,ab. (90667)
13 (singl$ adj blind$).ti,ab. (8183)
14 double-blind procedure.sh. (78190)
15 randomized controlled trial.sh. (189654)
16 single blind procedure.sh. (9526)
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17 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (553493)
18 animal/ or nonhuman/ or animal experiment/ (3698016)
19 human/ (7063453)
20 19 and 18 (617530)
21 18 not 20 (3080486)
22 17 not 21 (485728)
23 (lipid$ adj5 (low$ or reduc$ or modifi$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name] (46393)
24 (cholesterol$ adj5 (low$ or modific$ or reduc$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name] (64458)
25 24 or 23 (89868)
26 (diet$ or food$ or eat$ or nutrition$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name] (596443)
27 exp nutrition/ (977243)
28 26 or 27 (1182970)
29 28 and 25 (34840)
30 (fat adj5 (low$ or reduc$ or modifi$ or animal$ or saturat$ or unsatur$)).mp. [mp=title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug manufacturer name] (24569)
31 exp lipid diet/ or exp fat intake/ or exp low fat diet/ (31724)
32 31 or 29 or 30 (71041)
33 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 (1779345)
34 22 and 33 and 32 (3615)
35 limit 34 to yr=”2008 -Current“ (626)*
*Previous updates were from 1998, so the updated EMBASE searches covered the period January 1998 to June 2010.
WH A T ’ S N E W
Last assessed as up-to-date: 1 December 2010.
Date Event Description
27 May 2011 New citation required and conclusions have changed • The objectives have been clarified and extended
• Studies divided by major intervention type: reduced
fat, modified fat, reduced and modified fat intervention.
Studies comparing reduced with modified fat diets also
included.
• Analyses run in RevMan as relative risks (rather than
as rate ratios)
• All meta-analyses, sub-grouping, sensitivity analyses
and meta-regressions re-run
• Validity assessment updated in all included studies
• The first version of the review included 27 studies, 40
intervention arms, 30901 person years.
• This update includes 48 studies, including 60
comparisons and 80760 individual participants, published
between 1965 and 2009
• Of these 25 comparisons, including 61,958
participants compared a reduced fat diet with usual or
control diet, while 15 comparisons, including 13,004
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(Continued)
participants compared a modified fat diet with control or
usual diet
• In this update 10 interventions, including 4,931
participants compared a reduced and modified fat diet with
usual or control diet, while nine interventions, including
1290 participants compared a low fat diet with a modified
fat diet. The final comparison could not be classified.
27 May 2011 New search has been performed The searches were updated by the authors to June 2010.New
authors have been added.
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 2, 2000
Date Event Description
9 September 2008 Amended Converted to new review format.
1 February 2000 New citation required and conclusions have changed Substantive amendment
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Helen Moore, Diredre Sills and Felicia Roberts (with Indra Tumur and Dorothee Fagard) duplicated the inclusion / exclusion and
data extraction of all studies; and Rudolph Riemersma arbitrated on study inclusion where necessary. Shah Ebrahim and Carolyn
Summerbell were primary advisors to the initial review. Lee Hooper originated and was primarily responsible for planning and carrying
out the review and was the principal author of the first and update versions.
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